1 00:00:04,587 --> 00:00:08,625 NOW. WELCOME, EVERYONE, I WANT TO 2 00:00:08,625 --> 00:00:10,727 GAVEL US IN TO THE 34TH MEETING 3 00:00:10,727 --> 00:00:13,129 OF THE NATIONAL CENTER FOR 4 00:00:13,129 --> 00:00:15,165 ADVANCING TRANSLATIONAL SCIENCES 5 00:00:15,165 --> 00:00:19,736 ADVISORY COUNCIL. WELCOME. THANK 6 00:00:19,736 --> 00:00:21,271 YOU FOR PARTICIPATING IN THE 7 00:00:21,271 --> 00:00:22,906 MEETING TODAY THOSE HERE AND 8 00:00:22,906 --> 00:00:26,910 THOSE WHO ARE ONLINE. I DON'T 9 00:00:26,910 --> 00:00:28,645 HAVE A LOT TO START OUT WITH 10 00:00:28,645 --> 00:00:30,547 HERE TODAY BUT I'M GOING TO TURN 11 00:00:30,547 --> 00:00:33,116 IT OVER TO ANNA WHO WILL BRIEFLY 12 00:00:33,116 --> 00:00:34,851 GO THROUGH SOME OF THE LOGISTICS 13 00:00:34,851 --> 00:00:36,486 AND CONFIRM FUTURE MEETING DATES 14 00:00:36,486 --> 00:00:39,255 AND DO ROLL CALL. WE WILL DO 15 00:00:39,255 --> 00:00:42,992 THAT FIRST THEN START. 16 00:00:42,992 --> 00:00:48,064 >> ALL RIGHT. TODAY MEMBERS IN 17 00:00:48,064 --> 00:00:52,535 ATTENDANCE ARE PAUL HARRIS. 18 00:00:52,535 --> 00:00:55,405 ANNIE KENNEDY. MATTHIAS 19 00:00:55,405 --> 00:00:56,005 KRETZLER. 20 00:00:56,005 --> 00:00:57,073 >> PRESENT. 21 00:00:57,073 --> 00:01:00,610 >> ROBIN MERMELSTEIN. KEITH 22 00:01:00,610 --> 00:01:04,848 MUELLER. PAULA SHIREMAN. 23 00:01:04,848 --> 00:01:08,151 >> HERE. ANNICA WAYMAN. WE HAVE 24 00:01:08,151 --> 00:01:10,787 NO AD HOC MEMBERS PARTICIPATING 25 00:01:10,787 --> 00:01:13,490 TODAY. NEXT. 26 00:01:13,490 --> 00:01:14,958 >> KELLY MCVEARY. 27 00:01:14,958 --> 00:01:16,092 >> I DIDN'T SAY YOU? 28 00:01:16,092 --> 00:01:16,926 >> NO. 29 00:01:16,926 --> 00:01:20,230 >> I'M SORRY, KELLY. KELLY 30 00:01:20,230 --> 00:01:24,300 MCVEARY IS JOINING US. ALL 31 00:01:24,300 --> 00:01:26,669 RIGHT. SO AS YOU CAN SEE OUR 32 00:01:26,669 --> 00:01:28,805 AGENDA TODAY INCLUDES SOME 33 00:01:28,805 --> 00:01:30,039 ANNOUNCEMENT, OUR DIRECTORS 34 00:01:30,039 --> 00:01:33,910 REPORT. WE HAVE A GUEST SPEAKER, 35 00:01:33,910 --> 00:01:36,613 DR. RENEE WEGRZYN, DIRECTOR OF 36 00:01:36,613 --> 00:01:38,114 ARPAH WILL JOIN US THEN A BREAK 37 00:01:38,114 --> 00:01:39,816 AND CLEAR ANSWER OF A CONCEPT 38 00:01:39,816 --> 00:01:41,418 FOLLOWED BY TWO PROGRAM UPDATES 39 00:01:41,418 --> 00:01:42,886 ONE FROM DIVISION OF CLINICAL 40 00:01:42,886 --> 00:01:44,220 INNOVATION, ONE FROM THE OFFICE 41 00:01:44,220 --> 00:01:46,756 OF DRUG DEVELOPMENT AND 42 00:01:46,756 --> 00:01:47,490 PARTNERSHIP PROGRAMS AND THOSE 43 00:01:47,490 --> 00:01:51,661 ARE THE UPDATES THEN TWO CONCEPT 44 00:01:51,661 --> 00:01:53,229 CLEARANCE PRESENTATIONS. AFTER 45 00:01:53,229 --> 00:01:56,232 THAT WE WILL ADJOURN FOR TODAY, 46 00:01:56,232 --> 00:01:57,467 APPROXIMATELY 5, 5:30 THIS 47 00:01:57,467 --> 00:02:02,439 AFTERNOON. NEXT SLIDE. SO 48 00:02:02,439 --> 00:02:03,773 ANNOUNCEMENTS. BECAUSE WE ARE 49 00:02:03,773 --> 00:02:07,110 MEETING IN PERSON THIS ROOM IS 50 00:02:07,110 --> 00:02:10,079 NOT -- EXCUSE ME. BECAUSE WE ARE 51 00:02:10,079 --> 00:02:11,714 MEETING IN PERSON WE ARE NOT 52 00:02:11,714 --> 00:02:12,849 LOGGING IN TO THE ZOOM 53 00:02:12,849 --> 00:02:14,317 INDIVIDUALLY. THE ROOM ITSELF IS 54 00:02:14,317 --> 00:02:16,252 LOGGED IN TO THE ZOOM MEETING. 55 00:02:16,252 --> 00:02:17,520 THOSE WHO ARE ATTENDING 56 00:02:17,520 --> 00:02:19,889 VIRTUALLY OF COURSE ARE 57 00:02:19,889 --> 00:02:20,457 PARTICIPATING AS ZOOM 58 00:02:20,457 --> 00:02:22,392 PARTICIPANTS. FOR THIS REASON IT 59 00:02:22,392 --> 00:02:25,295 IS IMPORTANT TO TURN YOUR TABLE 60 00:02:25,295 --> 00:02:26,596 MICROPHONE ON AND REFRAIN FROM 61 00:02:26,596 --> 00:02:29,032 MOVING IT TO AVOID ADDITIONAL 62 00:02:29,032 --> 00:02:30,800 NOISE. WHEN YOU ARE SPEAKING TO 63 00:02:30,800 --> 00:02:31,701 ENSURE YOUR COMMENTS CAN BE 64 00:02:31,701 --> 00:02:33,069 HEARD BY THOSE WHO ARE CONNECTED 65 00:02:33,069 --> 00:02:35,772 VIRTUALLY. IF YOU ARE 66 00:02:35,772 --> 00:02:37,207 PARTICIPATING VIRTUALLY RAISE 67 00:02:37,207 --> 00:02:40,076 YOUR HAND OR USE THE CHAT 68 00:02:40,076 --> 00:02:41,311 FEATURE THEN WAIT UNTIL YOU ARE 69 00:02:41,311 --> 00:02:43,546 CALLED TO PROVIDE INPUT. ALL 70 00:02:43,546 --> 00:02:44,614 PARTICIPANTS PLEASE ALLOW 71 00:02:44,614 --> 00:02:46,716 SPEAKERS TO MOVE THROUGH THEIR 72 00:02:46,716 --> 00:02:47,617 PRESENTATION, NOTING YOUR 73 00:02:47,617 --> 00:02:49,752 COMMENTS AND/OR QUESTIONS AND 74 00:02:49,752 --> 00:02:50,620 PRESENTING THEM WHEN CALLED 75 00:02:50,620 --> 00:02:52,755 UPON. VIRTUAL PARTICIPANTS MUST 76 00:02:52,755 --> 00:02:54,491 ENSURE DURING THE MEETINGS 77 00:02:54,491 --> 00:02:55,758 DISCUSSIONS OF CONFIDENTIAL 78 00:02:55,758 --> 00:02:57,627 MATTERS ARE NOT INADVERTENTLY 79 00:02:57,627 --> 00:03:00,263 RECORDED OR OVERHEARD BY 80 00:03:00,263 --> 00:03:01,498 DISABLING MICROPHONE RECORDING 81 00:03:01,498 --> 00:03:03,399 FEATURE ON VOICE ENABLED 82 00:03:03,399 --> 00:03:06,836 DEVICES. THAT OCCURRED AND IS 83 00:03:06,836 --> 00:03:09,706 PROBLEMATIC. ANNOUNCEMENTS 84 00:03:09,706 --> 00:03:11,274 CONTINUED. WE ARE USING THE 85 00:03:11,274 --> 00:03:13,810 VIDEOCAST FEATURE TODAY SO 86 00:03:13,810 --> 00:03:15,578 AUDIENCE MEMBERS MAY SUBMIT 87 00:03:15,578 --> 00:03:16,946 COMMENTS UNTIL OCTOBER 14TH BY 88 00:03:16,946 --> 00:03:18,882 USING THE EMAIL FUNCTION 89 00:03:18,882 --> 00:03:19,949 AVAILABLE ON THE NIH VIDEOCAST 90 00:03:19,949 --> 00:03:23,653 SITE. USING THE FEEDBACK BUTTON 91 00:03:23,653 --> 00:03:27,190 OR SENDING EMAIL TO NCATS 92 00:03:27,190 --> 00:03:30,693 COUNCIL INPUT@MAIL.NIH.GOV. WHEN 93 00:03:30,693 --> 00:03:33,897 YOU ARE SPEAKING YOUR CAMERA IS 94 00:03:33,897 --> 00:03:35,798 ON TO SPOTLIGHT FOR REVIEW AS 95 00:03:35,798 --> 00:03:37,467 VIDEOCAST. IF YOU ARE NOT ON 96 00:03:37,467 --> 00:03:38,801 CAMERA, THE PREVIOUS SPEAKER 97 00:03:38,801 --> 00:03:40,403 REMAINS SPOT LIGHTED. BACK TO 98 00:03:40,403 --> 00:03:43,072 THE PREVIOUS SLIDE, I MISSPOKE 99 00:03:43,072 --> 00:03:43,873 ON THE LAST BULLET. THIS IS 100 00:03:43,873 --> 00:03:45,775 OPEN MEETING SO NO ISSUES IF 101 00:03:45,775 --> 00:03:47,310 THERE'S ANYTHING DURING THIS 102 00:03:47,310 --> 00:03:48,478 DISCUSSION THAT IS OVERHEARD. SO 103 00:03:48,478 --> 00:03:49,679 THAT IS A CORRECTION FOR THE 104 00:03:49,679 --> 00:03:55,919 RECORD. NEXT SLIDE. SO THE 105 00:03:55,919 --> 00:03:57,787 FUTURE MEETING DATES FOR NCATS 106 00:03:57,787 --> 00:04:00,023 ADVISORY COUNCIL AS OF NOW ARE 107 00:04:00,023 --> 00:04:04,661 JANUARY 18 AND 19 AND JANUARY 30 108 00:04:04,661 --> 00:04:08,331 AND 31ST IN 2024 AND 2025 109 00:04:08,331 --> 00:04:11,034 RESPECTIVELY. THE PLAN IS FOR 110 00:04:11,034 --> 00:04:12,135 JANUARY MEETINGS FOB VIRTUAL. IN 111 00:04:12,135 --> 00:04:15,438 PERSON MEETINGS IN 2024 ARE 112 00:04:15,438 --> 00:04:18,107 EXPECTED TO OCCUR MAY 23 AND 113 00:04:18,107 --> 00:04:21,377 SEPTEMBER 26 AND 2025 AND MAY 22 114 00:04:21,377 --> 00:04:25,281 AND SEPTEMBER 25TH. SO WITH 115 00:04:25,281 --> 00:04:27,517 THIS, I WILL ASK OUR DIRECTOR TO 116 00:04:27,517 --> 00:04:29,619 GO UP TO THE LECTERN AND DELIVER 117 00:04:29,619 --> 00:04:38,828 THE REPORT TO THE COUNCIL. 118 00:04:38,828 --> 00:04:48,938 >> ALL RIGHT. THANK YOU, ANNA. 119 00:04:48,938 --> 00:04:50,173 DO SOME PLUGGING TO MAKE SURE 120 00:04:50,173 --> 00:04:54,811 EVERYTHING IS WORKING FINE. 121 00:04:54,811 --> 00:04:58,247 THANK YOU ALL, I HAVE A VARIETY 122 00:04:58,247 --> 00:05:00,683 OF UPDATES TODAY. IT WAS -- 123 00:05:00,683 --> 00:05:02,785 THIS ROUND I'M TALKING MORE 124 00:05:02,785 --> 00:05:04,020 ABOUT INITIATIVE DEVELOPMENTS 125 00:05:04,020 --> 00:05:05,054 AND IDEAS AND SOME THINGS WE 126 00:05:05,054 --> 00:05:08,591 HAVE BEEN DOING OF LATE AND I 127 00:05:08,591 --> 00:05:10,693 HAVEN'T SHOWN AS MUCH DATA AS I 128 00:05:10,693 --> 00:05:12,695 USUALLY DO BUT HOPE THAT YOU 129 00:05:12,695 --> 00:05:13,663 WILL HAVE A GOOD SENSE OF WHAT 130 00:05:13,663 --> 00:05:14,897 WE HAVE BEEN UP TO AND KIND OF 131 00:05:14,897 --> 00:05:16,466 THE AREAS THAT WE ARE MOVING 132 00:05:16,466 --> 00:05:22,972 INTO AS WELL. SO I WILL ADVANCE. 133 00:05:22,972 --> 00:05:24,440 I HAVE BEEN TAKING TO THIS IDEA 134 00:05:24,440 --> 00:05:26,109 OF GIVING YOU A BIT OF A SUMMARY 135 00:05:26,109 --> 00:05:27,276 FROM WHAT WE TALKED ABOUT LAST 136 00:05:27,276 --> 00:05:32,348 TIME. JUST TO REMIND ME TO MAKE 137 00:05:32,348 --> 00:05:33,583 SURE I HAVE COMMUNICATED, 138 00:05:33,583 --> 00:05:35,151 THOUGHT I COMMUNICATED LAST TIME 139 00:05:35,151 --> 00:05:37,687 BUT HOPEFULLY JUST JOGS YOUR 140 00:05:37,687 --> 00:05:39,122 MEMORY WHAT WE DID TALK ABOUT. 141 00:05:39,122 --> 00:05:40,490 SO LAST TIME WE PRESENTED A 142 00:05:40,490 --> 00:05:43,626 VARIETY OF UPDATES ON COVID FOR 143 00:05:43,626 --> 00:05:44,494 EXAMPLE, AND SOME OF THE 144 00:05:44,494 --> 00:05:49,565 ANALYSIS THAT WE HAD ON PAXLOVID 145 00:05:49,565 --> 00:05:51,601 USE AND REAL DATA OF COVID-19 146 00:05:51,601 --> 00:05:54,470 THERAPEUTICS. AND THAT WAS 147 00:05:54,470 --> 00:05:56,372 REALLY THE FIRST INDICATION OF 148 00:05:56,372 --> 00:05:57,206 END OF THE PANDEMIC AUTHORITIES 149 00:05:57,206 --> 00:05:59,242 THAT WE HAD. SO I WILL BE 150 00:05:59,242 --> 00:06:00,476 SPEAKING MUCH LESS ABOUT COVID 151 00:06:00,476 --> 00:06:02,445 THIS TIME, A LITTLE MORE ON 152 00:06:02,445 --> 00:06:03,413 OTHER INITIATIVES WE ARE 153 00:06:03,413 --> 00:06:04,447 STARTING TO PULL THROUGH THE 154 00:06:04,447 --> 00:06:06,215 THREAD THERE. AND I ALSO 155 00:06:06,215 --> 00:06:07,984 MENTIONED A LOT ABOUT THERE WAS 156 00:06:07,984 --> 00:06:11,154 A LOT OF DISCUSSION ABOUT THE 157 00:06:11,154 --> 00:06:12,321 GENE THERAPY PROGRAMS BUT THE 158 00:06:12,321 --> 00:06:13,456 BULK OF CONVERSATION LAST TIME 159 00:06:13,456 --> 00:06:14,123 WAS AROUND THE STRATEGIC 160 00:06:14,123 --> 00:06:16,092 PLANNING PROCESS. AND THOSE 161 00:06:16,092 --> 00:06:18,861 DISCUSSIONS THERE IN. AND WE 162 00:06:18,861 --> 00:06:20,663 WERE SORT OF EARLY INTERIM AND I 163 00:06:20,663 --> 00:06:23,066 WOULD SAY NOW WE ARE LATE 164 00:06:23,066 --> 00:06:24,634 INTERIM. SOLID MORE UPDATE ON 165 00:06:24,634 --> 00:06:27,770 THAT FROM THERE. I LOOK FORWARD 166 00:06:27,770 --> 00:06:29,205 TO YOUR COMMENTS BUT THINGS ARE 167 00:06:29,205 --> 00:06:30,907 NOW A LITTLE MORE OFFICIAL AS I 168 00:06:30,907 --> 00:06:36,012 WILL TALK ABOUT IN A LITTLE BIT 169 00:06:36,012 --> 00:06:37,814 SO TODAY I WANT TO DIVE IN SOME 170 00:06:37,814 --> 00:06:40,783 NEWS AN ANNOUNCEMENTS THAT WE 171 00:06:40,783 --> 00:06:42,251 TYPICALLY DO AT BEGINNING OF 172 00:06:42,251 --> 00:06:45,188 DIRECTORS REPORTS. THIS SLIDE IS 173 00:06:45,188 --> 00:06:48,658 THE SAME SLIDE I SHOWED BACK IN 174 00:06:48,658 --> 00:06:50,560 MAY, STILL SAME STATUS BUT MORE 175 00:06:50,560 --> 00:06:52,995 I THINK UPDATE TO THIS 176 00:06:52,995 --> 00:06:56,332 PARTICULAR ANNOUNCEMENT NOW IS 177 00:06:56,332 --> 00:06:58,735 THERE WAS A STAT ARTICLE WITH 178 00:06:58,735 --> 00:07:00,503 BERNIE SANDERS SAYING THAT HE 179 00:07:00,503 --> 00:07:02,105 WOULD HAVE A NOMINATION HEARING 180 00:07:02,105 --> 00:07:05,575 IN THE NEXT MONTH. SO THAT IS 181 00:07:05,575 --> 00:07:07,977 WHAT WE UNDERSTAND MAY HAPPEN. 182 00:07:07,977 --> 00:07:09,912 AS THINGS ARE FLEXIBLE SEE HOW 183 00:07:09,912 --> 00:07:11,447 THINGS GO BUT HOPEFULLY STAY 184 00:07:11,447 --> 00:07:12,782 TRUE BUT WE ARE HOPEFUL THIS 185 00:07:12,782 --> 00:07:14,550 WILL START TO MOVE FORWARD. 186 00:07:14,550 --> 00:07:17,220 UNTIL THEN, THINGS ARE IN THE 187 00:07:17,220 --> 00:07:21,190 CAPABLE HANDS OF DR. LARRY 188 00:07:21,190 --> 00:07:23,126 TABAK, ACTING DIRECTOR OF NIH. 189 00:07:23,126 --> 00:07:26,996 STAY TUNED ON THIS. MEANWHILE 190 00:07:26,996 --> 00:07:28,331 COUPLE OF OTHER UPDATES GOING ON 191 00:07:28,331 --> 00:07:31,033 AT THE NIH AS WELL. SO WANT TO 192 00:07:31,033 --> 00:07:33,703 GIVE A SENSE OF THIS. WE HAVE A 193 00:07:33,703 --> 00:07:34,904 VARIETY OF OPEN POSITIONS 194 00:07:34,904 --> 00:07:38,341 DENOTED AS CIRCLES IN RED. AND 195 00:07:38,341 --> 00:07:40,743 SOME OF THE POSITIONS FILLED 196 00:07:40,743 --> 00:07:43,412 THAT ARE NOW IN GREEN. WITHIN 197 00:07:43,412 --> 00:07:45,414 OUR OFFICE OF DIRECTOR THERE'S A 198 00:07:45,414 --> 00:07:46,549 VARIETY OF LEADERSHIP POSITIONS 199 00:07:46,549 --> 00:07:47,750 THAT I DON'T LIST, QUITE A 200 00:07:47,750 --> 00:07:52,121 NUMBER OF THEM. BUT THERE HAS 201 00:07:52,121 --> 00:07:54,056 BEEN A FEW RECENT FIELD 202 00:07:54,056 --> 00:07:55,391 POSITIONS IN THOSE LEADERSHIP 203 00:07:55,391 --> 00:07:57,326 ROLES IN OFFICE OF DIRECTOR. THE 204 00:07:57,326 --> 00:07:58,628 TRIBAL HEALTH RESEARCH OFFICE 205 00:07:58,628 --> 00:08:02,498 WITH KARINA WALTERS. OFFICE OF 206 00:08:02,498 --> 00:08:04,367 BEHAVIORAL SOCIAL SCIENCES WITH 207 00:08:04,367 --> 00:08:06,769 JANE SIMONI AND LEGISLATIVE 208 00:08:06,769 --> 00:08:09,238 POLICY ANALYSIS DIRECTOR WITH 209 00:08:09,238 --> 00:08:10,339 KATE (INAUDIBLE) AND ALSO THE 210 00:08:10,339 --> 00:08:12,108 OFFICE OF NUTRITIONAL RESEARCH 211 00:08:12,108 --> 00:08:15,845 WITH THE DIRECTOR ANDREW 212 00:08:15,845 --> 00:08:17,446 BREMMER. THOSE ARE SOME 213 00:08:17,446 --> 00:08:18,214 POSITIONS STARTING TO BE FILLED 214 00:08:18,214 --> 00:08:19,782 AND THERE'S A FEW MORE IN OFFS 215 00:08:19,782 --> 00:08:21,784 IF OF DIRECTOR HOPE TO UPDATE 216 00:08:21,784 --> 00:08:23,553 YOU ON NEXT TIME WE SPEAK. ALSO 217 00:08:23,553 --> 00:08:27,023 MEANTIME VERY RECENTLY DR. PATTY 218 00:08:27,023 --> 00:08:28,457 BRENNAN, A DEAR COLLEAGUE AND 219 00:08:28,457 --> 00:08:31,994 FRIEND HAS ANNOUNCED HER 220 00:08:31,994 --> 00:08:33,229 RETIREMENT FROM FEDERAL SERVICE 221 00:08:33,229 --> 00:08:35,531 AS NLM DIRECTOR, HAS BEEN THE 222 00:08:35,531 --> 00:08:38,534 DIRECTOR FOR SEVEN YEARS AND IS 223 00:08:38,534 --> 00:08:42,772 RETIRING THE END OF THIS WEE WE. 224 00:08:42,772 --> 00:08:45,541 SO WILL MISS HER PARTNERSHIP, 225 00:08:45,541 --> 00:08:47,143 WORKING CLOSELY IN AREAS OF DATA 226 00:08:47,143 --> 00:08:48,444 SCIENCE AND INFORMATICS AND 227 00:08:48,444 --> 00:08:50,213 THAT'S NEAR AND DEAR TO OUR 228 00:08:50,213 --> 00:08:51,480 HEARTS TOO. SO I LOOK FORWARD TO 229 00:08:51,480 --> 00:08:52,915 SEEING HOW THIS PROCESS UNFOLDS 230 00:08:52,915 --> 00:08:57,987 AS WELL. THEN ANOTHER AREA OF 231 00:08:57,987 --> 00:09:00,890 BIG NEWS, WE HAVE ONE OF THE KEY 232 00:09:00,890 --> 00:09:04,827 POSITIONS FILLED WITH THE NIAID 233 00:09:04,827 --> 00:09:06,329 DIRECTOR NATIONAL INSTITUTE ON 234 00:09:06,329 --> 00:09:08,531 ALLERGY INFECTIOUS DISEASE WITH 235 00:09:08,531 --> 00:09:11,868 GENE MORATSO (PHONETIC) WE LOOK 236 00:09:11,868 --> 00:09:13,636 FORWARD TO HER JOINING US THIS 237 00:09:13,636 --> 00:09:15,304 FALL AT THE NIH. SO WE ARE 238 00:09:15,304 --> 00:09:17,006 GETTING THINGS ROUNDED OUT WITH 239 00:09:17,006 --> 00:09:18,608 PATTY REFIRING WE HAVE MORE TO 240 00:09:18,608 --> 00:09:20,543 GO. AS ALWAYS SEEMS TO HAPPEN 241 00:09:20,543 --> 00:09:21,878 THAT WAY. WE ARE EXCITED WITH 242 00:09:21,878 --> 00:09:24,847 THE NEW LEADERSHIP WE ARE 243 00:09:24,847 --> 00:09:28,351 BRINGING TO NIH. IN THE SAME 244 00:09:28,351 --> 00:09:29,819 VEIN WE HAVE VICTIM AREAS HERE 245 00:09:29,819 --> 00:09:34,023 IN TERMS OF HIRING AT THE NCATS. 246 00:09:34,023 --> 00:09:35,558 LAST TIME I SHOWED YOU A BUNCH 247 00:09:35,558 --> 00:09:37,994 OF RED BOXES AND THAT MEANT WE 248 00:09:37,994 --> 00:09:40,096 HAD POSITIONS AS OPEN POSITIONS. 249 00:09:40,096 --> 00:09:41,864 BUT NOW WE ARE STARTING TO FILL 250 00:09:41,864 --> 00:09:43,733 THOSE AND WE ARE STARTING TO 251 00:09:43,733 --> 00:09:45,067 TURN THOSE GREEN. SO YOU KNOW 252 00:09:45,067 --> 00:09:50,706 MOST OF THESE ALREADY. BECAUSE 253 00:09:50,706 --> 00:09:52,541 WE MADE PUBLIC ANNOUNCEMENTS 254 00:09:52,541 --> 00:09:54,243 ABOUT THEM BUT HIGHLIGHTING NOW 255 00:09:54,243 --> 00:10:00,883 FIRST AND FOREMOST IS DR. 256 00:10:00,883 --> 00:10:05,187 DOMINIQUE KASHARD (PHONETIC) 257 00:10:05,187 --> 00:10:07,423 SINCE 2017 HE SERVED PASS CHIEF 258 00:10:07,423 --> 00:10:08,958 SCIENCE OFFICER AT THE 259 00:10:08,958 --> 00:10:10,159 INTERNATIONAL SYNDROME 260 00:10:10,159 --> 00:10:12,028 FOUNDATION. A PHYSICIAN, BY 261 00:10:12,028 --> 00:10:13,829 TRAINING AND SHE HAS BEEN IN THE 262 00:10:13,829 --> 00:10:14,597 PRE-CLINICAL AND CLINICAL 263 00:10:14,597 --> 00:10:17,166 RESEARCH SPACE FOR A WHILE. AND 264 00:10:17,166 --> 00:10:19,335 SHE'S ALSO RARE DISEASE 265 00:10:19,335 --> 00:10:21,771 ADVOCATE. SO WE ARE EXCITED TO 266 00:10:21,771 --> 00:10:24,106 HAVE DR. PICHARD HERE AND SHE IS 267 00:10:24,106 --> 00:10:25,274 NOW I THINK TWO OR THREE WEEKS 268 00:10:25,274 --> 00:10:28,844 IN. SO VERY EARLY IN HER TENURE, 269 00:10:28,844 --> 00:10:31,280 WE ARE DELIGHTED SHE IS HERE. OF 270 00:10:31,280 --> 00:10:33,749 COURSE I WOULD BE REMISS IF I 271 00:10:33,749 --> 00:10:35,818 DIDN'T SAY MANY THANKS TO PJ 272 00:10:35,818 --> 00:10:37,954 BROOKS WHO SERVED VERY CAPABLY 273 00:10:37,954 --> 00:10:41,057 AS THE ACTING DIRECTOR IN THIS 274 00:10:41,057 --> 00:10:42,825 ROLE AND ALSO ALL OF THE STAFF 275 00:10:42,825 --> 00:10:46,162 IN DRDRI FOR EXPERTLY COVERING 276 00:10:46,162 --> 00:10:48,297 ALL OF THE THINGS THAT CAME OUR 277 00:10:48,297 --> 00:10:50,766 WAY OVER THIS TIME. IT IS A 278 00:10:50,766 --> 00:10:51,801 WONDERFUL TEAM TO BE WORKING 279 00:10:51,801 --> 00:10:54,770 WITH AND I'M EXCITED TO HAVE DR. 280 00:10:54,770 --> 00:10:58,107 PICHARD AT THE HELM. ANOTHER 281 00:10:58,107 --> 00:11:03,045 ROLE, NEW ROLE TO NCATS. WE HAVE 282 00:11:03,045 --> 00:11:05,348 A COUNCIL THAT IS HELPING US 283 00:11:05,348 --> 00:11:06,682 THINK THROUGH DIVERSITY EQUITY 284 00:11:06,682 --> 00:11:08,451 INCLUSION ISSUES AND HEALTH 285 00:11:08,451 --> 00:11:11,554 EQUITY ISSUESFUL ONE OF THE KEY 286 00:11:11,554 --> 00:11:12,254 RECOMMENDATIONS THEY HAVE GIVEN 287 00:11:12,254 --> 00:11:13,622 OVER THE COURSE OF THE TIME THEY 288 00:11:13,622 --> 00:11:16,225 HAVE BEEN CONVENING IS WE SHOULD 289 00:11:16,225 --> 00:11:18,027 BE THINKING ABOUT A SCIENTIFIC 290 00:11:18,027 --> 00:11:19,128 DIVERSITY OFFICER FOR NCATS SO 291 00:11:19,128 --> 00:11:20,997 WE TOOK THAT TO HEART. AND WE 292 00:11:20,997 --> 00:11:22,331 WERE DELIGHTED NOW TO ANNOUNCE 293 00:11:22,331 --> 00:11:27,837 FOR THE FIRST TIME DR. JEANITA 294 00:11:27,837 --> 00:11:29,505 PRICHETT, NCATS FIRST SCIENTIFIC 295 00:11:29,505 --> 00:11:31,741 DIVERSITY OFFICER ON OCTOBER 296 00:11:31,741 --> 00:11:33,743 10TH. SHE BRINGS OVER A DECADE 297 00:11:33,743 --> 00:11:35,745 OF GOVERNMENT EXPERIENCE AT THE 298 00:11:35,745 --> 00:11:37,680 NATIONAL INSTITUTE OF STANDARDS 299 00:11:37,680 --> 00:11:39,048 AND TECHNOLOGY AND SHE'S BEEN 300 00:11:39,048 --> 00:11:41,684 WORKING AS A BENCH RESEARCHER IN 301 00:11:41,684 --> 00:11:44,353 CHEMISTRY, AND SHE HAS BEEN AN 302 00:11:44,353 --> 00:11:45,821 ACADEMIC PROGRAMS AND AS A 303 00:11:45,821 --> 00:11:49,025 PROGRAM MANAGER MOST RECENTLY 304 00:11:49,025 --> 00:11:51,560 AND SHE HAS ALSO BEEN LEADER OF 305 00:11:51,560 --> 00:11:53,329 THE NIST OR INSTITUTE OF 306 00:11:53,329 --> 00:11:54,563 STANDARDS AND TECHNOLOGY 307 00:11:54,563 --> 00:11:56,232 DIVERSITY EQUITY AND INCLUSION 308 00:11:56,232 --> 00:11:57,800 AND ACCESSIBILITY EFFORTS FOR 309 00:11:57,800 --> 00:12:00,102 VARIETY OF YEARS THERE. MOST 310 00:12:00,102 --> 00:12:01,871 RECENTLY. SO WE ARE EXCITED TO 311 00:12:01,871 --> 00:12:03,506 HAVE HER BRING THAT EXPERTISE 312 00:12:03,506 --> 00:12:05,975 AND EXPERIENCE TO NCATS WHILE 313 00:12:05,975 --> 00:12:09,045 SHE WILL HELP US REALLY DEVELOP 314 00:12:09,045 --> 00:12:11,380 THIS PROGRAM EVEN MORE AND WORK 315 00:12:11,380 --> 00:12:13,816 CLOSELY WITH THE LEADERSHIP AT 316 00:12:13,816 --> 00:12:15,785 NCATS TO CONTINUE WORK WE ARE 317 00:12:15,785 --> 00:12:17,653 DOING IN THE DEI SPACE AND 318 00:12:17,653 --> 00:12:18,888 HEALTH EQUITY SPACE. I LOOK 319 00:12:18,888 --> 00:12:19,989 FORWARD TO TELLING YOU MORE 320 00:12:19,989 --> 00:12:21,891 ABOUT THIS ROLE AS IT STARTS TO 321 00:12:21,891 --> 00:12:27,997 UNFOLD AS WELL. LASTLY, YOU KNOW 322 00:12:27,997 --> 00:12:29,932 BALKY (PHONETIC) WELL ALREADY 323 00:12:29,932 --> 00:12:31,133 BUT THIS IS THE FIRST 324 00:12:31,133 --> 00:12:32,501 OPPORTUNITY TO SHOW HIM AS 325 00:12:32,501 --> 00:12:34,070 OFFICIAL DIRECTOR OF OFFICE OF 326 00:12:34,070 --> 00:12:38,240 STRATEGIC ALLIANCES. BALKY HAS 327 00:12:38,240 --> 00:12:42,011 BEEN AN NCATS SINCE 2011 328 00:12:42,011 --> 00:12:43,379 BRINGING LEADERSHIP TECHNOLOGY 329 00:12:43,379 --> 00:12:44,613 DEVELOPMENT AND EXPERTISE AND 330 00:12:44,613 --> 00:12:46,849 HE'S GAINED EXPERTISE FROM 331 00:12:46,849 --> 00:12:47,950 WORKING IN THE INDUSTRY SECTOR 332 00:12:47,950 --> 00:12:51,153 AS WELL AS THE GOVERNMENT SECTOR 333 00:12:51,153 --> 00:12:54,590 ACROSS THE NIH. HE SERVED AS THE 334 00:12:54,590 --> 00:12:58,127 OSA'S DEPUTY DIRECTOR FOR MANY 335 00:12:58,127 --> 00:13:00,096 YEARS AND SERVE AS ACTING 336 00:13:00,096 --> 00:13:02,231 DIRECTOR, NOW THE DIRECTOR OF 337 00:13:02,231 --> 00:13:04,333 THIS -- IN THIS ROLE. CONGRATS 338 00:13:04,333 --> 00:13:05,701 TO ALL THREE OF THESE 339 00:13:05,701 --> 00:13:07,136 INDIVIDUALS AND I'M EXCITED TO 340 00:13:07,136 --> 00:13:08,737 HAVE OUR LEADERSHIP STARTING TO 341 00:13:08,737 --> 00:13:11,140 BE ROUNDED OUT. THERE WERE THREE 342 00:13:11,140 --> 00:13:12,608 OTHER RED BOXES UP THERE AND I 343 00:13:12,608 --> 00:13:15,277 HOPE TO TALK TO YOU ABOUT THOSE 344 00:13:15,277 --> 00:13:17,179 LATER ON AT THE NEXT COUNCIL 345 00:13:17,179 --> 00:13:18,614 MEETING BUT WE ARE WORKING 346 00:13:18,614 --> 00:13:19,215 DILIGENTLY TO FILL THOSE AS 347 00:13:19,215 --> 00:13:25,855 WELCH A NOTE ON OUR BUDGET. THIS 348 00:13:25,855 --> 00:13:27,756 THE BUDGET OUTLOOK AT A GLANCE, 349 00:13:27,756 --> 00:13:29,024 A CHART I SHOW EVERY TIME TO 350 00:13:29,024 --> 00:13:29,959 GIVE YOU A SENSE OF WHERE WE 351 00:13:29,959 --> 00:13:32,795 ARE. THIS IS THE SAME EXACT 352 00:13:32,795 --> 00:13:34,597 SLIDE I SHOWED IN MAY BECAUSE 353 00:13:34,597 --> 00:13:37,933 REALLY NOTHING CHANGED TO DATE. 354 00:13:37,933 --> 00:13:40,769 BUT THE -- YOU CAN SEE IN A 355 00:13:40,769 --> 00:13:42,538 SENSE NCATS HAS TWO BUCKETS OF 356 00:13:42,538 --> 00:13:44,206 FUNDING STREAMS AND THE CLINICAL 357 00:13:44,206 --> 00:13:46,742 AND TRANSLATIONAL SCIENCE AWARDS 358 00:13:46,742 --> 00:13:49,411 PROGRAM IS 68% OF THE PIE. ALL 359 00:13:49,411 --> 00:13:50,880 OTHER OF THE NCATS ACTIVITIES 360 00:13:50,880 --> 00:13:54,216 ARE ABOUT 32% OF THAT PIE. WE 361 00:13:54,216 --> 00:13:56,919 ARE VERY GRATEFUL TO KNOW WE 362 00:13:56,919 --> 00:13:59,121 HAVE BEEN ON A TRAJECTORY OF 363 00:13:59,121 --> 00:14:00,890 INCREASING THAT PIE OVER LAST 364 00:14:00,890 --> 00:14:03,526 COUPLE OF YEARS. SO IN 2023, 365 00:14:03,526 --> 00:14:08,330 LAST YEAR WE HAD $923.3 MILLION 366 00:14:08,330 --> 00:14:12,401 TO WORK IN THIS SPACE. THE 367 00:14:12,401 --> 00:14:13,736 OUTLOOK FOR FY 24 IS THE 368 00:14:13,736 --> 00:14:15,738 PRESIDENT PROPOSED A FLAT BUDGET 369 00:14:15,738 --> 00:14:17,640 FOR 24 AND FOR NCATS 370 00:14:17,640 --> 00:14:18,774 SPECIFICALLY THE HOUSE AND 371 00:14:18,774 --> 00:14:20,576 SENATE HAVE PROPOSED THE SAME 372 00:14:20,576 --> 00:14:23,546 FLAT BUDGET FOR US. AND SO WE 373 00:14:23,546 --> 00:14:24,980 ARE CONTINUING TO WAIT AND SEE 374 00:14:24,980 --> 00:14:27,483 HOW THESE BILLS RESOLVE. AND WE 375 00:14:27,483 --> 00:14:29,385 WILL CERTAINLY KEEP YOU UPDATED 376 00:14:29,385 --> 00:14:32,354 WHEN WE KNOW MORE. BUT AS WE 377 00:14:32,354 --> 00:14:33,956 SPEAK WE ARE PREPARING FOR ALL 378 00:14:33,956 --> 00:14:36,759 SORTS OF SCENARIOS IN CASE THERE 379 00:14:36,759 --> 00:14:38,327 IS A NEED FOR PREPARING FOR 380 00:14:38,327 --> 00:14:39,862 TIGHT FUNDING IN 2024, WE WILL 381 00:14:39,862 --> 00:14:47,169 BE PREPARED FOR THAT AS WELL. 382 00:14:47,169 --> 00:14:48,837 SOME OF THESE ACTIVITIES WE HAVE 383 00:14:48,837 --> 00:14:54,476 DONE RECENTLY HAVE BEEN ALSO 384 00:14:54,476 --> 00:14:59,848 AROUND OPPORTUNITIES TO SPEAK TO 385 00:14:59,848 --> 00:15:00,749 CONGRESSIONAL COLLEAGUES ON THE 386 00:15:00,749 --> 00:15:02,651 HILL DOING BRIEFINGS AND 387 00:15:02,651 --> 00:15:03,886 ENGAGEMENTS ON THE HILL TO TALK 388 00:15:03,886 --> 00:15:06,755 ABOUT WHO NCATS IS, WHAT WE DO, 389 00:15:06,755 --> 00:15:08,657 AND HERE I'M SHOWING A FEW 390 00:15:08,657 --> 00:15:11,627 THINGS, THESE ARE TISSUE CHIPS 391 00:15:11,627 --> 00:15:13,696 WE HAVE I WAS ABLE TAKE ON A 392 00:15:13,696 --> 00:15:14,863 ROADSHOW IF YOU WILL TO GIVE A 393 00:15:14,863 --> 00:15:16,332 SENSE WHAT THE CHIPS ARE ABOUT, 394 00:15:16,332 --> 00:15:18,567 WHAT THEY LOOK LIKE AND ALWAYS 395 00:15:18,567 --> 00:15:20,669 IS SOMETHING THAT ENGENDERS 396 00:15:20,669 --> 00:15:21,804 EXCITEMENT ABOUT WHAT WE DO AT 397 00:15:21,804 --> 00:15:23,038 NCATS SO IMPORTANT TO GET THAT 398 00:15:23,038 --> 00:15:27,376 MESSAGE OUT THERE. ALSO A GOOD 399 00:15:27,376 --> 00:15:29,144 OPPORTUNITY TO GET FACES TO 400 00:15:29,144 --> 00:15:30,479 NAMES AND DEVELOP RELATIONSHIPS 401 00:15:30,479 --> 00:15:31,347 FOR THESE SORTS OF ACTIVITIES 402 00:15:31,347 --> 00:15:33,148 THAT WE DO IN CASE THERE ARE ANY 403 00:15:33,148 --> 00:15:34,583 QUESTIONS THAT COME ALONG OUR 404 00:15:34,583 --> 00:15:36,919 WAY WE ARE ABLE TO PANS 405 00:15:36,919 --> 00:15:38,721 QUESTIONS RELATED TO CLINICAL 406 00:15:38,721 --> 00:15:40,956 AND TRANSLATIONAL SCIENCE FOR 407 00:15:40,956 --> 00:15:42,658 OUR HILL COLLEAGUES. THEN ON THE 408 00:15:42,658 --> 00:15:46,395 OTHER SIDE OF THE EQUATION ON A 409 00:15:46,395 --> 00:15:48,030 VERY DIFFERENT NOTE, 410 00:15:48,030 --> 00:15:50,766 SERENDIPITOUSLY I RAN INTO 411 00:15:50,766 --> 00:15:53,535 SENATOR BOASEMAN ON ANOTHER 412 00:15:53,535 --> 00:15:55,271 EVENT, HE GRACIOUSLY INVITED ME 413 00:15:55,271 --> 00:15:57,039 TO SPEAK TO HIM AND HIS STAFFERS 414 00:15:57,039 --> 00:15:59,508 IN OUR OFFICE SO I WAS ABLE TO 415 00:15:59,508 --> 00:16:01,010 GO THERE AND TALK ABOUT CTSA 416 00:16:01,010 --> 00:16:05,814 PROGRAM IN, A A ARKANSAS AND WOK 417 00:16:05,814 --> 00:16:07,716 WITH FDA ON THE 418 00:16:07,716 --> 00:16:09,585 MICROPHYSIOLOGICAL SYSTEMS AND 419 00:16:09,585 --> 00:16:12,021 TISSUE CHIP WORK WE BECAUSE THAT 420 00:16:12,021 --> 00:16:13,289 WORK IS CENTERED IN ARKANSAS SO 421 00:16:13,289 --> 00:16:14,490 WE WERE ABLE TO TALK A LITTLE 422 00:16:14,490 --> 00:16:16,292 BIT ABOUT THAT WORK. SO I JUST 423 00:16:16,292 --> 00:16:19,561 WANTED TO SHOW THAT AS WELL. SO 424 00:16:19,561 --> 00:16:20,929 VARIETY OF ACTIVITIES ALWAYS 425 00:16:20,929 --> 00:16:22,931 ONGOING IN THAT SPACE. AND I 426 00:16:22,931 --> 00:16:24,500 LIKE TO MAKE SURE THAT PEOPLE 427 00:16:24,500 --> 00:16:26,835 ARE AWARE THAT WE HAVE THOSE 428 00:16:26,835 --> 00:16:28,103 OPPORTUNITIES ON SOME OCCASIONS 429 00:16:28,103 --> 00:16:34,176 TO DO THAT. ANOTHER ACTIVITY WE 430 00:16:34,176 --> 00:16:35,044 HAVE BEEN DOING IS A 431 00:16:35,044 --> 00:16:37,446 RECONSTRUCTION OF OUR WEB PAGE. 432 00:16:37,446 --> 00:16:38,981 YOU WON'T KNOW THIS YET BECAUSE 433 00:16:38,981 --> 00:16:40,215 IT IS NOT UP YET BUT WILL BE 434 00:16:40,215 --> 00:16:42,885 COMING UP THE NEXT MONTH OR SO. 435 00:16:42,885 --> 00:16:44,987 THIS WILL -- OUR NEW WEBSITE 436 00:16:44,987 --> 00:16:47,923 WILL HAVE A NEW LOOK, A NEW 437 00:16:47,923 --> 00:16:50,793 FEEL, AND I HOPE YOU WILL AGREE 438 00:16:50,793 --> 00:16:53,295 IT IS SORT OF A REALLY 439 00:16:53,295 --> 00:16:55,831 REFRESHING LOOK AND FEEL. EMILY 440 00:16:55,831 --> 00:16:57,466 MARTY AND HER TEAM AND OUR 441 00:16:57,466 --> 00:16:58,400 COMMUNICATIONS OFFICE WORKED 442 00:16:58,400 --> 00:17:01,537 HARD TO DO A DEEP DIVE AND 443 00:17:01,537 --> 00:17:04,139 ENGAGING THE NCATS COMMUNITY AND 444 00:17:04,139 --> 00:17:05,007 STAKEHOLDERS TO SAY HEY, WHAT DO 445 00:17:05,007 --> 00:17:06,975 YOU WANT TO SEE ON THE NCATS 446 00:17:06,975 --> 00:17:09,144 WEBSITE? AND TAKE ALL THAT TO 447 00:17:09,144 --> 00:17:10,412 HEART TO DEVELOP THIS MIGHT LOOK 448 00:17:10,412 --> 00:17:12,748 LIKE SO WE HAVE NEW SECTIONS ON 449 00:17:12,748 --> 00:17:14,750 IMPACT AND NEW SECTIONS ON 450 00:17:14,750 --> 00:17:16,618 RESOURCES SORT OF TAILORED TO 451 00:17:16,618 --> 00:17:17,853 AUDIENCES IN NEED. I HOPE THAT 452 00:17:17,853 --> 00:17:20,189 WILL BE EASIER TO NAVIGATE FOR 453 00:17:20,189 --> 00:17:21,724 PEOPLE WHO ENCOUNTER OUR 454 00:17:21,724 --> 00:17:22,991 WEBSITE. WE ALSO WILL BE 455 00:17:22,991 --> 00:17:24,993 PUTTING IN A WAY TO FILTER ALL 456 00:17:24,993 --> 00:17:28,097 SORTS OF RESEARCH ACTIVITIES. 457 00:17:28,097 --> 00:17:29,098 FUNDING AND NEWS AND THINGS OF 458 00:17:29,098 --> 00:17:31,233 THAT NATURE TOO. AND SO WE HOPE 459 00:17:31,233 --> 00:17:33,235 THIS WILL COME ACROSS AS A 460 00:17:33,235 --> 00:17:34,803 REFRESHED LOOK. BUT WILL ALSO 461 00:17:34,803 --> 00:17:36,271 HAVE THE ABILITY TO REALLY MAKE 462 00:17:36,271 --> 00:17:38,273 SURE THESE ARE THE LATEST AND 463 00:17:38,273 --> 00:17:39,708 GREATEST STATEMENTS WHAT NCATS 464 00:17:39,708 --> 00:17:42,244 IS DOING NEW INITIATIVES WE ARE 465 00:17:42,244 --> 00:17:43,846 DOING AND I'M EXCITED TO SEE 466 00:17:43,846 --> 00:17:46,415 THIS TAKE HOLD. SO AGAIN, STAY 467 00:17:46,415 --> 00:17:48,650 TUNED, WE ARE EXPECTING THIS 468 00:17:48,650 --> 00:17:50,219 NEXT MONTH MAYBE A LITTLE LONGER 469 00:17:50,219 --> 00:17:51,387 BUT SHOULD BE OUT RELATIVELY 470 00:17:51,387 --> 00:17:56,392 SHORTLY. NOW ON TO ACTIVITIES 471 00:17:56,392 --> 00:17:58,227 AND IMPACTS ACROSS THE 472 00:17:58,227 --> 00:18:01,563 TRANSLATIONAL SCIENCE PIPELINE. 473 00:18:01,563 --> 00:18:03,465 I KNOW I WOULDN'T SAY TOO MUCH 474 00:18:03,465 --> 00:18:05,033 ABOUT COVID BUT ONE THING THEN 475 00:18:05,033 --> 00:18:06,468 MOVE ON TO VARIETY OTHER 476 00:18:06,468 --> 00:18:09,037 ACTIVITIES AS WELL. SO THE 477 00:18:09,037 --> 00:18:10,472 REASON I WANT TO HIGHLIGHT COVID 478 00:18:10,472 --> 00:18:15,511 IS BECAUSE WE ARE STARTING OUR 479 00:18:15,511 --> 00:18:18,113 LAST ACTIVE 6 ARM OF THE 480 00:18:18,113 --> 00:18:18,714 DECENTRALIZED CLINICAL TRIAL. 481 00:18:18,714 --> 00:18:20,516 THIS IS A METAPHORMAN ARM THAT 482 00:18:20,516 --> 00:18:23,685 IS NOW OPEN FOR ENROLLMENT. WE 483 00:18:23,685 --> 00:18:25,888 EXPECT THIS TO HAPPEN OVER NEXT 484 00:18:25,888 --> 00:18:27,489 SIX OR SO MONTHS FOR THAT 485 00:18:27,489 --> 00:18:28,624 ENROLLMENT TO HAPPEN AND I WILL 486 00:18:28,624 --> 00:18:30,492 UPDATE YOU OF COURSE AS WE 487 00:18:30,492 --> 00:18:31,794 CONTINUE TO MOVE ALONG THAT 488 00:18:31,794 --> 00:18:34,663 PROCESS. BUT IT ALSO GIVES ME AN 489 00:18:34,663 --> 00:18:36,465 OPPORTUNITY TO HIGHLIGHT A FEW 490 00:18:36,465 --> 00:18:38,167 OTHER THINGS RELATED TO COVID IN 491 00:18:38,167 --> 00:18:42,337 TERMS OF IMPACT. USUALLY IN THIS 492 00:18:42,337 --> 00:18:43,472 PARTICULAR TIME OF THE YEAR I 493 00:18:43,472 --> 00:18:45,140 TALK ABOUT SOME AWARDS, USUALLY 494 00:18:45,140 --> 00:18:47,242 FROM THE EXTRAMURAL COMMUNITY 495 00:18:47,242 --> 00:18:48,577 BUT TODAY I HAVE THE HONOR AND 496 00:18:48,577 --> 00:18:51,780 PRIVILEGE OF FOCUSING ON OUR 497 00:18:51,780 --> 00:18:53,849 NCATS COMMUNITY AND I'M 498 00:18:53,849 --> 00:18:55,184 DELIGHTED TO SAY BECAUSE OF THE 499 00:18:55,184 --> 00:18:59,421 WORK THAT SARA DUNS MOORE HAD 500 00:18:59,421 --> 00:19:00,656 DONE ON CLINICAL TRIALS AND 501 00:19:00,656 --> 00:19:03,358 ACTIVE 6 SHE WAS RECOGNIZE AND 502 00:19:03,358 --> 00:19:04,726 RECEIVED SECRETARY'S 503 00:19:04,726 --> 00:19:06,328 COMMENDATION FOR THE EXCEPTIONAL 504 00:19:06,328 --> 00:19:08,864 SERVICE FOR WORK DONE IN THIS 505 00:19:08,864 --> 00:19:10,399 SPACE. SHE WILL TELL YOU SHE IS 506 00:19:10,399 --> 00:19:13,202 NOT ALONE IN THIS, THIS IS A 507 00:19:13,202 --> 00:19:14,770 TEAM EFFORT BUT FORTUNATELY WE 508 00:19:14,770 --> 00:19:15,771 WERE ABLE TO RECOGNIZE HER FOR 509 00:19:15,771 --> 00:19:17,139 THIS EFFORT TO REPRESENT THAT 510 00:19:17,139 --> 00:19:18,941 WHOLE TEAM. SO REALLY DELIGHTED 511 00:19:18,941 --> 00:19:22,811 TO SEE THIS HAPPEN. SHE RECEIVED 512 00:19:22,811 --> 00:19:24,279 THIS AWARD A FEW WEEKS AGO 513 00:19:24,279 --> 00:19:26,381 PERHAPS NOW BUT ALSO GOING TO 514 00:19:26,381 --> 00:19:27,549 TELL YOU THERE'S A FEW OTHER HHS 515 00:19:27,549 --> 00:19:28,317 AWARDS THAT I WANT TO TELL YOU 516 00:19:28,317 --> 00:19:32,087 ABOUT. AND THIS IS HOT OFF THE 517 00:19:32,087 --> 00:19:33,455 PRESSES BECAUSE THE PHOTO THAT 518 00:19:33,455 --> 00:19:35,290 IS IN HERE ON THE RIGHT HAND 519 00:19:35,290 --> 00:19:37,292 SIDE WAS TAKEN I THINK LITERALLY 520 00:19:37,292 --> 00:19:41,129 AN HOUR AGO. SO THESE AWARDS ARE 521 00:19:41,129 --> 00:19:43,031 BEING GIVEN TODA TODAY. THIS ISE 522 00:19:43,031 --> 00:19:44,900 SECRETARY'S AWARE FOR 523 00:19:44,900 --> 00:19:45,834 DISTINGUISHED SERVICE. THE 524 00:19:45,834 --> 00:19:46,768 HIGHEST AWARD GRANTED BY THE 525 00:19:46,768 --> 00:19:49,471 DEPARTMENT. AND THIS IS FOR THE 526 00:19:49,471 --> 00:19:50,806 CREATION AND ESTABLISHMENT OF 527 00:19:50,806 --> 00:19:54,042 THE NATIONAL -- NCATS NATIONAL 528 00:19:54,042 --> 00:19:57,779 COVID COHORT COLLABORATIVE OR N 529 00:19:57,779 --> 00:20:00,015 3C AS PEOPLE KNOW. SAM MICHAEL 530 00:20:00,015 --> 00:20:01,583 IS IN THE CENTER NEXT TO 531 00:20:01,583 --> 00:20:03,485 SECRETARY BECERRA AND THE TEAM 532 00:20:03,485 --> 00:20:05,120 HERE ON THE LEFT-HAND SIDE ARE 533 00:20:05,120 --> 00:20:06,889 THE ONES WHO HAVE BEEN REALLY 534 00:20:06,889 --> 00:20:08,657 THE LEADERSHIP OF THIS PROGRAM 535 00:20:08,657 --> 00:20:11,226 THAT SAM IS ABLE TO REPRESENT US 536 00:20:11,226 --> 00:20:13,629 AND PICK UP THIS AWARDS FOR THIS 537 00:20:13,629 --> 00:20:17,900 WORK. SO WE ARE OVER THE MOON 538 00:20:17,900 --> 00:20:19,434 EXCITED THAT THE SECRETARY OF 539 00:20:19,434 --> 00:20:23,639 HHS IS REALLY HAS RECOGNIZED THE 540 00:20:23,639 --> 00:20:25,874 WORK N 3C HAS DONE IN THIS SPACE 541 00:20:25,874 --> 00:20:27,109 AND WE HOPE TO CONTINUE THIS 542 00:20:27,109 --> 00:20:28,777 WORK AS WELL AS IT HAS BEEN 543 00:20:28,777 --> 00:20:29,678 PIONEERING IN THE WORK THAT WE 544 00:20:29,678 --> 00:20:31,880 HAVE BEEN DOING IN CLINICAL 545 00:20:31,880 --> 00:20:34,449 INFORMATICS. I WANT TO THANK THE 546 00:20:34,449 --> 00:20:35,784 TEAM HERE THAT HAS BEEN 547 00:20:35,784 --> 00:20:37,419 RECOGNIZED THE LEADERS OF THIS 548 00:20:37,419 --> 00:20:39,755 PROGRAM. AGAIN, REFLECTING THE 549 00:20:39,755 --> 00:20:42,724 BROAD EXTRAMURAL COMMUNITY 550 00:20:42,724 --> 00:20:45,561 INVOLVED IN THIS CTSA 551 00:20:45,561 --> 00:20:46,628 ESPECIALLY. AND MANY OTHER 552 00:20:46,628 --> 00:20:48,497 PEOPLE WHO REALLY MADE THIS 553 00:20:48,497 --> 00:20:50,666 HAPPEN ALONG WITH COLLEAGUES AT 554 00:20:50,666 --> 00:20:54,002 NIH, PARTNERS IN THIS AS WELL. 555 00:20:54,002 --> 00:20:58,574 THAT IS NOT IT. TURNS OUT THAT 556 00:20:58,574 --> 00:21:01,443 THE SECRETARY'S AWARD FORMER 557 00:21:01,443 --> 00:21:02,511 TORRIOUS SERVICE, THE SECOND 558 00:21:02,511 --> 00:21:04,313 HIGHEST AWARD GRANTED BY THE 559 00:21:04,313 --> 00:21:06,548 DEPARTMENT, ALSO RECOGNIZED THE 560 00:21:06,548 --> 00:21:08,116 NCATS OPEN DATA PORTAL TEAM, SO 561 00:21:08,116 --> 00:21:11,486 THIS IS A GROUP LED BY MATT HALL 562 00:21:11,486 --> 00:21:13,755 AND HE'S THE ONE WHO IS 563 00:21:13,755 --> 00:21:15,123 ACCEPTING THE AWARD ABOUT AN 564 00:21:15,123 --> 00:21:16,992 HOUR AGO DOWNTOWN RECEIVING THIS 565 00:21:16,992 --> 00:21:18,994 AWARD AND SENDING ME THE PHOTOS 566 00:21:18,994 --> 00:21:21,163 WE HAVE LEADERSHIP TEAM SHOWN 567 00:21:21,163 --> 00:21:23,565 HERE REFLECTIVE OF COURSE ACROSS 568 00:21:23,565 --> 00:21:25,534 A VARIETY OF GROUPS, THIS IS A 569 00:21:25,534 --> 00:21:26,802 PUBLIC PRIVATE PARTNERSHIP FOR 570 00:21:26,802 --> 00:21:28,837 EXAMPLE THAT REALLY MADE THIS 571 00:21:28,837 --> 00:21:31,106 HAPPEN. BLUE I WAS EXCITED TO 572 00:21:31,106 --> 00:21:33,342 SEE AGAIN NCATS RECOGNIZED FOR 573 00:21:33,342 --> 00:21:35,544 THE KEY WORK WE DO BUT IT IS 574 00:21:35,544 --> 00:21:36,778 ALWAYS ABOUT THE PEOPLE 575 00:21:36,778 --> 00:21:42,017 UNDERLYING THAT MAKE IT HAPPEN I 576 00:21:42,017 --> 00:21:43,285 WANTED TO MAKE SURE I WAS ABLE 577 00:21:43,285 --> 00:21:44,319 TO RECOGNIZE THEM HERE TODAY. 578 00:21:44,319 --> 00:21:50,058 ONE OTHER AWARD IS SORT OF 579 00:21:50,058 --> 00:21:52,728 UNUSUAL AND FELT IT WORTHY TO 580 00:21:52,728 --> 00:21:54,363 HONOR THIS GROUP, DR. 581 00:21:54,363 --> 00:21:57,499 (INAUDIBLE) RECEIVED A HONORARY 582 00:21:57,499 --> 00:21:58,867 AWARD FROM THE UNIVERSITY OF 583 00:21:58,867 --> 00:22:01,570 SIDNEY STRAYIA. THE HIGHEST 584 00:22:01,570 --> 00:22:02,771 AWARD BEST STOWED UPON GRADUATES 585 00:22:02,771 --> 00:22:04,973 FROM UNIVERSITY OF SIDNEY. IT 586 00:22:04,973 --> 00:22:06,875 RECOGNIZES HIS WORK ON 587 00:22:06,875 --> 00:22:08,243 SUPPORTING LNI RELATIONS FOR THE 588 00:22:08,243 --> 00:22:09,745 UNIVERSITY AS WELL AS 589 00:22:09,745 --> 00:22:12,948 OUTSTANDING SCIENTIFIC 590 00:22:12,948 --> 00:22:14,316 ACCOMPLISHMENTS. SINCE THEN. SO 591 00:22:14,316 --> 00:22:16,284 RECOGNIZING FROM AFAR FROM DOWN 592 00:22:16,284 --> 00:22:18,553 UNDER AND I'M REALLY EXCITED TO 593 00:22:18,553 --> 00:22:20,889 SEE THIS RECOGNITION HAPPEN AS 594 00:22:20,889 --> 00:22:22,824 WELL FOR NCATS STAFF SO 595 00:22:22,824 --> 00:22:24,593 CONGRATULATIONS TO ALL OF THOSE 596 00:22:24,593 --> 00:22:26,862 FOLKS WHO REALLY BEEN AT THE 597 00:22:26,862 --> 00:22:28,530 FOREFRONT THE LAST COUPLE OF 598 00:22:28,530 --> 00:22:30,232 YEARS LEADING IN THIS SPACE, IN 599 00:22:30,232 --> 00:22:38,740 THESE SPACES. SO IT IS SORT OF 600 00:22:38,740 --> 00:22:41,977 AS WE COME BACK OUT OF THE 601 00:22:41,977 --> 00:22:43,078 PANDEMIC, THIS IS WHERE YOU KNOW 602 00:22:43,078 --> 00:22:44,980 OF THE FIRST TIMES WE HAD TO 603 00:22:44,980 --> 00:22:47,883 HOLD NIH RESEARCH FESTIVAL THAT 604 00:22:47,883 --> 00:22:49,418 IS SOMETHING THAT IS FOR 605 00:22:49,418 --> 00:22:50,085 INTRAMURAL RESEARCH PROGRAM. SO 606 00:22:50,085 --> 00:22:51,620 I WANTED TO JUST DEPICT A 607 00:22:51,620 --> 00:22:53,822 VARIETY OF OUR TRAINEES AND POST 608 00:22:53,822 --> 00:22:55,657 DOCS WHO WERE PRESENTING POSTERS 609 00:22:55,657 --> 00:22:57,993 AT THE RESEARCH FESTIVAL. M CATS 610 00:22:57,993 --> 00:23:00,696 HAS AMAZING PRESENCE THERE. WE 611 00:23:00,696 --> 00:23:02,731 WERE REPRESENTED 3.5 FOLD MORE 612 00:23:02,731 --> 00:23:05,000 THAN OTHER ICs SO I'M EXCITED 613 00:23:05,000 --> 00:23:09,438 TO SEE THE SCIENCE CONTINUE AND 614 00:23:09,438 --> 00:23:10,706 ADVANCEMENT THEY BRING TO THIS 615 00:23:10,706 --> 00:23:12,474 RESEARCH FESTIVAL, IT IS ALWAYS 616 00:23:12,474 --> 00:23:15,510 IMPORTANT, THIS IS PART OF 617 00:23:15,510 --> 00:23:16,845 TRAINING, YOU GO AND PRESENT 618 00:23:16,845 --> 00:23:18,080 POSTERS, TALK TO PEOPLE TELL 619 00:23:18,080 --> 00:23:20,882 THEM ABOUT THE WORK YOU DO. THIS 620 00:23:20,882 --> 00:23:24,052 IS HELPING US DEVELOP TRAINEES 621 00:23:24,052 --> 00:23:26,822 AND FUTURE LEADERS FOR 622 00:23:26,822 --> 00:23:28,356 TRANSLATIONAL SCIENCE SO EXCITED 623 00:23:28,356 --> 00:23:29,758 TO HAVE THIS BATCH IN THE NIH 624 00:23:29,758 --> 00:23:31,426 FOLD THAT WE ARE ABLE TO 625 00:23:31,426 --> 00:23:33,261 PARTICIPATE IN IN AGAIN AND I 626 00:23:33,261 --> 00:23:35,163 LOOK FORWARD TO FUTURE NIH 627 00:23:35,163 --> 00:23:38,400 RESEARCH FESTIVALS AS WELL. ALL 628 00:23:38,400 --> 00:23:40,535 RIGHT. NOW I WANT TO MENTION A 629 00:23:40,535 --> 00:23:44,206 FINISHTIVES THAT NCATS HAS BEEN 630 00:23:44,206 --> 00:23:45,607 PARTICULARLY INVOLVED IN OVER 631 00:23:45,607 --> 00:23:47,976 THE LAST FEW MONTHS SINCE WE MET 632 00:23:47,976 --> 00:23:50,078 LAST. WE HAVE BEEN OF COURSE 633 00:23:50,078 --> 00:23:52,314 WORKING THE HELPING END 634 00:23:52,314 --> 00:23:53,248 ADDICTIONS LONG TERM SPACE AND 635 00:23:53,248 --> 00:23:56,251 THIS IS THE HEAL SPACE. SO NO 636 00:23:56,251 --> 00:23:59,554 STRANGER TO THIS PROGRAM BUT 637 00:23:59,554 --> 00:24:05,560 THERE IS A NEW INITIATIVE WE ARE 638 00:24:05,560 --> 00:24:07,162 EXCITED ABOUT THE ROLE IS UNIQUE 639 00:24:07,162 --> 00:24:10,632 AND THIS IS A PARTNERSHIP WITH 640 00:24:10,632 --> 00:24:13,435 HELP FROM ANNA RAMSEY EWING AND 641 00:24:13,435 --> 00:24:16,605 HER OFFICE AND STACY FLETCHER. 642 00:24:16,605 --> 00:24:21,943 THIS IS THE NCREW PROGRAM, A 643 00:24:21,943 --> 00:24:23,078 PRESTIGIOUS PROGRAM WITHIN THE 644 00:24:23,078 --> 00:24:25,213 HEAL COMMUNITY TO HELP US 645 00:24:25,213 --> 00:24:27,783 CONSIDER HOW TO BRING IN AND 646 00:24:27,783 --> 00:24:29,451 RESPOND TO THE NEEDS WITHIN THE 647 00:24:29,451 --> 00:24:32,020 TRIBAL COMMUNITIES. SO THIS 648 00:24:32,020 --> 00:24:34,022 EFFORT IS TO SUPPORT TRIBES 649 00:24:34,022 --> 00:24:36,057 NATIVE AMERICANS SERVING 650 00:24:36,057 --> 00:24:40,462 ORGANIZATIONS TO CONDUCT THE 651 00:24:40,462 --> 00:24:42,197 LOCAL RESEARCH TO ADDRESS 652 00:24:42,197 --> 00:24:44,666 OVERDOSE, SUBSTANCE USE PAIN AND 653 00:24:44,666 --> 00:24:45,901 INTERSECTIONS WITH THOSE ALONG 654 00:24:45,901 --> 00:24:47,502 WITH OTHER HEALTH AND WELLNESS 655 00:24:47,502 --> 00:24:49,104 FACTORS SO THIS N CREW 656 00:24:49,104 --> 00:24:51,173 INITIATIVE IS OUT. AND WE ARE 657 00:24:51,173 --> 00:24:53,008 PARTNERING ON THIS WITH THE 658 00:24:53,008 --> 00:24:54,376 NATIONAL INSTITUTE ON DRUG ABUSE 659 00:24:54,376 --> 00:24:56,211 WHO WILL HAVE OVERALL PROGRAM 660 00:24:56,211 --> 00:24:57,212 OVERSIGHT. BUT BECAUSE OF THE 661 00:24:57,212 --> 00:25:00,448 NATURE OF THIS AWARDS, THE 662 00:25:00,448 --> 00:25:01,082 PROGRAMMATIC OVERSIGHT GOES HAND 663 00:25:01,082 --> 00:25:03,318 IN HAND WITH THE SORT OF OTHER 664 00:25:03,318 --> 00:25:04,753 TRANSACTION AWARDS AND 665 00:25:04,753 --> 00:25:06,288 ADMINISTRATIVE AND REVIEW 666 00:25:06,288 --> 00:25:07,622 OVERSIGHT. THAT IS WHAT WE 667 00:25:07,622 --> 00:25:08,790 BRINGING TO THE TABLE. WE ARE 668 00:25:08,790 --> 00:25:11,026 VERY EXCITED ABOUT THIS BECAUSE 669 00:25:11,026 --> 00:25:12,394 THIS WILL ALSO I THINK 670 00:25:12,394 --> 00:25:13,428 STRENGTHEN OUR OWN ABILITIES TO 671 00:25:13,428 --> 00:25:14,029 UNDERSTAND WHAT IS NEEDED FOR 672 00:25:14,029 --> 00:25:17,232 THESE TYPES OF COMMUNITIES AND 673 00:25:17,232 --> 00:25:18,366 HOW TO EXPAND TO OTHER 674 00:25:18,366 --> 00:25:20,902 COMMUNITIES AS WELL THAT MAY NOT 675 00:25:20,902 --> 00:25:22,470 NECESSARILY BE AS TRADITIONAL 676 00:25:22,470 --> 00:25:24,840 KINDS OF NIH AWARDEES. SO THIS 677 00:25:24,840 --> 00:25:26,208 MIGHT HELP EXPAND OUR REPERTOIRE 678 00:25:26,208 --> 00:25:27,475 IN THAT WAY. SO WE ARE EXCITED 679 00:25:27,475 --> 00:25:30,779 ABOUT IT FOR THIS REASON. NOT 680 00:25:30,779 --> 00:25:32,180 ONLY THE SCIENTIFIC WORK AT N 681 00:25:32,180 --> 00:25:33,248 CATS BUT OPERATIONAL WORK THAT 682 00:25:33,248 --> 00:25:37,519 WE DO TOO. THAT HELP US LEAD AN 683 00:25:37,519 --> 00:25:38,753 INNOVATE IN THIS SPACE SO I WANT 684 00:25:38,753 --> 00:25:40,555 TO LET YOU KNOW WE ARE INVOLVED 685 00:25:40,555 --> 00:25:42,691 IN THIS, IF YOU WANT TO KNOW 686 00:25:42,691 --> 00:25:43,859 MORE ABOUT THE PROGRAM I HAVE 687 00:25:43,859 --> 00:25:45,527 THE QR CODE THERE. RECENTLY I 688 00:25:45,527 --> 00:25:48,930 THINK THIS CAME OUT THE LATEST 689 00:25:48,930 --> 00:25:51,166 DIRECTORS BLOG FROM DR. TABAK, 690 00:25:51,166 --> 00:25:53,501 HE TALKED ABOUT THE TARGETED 691 00:25:53,501 --> 00:25:55,403 CHALLENGE THAT WE HAVE, THE 692 00:25:55,403 --> 00:25:57,205 TARGETED GENOME EDITOR DELIVERY. 693 00:25:57,205 --> 00:25:59,474 THIS IS A CHALLENGE WE HAVE LIEU 694 00:25:59,474 --> 00:26:03,211 THE COMMON FUND SOMATIC CELL 695 00:26:03,211 --> 00:26:04,746 GENE EDITING PROGRAM THAT NCATS 696 00:26:04,746 --> 00:26:07,182 IS ONE OF THE LEADERS OF ALONG 697 00:26:07,182 --> 00:26:08,917 WITH NINDS AND WALTER KOROSHETZ, 698 00:26:08,917 --> 00:26:11,586 PJ BROOKS IS LEAD AT NCATS WHO 699 00:26:11,586 --> 00:26:13,655 IS REALLY HELPED DEVELOP THIS 700 00:26:13,655 --> 00:26:15,557 CHALLENGE BUT THIS IS TO HELP 701 00:26:15,557 --> 00:26:17,359 GET TARGETED DELIVERIES TO 702 00:26:17,359 --> 00:26:19,594 UNUSUAL PLACES IN THE BODY AND 703 00:26:19,594 --> 00:26:20,962 UNDERSTAND HOW IT CAN INNOVATE 704 00:26:20,962 --> 00:26:23,231 IN THIS SPACE TO MAKE GENE 705 00:26:23,231 --> 00:26:24,866 EDITING A VARIETY FOR DIFFERENT 706 00:26:24,866 --> 00:26:26,101 KINDS OF DISEASES. IF YOU ARE 707 00:26:26,101 --> 00:26:27,702 INTERESTED IN THIS THE QR CODE 708 00:26:27,702 --> 00:26:28,770 IS THERE AND CHALLENGE IS NOW 709 00:26:28,770 --> 00:26:34,075 OPEN. LASTLY ANOTHER NEW 710 00:26:34,075 --> 00:26:35,644 INITIATIVE THAT I WANT TO 711 00:26:35,644 --> 00:26:38,647 PRESENT IS ONE CALLED 712 00:26:38,647 --> 00:26:40,115 COMPLIMENTARY. LUCKILY THIS IS 713 00:26:40,115 --> 00:26:42,050 NOT A FULL ACRONYM ONLY THE ARIE 714 00:26:42,050 --> 00:26:44,386 IS THE ACRONYM BUT COMPLIMENTARY 715 00:26:44,386 --> 00:26:45,987 IS THE FULL NAME OF THE PROGRAM 716 00:26:45,987 --> 00:26:49,557 AND THIS IS ABOUT COMPLIMENTING 717 00:26:49,557 --> 00:26:51,026 ANIMAL RESEARCH AND 718 00:26:51,026 --> 00:26:54,763 EXPERIMENTATION. THIS BUILDS 719 00:26:54,763 --> 00:26:56,765 FROM LAST DECADE OF WORK THAT 720 00:26:56,765 --> 00:26:59,301 DAN TAGLEY AND HIS TEAM LED IN 721 00:26:59,301 --> 00:27:00,902 THE MICROPHYSIOLOGICAL SYSTEMS 722 00:27:00,902 --> 00:27:02,971 SPACE TO THINK HOW TO BRING THAT 723 00:27:02,971 --> 00:27:05,907 -- THOSE TISSUE CHIP KINDS OF 724 00:27:05,907 --> 00:27:08,343 PROGRAMS THE 3-D PROGRAMS TO 725 00:27:08,343 --> 00:27:09,611 BEAR ON EARLY EXPANDING AND 726 00:27:09,611 --> 00:27:12,714 INNOVATING IN THE RESEARCH SPACE 727 00:27:12,714 --> 00:27:14,349 AND PERHAPS ADDRESSING HOW WE 728 00:27:14,349 --> 00:27:16,084 CAN COMPLIMENT ANIMAL RESEARCH 729 00:27:16,084 --> 00:27:18,687 AND EXPERIMENTATION. NOT REDUCE, 730 00:27:18,687 --> 00:27:22,157 NOT REPLACE, BUT -- NOT TO 731 00:27:22,157 --> 00:27:24,526 REPLACE BUT CERTAINLY REDUCE AND 732 00:27:24,526 --> 00:27:26,094 HELP US UNDERSTAND WHERE AND HOW 733 00:27:26,094 --> 00:27:27,529 IT IS GOING TO BE APPROPRIATE TO 734 00:27:27,529 --> 00:27:29,898 USE THESE SORTS OF NEW MODELS. 735 00:27:29,898 --> 00:27:31,933 BUT IT WON'T BE ALL THE TIME 736 00:27:31,933 --> 00:27:35,270 THAT WE ARE GOING TO BE ABLE TO 737 00:27:35,270 --> 00:27:36,438 JUST USE THESE MODELS IN PLACE 738 00:27:36,438 --> 00:27:38,807 OF ANIMALS. THEY ARE ANIMAL 739 00:27:38,807 --> 00:27:40,675 MODELS ARE STILL INCREDIBLY 740 00:27:40,675 --> 00:27:41,843 IMPORTANT AND WE NEED TO MAKE 741 00:27:41,843 --> 00:27:43,445 SURE WE KNOW WHEN AND HOW TO USE 742 00:27:43,445 --> 00:27:44,813 THE DIFFERENT MODELS MOST 743 00:27:44,813 --> 00:27:47,682 APPROPRIATE FOR THE QUESTI QUESO 744 00:27:47,682 --> 00:27:49,017 THE PURPOSE OF THE PROGRAM IS 745 00:27:49,017 --> 00:27:50,952 CATALYZE DEVELOPMENT AND 746 00:27:50,952 --> 00:27:51,820 STANDARDIZATION VALIDATION OF 747 00:27:51,820 --> 00:27:53,555 THESE KIND OF APPROACHES. SO 748 00:27:53,555 --> 00:27:55,357 THESE ARE SPECIFICALLY HUMAN 749 00:27:55,357 --> 00:27:56,858 BASED APPROACH TO DEVELOP THOSE 750 00:27:56,858 --> 00:28:00,762 NEW APPROACH METHODOLOGIES THAT 751 00:28:00,762 --> 00:28:02,497 WILL HOPEFULLY TRANSFORM HOW WE 752 00:28:02,497 --> 00:28:03,965 THINK ABOUT TRANSLATIONAL AND 753 00:28:03,965 --> 00:28:06,067 CLINICAL SCIENCE. IN VITRO 754 00:28:06,067 --> 00:28:09,137 INNOVATIONS IN SILICO INNOVATION 755 00:28:09,137 --> 00:28:12,841 AND THE (INAUDIBLE) INNOVATIONS 756 00:28:12,841 --> 00:28:14,642 SO USING THE TECHNOLOGIES WE 757 00:28:14,642 --> 00:28:16,544 HEARD ABOUT AND BRINGING TO BARE 758 00:28:16,544 --> 00:28:17,879 ON VARIETY OF DISEASES SO 759 00:28:17,879 --> 00:28:20,215 BUILDING BETTER MODELS, GETTING 760 00:28:20,215 --> 00:28:21,750 WAYS IN WHICH WE CAN PROVIDE 761 00:28:21,750 --> 00:28:23,585 INITIATIVES TO GET INSIGHT INTO 762 00:28:23,585 --> 00:28:25,387 SPECIFIC BIOLOGICAL PROCESSES. 763 00:28:25,387 --> 00:28:28,590 HOW TO VALIDATE THESE MODELS 764 00:28:28,590 --> 00:28:30,058 EFFECTIVELY AND THINK ABOUT WHEN 765 00:28:30,058 --> 00:28:31,860 AND HOW TO USE THEM FOR 766 00:28:31,860 --> 00:28:33,028 REGULATORY USE OR WHEN AND HOW 767 00:28:33,028 --> 00:28:34,396 TO USE THEM FOR EXPERIMENTAL 768 00:28:34,396 --> 00:28:37,132 USE. THEN COMPLIMENTING THESE 769 00:28:37,132 --> 00:28:40,035 DIFFERENT MAMMALIAN MODELS IS 770 00:28:40,035 --> 00:28:40,735 SOMETHING THAT WILL BE 771 00:28:40,735 --> 00:28:42,070 IMPORTANT. GENORA I WILL 772 00:28:42,070 --> 00:28:43,204 UNDERSTANDING HOW WE CAN MAKE 773 00:28:43,204 --> 00:28:44,706 THIS MORE EFFICIENT AND 774 00:28:44,706 --> 00:28:46,274 EFFECTIVE FOR DRIVING THE 775 00:28:46,274 --> 00:28:48,243 PROCESS OF TRANSLATIONAL SCIENCE 776 00:28:48,243 --> 00:28:49,611 FASTER AND BETTER MORE 777 00:28:49,611 --> 00:28:54,582 EFFECTIVELY. THERE HAVE BEEN A 778 00:28:54,582 --> 00:28:55,817 VARIETY OF PLANNING EFFORTS 779 00:28:55,817 --> 00:28:57,619 UNDERWAY FOR THIS PROGRAM BUT 780 00:28:57,619 --> 00:28:59,320 ONE THAT IS CURRENTLY OUT IS 781 00:28:59,320 --> 00:29:01,656 THAT WE ARE DOING IT A LISTENING 782 00:29:01,656 --> 00:29:07,062 SESSION FOR THE COMMUNITY. SO 783 00:29:07,062 --> 00:29:07,996 THIS IS TO JUST UNDERSTAND WHAT 784 00:29:07,996 --> 00:29:11,266 THE NEEDS ARE IN THE COMMUNITY 785 00:29:11,266 --> 00:29:12,434 AND UNDERSTAND WHAT KINDS OF 786 00:29:12,434 --> 00:29:14,002 INSIGHTS PEOPLE ARE LOOK FOR, 787 00:29:14,002 --> 00:29:15,503 FOR HOW THE COMPLIMENTARY 788 00:29:15,503 --> 00:29:17,505 PROGRAM CAN REALLY PROVIDE 789 00:29:17,505 --> 00:29:18,440 OPPORTUNITIES AND START TO 790 00:29:18,440 --> 00:29:19,707 ADDRESS ROAD BLOCKS THAT ARE 791 00:29:19,707 --> 00:29:21,876 CURRENTLY ONGOING IN THE NOVEL 792 00:29:21,876 --> 00:29:23,978 APPROACH METHODOLOGIES 793 00:29:23,978 --> 00:29:25,480 DEVELOPMENT. SO THE THREE ROUND 794 00:29:25,480 --> 00:29:26,815 TABLES OR LISTENING SESSIONS 795 00:29:26,815 --> 00:29:28,416 THAT WILL BE CONDUCTED ARE SHOWN 796 00:29:28,416 --> 00:29:33,221 HERE. ALL IN OCTOBER. THERE ARE 797 00:29:33,221 --> 00:29:34,355 SECTIONED OUT BY DIFFERENT 798 00:29:34,355 --> 00:29:35,824 SECTORS THAT WILL BE LISTENING 799 00:29:35,824 --> 00:29:37,959 TO AT THOSE TIMES. IF YOU ARE 800 00:29:37,959 --> 00:29:39,294 INTERESTED IN JOINING ANY OF 801 00:29:39,294 --> 00:29:41,029 THOSE TAKE A NOTE OF THE QR CODE 802 00:29:41,029 --> 00:29:43,798 HERE AND YOU CAN REGISTER FOR 803 00:29:43,798 --> 00:29:45,233 THOSE ACTIVITIES. THEN AFTER 804 00:29:45,233 --> 00:29:46,734 THAT WILL BE THINKING ABOUT A 805 00:29:46,734 --> 00:29:48,103 BROADER LANDSCAPE ANALYSIS, AND 806 00:29:48,103 --> 00:29:51,806 THIS IS GOING TO BE IN 807 00:29:51,806 --> 00:29:52,774 CONJUNCTION WITH THE ACTIVITIES 808 00:29:52,774 --> 00:29:54,609 THAT ARE ACTUALLY ONGOING IN THE 809 00:29:54,609 --> 00:29:56,444 ADVISORY COMMITTEE TO THE 810 00:29:56,444 --> 00:29:58,680 DIRECTOR. THAT -- WHO HAS A 811 00:29:58,680 --> 00:30:00,515 WORKING GROUP DEDICATED TO NOVEL 812 00:30:00,515 --> 00:30:02,817 APPROACH METHODOLOGIES. SO THEY 813 00:30:02,817 --> 00:30:04,919 HAVE BEEN DOING WORK OVER THE 814 00:30:04,919 --> 00:30:06,821 LAST SIX MONTHS, NINE MONTHS, I 815 00:30:06,821 --> 00:30:08,523 GUESS SEPTEMBER, THE LAST NINE 816 00:30:08,523 --> 00:30:09,991 MONTHS AND THEY HAVE A FEW MORE 817 00:30:09,991 --> 00:30:11,459 MONTHS TO GO THEN PROVIDE 818 00:30:11,459 --> 00:30:12,760 RECOMMENDATIONS TO THE NIH AT 819 00:30:12,760 --> 00:30:14,562 THE END OF THE YEAR. BASED ON 820 00:30:14,562 --> 00:30:15,830 THOSE RECOMMENDATIONS WE WILL 821 00:30:15,830 --> 00:30:17,832 INTEGRATE THAT INTO THE -- WHAT 822 00:30:17,832 --> 00:30:19,534 WE ARE DEVELOPING FOR 823 00:30:19,534 --> 00:30:21,469 COMPLIMENTARY, SO WE CAN REALLY 824 00:30:21,469 --> 00:30:23,404 GENERATE A VERY WELL INFORMED 825 00:30:23,404 --> 00:30:24,772 AND ROBUST PROGRAM FOR THE 826 00:30:24,772 --> 00:30:26,975 COMMON FUND PROGRAM TO PURSUE 827 00:30:26,975 --> 00:30:28,610 THE NEXT SEVERAL YEARS. STAY 828 00:30:28,610 --> 00:30:30,378 TUNED. AND WE ARE EXCITED THAT 829 00:30:30,378 --> 00:30:32,280 THE WORK THAT WE HAVE BEEN DOING 830 00:30:32,280 --> 00:30:33,648 HAS BEEN ABLE TO FOLD INTO 831 00:30:33,648 --> 00:30:36,584 SOMETHING OF THIS NATURE. WE ARE 832 00:30:36,584 --> 00:30:39,454 GRATIFIED TO SEE THAT WORK. ONE 833 00:30:39,454 --> 00:30:42,724 LAST THING TO HIGHLIGHT THAT HAS 834 00:30:42,724 --> 00:30:45,627 ACTUALLY COME TO A CULMINATION 835 00:30:45,627 --> 00:30:47,529 OVER MORE THAN FIVE YEARS OF 836 00:30:47,529 --> 00:30:49,430 WORK INCLUDING DURING THE 837 00:30:49,430 --> 00:30:51,266 PANDEMIC, THIS WAS STARTED WITH 838 00:30:51,266 --> 00:30:53,368 MY PREDECESSOR CHRIS AUSTIN AND 839 00:30:53,368 --> 00:30:54,469 VARIETY OF OTHER FOLKS AT 840 00:30:54,469 --> 00:30:57,372 NATIONAL ACADEMIES OF MEDICINE. 841 00:30:57,372 --> 00:30:59,073 WHEN I JOIN AD FEW YEARS AGO 842 00:30:59,073 --> 00:31:03,278 DURING THE PANDEMIC I AM PART OF 843 00:31:03,278 --> 00:31:04,412 DRUG DISCOVERY DEVELOPMENT 844 00:31:04,412 --> 00:31:05,580 TRANSLATION FOR THE NATIONAL 845 00:31:05,580 --> 00:31:07,048 ACADEMIES SO PART OF MY 846 00:31:07,048 --> 00:31:09,017 AGREEMENT WAS TO HELP WORK 847 00:31:09,017 --> 00:31:10,885 THROUGH AND FINALIZE THIS 848 00:31:10,885 --> 00:31:12,887 FRAMEWORK FOR ASSESSING CLINICAL 849 00:31:12,887 --> 00:31:15,857 TRIALS SITE READINESS. THIS IS 850 00:31:15,857 --> 00:31:17,559 SEEN AS A REAL NEED WITHIN THE 851 00:31:17,559 --> 00:31:18,993 COMMUNITY TO HELP PROVIDE 852 00:31:18,993 --> 00:31:21,462 GUIDANCE AND RESOURCES FOR 853 00:31:21,462 --> 00:31:22,830 SIGHTS OUT THERE DOING CLINICAL 854 00:31:22,830 --> 00:31:24,532 TRIALS. HOW WE CAN START TO 855 00:31:24,532 --> 00:31:28,002 BRING THESE TOGETHER TO MAKE 856 00:31:28,002 --> 00:31:30,972 THEM MORE STREAMLINED FOR A 857 00:31:30,972 --> 00:31:32,140 VARIETY OF REASONS. THERE ARE 858 00:31:32,140 --> 00:31:34,342 FOUR PIECES THAT WILL BE 859 00:31:34,342 --> 00:31:36,244 PUBLISHED ON THIS COMPENDIUM 860 00:31:36,244 --> 00:31:37,946 GROUP OF PAPERS BEING PUT 861 00:31:37,946 --> 00:31:39,747 FORWARD. THE MAIN IS FRAMEWORK 862 00:31:39,747 --> 00:31:41,216 FOR ASSESSING CLINICAL TRIAL 863 00:31:41,216 --> 00:31:43,051 SITE READINESS AT THE TOP BUT 864 00:31:43,051 --> 00:31:45,420 THERE ARE THREE PARALLEL PAPERS 865 00:31:45,420 --> 00:31:48,022 OR PERSPECTIVES. ONE IS ACTUALLY 866 00:31:48,022 --> 00:31:49,958 CONSIDERATIONS FROM THE CTSA 867 00:31:49,958 --> 00:31:51,826 PROGRAM. AND SO THERE ARE IS -- 868 00:31:51,826 --> 00:31:54,495 I WILL TALK MORE ABOUT THAT. 869 00:31:54,495 --> 00:31:55,730 THEN THERE WILL BE ONE -- THERE 870 00:31:55,730 --> 00:31:57,532 ARE TWO IN PRESS, ONE ON THE 871 00:31:57,532 --> 00:32:00,768 DIVERSITY EQUITY INCLUSION 872 00:32:00,768 --> 00:32:02,303 ACCESS NEEDS AND THINKING ABOUT 873 00:32:02,303 --> 00:32:03,404 CLINICAL TRIALS SITE READINESS 874 00:32:03,404 --> 00:32:06,441 SPECIFICALLY. AND THEN ALSO ON 875 00:32:06,441 --> 00:32:07,742 DECENTRALIZED TRIALS SO TWO 876 00:32:07,742 --> 00:32:09,210 OTHER PERSPECTIVES COMING OUT 877 00:32:09,210 --> 00:32:10,278 BUT CURRENTLY IN PRESS SO I 878 00:32:10,278 --> 00:32:11,346 WASN'T ABLE TO SHOW YOU THAT 879 00:32:11,346 --> 00:32:16,084 TODAY. SO A LITTLE BIT MORE 880 00:32:16,084 --> 00:32:18,653 WHAT THIS WORK WAS ALL ABOUT WAS 881 00:32:18,653 --> 00:32:20,188 TRYING TO UNDERSTAND WHAT THIS 882 00:32:20,188 --> 00:32:23,324 FRAMEWORK SHOULD LOOK LIKE. SO 883 00:32:23,324 --> 00:32:24,325 THERE WERE SOME FOUNDATIONAL 884 00:32:24,325 --> 00:32:27,228 COMMON PRINCIPLES IDENTIFIED AS 885 00:32:27,228 --> 00:32:28,296 CORE TO SITE READINESS FOR 886 00:32:28,296 --> 00:32:30,465 CLINICAL TRIALS. A CULTURE OF 887 00:32:30,465 --> 00:32:32,967 QUALITY AND THINKING HOW TO BE 888 00:32:32,967 --> 00:32:36,070 IN THIS CONTINUOUS NEED OF 889 00:32:36,070 --> 00:32:37,005 INCREMENTAL IMPROVEMENT OVER THE 890 00:32:37,005 --> 00:32:39,374 COURSE OF DOING CLINICAL TRIALS 891 00:32:39,374 --> 00:32:41,976 FOR ANY SITE OUT THERE. TO BE 892 00:32:41,976 --> 00:32:43,745 THINKING HOW PERSON CENTEREDNESS 893 00:32:43,745 --> 00:32:45,847 SHOULD BE AT THE CENTER OF 894 00:32:45,847 --> 00:32:47,815 CLINICAL TRIAL SITE READINESS, 895 00:32:47,815 --> 00:32:49,651 TO BE RESPECTING FOR RESPECTING 896 00:32:49,651 --> 00:32:51,819 OF HUMAN RIGHTS AND WELFARE FOR 897 00:32:51,819 --> 00:32:52,620 TRIAL PARTICIPANTS AND MAKING 898 00:32:52,620 --> 00:32:55,423 SURE THAT THAT IS WELL INFORMED 899 00:32:55,423 --> 00:32:57,492 ENGAGED. AND CLINICAL RESEARCH 900 00:32:57,492 --> 00:32:59,327 LITERACY, THINKING ABOUT HOW TO 901 00:32:59,327 --> 00:33:01,729 ENGAGE AND INFORM STAKEHOLDERS 902 00:33:01,729 --> 00:33:04,098 THAT ABOUT THE SITE READINESS 903 00:33:04,098 --> 00:33:06,734 PROGRAMS AND TO ELEVATE 904 00:33:06,734 --> 00:33:07,268 CONFIDENCE IN THE CLINICAL 905 00:33:07,268 --> 00:33:10,171 TRIALS CONDUCTED. SO THAT IS 906 00:33:10,171 --> 00:33:12,407 THE WRAPPER AROUND THEN SIX 907 00:33:12,407 --> 00:33:14,042 DIFFERENT DOMAINS OF CLINICAL 908 00:33:14,042 --> 00:33:18,479 TRIALS SITE READINESS THAT THIS 909 00:33:18,479 --> 00:33:19,514 BODY HAS COME TOGETHER ON. 910 00:33:19,514 --> 00:33:23,184 THROUGH A VARIETY OF LOOKING AT 911 00:33:23,184 --> 00:33:24,986 OVER 200 OF THESE SORTS OF 912 00:33:24,986 --> 00:33:26,854 FACTORS THAT GO INTO CLINICAL 913 00:33:26,854 --> 00:33:28,656 TRIAL SITE READINESS, LOOKING AT 914 00:33:28,656 --> 00:33:30,325 WHAT THE IS CRUX OF THOSE WHAT 915 00:33:30,325 --> 00:33:33,561 IS COMMON AMONG THEM. GOING 916 00:33:33,561 --> 00:33:35,797 THROUGH A SEMIDELPHI METHOD TO 917 00:33:35,797 --> 00:33:37,398 WHITTLE THIS DOWN TO THE VERY 918 00:33:37,398 --> 00:33:40,968 IMPORTANT PIECES HERE. SO 919 00:33:40,968 --> 00:33:41,769 RESEARCH TEAMS INFRASTRUCTURE 920 00:33:41,769 --> 00:33:44,005 STUDY MANAGEMENT, DATA 921 00:33:44,005 --> 00:33:47,542 COLLECTION MANAGEMENT, QUALITY 922 00:33:47,542 --> 00:33:49,777 OVER SIGHT, ETHICS AND SAFETY 923 00:33:49,777 --> 00:33:51,346 ARE THE SIX DOMAINS OF FRAMEWORK 924 00:33:51,346 --> 00:33:52,480 FOR ASSESSING CLINICAL TRIAL 925 00:33:52,480 --> 00:33:55,850 SIDE READINESS. IN THE PAPER IT 926 00:33:55,850 --> 00:33:57,085 OUTLINES VERY SPECIFIC KEY 927 00:33:57,085 --> 00:33:59,987 OBJECTIVES UNDER EACH OF THESE 928 00:33:59,987 --> 00:34:04,425 SIX DOMAINS THAT WE PROVIDE TO 929 00:34:04,425 --> 00:34:06,227 ANY CLINICAL TRIAL SITE OR ANY 930 00:34:06,227 --> 00:34:08,162 SITE LOOKING TO BE CLINICAL 931 00:34:08,162 --> 00:34:09,464 TRIAL SITE READY. SO THEY CAN 932 00:34:09,464 --> 00:34:10,498 PERFORM THEIR OWN 933 00:34:10,498 --> 00:34:11,566 SELF-ASSESSMENT IF YOU WILL. 934 00:34:11,566 --> 00:34:12,934 WHERE DO THEY STAND? WHERE ARE 935 00:34:12,934 --> 00:34:15,603 THEY IN THE STATUS OF THESE KEY 936 00:34:15,603 --> 00:34:17,205 DOMAINS AND HOW DO THEY NEED TO 937 00:34:17,205 --> 00:34:18,373 ELEVATE THOSE OR MAKE SURE THEY 938 00:34:18,373 --> 00:34:21,743 ARE CONTINUING TO MAINTAIN THE 939 00:34:21,743 --> 00:34:23,111 HIGH LEVELS THEY ARE AT 940 00:34:23,111 --> 00:34:25,213 CURRENTLY. THIS IS THE IDEA, FOR 941 00:34:25,213 --> 00:34:28,483 EXISTING SITES, IT IS ALSO FOR 942 00:34:28,483 --> 00:34:31,819 NEW SITES TO HELP COMING ON 943 00:34:31,819 --> 00:34:36,190 BOARD PART OF CLINICAL TRIAL 944 00:34:36,190 --> 00:34:40,228 INFRASTRUCTURE I WANT TO 945 00:34:40,228 --> 00:34:42,497 HIGHLIGHT FROM THE CTSA PROGRAM, 946 00:34:42,497 --> 00:34:43,765 SPECIFIC COMMENTS MADE IN TERMS 947 00:34:43,765 --> 00:34:45,633 OF DEVELOPING STANDARDIZED 948 00:34:45,633 --> 00:34:47,368 OPERATING PROCEDURES WITHIN 949 00:34:47,368 --> 00:34:49,070 INSTITUTIONS AN COMMUNICATING 950 00:34:49,070 --> 00:34:50,571 WITH THE CLINICAL TRIAL SITES 951 00:34:50,571 --> 00:34:52,006 WITHIN INSTITUTIONS AT THE 952 00:34:52,006 --> 00:34:53,207 ACADEMIC MEDICAL ORGANIZATIONS, 953 00:34:53,207 --> 00:34:54,175 HAVING LEADERSHIP UNDERSTAND 954 00:34:54,175 --> 00:34:56,110 WHAT THE NEEDS ARE TO MAKE SURE 955 00:34:56,110 --> 00:34:57,612 THOSE ARE MAINTAINED. 956 00:34:57,612 --> 00:34:58,980 DEVELOPING STANDARDIZED THEM 957 00:34:58,980 --> 00:35:00,982 PLACE IS IMPORTANT AND AS WELL 958 00:35:00,982 --> 00:35:03,418 AS IMPLEMENTATION PLANS FOR 959 00:35:03,418 --> 00:35:06,053 TRANSITIONING TO NEW PROCEDURES. 960 00:35:06,053 --> 00:35:09,390 SO IF AND WHEN OR IF SAY 961 00:35:09,390 --> 00:35:11,559 PANDEMIC WERE TO COME ACROSS OUR 962 00:35:11,559 --> 00:35:13,461 WAY AGAIN, PERHAPS THESE ARE 963 00:35:13,461 --> 00:35:14,595 SOPs THAT CAN BE PULLED OFF 964 00:35:14,595 --> 00:35:19,834 THE SHELF, DUSTED OFF A BIT, AND 965 00:35:19,834 --> 00:35:20,968 REFINED TO MEET THE NEEDS OF 966 00:35:20,968 --> 00:35:22,003 WHAT IS HAPPENING SO THIS WOULD 967 00:35:22,003 --> 00:35:25,440 BE CERTAINLY THE IDEA BUT YOU 968 00:35:25,440 --> 00:35:28,009 DON'T NEED A PANDEMIC FOR ANY 969 00:35:28,009 --> 00:35:28,943 NEW CLINICAL TRIAL. THESE ARE 970 00:35:28,943 --> 00:35:29,777 PLANS YOU CAN CONTINUE TO 971 00:35:29,777 --> 00:35:34,982 MAINTAIN. REALLY THINKING ABOUT 972 00:35:34,982 --> 00:35:37,785 THESE HOW TO HARMON RECOGNIZE 973 00:35:37,785 --> 00:35:39,387 DOCUMENTATION ACROSS THE SITES O 974 00:35:39,387 --> 00:35:41,689 SO THERE'S INTEROPERABILITY 975 00:35:41,689 --> 00:35:43,925 ACROSS THE INFRASTRUCTURE 976 00:35:43,925 --> 00:35:45,593 GLOBALLY OF THE CLINICAL TRIAL 977 00:35:45,593 --> 00:35:46,928 ENTERPRISE. THESE ARE KEY 978 00:35:46,928 --> 00:35:49,730 FEATURES THE CTSA PROGRAM CAME 979 00:35:49,730 --> 00:35:51,599 OUT WITH, I WANT TO HIGHLIGHT 980 00:35:51,599 --> 00:35:52,967 THE QR CODE FOR THIS 981 00:35:52,967 --> 00:35:54,302 PUBLICATION. WHY IMPORTANT? 982 00:35:54,302 --> 00:35:55,903 THERE'S TWO MORE PUBLICATIONS 983 00:35:55,903 --> 00:35:57,738 COMING TO STAY TUNED FOR THOSE. 984 00:35:57,738 --> 00:36:01,075 BUT I THINK THIS IS IMPORTANT, I 985 00:36:01,075 --> 00:36:03,110 REALLY WANT TO RELATE TO THIS 986 00:36:03,110 --> 00:36:04,512 GROUP SPECIFICALLY, HAVING THIS 987 00:36:04,512 --> 00:36:08,015 PER SHARED UNDERSTANDING OF SITE 988 00:36:08,015 --> 00:36:10,184 READINESS WILL HELP US BE ABLE 989 00:36:10,184 --> 00:36:11,886 TO HAVE A LOT MORE CONFIDENCE 990 00:36:11,886 --> 00:36:14,121 NOT JUST WITHIN OURSELVES BUT 991 00:36:14,121 --> 00:36:16,557 STUDY SPONSORS AND ALSO THE 992 00:36:16,557 --> 00:36:18,159 CLINICAL TRIAL PARTICIPANTS WHO 993 00:36:18,159 --> 00:36:19,961 RELY ON US TO CONDUCT THESE 994 00:36:19,961 --> 00:36:23,564 TRIALS AND PROVIDE EVIDENCE FOR 995 00:36:23,564 --> 00:36:24,999 SUPPORT OR NOT FOR WHAT WE 996 00:36:24,999 --> 00:36:29,971 TRYING TO ADDRE ADDRESS. WE HOPE 997 00:36:29,971 --> 00:36:32,139 FRAMEWORK LOWERS BARRIERS FOR 998 00:36:32,139 --> 00:36:34,942 ENTRY FOR SITES TO DO SELF 999 00:36:34,942 --> 00:36:36,611 ASSESSMENT, WHAT THEY NEED TO DO 1000 00:36:36,611 --> 00:36:38,212 FOR CLINICAL TRIAL SITE 1001 00:36:38,212 --> 00:36:40,214 READINESS. MAINTAINS CONFIDENCE, 1002 00:36:40,214 --> 00:36:41,349 AND ALSO HELP INCREASE DIVERSITY 1003 00:36:41,349 --> 00:36:42,984 AND INCREASE THE 1004 00:36:42,984 --> 00:36:43,784 GENERALIZABILITY OF CLINICAL 1005 00:36:43,784 --> 00:36:46,988 TRIALS THAT WE SUPPORT. SO I 1006 00:36:46,988 --> 00:36:49,891 HOPE THESE TYPES OF OR THIS 1007 00:36:49,891 --> 00:36:51,058 FRAMEWORK AND THE TYPES OF IDEAS 1008 00:36:51,058 --> 00:36:52,627 THAT ARE GENERATED HERE ARE 1009 00:36:52,627 --> 00:36:55,830 REALLY EMBRACED BY THE COMMUNITY 1010 00:36:55,830 --> 00:36:57,098 AND MAYBE WE CAN EVEN TAKE A 1011 00:36:57,098 --> 00:36:58,699 STEP FURTHER AND PROVIDE BEST 1012 00:36:58,699 --> 00:37:01,536 PRACTICES AS WE START TO LEARN 1013 00:37:01,536 --> 00:37:03,671 MORE AND KICK THE TIRES HOW 1014 00:37:03,671 --> 00:37:05,573 IMPORTANT EACH OF THESE ARE. SO 1015 00:37:05,573 --> 00:37:07,742 I HOPE THAT THIS WILL BE HELPFUL 1016 00:37:07,742 --> 00:37:11,479 OF VARIETY OF YOUR PARTNERS AND 1017 00:37:11,479 --> 00:37:12,980 COMMUNITIES. SO I WANT TO TAKE A 1018 00:37:12,980 --> 00:37:17,818 FEW MINUTES AND END ON THE 1019 00:37:17,818 --> 00:37:19,420 STRATEGIC PLAN PROCESS. I WANT 1020 00:37:19,420 --> 00:37:21,055 TO HAVE A FEW SLIDES TO CATCH 1021 00:37:21,055 --> 00:37:22,323 YOU UP ON WHAT WE HAVE BEEN 1022 00:37:22,323 --> 00:37:23,925 DOING SINCE WE MET. WE ARE NOW 1023 00:37:23,925 --> 00:37:25,860 AT THE POINT WE HAVE WRITTEN RFI 1024 00:37:25,860 --> 00:37:28,396 AND THE RFI IS OUT ON THE 1025 00:37:28,396 --> 00:37:30,431 STREET. AND THAT IS A QR CODE 1026 00:37:30,431 --> 00:37:34,969 FOR THE RFI, YOU CAN TAKE A 1027 00:37:34,969 --> 00:37:37,138 PICTURE BUT I HAVE MORE QR CODES 1028 00:37:37,138 --> 00:37:39,106 LATER ON THE RFI SO IF MISSED 1029 00:37:39,106 --> 00:37:40,641 NOW YOU CAN GET IT LATER BUT WE 1030 00:37:40,641 --> 00:37:41,909 ARE EXCITED TO BE AT THIS STAGE. 1031 00:37:41,909 --> 00:37:44,378 THE RFI IS INTERIM. AND IT IS 1032 00:37:44,378 --> 00:37:47,582 MEANT TO SAY GOSH, WE HAVE HAD 1033 00:37:47,582 --> 00:37:49,550 NEARLY 50 POUNDS TABLES TO HEAR 1034 00:37:49,550 --> 00:37:51,819 INPUT AND FEEDBACK ON WHAT NCATS 1035 00:37:51,819 --> 00:37:53,754 IS DOING WHERE WE WANT TO GO, 1036 00:37:53,754 --> 00:37:55,022 OUR HIGH LEVEL MORE TREATMENTS 1037 00:37:55,022 --> 00:37:57,258 FOR ALL PEOPLE MORE QUICKLY 1038 00:37:57,258 --> 00:37:58,726 AUDACIOUS GOALS, HOW WE CAN 1039 00:37:58,726 --> 00:37:59,994 ALIGN THOSE WITH HOW WE CAN MOVE 1040 00:37:59,994 --> 00:38:04,966 NEXT. WE ENGAGED 1150 1041 00:38:04,966 --> 00:38:10,705 INDIVIDUALS AND HAD OVER 1700 1042 00:38:10,705 --> 00:38:11,539 UNIQUE COMMENTS DURING THIS 1043 00:38:11,539 --> 00:38:13,441 PROCESS. A ARE THE OF DATA; WE 1044 00:38:13,441 --> 00:38:14,241 DON'T HAVE NATURAL LANGUAGE 1045 00:38:14,241 --> 00:38:15,509 PROCESSING WELL HONED FOR THIS 1046 00:38:15,509 --> 00:38:18,312 PROCESS BUT BEST WE COULD IN 1047 00:38:18,312 --> 00:38:20,715 EMERITUS TEMPLE O'CONNER AND HER 1048 00:38:20,715 --> 00:38:21,849 BRAIN AND TEAM PULLING THIS 1049 00:38:21,849 --> 00:38:22,850 TOGETHER TO MAKE IT HAPPEN. WHAT 1050 00:38:22,850 --> 00:38:26,988 WE HAD A VARIETY OF LISTENING 1051 00:38:26,988 --> 00:38:28,823 SESSIONS WITH A VARIETY OF 1052 00:38:28,823 --> 00:38:29,423 CONSTITUENT SAYS AND I WANT TO 1053 00:38:29,423 --> 00:38:31,325 GIVE YOU A SENSE AND I AT A 1054 00:38:31,325 --> 00:38:32,927 GLANCE SNAP SHOT WHAT WE HEARD. 1055 00:38:32,927 --> 00:38:34,762 SO FOR EACH OF THESE DIFFERENT 1056 00:38:34,762 --> 00:38:36,030 GROUPS OR STAKEHOLDERS WE HAD, 1057 00:38:36,030 --> 00:38:38,165 WE HAD A VARIETY OF TOPICS. YOU 1058 00:38:38,165 --> 00:38:39,867 WILL SEE THOSE TOPICS ON THE 1059 00:38:39,867 --> 00:38:42,837 RIGHT HAND SIDE WHEN YOU HEAR 1060 00:38:42,837 --> 00:38:46,073 1790 UNIQUE COMMENTS WE WERE 1061 00:38:46,073 --> 00:38:49,410 ABLE TO BOIL THEM INTO A ROLE UP 1062 00:38:49,410 --> 00:38:51,379 INTO HIGH TOPIC CONSIDERATIONS. 1063 00:38:51,379 --> 00:38:52,947 SO YOU CAN SEE HOW THOSE 1064 00:38:52,947 --> 00:38:54,548 COMMENTS PLAYED OUT WITH THE 1065 00:38:54,548 --> 00:38:55,516 DIFFERENT LISTENING SESSIONS. T 1066 00:38:55,516 --> 00:39:00,388 SO I WANTED TO JUST GIVE YOU A 1067 00:39:00,388 --> 00:39:03,157 SENSE OF VARIOUS AREAS 1068 00:39:03,157 --> 00:39:04,358 COLLABORATION PART SHIPS, DATA 1069 00:39:04,358 --> 00:39:06,260 SCIENCE, COMMUNITY ENGAGEMENT, 1070 00:39:06,260 --> 00:39:10,231 WORK FORCE DEVELOPMENT, DEIA, 1071 00:39:10,231 --> 00:39:12,767 RARE DISEASE, AND HOW WE SET 1072 00:39:12,767 --> 00:39:14,268 PRIORITIES ALL TOPICS RELAY AND 1073 00:39:14,268 --> 00:39:15,636 COMMON THEMES WE PULLED OUT OF 1074 00:39:15,636 --> 00:39:21,042 THAT. SO AS WE GO FORWARD, THIS 1075 00:39:21,042 --> 00:39:23,010 IS A SPAGHETTI DIAGRAM OF 1076 00:39:23,010 --> 00:39:24,345 INPUTS, SO YOU CAN SEE THE 1077 00:39:24,345 --> 00:39:25,613 PRIORITIZATION START TO SHAKE 1078 00:39:25,613 --> 00:39:27,281 OUT BASED ON THE DIFFERENT 1079 00:39:27,281 --> 00:39:28,582 COMMUNITY NEEDS SO WE CAN START 1080 00:39:28,582 --> 00:39:30,551 TO TAILOR THIS TO THE OTHER 1081 00:39:30,551 --> 00:39:32,486 PROGRAMS NCATS SUPPORTS BUT WE 1082 00:39:32,486 --> 00:39:34,088 WANT TO MAKE SURE THAT WE HAVE 1083 00:39:34,088 --> 00:39:38,025 BEEN HEARD THE COMMUNITY IN THE 1084 00:39:38,025 --> 00:39:38,959 RIGHT WAY SO ESSENTIALLY WE HAVE 1085 00:39:38,959 --> 00:39:43,864 COME UP WITH THIS IDEA OF THE 1086 00:39:43,864 --> 00:39:45,633 DRAFT FRAMEWORK, MORE TREATMENTS 1087 00:39:45,633 --> 00:39:48,002 MORE PEOPLE MORE QUICKLY BUT IT 1088 00:39:48,002 --> 00:39:49,770 TRANSLATES TO THE THREE PURPLE 1089 00:39:49,770 --> 00:39:51,272 SECTION, APPLYING APPROACHES TO 1090 00:39:51,272 --> 00:39:52,973 FOSTER THE IDENTIFICATION AND 1091 00:39:52,973 --> 00:39:55,376 DEVELOPMENT OF ACCESS TO MORE 1092 00:39:55,376 --> 00:39:57,478 TREATMENT. ENABLING PEOPLE TO 1093 00:39:57,478 --> 00:39:58,946 CONTRIBUTE BENEFIT FROM 1094 00:39:58,946 --> 00:40:00,081 TRANSLATIONAL SCIENCE. 1095 00:40:00,081 --> 00:40:01,949 ACCELERATING TRANSLATION BY BOTH 1096 00:40:01,949 --> 00:40:03,050 ADDRESSING THE SCIENTIFIC AND 1097 00:40:03,050 --> 00:40:04,418 OPERATIONAL CHALLENGES. AND OF 1098 00:40:04,418 --> 00:40:05,820 COURSE CROSS CUTTING ALL THOSE 1099 00:40:05,820 --> 00:40:08,856 ARE A VARIETY OF AREAS IN THOSE 1100 00:40:08,856 --> 00:40:10,257 OPERATIONS THAT CUT ACROSS THE 1101 00:40:10,257 --> 00:40:14,729 WORK THAT WE DO. AND HOW TO 1102 00:40:14,729 --> 00:40:18,766 ADVANCE TRANSLATIONAL SCIENCE. 1103 00:40:18,766 --> 00:40:20,501 SO THOSE ARE START TO PUT MEAT 1104 00:40:20,501 --> 00:40:23,237 ON THE BONES WHEN WE GET RFI 1105 00:40:23,237 --> 00:40:24,739 BACK FROM THE COMMUNITY. SO HERE 1106 00:40:24,739 --> 00:40:28,609 AGAIN IS THE PHOTO OF THE RFI. I 1107 00:40:28,609 --> 00:40:32,580 WOULD ENCOURAGE YO YOU TO PLACE 1108 00:40:32,580 --> 00:40:34,181 TAKE A LOOK AT THE REQUEST FOR 1109 00:40:34,181 --> 00:40:35,216 INFORMATION. SEND TO YOUR 1110 00:40:35,216 --> 00:40:36,617 FRIENDS AND COLLEAGUES, WE WANT 1111 00:40:36,617 --> 00:40:37,985 YOUR FEED BECOME AND PAY 1112 00:40:37,985 --> 00:40:39,453 ATTENTION TO SOME OF THE 1113 00:40:39,453 --> 00:40:42,223 QUESTIONS WE ASK THERE. BUT ALSO 1114 00:40:42,223 --> 00:40:43,524 DIDN'T WE HEAR YOU RIGHT? WHAT 1115 00:40:43,524 --> 00:40:44,658 FROM KEY THINGS WE MISS? WE 1116 00:40:44,658 --> 00:40:46,260 DON'T WANT TO REHASH THE WHOLE 1117 00:40:46,260 --> 00:40:49,163 IDEA BUT WE WANT TO MAKE SURE WE 1118 00:40:49,163 --> 00:40:50,531 DIDN'T MISS ANYTHING MAJOR AND 1119 00:40:50,531 --> 00:40:51,832 WE ALSO WANT TO MAKE SURE WE 1120 00:40:51,832 --> 00:40:53,701 HEAR YOU ON HOW WE PRIORITIZE 1121 00:40:53,701 --> 00:40:57,104 THESE ASPECTS AND HOW WE THINK 1122 00:40:57,104 --> 00:41:00,775 ABOUT METRASIZING AS WELL SO 1123 00:41:00,775 --> 00:41:02,476 THESE ARE THE THINGS WE ARE 1124 00:41:02,476 --> 00:41:04,512 ASKING DURING THIS RFI TIME 1125 00:41:04,512 --> 00:41:06,080 FRAME. SO CLOSES NOVEMBER 1 AND 1126 00:41:06,080 --> 00:41:07,214 WE LOOK FORWARD TO REVIEWING 1127 00:41:07,214 --> 00:41:08,816 THAT FEEDBACK AND COMING UP WITH 1128 00:41:08,816 --> 00:41:12,453 THEN OUR FULL PLAN AFTER THAT. 1129 00:41:12,453 --> 00:41:14,188 AFTER THAT OUR TEAM WILL TAKE IT 1130 00:41:14,188 --> 00:41:16,090 FROM THERE AND TRY TO SIT DOWN 1131 00:41:16,090 --> 00:41:17,658 AND DEVELOP IT. IT IS A 1132 00:41:17,658 --> 00:41:19,360 STRATEGIC PLAN, IT IS NOT A 1133 00:41:19,360 --> 00:41:20,928 TACTICAL PLAN BUT WE HOPE THE 1134 00:41:20,928 --> 00:41:22,530 STRATEGIES THAT WE OUTLINE WILL 1135 00:41:22,530 --> 00:41:24,031 PROVIDE A VERY CLEAR OBJECTIVES 1136 00:41:24,031 --> 00:41:25,533 THAT WE ARE LOOKING FORWARD TO 1137 00:41:25,533 --> 00:41:30,104 MAKE PROGRESS. WITH THAT, I 1138 00:41:30,104 --> 00:41:32,373 SUMMARIZE HERE, WE HAD AGAIN A 1139 00:41:32,373 --> 00:41:35,810 VARIETY OF IMPACTFUL ADVANCES 1140 00:41:35,810 --> 00:41:39,346 REFLECTED A LOT BY THE HONORS 1141 00:41:39,346 --> 00:41:41,415 AND RECOGNITION WE RECEIVED, THE 1142 00:41:41,415 --> 00:41:43,317 WORK WE ARE CONTINUING TO DO, 1143 00:41:43,317 --> 00:41:46,253 AND DECENTRALIZED TRIALS, AND 1144 00:41:46,253 --> 00:41:48,155 THE SITE READINESS FRAMEWORK AND 1145 00:41:48,155 --> 00:41:51,992 THE NEW COMPLIMENTARY PROGRAM AS 1146 00:41:51,992 --> 00:41:56,697 WELL. OUR RFI IS OUTS, WE ARE ON 1147 00:41:56,697 --> 00:41:58,566 TRACK FOR THE QUARTER 1 RELEASE 1148 00:41:58,566 --> 00:42:00,367 IN 2024. WITH THAT WE WILL STOP 1149 00:42:00,367 --> 00:42:01,268 THERE AND SEE IF THERE'S 1150 00:42:01,268 --> 00:42:02,970 QUESTIONS BEFORE WE MOVE ON TO 1151 00:42:02,970 --> 00:42:04,305 THE OTHER UPDATES WE WILL BE 1152 00:42:04,305 --> 00:42:07,408 DOING LATER TODAY FROM MIKE 1153 00:42:07,408 --> 00:42:09,410 KURILLA AND DIVISION OF CLINICAL 1154 00:42:09,410 --> 00:42:10,811 INNOVATIONS AND CHRISTINE 1155 00:42:10,811 --> 00:42:12,213 COLVIS, OFFICE OF DRUG 1156 00:42:12,213 --> 00:42:17,051 DEVELOPMENT PARTNERSHIP PROGRAM 1157 00:42:17,051 --> 00:42:17,685 I WILL STOP THERE. ANY 1158 00:42:17,685 --> 00:42:26,927 QUESTIONS? 1159 00:42:26,927 --> 00:42:28,095 >> I HAVE A QUESTION. JUST 1160 00:42:28,095 --> 00:42:30,531 BECAUSE I'M NOT QUITE FAMILIAR. 1161 00:42:30,531 --> 00:42:32,600 YOU MENTIONED IN THE CLINICAL 1162 00:42:32,600 --> 00:42:35,870 TRIALS READINESS FRAMEWORK 1163 00:42:35,870 --> 00:42:39,006 RESEARCH TEAMS AND YOU REFERRED 1164 00:42:39,006 --> 00:42:41,842 LATER ON ABOUT TRYING TO EXPAND 1165 00:42:41,842 --> 00:42:43,510 AND DIVERSIFY THEM. WHAT DOES 1166 00:42:43,510 --> 00:42:47,615 THE WORK FORCE LOOK LIKE RELATES 1167 00:42:47,615 --> 00:42:49,183 TO CLINICAL TRIALS RESEARCH 1168 00:42:49,183 --> 00:42:51,685 TEAMS AND TRIAL LIST, IS THERE A 1169 00:42:51,685 --> 00:42:52,586 SHORTAGE, WHAT DOES THE 1170 00:42:52,586 --> 00:42:53,287 DIVERSITY LOOK LIKE? 1171 00:42:53,287 --> 00:42:58,692 >> GREAT QUESTION. THAT SPECIFIC 1172 00:42:58,692 --> 00:43:05,900 QUESTION NATIONAL ACADEMIES, 1173 00:43:05,900 --> 00:43:08,369 WHAT THEY ARE DOING TOO, WE NEED 1174 00:43:08,369 --> 00:43:09,703 MORE THOUGHT AROUND WHAT THAT 1175 00:43:09,703 --> 00:43:13,207 WORK FORCE LOOKS LIKE. IT IS NOT 1176 00:43:13,207 --> 00:43:16,911 TO SAY THAT THAT WE DON'T 1177 00:43:16,911 --> 00:43:18,812 RECOGNIZE VARIOUS DIVERSITIES 1178 00:43:18,812 --> 00:43:21,248 NEEDING BIOSTATISTICIANS YOU 1179 00:43:21,248 --> 00:43:23,284 NEED CLINICIANS, YOU NEED PEOPLE 1180 00:43:23,284 --> 00:43:24,752 WHO CAN HELP PATIENTS NAVIGATE 1181 00:43:24,752 --> 00:43:28,522 THE PROCESS. PHARMACISTS. YOU 1182 00:43:28,522 --> 00:43:30,624 NEED ALL THE PEOPLE AT TABLE TO 1183 00:43:30,624 --> 00:43:31,792 DEVELOP CLINICAL TRIAL AND 1184 00:43:31,792 --> 00:43:38,032 PROTOCOLS TO MOVE THEM FORWARD. 1185 00:43:38,032 --> 00:43:39,266 SO OUTLEUPPS WHAT THOSE ARE AS 1186 00:43:39,266 --> 00:43:40,968 CAREER DEVELOPMENT PROGRAMS AND 1187 00:43:40,968 --> 00:43:43,737 ENGAGING AND MAKING 1188 00:43:43,737 --> 00:43:44,872 RECOMMENDATIONS TO INSTITUTIONS 1189 00:43:44,872 --> 00:43:46,340 PERHAPS TO HOW TO BUILD THEIR 1190 00:43:46,340 --> 00:43:48,876 PROGRAMS TO SUPPORT MAINTAIN, 1191 00:43:48,876 --> 00:43:53,580 THAT IS ACTUALLY A -- ANOTHER 1192 00:43:53,580 --> 00:43:54,715 NATIONAL ACADEMIES MEETING THAT 1193 00:43:54,715 --> 00:43:57,985 WILL BE HAPPENING LATER THIS 1194 00:43:57,985 --> 00:44:00,254 MONTH. I THINK MIKE KURILLA WILL 1195 00:44:00,254 --> 00:44:03,624 BE THE ONE ATTENDING. MIGHT BE 1196 00:44:03,624 --> 00:44:04,792 SOMEBODY ELSE. BUT WE HAVE A 1197 00:44:04,792 --> 00:44:06,460 ROLE IN THAT TOO, UNFORTUNATELY 1198 00:44:06,460 --> 00:44:07,928 I HAD A CONFLICT SO COULDN'T 1199 00:44:07,928 --> 00:44:10,264 MAKE IT BUT WE ARE EXCITED TO BE 1200 00:44:10,264 --> 00:44:12,933 PART OF THAT TOO BECAUSE IT 1201 00:44:12,933 --> 00:44:14,068 HELPS IDENTIFY HOW WE CAN HELP 1202 00:44:14,068 --> 00:44:18,372 THE COMMUNITIES PREPARE FOR K 1203 00:44:18,372 --> 00:44:20,174 SCHOLARS T SCHOLARS ET CETERA 1204 00:44:20,174 --> 00:44:21,475 AND HELPING DEVELOP THE NEEDS 1205 00:44:21,475 --> 00:44:22,276 AND WHAT THE CLINICAL TRIALS OF 1206 00:44:22,276 --> 00:44:25,713 THE FUTURE LOOKS LIKE. THE IDEA 1207 00:44:25,713 --> 00:44:26,947 OF CONSTANT IMPROVEMENT AND 1208 00:44:26,947 --> 00:44:28,515 ENGAGEMENT OF CLINICAL TRIALS IS 1209 00:44:28,515 --> 00:44:32,152 IMPORTANT FOR THIS VERY IDEA. AS 1210 00:44:32,152 --> 00:44:34,154 WE THINK ABOUT THE TYPICAL 1211 00:44:34,154 --> 00:44:35,823 CLINICAL TRIALS USUALLY HAVE 1212 00:44:35,823 --> 00:44:37,858 BEEN IN METHODS DEVELOPMENT OR 1213 00:44:37,858 --> 00:44:40,027 REGISTRATIONAL CLINICAL TRIALS 1214 00:44:40,027 --> 00:44:43,097 IN TERMS OF SMALL MOLECULE 1215 00:44:43,097 --> 00:44:45,432 MODALITIES. TESTING THEM IN THE 1216 00:44:45,432 --> 00:44:47,134 CLINICAL TRIAL SPACE. WITH NEW 1217 00:44:47,134 --> 00:44:48,369 MODALITIES THAT ARE COMING OUT 1218 00:44:48,369 --> 00:44:50,270 MORE AND MORE, WE ARE HEARING 1219 00:44:50,270 --> 00:44:54,475 ABOUT GENE THERAPIES. ANTISENSE 1220 00:44:54,475 --> 00:44:55,609 OLIGONUCLEOTIDES, GENE EDITING 1221 00:44:55,609 --> 00:44:56,944 THERAPIES. WE NEED TO BE 1222 00:44:56,944 --> 00:44:58,278 PREPARED FOR THE KINDS OF 1223 00:44:58,278 --> 00:44:59,513 CLINICAL TRIALS AND RESEARCH 1224 00:44:59,513 --> 00:45:01,615 NEEDED TO SUPPORT THOSE 1225 00:45:01,615 --> 00:45:04,485 ACTIVITIES. SO THAT CONSTANT 1226 00:45:04,485 --> 00:45:05,652 IMPROVEMENT AND ALWAYS CONSTANT 1227 00:45:05,652 --> 00:45:07,087 UNDERSTANDING WHAT THE WORK 1228 00:45:07,087 --> 00:45:12,493 FORCE NEEDS ARE ALONG THE WAY BE 1229 00:45:12,493 --> 00:45:14,094 MORE EFFICIENT TO MAINTAIN THE 1230 00:45:14,094 --> 00:45:15,229 READINESS ASPECTS WE ARE TRYING 1231 00:45:15,229 --> 00:45:21,368 TO GO FOR. IT IS ITERATIVE BUT 1232 00:45:21,368 --> 00:45:21,969 DEFINITELY PART OF THE 1233 00:45:21,969 --> 00:45:26,306 DISCUSSION. MATTHIAS. 1234 00:45:26,306 --> 00:45:28,876 >> THANKS A LOT FOR THE UPDATE 1235 00:45:28,876 --> 00:45:32,079 CERTAINLY CONGRATULATIONS TO 1236 00:45:32,079 --> 00:45:35,416 NCATS STAFF. I THINK FUTURE ON 1237 00:45:35,416 --> 00:45:38,118 CLINICAL TRIAL READINESS IS WE 1238 00:45:38,118 --> 00:45:41,321 ARE SEEING PHILOSOPHY OF 1239 00:45:41,321 --> 00:45:42,990 CLINICAL TRIALS ARE DONE 1240 00:45:42,990 --> 00:45:45,859 INCREMENTALLY CHANGE, HAS CHANGE 1241 00:45:45,859 --> 00:45:50,330 POSITIVE FOR THE WORK FORC FORCO 1242 00:45:50,330 --> 00:45:50,898 GOOD NEWS RECEIVE RESEVERAL 1243 00:45:50,898 --> 00:45:53,634 ACTIVITY WHICH COVERS MANY 1244 00:45:53,634 --> 00:45:56,136 DOMAINS AND ALSO MORE LATER THIS 1245 00:45:56,136 --> 00:45:57,571 AFTERNOON WE WILL HEAR 1246 00:45:57,571 --> 00:45:58,906 INNOVATIVE SOLUTIONS. IT IS 1247 00:45:58,906 --> 00:46:04,645 CLEAR THAT ALL THOSE TOOLS 1248 00:46:04,645 --> 00:46:06,647 PARTICULARLY MINORITIES, 1249 00:46:06,647 --> 00:46:07,915 PARTICULARLY BRINGING STUDIES TO 1250 00:46:07,915 --> 00:46:09,483 PEOPLE AND MORE PEOPLE TO 1251 00:46:09,483 --> 00:46:13,087 STUDIES, WITH RESPECT TO THEM, 1252 00:46:13,087 --> 00:46:14,655 SO OTHER COMMON DISEASES ARE 1253 00:46:14,655 --> 00:46:16,657 ASSAY TO BE DEVELOPED, EXPECTED 1254 00:46:16,657 --> 00:46:24,932 TO CTSA, AS (INDISCERNIBLE) BUT 1255 00:46:24,932 --> 00:46:29,103 ALSO AS PROVIDING ON TOPICS 1256 00:46:29,103 --> 00:46:32,106 (INAUDIBLE). WORK FORCE ISSUE IS 1257 00:46:32,106 --> 00:46:36,610 REAL, IT HAS SIGNIFICANTLY 1258 00:46:36,610 --> 00:46:38,612 ACCELERATED PANDEMICS IN OUR 1259 00:46:38,612 --> 00:46:41,081 FIELD OF KIDNEY RESEARCH, 1260 00:46:41,081 --> 00:46:42,716 SOMETIMES USE AWARD CRISIS THAT 1261 00:46:42,716 --> 00:46:46,920 WE REALLY HAVE NOT PARTICULARLY 1262 00:46:46,920 --> 00:46:50,057 STAFFED TO BRING OUR STUDIES AND 1263 00:46:50,057 --> 00:46:53,660 (INAUDIBLE) WHICH ARE FINALLY 1264 00:46:53,660 --> 00:46:56,029 AVAILABLE TO OUR CLIENTS. THIS 1265 00:46:56,029 --> 00:46:58,432 APPEARS TO LESSER EXTENT TO BE 1266 00:46:58,432 --> 00:47:00,968 THE CASE IN PARTS OF EUROPE, 1267 00:47:00,968 --> 00:47:02,803 JAPAN, THE INFRASTRUCTURE HAS 1268 00:47:02,803 --> 00:47:06,473 RECOVERED MORE QUICKLY. AND IS 1269 00:47:06,473 --> 00:47:08,142 FULLY (INAUDIBLE) COMPARE TO 1270 00:47:08,142 --> 00:47:09,910 WHAT WE HAVE SEEN HERE. ONE 1271 00:47:09,910 --> 00:47:12,412 FOCUS TO KEEP INCLUSIVE 1272 00:47:12,412 --> 00:47:15,048 PARTICULARLY IN TIMES OF 1273 00:47:15,048 --> 00:47:17,918 (INAUDIBLE) NOT ONLY FOCUS ON 1274 00:47:17,918 --> 00:47:20,521 THE M.D. Ph.D. LEVEL 1275 00:47:20,521 --> 00:47:22,890 SCIENTISTS BUT ALSO TO STAFF 1276 00:47:22,890 --> 00:47:24,892 SCIENTISTS. THOSE ARE THE ONES 1277 00:47:24,892 --> 00:47:29,730 WHO IN OUR EXPERIENCES RIGHT NOW 1278 00:47:29,730 --> 00:47:33,066 MANY ACTIVITIES SO FINDING WAYS 1279 00:47:33,066 --> 00:47:35,269 TO BUILD CARRIER (INAUDIBLE) 1280 00:47:35,269 --> 00:47:37,638 EXCITING INNOVATIVE AND WHO HAVE 1281 00:47:37,638 --> 00:47:39,606 SECURITY ATTACHED TO THEM, 1282 00:47:39,606 --> 00:47:41,975 SOMETHING I THINK NCATS MIGHT BE 1283 00:47:41,975 --> 00:47:44,811 ONE OF THE TREATMENTS. 1284 00:47:44,811 --> 00:47:45,445 >> THANK YOU VERY MUCH FOR THAT 1285 00:47:45,445 --> 00:47:49,716 COMMENT. YOU ARE EXACTLY RIGHT. 1286 00:47:49,716 --> 00:47:51,451 THAT SOMETHING WE HAVE TALKED 1287 00:47:51,451 --> 00:47:53,787 ABOUT THROUGH THE NATIONAL 1288 00:47:53,787 --> 00:47:55,822 ACADEMIES IS EXACTLY IDEA OF HOW 1289 00:47:55,822 --> 00:47:57,558 TO BUILD AND SUSTAIN THOSE 1290 00:47:57,558 --> 00:47:59,259 CAREER PATHS THAT ARE NOT 1291 00:47:59,259 --> 00:48:01,695 M.D.s AND Ph.D.s. HIGH 1292 00:48:01,695 --> 00:48:06,099 LEVEL DEGREES. THESE ARE 1293 00:48:06,099 --> 00:48:07,234 CRITICAL CAREER POSITIONS THAT 1294 00:48:07,234 --> 00:48:09,536 ENABLE A VERY ROBUST CLINICAL 1295 00:48:09,536 --> 00:48:11,805 TRIAL WORK FORCE. MAKING THOSE 1296 00:48:11,805 --> 00:48:13,473 ATTRACTIVE TO PEOPLE IS 1297 00:48:13,473 --> 00:48:15,375 SOMETHING THAT IS OF INTEREST 1298 00:48:15,375 --> 00:48:17,044 WITH THAT GROUP AND HAS BEEN 1299 00:48:17,044 --> 00:48:19,179 DISCUSSED. I AGREE WITH YOU AS 1300 00:48:19,179 --> 00:48:21,515 WELL, THIS IS PERHAPS AN AREA 1301 00:48:21,515 --> 00:48:23,083 WHERE NCATS CAN PLAY A ROLE 1302 00:48:23,083 --> 00:48:25,219 SUPPORTING SOME OF THAT 1303 00:48:25,219 --> 00:48:28,722 DEVELOPMENT. I APPRECIATE THAT 1304 00:48:28,722 --> 00:48:32,793 COMMENT FOR SURE. FOR THE 1305 00:48:32,793 --> 00:48:36,730 CLINICAL TRIAL SITE READINESS, 1306 00:48:36,730 --> 00:48:38,966 NOW THIS IS COMING OUT I HOPE 1307 00:48:38,966 --> 00:48:41,335 THAT WE WILL START TO HEAR HOW 1308 00:48:41,335 --> 00:48:43,971 IT IS HELPED INFORM OR SHAPE 1309 00:48:43,971 --> 00:48:45,606 WHAT PEOPLE ARE DOING ON BOOTS 1310 00:48:45,606 --> 00:48:47,441 ON THE GROUND HOW THEY ARE 1311 00:48:47,441 --> 00:48:48,442 THINKING ABOUT THAT SO WE CAN 1312 00:48:48,442 --> 00:48:51,078 START TO INSTANTIATE THEM MORE, 1313 00:48:51,078 --> 00:48:54,881 PERHAPS AS BEST PRACTICES AS I 1314 00:48:54,881 --> 00:48:56,617 MENTIONED. AND THOSE ARE AREAS 1315 00:48:56,617 --> 00:48:59,019 WE CAN MAKE SURE WE WILL PROVIDE 1316 00:48:59,019 --> 00:49:00,287 THAT ROBUST NATURE AROUND THE 1317 00:49:00,287 --> 00:49:03,357 CLINICAL TRIAL SO I COULDN'T 1318 00:49:03,357 --> 00:49:07,861 AGREE MORE, YOU MENTIONED THE 1319 00:49:07,861 --> 00:49:11,031 KIDNEY WORK YOU DO AND RARE 1320 00:49:11,031 --> 00:49:14,101 DISEASE SPACE, SO MUCH 1321 00:49:14,101 --> 00:49:15,435 INNOVATION IS NEED IN THAT SPACE 1322 00:49:15,435 --> 00:49:17,771 AND THIS WILL INFORM THAT WORK 1323 00:49:17,771 --> 00:49:23,744 NATIONALLY AND INTERNATIONALLY. 1324 00:49:23,744 --> 00:49:30,550 OTHER COMMENTS? QUESTIONS? 1325 00:49:30,550 --> 00:49:32,352 >> JUST A COMMENT ON THE LAST 1326 00:49:32,352 --> 00:49:34,354 COMMENT. I DO AGREE, THESE 1327 00:49:34,354 --> 00:49:37,658 POSITION PAPERS OR THESE 1328 00:49:37,658 --> 00:49:39,693 FRAMEWORK PAPERS WITH INPUT FROM 1329 00:49:39,693 --> 00:49:43,230 NCATS AND LEADERSHIP FROM NCATS, 1330 00:49:43,230 --> 00:49:45,699 THOSE TEND TO BECOME MATURITY 1331 00:49:45,699 --> 00:49:47,567 MODELS OVER TIME, THAT IS A GOOD 1332 00:49:47,567 --> 00:49:48,035 INVESTMENT. THANK YOU. 1333 00:49:48,035 --> 00:49:51,271 >> THANK YOU VERY MUCH. THIS WAS 1334 00:49:51,271 --> 00:49:54,808 NOT AN EASY TASK. THIS TOOK A 1335 00:49:54,808 --> 00:49:58,011 LOT OF TIME, A LOT OF DEBATE. 1336 00:49:58,011 --> 00:50:01,848 THAT JUST GOES TO THIS POINT 1337 00:50:01,848 --> 00:50:03,784 THAT WE ARE TRYING TO GET TO 1338 00:50:03,784 --> 00:50:11,024 ESSENCE, WHAT CAN WE PROVIDE 1339 00:50:11,024 --> 00:50:12,559 CHEWABLE, DIGESTIBLE, NOT SURE 1340 00:50:12,559 --> 00:50:14,461 OF THE WORLD BUT MEANINGFUL 1341 00:50:14,461 --> 00:50:17,364 IMPACTFUL THAT CAN BE USED AND 1342 00:50:17,364 --> 00:50:20,133 TAKEN UP SO WE SPENT TIME 1343 00:50:20,133 --> 00:50:22,135 THINKING ABOUT THAT, IT IS THE 1344 00:50:22,135 --> 00:50:24,905 COLLECTIVE OFFER PEOPLE WHO ARE 1345 00:50:24,905 --> 00:50:27,774 INVOLVED IN CLINICAL TRIALS BUT 1346 00:50:27,774 --> 00:50:29,109 THAT IS WHAT THE NATIONAL 1347 00:50:29,109 --> 00:50:30,344 ACADEMIES IS ABOUT, BRINGING 1348 00:50:30,344 --> 00:50:31,345 PEOPLE TO TABLE WITH THAT 1349 00:50:31,345 --> 00:50:32,479 EXPERTISE TO MAKE THAT HAPPEN. 1350 00:50:32,479 --> 00:50:35,015 SO I HOPE THIS, MY FINGERS ARE 1351 00:50:35,015 --> 00:50:36,149 CROSSED, IT WILL BE SOMEWHAT 1352 00:50:36,149 --> 00:50:37,584 THAT MATURITY MODEL YOU TALK 1353 00:50:37,584 --> 00:50:38,819 ABOUT, SEEMS LIKE THAT IS WHAT 1354 00:50:38,819 --> 00:50:41,021 THE CTSAs DO REALLY WELL IS 1355 00:50:41,021 --> 00:50:42,456 REALLY DEVELOP THOSE MATURITY 1356 00:50:42,456 --> 00:50:44,691 MODELS. SO THIS IS AN 1357 00:50:44,691 --> 00:50:45,826 OPPORTUNITY FOR US TO LEAD IN 1358 00:50:45,826 --> 00:50:56,370 THAT SPACE FOR SURE. I STAND UP 1359 00:51:01,608 --> 00:51:02,776 TRIAL READINESS INFRASTRUCTURE 1360 00:51:02,776 --> 00:51:08,181 FOR LUPUS. LUPUS RESEARCH 1361 00:51:08,181 --> 00:51:10,283 ALLIANCE I'M PART O. WE PROVIDED 1362 00:51:10,283 --> 00:51:12,185 MONEY AS PRIVATE FUNDER FOR 1363 00:51:12,185 --> 00:51:13,720 CLINICAL TRIAL READINESS AT 57 1364 00:51:13,720 --> 00:51:16,423 ACADEMIC MEDICAL CENTERS. THERE 1365 00:51:16,423 --> 00:51:17,657 IS A VOICE I WANT TO HE WILL 1366 00:51:17,657 --> 00:51:18,892 INVESTIGATE, CO-CHAIR OF 1367 00:51:18,892 --> 00:51:22,996 CLINICAL INVESTIGATORS NETWORK 1368 00:51:22,996 --> 00:51:25,098 IS THE CHAIR OF RHEUMATOLOGY AT 1369 00:51:25,098 --> 00:51:29,002 UCSF. SHE IS ABLE TO TAKE TIME 1370 00:51:29,002 --> 00:51:31,471 TO LEAD AND EMBRACE THE VALUE OF 1371 00:51:31,471 --> 00:51:32,406 CLINICAL TRIALS; OBVIOUS TO 1372 00:51:32,406 --> 00:51:35,442 EVERYONE IN THIS ROOM. SHE HAS 1373 00:51:35,442 --> 00:51:40,213 DECLARED A CRISIS IN CLINICAL 1374 00:51:40,213 --> 00:51:41,515 TRIALS FOR DOING RHEUMATOLOGY 1375 00:51:41,515 --> 00:51:43,083 STUDIES BECAUSE THE YOUNGER 1376 00:51:43,083 --> 00:51:43,784 GENERATION FEELS TOO MUCH 1377 00:51:43,784 --> 00:51:45,786 PRESSURE TO TRY TO BE ON TENURE 1378 00:51:45,786 --> 00:51:49,189 TRACK. SOMEHOW WE NEED THAT 1379 00:51:49,189 --> 00:51:50,624 CONVERSATION WITH THE NATIONAL 1380 00:51:50,624 --> 00:51:54,861 ACADEMIES TO ELEVATE ROLE OF 1381 00:51:54,861 --> 00:51:55,829 CLINICAL TRIALS BECAUSE WE ARE 1382 00:51:55,829 --> 00:51:57,330 HAVING PA TOUGH TIME GETTING THE 1383 00:51:57,330 --> 00:51:58,532 NEXT GENERATION THOSE THERE'S 1384 00:51:58,532 --> 00:52:01,735 FUNDING AVAILABLE THEY ARE NOT 1385 00:52:01,735 --> 00:52:04,104 SEEING IT AS GIVING THEM SKILLS, 1386 00:52:04,104 --> 00:52:05,806 WHAT TO DO HOW TO DO IT, IT IS 1387 00:52:05,806 --> 00:52:07,808 THE WRONG CHOICE IF THEY WANT TO 1388 00:52:07,808 --> 00:52:11,378 BE IN ACADEMIC MEDICINE. IT IS 1389 00:52:11,378 --> 00:52:12,646 DECLARED A CRISIS IN OUR 1390 00:52:12,646 --> 00:52:13,980 CLINICAL TRIAL NETWORK SO I'M 1391 00:52:13,980 --> 00:52:15,115 SHARING THAT AND MAYBE YOU WILL 1392 00:52:15,115 --> 00:52:19,486 HAVE AN OPPORTUNITY TO ELEVATE 1393 00:52:19,486 --> 00:52:20,187 THAT 1394 00:52:20,187 --> 00:52:21,655 >> ABSOLUTELY. THANK YOU FOR 1395 00:52:21,655 --> 00:52:23,523 SHARING THAT.LY KEEP YOU POSTED 1396 00:52:23,523 --> 00:52:24,591 ON THE CONVERSATIONS THAT HAPPEN 1397 00:52:24,591 --> 00:52:26,560 THAT HOPEFULLY CAN REFLECT THAT 1398 00:52:26,560 --> 00:52:33,667 INPUT. AND HIGHLIGHT AREAS WE 1399 00:52:33,667 --> 00:52:35,469 CAN PROVIDE GUIDANCE BACK. SO I 1400 00:52:35,469 --> 00:52:39,339 COULDN'T AGREE WITH YOU MORE, 1401 00:52:39,339 --> 00:52:41,041 BUILDS ON WHAT MATTHIAS 1402 00:52:41,041 --> 00:52:43,243 MENTIONED AS WELL, THIS IS AN 1403 00:52:43,243 --> 00:52:46,813 AREA IN NEED OF MANUFACTURE 1404 00:52:46,813 --> 00:52:49,282 CAREERS NECESSARY TO MAKE THIS 1405 00:52:49,282 --> 00:52:50,750 HAPPEN, SUPER IMPORTANT FOR 1406 00:52:50,750 --> 00:52:53,954 MAKING THIS SUCCESSFUL. 1407 00:52:53,954 --> 00:52:57,324 >> THIS IS PARTNERSHIPS WE 1408 00:52:57,324 --> 00:53:02,496 ESTABLISH OBVIOUSLY AS NIH MUST 1409 00:53:02,496 --> 00:53:07,801 BE TO TAKEN, 65% MEDICAL CENTERS 1410 00:53:07,801 --> 00:53:09,936 BANKRUPTCY ACADEMIC MEDICAL 1411 00:53:09,936 --> 00:53:13,039 CENTERS MEANING NO LEEWAY 1412 00:53:13,039 --> 00:53:16,576 AVAILABLE TO SUPPORT ACADEMIC 1413 00:53:16,576 --> 00:53:18,178 MISSION FOR CLINICAL (INAUDIBLE) 1414 00:53:18,178 --> 00:53:19,513 CUTTING ACROSS ALL MAJOR 1415 00:53:19,513 --> 00:53:21,715 (INAUDIBLE). THAT'S BEEN A 1416 00:53:21,715 --> 00:53:25,819 SIGNIFICANT RESOURCE IN THE PAST 1417 00:53:25,819 --> 00:53:27,020 IF YOU BUILD UP A FRAMEWORK YOU 1418 00:53:27,020 --> 00:53:29,189 HAVE TO INVEST FIRST TO GET YOUR 1419 00:53:29,189 --> 00:53:33,627 OPERATION OFF THE GROUND THEN IT 1420 00:53:33,627 --> 00:53:37,163 CAN HAPPEN BUT COMING UP 1421 00:53:37,163 --> 00:53:39,900 INNOVATIVE SOLUTIONS THE 1422 00:53:39,900 --> 00:53:41,668 INDUSTRY WHO OBVIOUSLY NEEDS US 1423 00:53:41,668 --> 00:53:45,539 CRITICALLY IN THAT PROCESS AS 1424 00:53:45,539 --> 00:53:48,742 WELL. MIGHT DECIDE TO FIND SOME 1425 00:53:48,742 --> 00:53:50,010 CREATIVE SOLUTION BEYOND 1426 00:53:50,010 --> 00:53:54,147 CRITICAL FUNDING SUPPORT. 1427 00:53:54,147 --> 00:53:55,582 >> EXCELLENT SUGGESTIONS ALL 1428 00:53:55,582 --> 00:53:59,619 AROUND. ANY OTHER THOUGHTS OR 1429 00:53:59,619 --> 00:54:04,424 COMMENTS? 1430 00:54:04,424 --> 00:54:06,426 >> DEBATING WHETHER THIS IS 1431 00:54:06,426 --> 00:54:09,696 NCATS MISSION BUT FEEL LIKE 1432 00:54:09,696 --> 00:54:11,031 FALLS WITHIN THE TWO MORE 1433 00:54:11,031 --> 00:54:15,201 PATIENTS MORE QUICKLY ELEMENTS 1434 00:54:15,201 --> 00:54:17,103 THINKING PUBLICATIONS AND WORK 1435 00:54:17,103 --> 00:54:21,942 YOU ARE DOING CTSA AND NATIONAL 1436 00:54:21,942 --> 00:54:22,943 ACADEMIES ALSO THINKING MORE 1437 00:54:22,943 --> 00:54:24,744 RECENT INNOVATIVE APPROVALS 1438 00:54:24,744 --> 00:54:28,648 WITHIN THE RARE DISEASE SPACE. 1439 00:54:28,648 --> 00:54:31,518 OFTEN TIMES THE CLINICAL TRIAL 1440 00:54:31,518 --> 00:54:32,786 SITES BECOME DELIVERY SITES FOR 1441 00:54:32,786 --> 00:54:34,588 THOSE INNOVATIVE THERAPIES. 1442 00:54:34,588 --> 00:54:38,525 THOSE ARE THE SITES THAT ARE 1443 00:54:38,525 --> 00:54:41,428 ABLE AS INNOVATIVE THERAPIES 1444 00:54:41,428 --> 00:54:42,295 BECAUSE THOSE ARE CRITICAL IN 1445 00:54:42,295 --> 00:54:43,530 PLACE GETTING TO THE PATIENT 1446 00:54:43,530 --> 00:54:50,804 MORE QUICKLY. SO CONSIDERED OR 1447 00:54:50,804 --> 00:54:52,606 HAVING THIS IN THE WORKS IS 1448 00:54:52,606 --> 00:54:54,174 TERRIFIC BUT TAKE THE SOPs AND 1449 00:54:54,174 --> 00:54:58,144 TRANSLATE INTO PROTOCOLS FOR 1450 00:54:58,144 --> 00:54:59,312 THERAPEUTIC DELIVERY, THAT CAN 1451 00:54:59,312 --> 00:55:02,115 BE DISSEMINATED BEYOND THIS 1452 00:55:02,115 --> 00:55:09,456 CLINICAL TRIALS SITES. 1453 00:55:09,456 --> 00:55:11,091 >> THAT IS A GREAT SUGGESTION. 1454 00:55:11,091 --> 00:55:16,396 WE PROBABLY COULD DO THAT NOW. 1455 00:55:16,396 --> 00:55:18,598 BUT I THINK FOR EXAMPLE, THE 1456 00:55:18,598 --> 00:55:20,734 WORK WE ARE DOING AT NCATS 1457 00:55:20,734 --> 00:55:23,236 THROUGH THE PEGT PROGRAM AND 1458 00:55:23,236 --> 00:55:24,971 GENE THERAPY CONSORTIUM PROGRAM 1459 00:55:24,971 --> 00:55:29,676 ARE TWO BOTTLES IN A WAY OF 1460 00:55:29,676 --> 00:55:33,046 DELIVERING DIFFERENT THERAPEUTIC 1461 00:55:33,046 --> 00:55:40,453 MODALITIES. RARE DISEASE -- RARE 1462 00:55:40,453 --> 00:55:41,755 DISEASE TRIALS. WE STAND TO 1463 00:55:41,755 --> 00:55:43,523 LEARN THE NEXT COUPLE OF YEARS A 1464 00:55:43,523 --> 00:55:46,326 LOT FROM THAT. THE FACT THAT WE 1465 00:55:46,326 --> 00:55:50,463 ARE DOING THOSE -- THAT WORK AT 1466 00:55:50,463 --> 00:55:53,700 NCATS NIH WITH OUR PARTNERS 1467 00:55:53,700 --> 00:55:55,268 NHGRI NINDS AND CLINICAL CENTER 1468 00:55:55,268 --> 00:55:56,670 AND PUBLIC PRIVATE PARTNERSHIP 1469 00:55:56,670 --> 00:55:59,139 OF THE BGTC PROGRAM WE HAVE AN 1470 00:55:59,139 --> 00:56:01,374 OPPORTUNITY TO PERHAPS REALLY 1471 00:56:01,374 --> 00:56:05,245 TAKE A LOOK AT HOW THOSE WORK, 1472 00:56:05,245 --> 00:56:08,248 WE ARE RIGHT NOW IN MORE OF THE 1473 00:56:08,248 --> 00:56:09,149 PRE-CLINICAL PHASE NOW AND 1474 00:56:09,149 --> 00:56:11,017 GETTING READY TO MOVE INTO THE 1475 00:56:11,017 --> 00:56:12,852 CLINIC THE NEXT COUPLE OF YEARS. 1476 00:56:12,852 --> 00:56:14,454 SO I THINK PROBABLY ABOUT FIVE 1477 00:56:14,454 --> 00:56:16,990 YEARS WE WILL BE ABLE TO WRITE 1478 00:56:16,990 --> 00:56:18,491 SOMETHING THAT LOOKS LIKE THIS 1479 00:56:18,491 --> 00:56:20,593 TO DISSEMINATE TO COMMUNITIES 1480 00:56:20,593 --> 00:56:22,595 THAT COULD POTENTIALLY BE 1481 00:56:22,595 --> 00:56:25,398 HELPFUL AS WELL NOT JUST 1482 00:56:25,398 --> 00:56:27,267 COMMUNITIES BUT THE BROADER 1483 00:56:27,267 --> 00:56:28,601 ACADEMIC MEDICAL ORGANIZATIONS 1484 00:56:28,601 --> 00:56:30,670 THAT ALSO PROVIDE INFRASTRUCTURE 1485 00:56:30,670 --> 00:56:34,074 NEEDED TO MAKE THESE MUCH MORE 1486 00:56:34,074 --> 00:56:38,278 ROBUST. ACROSS THE BOARD. THIS 1487 00:56:38,278 --> 00:56:40,180 IS A GREAT IDEA AND PJ IS TAKING 1488 00:56:40,180 --> 00:56:41,948 NOTE OF THAT AS WELL, WE WILL 1489 00:56:41,948 --> 00:56:49,456 CONSIDER THAT TOO. WE HAVE BEEN 1490 00:56:49,456 --> 00:56:50,990 THINKING DISSEMINATION OF 1491 00:56:50,990 --> 00:56:53,226 PRE-CLINICAL SPACE AND ORPHAN 1492 00:56:53,226 --> 00:56:54,561 DRUG DEVELOPMENT TEMPLATE, THE 1493 00:56:54,561 --> 00:56:56,996 RARE PEDIATRIC DESIGNATION 1494 00:56:56,996 --> 00:56:59,432 TEMPLATE WITH THE FDA. WE HAVE 1495 00:56:59,432 --> 00:57:00,900 MADE THE WORK THAT WE HAVE DONE 1496 00:57:00,900 --> 00:57:02,502 PUBLICLY AVAILABLE SO OTHERS CAN 1497 00:57:02,502 --> 00:57:05,505 LEARN FROM THAT. BUT THE 1498 00:57:05,505 --> 00:57:07,140 MATURITY MODEL THE SITE 1499 00:57:07,140 --> 00:57:10,009 PRACTICES AND READINESS ARE 1500 00:57:10,009 --> 00:57:12,312 STILL KEY NEEDS FOR COMMUNITIES 1501 00:57:12,312 --> 00:57:13,480 TO UNDERSTAND HOW THAT NEEDS TO 1502 00:57:13,480 --> 00:57:15,515 BE TRANSLATED TO RARE DISEASE. 1503 00:57:15,515 --> 00:57:17,183 SO I THINK IT IS A REALLY GOOD 1504 00:57:17,183 --> 00:57:18,885 POINT. THANK YOU. 1505 00:57:18,885 --> 00:57:27,827 >> ALL RIGHT. I THINK DO WE HAVE 1506 00:57:27,827 --> 00:57:32,999 DR. WEGRZYN ON THE LINE? 1507 00:57:32,999 --> 00:57:35,268 >> SHE IS ON THE PHONE. 1508 00:57:35,268 --> 00:57:37,904 >> RENEE I CAN'T SEE YOU YET BUT 1509 00:57:37,904 --> 00:57:40,974 SO GLAD YOU ARE HERE. IT IS MY 1510 00:57:40,974 --> 00:57:43,076 PLEASURE TO INTRODUCE DR. RENEE 1511 00:57:43,076 --> 00:57:45,445 WEGRZYN AS THE FIRST DIRECTOR OF 1512 00:57:45,445 --> 00:57:47,580 THE ADVANCED RESEARCH PROJECTS 1513 00:57:47,580 --> 00:57:50,150 AGENCY FOR HEALTH OR ARPA H AS 1514 00:57:50,150 --> 00:57:52,118 YOU HAVE HEARD IT CALLED. WAR 1515 00:57:52,118 --> 00:57:55,588 PA SHE WAS APPOINTED IN OCTOBER 1516 00:57:55,588 --> 00:57:58,224 11, SO ALMOST A YEAR AGO BY 1517 00:57:58,224 --> 00:58:00,026 PRESIDENT JOE BIDEN. SHE 1518 00:58:00,026 --> 00:58:01,561 PREVIOUSLY SERVED AS THE VICE 1519 00:58:01,561 --> 00:58:03,429 PRESIDENT OF BUSINESS 1520 00:58:03,429 --> 00:58:05,431 DEVELOPMENT AT GINKO BIOWORKS 1521 00:58:05,431 --> 00:58:08,668 AND HEAD OF INNOVATION AT 1522 00:58:08,668 --> 00:58:10,737 CONCENTRIC BY GEEKO SHE FOCUSED 1523 00:58:10,737 --> 00:58:13,106 ON APPLYING SYNTHETIC BIOLOGY TO 1524 00:58:13,106 --> 00:58:14,774 OUTPACE INFECTIOUS DISEASE. 1525 00:58:14,774 --> 00:58:17,944 INCLUDING COVID-19. THROUGH 1526 00:58:17,944 --> 00:58:19,078 BIOMANUFACTURING, VACCINE 1527 00:58:19,078 --> 00:58:20,780 INNOVATION, AND BIOSURVEILLANCE 1528 00:58:20,780 --> 00:58:22,148 OF PATHOGENS AT SCALE THAT, IS 1529 00:58:22,148 --> 00:58:23,950 WHERE THE -- A LOT OF WORK SHE 1530 00:58:23,950 --> 00:58:27,053 HAS DONE COMES FROM. SHE COMES 1531 00:58:27,053 --> 00:58:28,221 WITH EXPERIENCE WORKING FOR TWO 1532 00:58:28,221 --> 00:58:30,023 INSTITUTIONS THAT INSPIRED THE 1533 00:58:30,023 --> 00:58:33,860 CREATION OF ARPA H. AT DARPA 1534 00:58:33,860 --> 00:58:38,064 THEN AT IARPA AS WELL SO DARPA 1535 00:58:38,064 --> 00:58:40,934 IS DEFENSE AND IARPA IS 1536 00:58:40,934 --> 00:58:42,936 INTELLIGENCE ARPA AND PROGRAM 1537 00:58:42,936 --> 00:58:45,071 MANAGER AT DARPA FOR A VARIETY 1538 00:58:45,071 --> 00:58:49,609 OF YEARS, AND SHE HAD A 1539 00:58:49,609 --> 00:58:51,411 PORTFOLIO AROUND SAFE GENES 1540 00:58:51,411 --> 00:58:52,545 PREEMPTIVE EXPRESSION OF 1541 00:58:52,545 --> 00:58:54,280 PROTECTIVE ALLELES AND RESPONSE 1542 00:58:54,280 --> 00:58:56,249 ELEMENTS AS WELL AS VARIETY OF 1543 00:58:56,249 --> 00:58:58,518 WAYS WHICH TO DETECT AND FIGURE 1544 00:58:58,518 --> 00:59:01,421 OUT WAYS TO GENE EDIT DEVELOP 1545 00:59:01,421 --> 00:59:03,223 GENE EDITING TECHNOLOGIES AND 1546 00:59:03,223 --> 00:59:04,791 PROGRAMS. SHE RECEIVED THE 1547 00:59:04,791 --> 00:59:07,360 SUPERIOR PUBLIC SERVICE MEDAL 1548 00:59:07,360 --> 00:59:09,262 FOR WORK IN CONTRIBUTIONS AT 1549 00:59:09,262 --> 00:59:11,264 DARPA AND SO WE ARE REALLY 1550 00:59:11,264 --> 00:59:12,799 EXCITED TO HAVE HER TODAY TO 1551 00:59:12,799 --> 00:59:14,868 JOIN US TO TELL US A LITTLE BIT 1552 00:59:14,868 --> 00:59:16,002 MORE ABOUT WHAT SHE WILL BE 1553 00:59:16,002 --> 00:59:18,605 DOING AT ARPA H, WHAT SHE'S BEEN 1554 00:59:18,605 --> 00:59:19,706 DOING AND WHAT SHE WILL BE 1555 00:59:19,706 --> 00:59:21,908 DOING. I HOPE WE WILL ALSO TALK 1556 00:59:21,908 --> 00:59:23,376 A LITTLE BIT ABOUT SOME OF THE 1557 00:59:23,376 --> 00:59:25,411 WORK WE HAVE BEEN DONE TOGETHER. 1558 00:59:25,411 --> 00:59:27,180 SO IT IS REALLY DELIGHTFUL TO 1559 00:59:27,180 --> 00:59:29,282 SEE YOU HERE, RENEE. WELCOME TO 1560 00:59:29,282 --> 00:59:31,084 OUR NCATS COUNCIL. TAKE IT AWAY 1561 00:59:31,084 --> 00:59:33,987 >> THANK YOU SO MUCH, JONI. 1562 00:59:33,987 --> 00:59:36,489 REALLY APPRECIATE THE TIME TODAY 1563 00:59:36,489 --> 00:59:38,725 TO TALK A LITTLE BIT ABOUT ARPA 1564 00:59:38,725 --> 00:59:42,161 H. I WILL SAY BEEN A DELIGHT TO 1565 00:59:42,161 --> 00:59:44,597 WORK WITH JONI AND TEAM AND HOPE 1566 00:59:44,597 --> 00:59:46,165 THIS IS OUR PARTNERSHIP 1567 00:59:46,165 --> 00:59:47,400 CONTINUES TO GROW AND SOME OF 1568 00:59:47,400 --> 00:59:49,535 THE THINGS YOU HEAR TODAY I HOPE 1569 00:59:49,535 --> 00:59:51,337 INSPIRE YOU TO FIGURE OUT WAYS 1570 00:59:51,337 --> 00:59:54,307 TO WORK TOGETHER EVEN MORE. I 1571 00:59:54,307 --> 00:59:56,009 WILL SPEND MAYBE 15, 20 MINUTES 1572 00:59:56,009 --> 00:59:56,910 TALKING ABOUT THE MISSION AND 1573 00:59:56,910 --> 01:00:00,613 WHAT WE DO AND I THINK I HAVE AT 1574 01:00:00,613 --> 01:00:01,814 LEAST TEN MINUTES FOR QUESTIONS. 1575 01:00:01,814 --> 01:00:04,083 I LOVE THIS TO BE A DYNAMIC Q&A 1576 01:00:04,083 --> 01:00:05,351 SECTION. IF ANYTHING IS UNCLEAR 1577 01:00:05,351 --> 01:00:06,686 FEEL FREE TO INTERRUPT AND I 1578 01:00:06,686 --> 01:00:11,557 WILL TRY TO CLARIFY ALONG THE 1579 01:00:11,557 --> 01:00:15,862 WAY. SO CAN YOU SEE THE DECK? 1580 01:00:15,862 --> 01:00:17,230 YOU GUYS ARE TINY. 1581 01:00:17,230 --> 01:00:18,698 >> YES. 1582 01:00:18,698 --> 01:00:23,069 >> GREAT. PERFECT. SO ARPA H AS 1583 01:00:23,069 --> 01:00:25,104 JONI MENTIONED HAS BEEN AROUND A 1584 01:00:25,104 --> 01:00:27,040 LITTLE OVER A YEAR, I WAS SWORN 1585 01:00:27,040 --> 01:00:30,677 IN LAST OCTOB OCTOBER. LAST MAR, 1586 01:00:30,677 --> 01:00:32,712 2022, PRESIDENT BIDEN CALLED ON 1587 01:00:32,712 --> 01:00:36,482 CONGRESS TO FUND ARPA H 1588 01:00:36,482 --> 01:00:37,283 INITIALLY, REALLY SPEAKING WITH 1589 01:00:37,283 --> 01:00:38,418 THE PRESIDENT ABOUT THIS, HE HAD 1590 01:00:38,418 --> 01:00:40,653 A CLEAR VISION ON APPLYING THE 1591 01:00:40,653 --> 01:00:41,988 DARPA BUSINESS MODEL WHICH IS 1592 01:00:41,988 --> 01:00:43,690 MOVING VERY QUICKLY, HAVING A 1593 01:00:43,690 --> 01:00:46,125 LOT OF AUTONOMY AND DECISION 1594 01:00:46,125 --> 01:00:47,560 MAKING BUT PIN STEAD OF DOING 1595 01:00:47,560 --> 01:00:48,895 THAT FOR DEFENSE TO BE ABLE TO 1596 01:00:48,895 --> 01:00:50,396 DO THAT FOR HEALTH AND MAKE 1597 01:00:50,396 --> 01:00:51,998 REALLY BIG BETS IN HEALTH AND 1598 01:00:51,998 --> 01:00:53,533 CREATE AN AGENCY THAT CAN 1599 01:00:53,533 --> 01:00:55,969 SUPPORT AND DO THAT. I'M TOLD 1600 01:00:55,969 --> 01:00:57,236 JONI THIS BEFORE, I DON'T THINK 1601 01:00:57,236 --> 01:00:59,639 THERE WOULD BE AN ARPA H IF NOT 1602 01:00:59,639 --> 01:01:01,641 FOR NCATS FIRST WHERE YOU CAN 1603 01:01:01,641 --> 01:01:03,009 REALLY SHOW BY HAVING A LITTLE 1604 01:01:03,009 --> 01:01:05,945 BIT OF A DIFFERENT MODEL YOU CAN 1605 01:01:05,945 --> 01:01:07,313 REALLY ACCELERATE SOME OF 1606 01:01:07,313 --> 01:01:08,815 BRINGING THOSE BETTER HEALTH 1607 01:01:08,815 --> 01:01:10,616 OUTCOMES TO AMERICANS. SO WE 1608 01:01:10,616 --> 01:01:13,386 HOPE TO REALLY CAPITALIZE ON THE 1609 01:01:13,386 --> 01:01:16,155 WORK THAT NCATS HAS DONE BUT 1610 01:01:16,155 --> 01:01:18,191 ACCELERATE FURTHER WITH BROADER 1611 01:01:18,191 --> 01:01:23,229 MMANDATE AS WELL. SO OUR MISSIO, 1612 01:01:23,229 --> 01:01:26,065 ONE FIRST THING WALKING INTO 1613 01:01:26,065 --> 01:01:27,433 ARPA H WAS TO CREATE A MISSION 1614 01:01:27,433 --> 01:01:31,237 STATEMENT. TO SPEND A SECOND, 1615 01:01:31,237 --> 01:01:33,740 ACT RATE ACCELERATE BETTER 1616 01:01:33,740 --> 01:01:35,074 HEALTH OUTCOMES FOR EVERYBODY. A 1617 01:01:35,074 --> 01:01:36,976 LOT OF GOOD WORK HAPPENING AT 1618 01:01:36,976 --> 01:01:38,244 UNIVERSITY AND PRIVATE SECTOR, 1619 01:01:38,244 --> 01:01:40,546 IF WE WAITED 20, 25 YEARS THE 1620 01:01:40,546 --> 01:01:42,115 WORK WE INTEND TO FUND WOULD 1621 01:01:42,115 --> 01:01:44,250 BECOME A REALITY BUT WE ARE VERY 1622 01:01:44,250 --> 01:01:45,785 IMPATIENT AND WE DON'T WANT TO 1623 01:01:45,785 --> 01:01:47,787 WAIT. SO THROUGH OUR INVESTMENTS 1624 01:01:47,787 --> 01:01:49,822 ARPA H WANTS TO ACCELERATE 1625 01:01:49,822 --> 01:01:50,790 BRINGING A LOT OF THOSE THINGS 1626 01:01:50,790 --> 01:01:52,959 TO THE MARKET AND INTO THE REAL 1627 01:01:52,959 --> 01:01:54,660 WORLD TO IMPACT HEALTH OUTCOMES. 1628 01:01:54,660 --> 01:01:56,462 SO WE DON'T MEASURE OUR PROGRESS 1629 01:01:56,462 --> 01:01:58,364 BY NUMBER OF COMPANIES WE LAUNCH 1630 01:01:58,364 --> 01:02:01,334 OR NUMBER OF PAPERS WE PUBLISH, 1631 01:02:01,334 --> 01:02:02,802 BUT ACTUAL MEASURABLE CHANGES 1632 01:02:02,802 --> 01:02:05,772 AND QUALITY OF LIFE OF AMERICANS 1633 01:02:05,772 --> 01:02:08,441 AND ALL AMERICANS, IT SHOULD BE 1634 01:02:08,441 --> 01:02:10,576 FOR EVERYONE. SO ACCESSIBILITY 1635 01:02:10,576 --> 01:02:12,445 COSTS EQUITY ARE REALLY BIG 1636 01:02:12,445 --> 01:02:14,647 FOCUS OF THE WORK THAT WE DO. SO 1637 01:02:14,647 --> 01:02:16,883 HOW CAN WE GO AFTER THESE BIG 1638 01:02:16,883 --> 01:02:18,184 BETS THE PRESIDENT HAS CALLED US 1639 01:02:18,184 --> 01:02:21,020 TO DO? PART OF THAT IS THROUGH 1640 01:02:21,020 --> 01:02:22,822 OUR AUTHORITIES AND HOW WE WERE 1641 01:02:22,822 --> 01:02:24,157 SET UP. SO THE FIRST THREE 1642 01:02:24,157 --> 01:02:26,692 MONTHS AT MY JOB AT ARPA H WERE 1643 01:02:26,692 --> 01:02:28,094 SPENT TIME ON THE HILL WITH 1644 01:02:28,094 --> 01:02:29,495 MEMBERS OF CONGRESS TO TALK 1645 01:02:29,495 --> 01:02:32,165 ABOUT THE THINGS THAT WE CAN BE 1646 01:02:32,165 --> 01:02:35,234 UNCOMPROMISING ON. OUR UNIQUE 1647 01:02:35,234 --> 01:02:37,103 STRUCTURE IS VERIFY AN INSTITUTE 1648 01:02:37,103 --> 01:02:39,806 AT NIH BUT WE ARE WITHIN NIH SO 1649 01:02:39,806 --> 01:02:41,908 I CAN LEVERAGE A LOT OF 1650 01:02:41,908 --> 01:02:43,609 EXPERTISE INSTITUTES LIKE NCATS. 1651 01:02:43,609 --> 01:02:46,045 BUT WE ARE OUR OWN AGENCY, OUR 1652 01:02:46,045 --> 01:02:47,346 OWN BUDGET AND I DON'T REPORT TO 1653 01:02:47,346 --> 01:02:49,515 THE ARPA H -- I'M SORRY TO THE 1654 01:02:49,515 --> 01:02:50,983 NIH DIRECTOR. I REPORT TO 1655 01:02:50,983 --> 01:02:53,286 SECRETARY BECERRA. SO THAT ALLOW 1656 01:02:53,286 --> 01:02:55,188 US TO NOT ONLY HAVE AUTONOMY 1657 01:02:55,188 --> 01:02:56,656 HAVING A DIFFERENT BUDGET BUT 1658 01:02:56,656 --> 01:02:57,790 ALSO A DIFFERENT REPORTING 1659 01:02:57,790 --> 01:02:59,659 STRUCTURE AND DIFFERENT AGENDA. 1660 01:02:59,659 --> 01:03:00,827 WE DON'T HAVE ANY INTERNAL 1661 01:03:00,827 --> 01:03:03,796 RESEARCH LABS SO JUST A FUNDING 1662 01:03:03,796 --> 01:03:05,998 AGENCY. AND WE GENERALLY WILL 1663 01:03:05,998 --> 01:03:08,434 FUND CONTRACTS, NOT GRANTS, SO 1664 01:03:08,434 --> 01:03:09,869 COOPERATIVE AGREEMENTS, BECAUSE 1665 01:03:09,869 --> 01:03:11,871 WE WANTS TO A SEAT AT THE TABLE, 1666 01:03:11,871 --> 01:03:13,005 WANT TO BE PART OF THE DECISION 1667 01:03:13,005 --> 01:03:15,208 MAKING PROCESS AND AS THE MARKET 1668 01:03:15,208 --> 01:03:16,542 SHIFTS AND NEEDS CHANGE WE WANT 1669 01:03:16,542 --> 01:03:18,744 OUR CONTRACTS AND TOOLS TO BE 1670 01:03:18,744 --> 01:03:21,514 ABLE TO CHANGE AS WELL. OUR 1671 01:03:21,514 --> 01:03:24,717 INITIAL APPROPRIATION WE HAD AN 1672 01:03:24,717 --> 01:03:25,551 INITIAL TWO AND A HALF BILLION 1673 01:03:25,551 --> 01:03:27,320 DOLLARS THAT WE LAUNCHED. WE 1674 01:03:27,320 --> 01:03:28,554 HOPE TO GROW THAT BUDGET OVER 1675 01:03:28,554 --> 01:03:34,160 TIME. THESE AUTHORITIES SHAPE 1676 01:03:34,160 --> 01:03:37,463 FEATURES OF WHAT IS ARPA H. I 1677 01:03:37,463 --> 01:03:38,364 HAVEN'T MENTIONED PROGRAM 1678 01:03:38,364 --> 01:03:39,465 MANAGERS YET. THAT IS A BIG PART 1679 01:03:39,465 --> 01:03:42,101 OF THE AGENCY SO THROUGH OUR 1680 01:03:42,101 --> 01:03:44,036 AUTHORITIES WE CAN HIRE PROGRAM 1681 01:03:44,036 --> 01:03:47,473 MANAGERS FOR TERM LIMITS THREE 1682 01:03:47,473 --> 01:03:49,509 YEARS TO START, UP TO ADDITIONAL 1683 01:03:49,509 --> 01:03:52,512 THREE YEARS, AND THESE ARE FOLKS 1684 01:03:52,512 --> 01:03:54,514 THAT WE HIRE NOT BECAUSE OF 1685 01:03:54,514 --> 01:03:56,082 THEIR BRILLIANT MINDS, THEY ARE 1686 01:03:56,082 --> 01:03:57,583 CLEAR DOERS IN THEIR FIELDS BUT 1687 01:03:57,583 --> 01:03:59,385 BRING ARPA H A PROBLEM THEY WANT 1688 01:03:59,385 --> 01:04:01,387 TO SOLVE. SO I'M WHEN SELECTING 1689 01:04:01,387 --> 01:04:02,955 A CANDIDATE IT IS NOT JUST 1690 01:04:02,955 --> 01:04:04,457 BECAUSE THEY ARE AMAZING PERSON 1691 01:04:04,457 --> 01:04:05,925 BUT ALSO HAVE A PROBLEM, THAT I 1692 01:04:05,925 --> 01:04:09,028 THINK ARPA H INVESTMENT GIVE 1693 01:04:09,028 --> 01:04:10,596 ASIP METRICAL ADVANTAGE TO 1694 01:04:10,596 --> 01:04:11,931 HEALTHCARE IF WE ABLE TO MOVE 1695 01:04:11,931 --> 01:04:13,933 THE NEEDLE ON THAT GIVEN 1696 01:04:13,933 --> 01:04:16,169 PROBLEM. T I MENTION ACCELERATED 1697 01:04:16,169 --> 01:04:18,337 CONTRACTING AND EVEN THE 1698 01:04:18,337 --> 01:04:19,805 FLEXIBILITY IN HIRING WHEN YOU 1699 01:04:19,805 --> 01:04:20,940 FIND PROGRAM MANAGERS YOU WANT 1700 01:04:20,940 --> 01:04:22,074 TO BRING THEM HON IMMEDIATELY SO 1701 01:04:22,074 --> 01:04:23,543 WE HAVE ADMINISTRATIVELY 1702 01:04:23,543 --> 01:04:25,111 DETERMINED POSITIONS AS WELL AS 1703 01:04:25,111 --> 01:04:27,013 DIRECT HIRING AUTHORITIES SO WE 1704 01:04:27,013 --> 01:04:30,650 DON'T USE USA JOBS. WE CAN GO 1705 01:04:30,650 --> 01:04:33,186 DIRECTLY TO A PERSON HIRE THEM 1706 01:04:33,186 --> 01:04:34,887 BUT ALSO RELATIVELY COMPETITIVE 1707 01:04:34,887 --> 01:04:39,091 SALARY THAT IS OUT -- OUTSIDE OF 1708 01:04:39,091 --> 01:04:41,327 THE GS SCALE GOVERNMENT. SO 1709 01:04:41,327 --> 01:04:42,195 THESE PROGRAM MANAGER IT IS 1710 01:04:42,195 --> 01:04:43,663 PROGRAMS THEY LAUNCH AND AGENCY 1711 01:04:43,663 --> 01:04:47,633 AS A WHOLE, WE SERVE THE HEALTH 1712 01:04:47,633 --> 01:04:49,835 ECOSYSTEM FROM OUR CUSTOMERS IN 1713 01:04:49,835 --> 01:04:51,003 PUBLIC AND HEALTHCARE PROVIDERS 1714 01:04:51,003 --> 01:04:52,738 TO PERFORMERS AND ACADEMIA AND 1715 01:04:52,738 --> 01:04:55,875 INDUSTRY, BUT ALSO STAKEHOLDERS 1716 01:04:55,875 --> 01:04:58,211 LIKE NIH BUT ALSO FDA AND CMS 1717 01:04:58,211 --> 01:04:59,645 AND OTHERS WE KNOW IN ADDITION 1718 01:04:59,645 --> 01:05:01,347 TO AMAZING INNOVATION TECHNOLOGY 1719 01:05:01,347 --> 01:05:02,648 TO BRIDGE THAT GAP TO THOSE 1720 01:05:02,648 --> 01:05:04,684 OUTCOMES. WE NEED TO MAKE SURE 1721 01:05:04,684 --> 01:05:07,820 IT IS REGULATED AN PAID FOR AS 1722 01:05:07,820 --> 01:05:11,524 WE MOVE FORWARD. SO I TALKED 1723 01:05:11,524 --> 01:05:13,726 ABOUT THESE ORGANIZATIONAL 1724 01:05:13,726 --> 01:05:14,560 ATTRIBUTES LIKE THE PROGRAM 1725 01:05:14,560 --> 01:05:16,896 MANAGERS FOCUSING ON THESE 1726 01:05:16,896 --> 01:05:19,031 PROGRAMS AND RADICAL CHANGES 1727 01:05:19,031 --> 01:05:21,267 USHERED IN, FOR THIS GROUP IN 1728 01:05:21,267 --> 01:05:22,401 PARTICULAR IT IS IMPORTANT TO 1729 01:05:22,401 --> 01:05:27,807 MENTION AUTONOMY WE HAVE IN OUR 1730 01:05:27,807 --> 01:05:29,175 DECISION MAKE SO THROUGH 1731 01:05:29,175 --> 01:05:30,276 AUTHORITIES WE CAN GIVE PROGRAM 1732 01:05:30,276 --> 01:05:33,179 MANAGER IT IS SOLD DISCRETION TO 1733 01:05:33,179 --> 01:05:34,447 SELECT AND FUNDS PROJECTS SO 1734 01:05:34,447 --> 01:05:35,815 THIS IS DIFFERENT THAN USING A 1735 01:05:35,815 --> 01:05:39,452 STUDY SECTION OR A COMMITTEE. TO 1736 01:05:39,452 --> 01:05:40,720 MAKE THOSE DECISIONS WE WANT TO 1737 01:05:40,720 --> 01:05:41,854 TAKE ON A LOT OVARIES INCOME THE 1738 01:05:41,854 --> 01:05:43,923 WORK THAT WE DO, TECHNICAL RISK 1739 01:05:43,923 --> 01:05:46,125 NOT EXECUTION. AND WE DO THAT BY 1740 01:05:46,125 --> 01:05:49,862 HAVING A SINGLE THREAD OF 1741 01:05:49,862 --> 01:05:52,265 DECISION MAKER P P WHICH IS 1742 01:05:52,265 --> 01:05:55,801 UNIQUE FOR OUR MODEL. TAKEN 1743 01:05:55,801 --> 01:05:56,936 TOGETHER WHEN PROGRAM MANAGERS 1744 01:05:56,936 --> 01:05:58,404 COME ON BOARD THEY BRING A 1745 01:05:58,404 --> 01:05:59,639 PROGRAM IDEA WITH THEM THEY 1746 01:05:59,639 --> 01:06:03,342 LAUNCH RIGHT AWAY AND ONCE A 1747 01:06:03,342 --> 01:06:04,710 YEAR, I CALL ON THEM TO LAUNCH 1748 01:06:04,710 --> 01:06:06,178 ANOTHER PROGRAM. IF YOU ARE HERE 1749 01:06:06,178 --> 01:06:09,181 THREE YEARS YOU LAUNCH THREE 1750 01:06:09,181 --> 01:06:10,449 PROGRAMS. THOSE CAN BE DIFFERENT 1751 01:06:10,449 --> 01:06:12,418 FROM ONE ANOTHER BY PORTFOLIO AT 1752 01:06:12,418 --> 01:06:14,453 DARPA AS JAMIE MENTIONED WAS 1753 01:06:14,453 --> 01:06:16,322 DIVERSE. SO WE EXPECT THOSE 1754 01:06:16,322 --> 01:06:18,557 PROGRAM MANAGERS TO BRING IN 1755 01:06:18,557 --> 01:06:21,560 THOSE NEW PROGRAMS AND YOU GO 1756 01:06:21,560 --> 01:06:23,663 FLY WHEEL OF NEW STAFF, NEW 1757 01:06:23,663 --> 01:06:29,302 PROGRAMS WE INVEST IN. SO THE 1758 01:06:29,302 --> 01:06:30,636 PORTFOLIO WHAT IT FUNDS IS 1759 01:06:30,636 --> 01:06:32,104 PROGRAM MANAGERS IS DYNAMIC AND 1760 01:06:32,104 --> 01:06:33,306 CHANGES FREQUENTLY. SO THE 1761 01:06:33,306 --> 01:06:35,207 PORTFOLIO WE FUND THIS YEAR I 1762 01:06:35,207 --> 01:06:36,442 WILL TALK ABOUT THE INVESTMENTS 1763 01:06:36,442 --> 01:06:42,515 YOU MADE IN CANCER MOON SHOT, WE 1764 01:06:42,515 --> 01:06:44,183 ANNOUNCED A BIOFABRICATED HEART 1765 01:06:44,183 --> 01:06:45,885 PROJECT. SO THESE ARE DIVERSE, 1766 01:06:45,885 --> 01:06:47,653 DOLLARS ARE NOT ALIGNED TO A 1767 01:06:47,653 --> 01:06:51,957 SINGLE DISEASE THAT ALLOWS US TO 1768 01:06:51,957 --> 01:06:53,592 FUND AREAS WE THINK HAVE 1769 01:06:53,592 --> 01:06:55,628 GREATEST IMPACT. SO THESE OUR 1770 01:06:55,628 --> 01:06:57,496 FIRST COHORT OF PROGRAM 1771 01:06:57,496 --> 01:06:58,397 MANAGERS, WE HAVE 15 BETWEEN 1772 01:06:58,397 --> 01:06:59,598 THOSE IN HOUSE AND COMMITTED TO 1773 01:06:59,598 --> 01:07:02,902 BRING ON BOARD BOARD. I LOVE TOK 1774 01:07:02,902 --> 01:07:04,370 GROUPS LIKE THIS THINK OF ONE OR 1775 01:07:04,370 --> 01:07:05,738 TWO PEOPLE IN YOUR NETWORK, A 1776 01:07:05,738 --> 01:07:08,274 GREAT PROGRAM MANAGER THAT HAVE 1777 01:07:08,274 --> 01:07:09,875 THESE UNCOMMON PEOPLE WITH 1778 01:07:09,875 --> 01:07:12,178 COMMON TRAITS, LIKE HAVING THE 1779 01:07:12,178 --> 01:07:14,313 SERIOUS DRIVE YOU THINK LIKE A 1780 01:07:14,313 --> 01:07:16,315 CEO BUT THEY ALSO HAVE TECHNICAL 1781 01:07:16,315 --> 01:07:18,317 HONESTY SO A CEO HAS TO KNOW 1782 01:07:18,317 --> 01:07:21,554 WHAT THE GOAL IS, AT THE END, IF 1783 01:07:21,554 --> 01:07:22,922 THINGS ARE NOT WORKING OUT TO 1784 01:07:22,922 --> 01:07:24,457 PIVOT RESOURCE SO THAT IS 1785 01:07:24,457 --> 01:07:26,025 DIFFERENT ABOUT ARPA H AS WELL, 1786 01:07:26,025 --> 01:07:27,827 IF A PROJECT IS NOT WORKING WE 1787 01:07:27,827 --> 01:07:29,628 WILL PIVOT RESOURCES, WE MIGHT 1788 01:07:29,628 --> 01:07:33,165 NOT AWARD A PHASE 2 OF A PROJECT 1789 01:07:33,165 --> 01:07:34,467 IF ANOTHER LOOK MORRIS 1790 01:07:34,467 --> 01:07:37,903 PROMISING. THE FOLKS WE HIRE CAN 1791 01:07:37,903 --> 01:07:38,938 BE DIFFERENT STAGE OF THEIR 1792 01:07:38,938 --> 01:07:40,373 CAREER, WHETHER EARLY STAGE, THE 1793 01:07:40,373 --> 01:07:43,509 WORLD IS YOUR OYSTER TO STATUS 1794 01:07:43,509 --> 01:07:44,810 QUO CHALLENGES THAT ARE MID 1795 01:07:44,810 --> 01:07:46,946 CAREER BUT HAVE A BLOCKER TO SAY 1796 01:07:46,946 --> 01:07:48,214 MY FIELD WOULD BE TOTALLY 1797 01:07:48,214 --> 01:07:50,349 DIFFERENT IF WE HAD X. I SAY OUR 1798 01:07:50,349 --> 01:07:52,785 FIRST PROGRAM MANAGER OF US FELL 1799 01:07:52,785 --> 01:07:54,220 INTO THIS CATEGORY HE IS A 1800 01:07:54,220 --> 01:07:57,156 SURGEON AND DID THE MATH AND 1801 01:07:57,156 --> 01:08:01,260 SAID I CAN DO A THOUSANDS, 2,000 1802 01:08:01,260 --> 01:08:03,162 KNEE TRANSPLANTS OVER THE COURSE 1803 01:08:03,162 --> 01:08:07,066 OF CAREER OR COME TO ARPA H AND 1804 01:08:07,066 --> 01:08:08,267 REVERSE OSTEOARTHRITIS, IS 1805 01:08:08,267 --> 01:08:09,435 THAT'S WHAT I WANT TO DO AND THE 1806 01:08:09,435 --> 01:08:10,703 SCALE I WANT TO WORK ON. SO WE 1807 01:08:10,703 --> 01:08:12,238 HAVE A CHALLENGE WITH DIVERSITY, 1808 01:08:12,238 --> 01:08:13,806 THE PROGRAM MANAGERS WE ARE 1809 01:08:13,806 --> 01:08:16,375 HIRING STEM DOES GENERALLY SO 1810 01:08:16,375 --> 01:08:17,410 THINK ABOUT PLACE YOU THINK 1811 01:08:17,410 --> 01:08:20,246 ABOUT DIVERSE NETWORK WE ALSO 1812 01:08:20,246 --> 01:08:22,114 WANT TO SERVE COMMUNITIES THAT 1813 01:08:22,114 --> 01:08:24,417 REFLECT ALL OF AMERICA. SO WE 1814 01:08:24,417 --> 01:08:27,753 EDNA TO CLOSE THAT GAP BETTER. 1815 01:08:27,753 --> 01:08:31,290 WHEN WE FRAME OUR QUESTIONS OF 1816 01:08:31,290 --> 01:08:32,792 HOW WHICH WORK ON A PROBLEM AT 1817 01:08:32,792 --> 01:08:34,660 ARPA H WE TACKINESSRY OPERATION 1818 01:08:34,660 --> 01:08:42,601 FROM DARPA. WE TAKE INSPIRATION 1819 01:08:42,601 --> 01:08:45,471 FROM DARP. THEY CAN THESE 1820 01:08:45,471 --> 01:08:46,505 QUESTIONS AND FUND ANY PROJECT 1821 01:08:46,505 --> 01:08:48,007 YOU ARE WORKING ON FROM EXPERT 1822 01:08:48,007 --> 01:08:49,141 TO LAY PERSON. WHAT PROBLEM ARE 1823 01:08:49,141 --> 01:08:50,843 YOU TRYING TO SOLVE? HOW IS IT 1824 01:08:50,843 --> 01:08:52,411 DONE TODAY? NEW IN YOUR 1825 01:08:52,411 --> 01:08:53,446 APPROACH, THIS IS WHERE THAT 1826 01:08:53,446 --> 01:08:55,414 DEEP TECHNICAL INSIGHT, ONCE THE 1827 01:08:55,414 --> 01:08:58,317 PAPER THE PATENT THE DATA THAT 1828 01:08:58,317 --> 01:09:01,887 CONVINCES YOU GAME CHANGING AT 1829 01:09:01,887 --> 01:09:04,123 THIS TIME. WHO IMPACT, WHAT ARE 1830 01:09:04,123 --> 01:09:05,791 RISKS, HOW LONG IT WILL TAKE AND 1831 01:09:05,791 --> 01:09:07,626 COST. BECAUSE OF THESE BIG BETS 1832 01:09:07,626 --> 01:09:11,597 YOU MIGHT NOT SEE WHAT THEY 1833 01:09:11,597 --> 01:09:13,299 DELIVER UNTIL 10, 15 YEARS DOWN 1834 01:09:13,299 --> 01:09:15,067 THE ROAD. WHAT ARE THE MIDTERM 1835 01:09:15,067 --> 01:09:16,669 EXAMS, YOU KNOW YOU ARE ON THE 1836 01:09:16,669 --> 01:09:18,437 RIGHT TRACK A YEAR FROM NOW, TWO 1837 01:09:18,437 --> 01:09:21,340 YEARS FROM NOW. THEN WE ADDED 1838 01:09:21,340 --> 01:09:22,908 TWO ADDITIONAL QUESTIONS, ONE 1839 01:09:22,908 --> 01:09:26,245 THAT REALLY WANT TO ENSURE 1840 01:09:26,245 --> 01:09:28,380 EQUITABLE ACCESS FOR ALL PEOPLE, 1841 01:09:28,380 --> 01:09:29,715 ADDRESSING COST ACCESSIBILITY 1842 01:09:29,715 --> 01:09:31,283 USER EXPERIENCE, WE HAVE TALKED 1843 01:09:31,283 --> 01:09:32,418 WITH RARE DISEASE GROUPS AND WE 1844 01:09:32,418 --> 01:09:37,289 ARE ASKING, WE DON'T WANT TO 1845 01:09:37,289 --> 01:09:38,390 CREATE THE NEXT MILLION DOLLARS 1846 01:09:38,390 --> 01:09:40,059 SINGLE DOSE THERAPY, IF YOU WANT 1847 01:09:40,059 --> 01:09:42,995 A SOLUTION TO ARPA H TO MOVE 1848 01:09:42,995 --> 01:09:44,663 FORWARD HOW ARE YOU ADDRESSING 1849 01:09:44,663 --> 01:09:47,433 SUPPLY CHANGE SO WE CAN THOUSAND 1850 01:09:47,433 --> 01:09:48,701 X, 10,000 X REDUCE THAT COST 1851 01:09:48,701 --> 01:09:50,002 GOING FORWARDS. THE LAST IS 1852 01:09:50,002 --> 01:09:52,204 ABOUT BUILDING TRUST WITH 1853 01:09:52,204 --> 01:09:53,873 COMMUNITIES. WE DESIGNED WITH 1854 01:09:53,873 --> 01:09:55,307 CUSTOMER EXPERIENCE IN MIND, 1855 01:09:55,307 --> 01:09:57,743 CREATE TOOLS PEOPLE WANT TO 1856 01:09:57,743 --> 01:09:58,911 ENTHUSIASTICALLY ADOPT, WE DON'T 1857 01:09:58,911 --> 01:10:01,347 WANT TO PRESCRIBE SOLUTIONS, WE 1858 01:10:01,347 --> 01:10:02,481 WANT TO WORK WITH COMMUNITIES 1859 01:10:02,481 --> 01:10:07,553 AND MAKE SURE THERE'S NO 1860 01:10:07,553 --> 01:10:08,354 MISPERCEPTION ENVISION JOB 1861 01:10:08,354 --> 01:10:10,589 CREATING FUTURES FOR HEALTH. IS 1862 01:10:10,589 --> 01:10:12,024 IT FUTURE YOU WANT TO LIVE IN 1863 01:10:12,024 --> 01:10:13,425 AND HOW DO YOU COMMUNICATE WITH 1864 01:10:13,425 --> 01:10:19,798 THAT FUTURE IS, SO THAT I IT IS 1865 01:10:19,798 --> 01:10:21,166 NOT SCARY AND WE CAN BRING 1866 01:10:21,166 --> 01:10:23,202 PEOPLE ALONG THE RIDE. THE NEXT 1867 01:10:23,202 --> 01:10:26,438 ARE CARTOONS HOW WE WORK ON THIS 1868 01:10:26,438 --> 01:10:27,806 MODEL SO BRINGING THE PROGRAM 1869 01:10:27,806 --> 01:10:29,808 MANAGER AND IDEA TOGETHER, I 1870 01:10:29,808 --> 01:10:31,377 GIVE THEM A BANK ACCOUNT TO HIT 1871 01:10:31,377 --> 01:10:32,811 THE GROUND RUNNING AND LAUNCH A 1872 01:10:32,811 --> 01:10:35,514 PROGRAM, THEY SOLICIT IDEAS FROM 1873 01:10:35,514 --> 01:10:38,951 THE COMMUNITY SO THEY FUND TEAMS 1874 01:10:38,951 --> 01:10:40,753 OF PERFORMER THAT HAVE DIFFERENT 1875 01:10:40,753 --> 01:10:45,558 WAY TO APPROACH A SOLUTION. TO 1876 01:10:45,558 --> 01:10:46,525 THAT PROBLEM SO PORTFOLIO OF 1877 01:10:46,525 --> 01:10:47,760 RISK AS WELL IN PERFORMERS THAT 1878 01:10:47,760 --> 01:10:50,029 ARE SELECTED FORGIVEN PROGRAM. 1879 01:10:50,029 --> 01:10:52,731 SO CAN BE HIGH RISK, SOME MIGHT 1880 01:10:52,731 --> 01:10:56,001 MITIGATE IT A LITTLE BIT. THEN 1881 01:10:56,001 --> 01:10:57,603 THE PROGRAM MANAGER THIS IS WHY 1882 01:10:57,603 --> 01:10:58,938 WE HAVE CONTRACTS COOPERATIVE 1883 01:10:58,938 --> 01:11:01,974 AGREEMENTS AND OTHER TRANSAC 1884 01:11:01,974 --> 01:11:03,442 TRANSACTIONS BECAUSE EVEN 1885 01:11:03,442 --> 01:11:05,110 SOMETIMESES ON A DAY-TO-DAY 1886 01:11:05,110 --> 01:11:06,245 BASIS INTERACT WITH PERFORMERS 1887 01:11:06,245 --> 01:11:08,514 AND GUIDE THE RESEARCH AND SERVE 1888 01:11:08,514 --> 01:11:10,215 AS PARTNER. SO OVER THE COURSE 1889 01:11:10,215 --> 01:11:11,617 OF THE PROJECT, THEY ARE NOT 1890 01:11:11,617 --> 01:11:12,885 ONLY PROVIDING SUPPORT THEY WANT 1891 01:11:12,885 --> 01:11:15,554 THEM TO BE SUCCESSFUL AND REACH 1892 01:11:15,554 --> 01:11:17,456 THAT END DELIVERABLE BETTER 1893 01:11:17,456 --> 01:11:19,391 HEALTH OUTCOMES. IF A PERFORMER 1894 01:11:19,391 --> 01:11:20,759 FOR WHATEVER REASON, MAYBE THERE 1895 01:11:20,759 --> 01:11:24,096 IS LAW OF PHYSICS THEY COME UP 1896 01:11:24,096 --> 01:11:25,898 AGAINST AND THEIR FUNDING IS NOT 1897 01:11:25,898 --> 01:11:27,166 EXTENDED, THE PROGRAM MANAGER 1898 01:11:27,166 --> 01:11:29,168 WILL MAKE THOSE HARD DECISIONS 1899 01:11:29,168 --> 01:11:32,204 OVER THE COURSE OF A PROJECT 1900 01:11:32,204 --> 01:11:33,672 BECAUSE THEIR GOAL IS TO GET AT 1901 01:11:33,672 --> 01:11:35,007 LEAST ONE GROUP ACROSS THE 1902 01:11:35,007 --> 01:11:38,344 FINISH LINE. WE HAVE A REAL 1903 01:11:38,344 --> 01:11:39,845 COMMITMENT TO TRANSITION, WHAT I 1904 01:11:39,845 --> 01:11:41,080 MEAN BY TRANSITION IS LIKE 1905 01:11:41,080 --> 01:11:42,781 TRANSITION OUT OF THE AGENCY. 1906 01:11:42,781 --> 01:11:44,216 SOME OF THIS WILL BE 1907 01:11:44,216 --> 01:11:46,251 TRANSLATIONAL, NOT ALL OF IT IS. 1908 01:11:46,251 --> 01:11:48,721 BUT ARPA H FUNDING IS A 1909 01:11:48,721 --> 01:11:50,923 TRANSACTION. WE ARE HERE TO 1910 01:11:50,923 --> 01:11:52,625 DEMONSTRATE AND SHOW THAT 1911 01:11:52,625 --> 01:11:54,193 SOMETHING IS POSSIBLE, REMOVE A 1912 01:11:54,193 --> 01:11:56,862 LOT OF UNCERTAINTY AROUND A 1913 01:11:56,862 --> 01:11:59,064 CONCEPT. IF SUCCESSFUL MAYBE 1914 01:11:59,064 --> 01:12:00,566 NCATS PICKS IT UP OR MAYBE 1915 01:12:00,566 --> 01:12:02,267 PRIVATE SECTOR PICKS UP. MAKE IT 1916 01:12:02,267 --> 01:12:03,736 GOES OVER TO A CLINICAL TRIAL, 1917 01:12:03,736 --> 01:12:05,337 ALL THOSE ARE VALID 1918 01:12:05,337 --> 01:12:06,905 POSSIBILITIES. BUT WE WILL NOT 1919 01:12:06,905 --> 01:12:08,140 BE A FOREVER FUNDER OF A 1920 01:12:08,140 --> 01:12:10,209 PROJECT. WE ARE HERE TO BUY DOWN 1921 01:12:10,209 --> 01:12:13,646 THAT RISK. THIS IS ONE OF THE 1922 01:12:13,646 --> 01:12:16,181 WAYS PEOPLE ARE LIKE, YOU ARE 1923 01:12:16,181 --> 01:12:18,250 INSPIRED BY DARPA BUT DIFFERENT 1924 01:12:18,250 --> 01:12:19,952 SO WHAT ARE SOME OF THE WAYS YOU 1925 01:12:19,952 --> 01:12:21,053 ARE DIFFERENT? THIS IS ONE OF 1926 01:12:21,053 --> 01:12:22,388 THE MAJOR WAYINGS THAT WE ARE 1927 01:12:22,388 --> 01:12:24,089 DIFFERENT. IS -- WAYS WE ARE 1928 01:12:24,089 --> 01:12:25,224 DIFFERENT IS HOW TO TRANSITION 1929 01:12:25,224 --> 01:12:28,227 AND ACCELERATE. SO IF YOU ARE AT 1930 01:12:28,227 --> 01:12:30,162 DARPA, PROJECT SUCCESSFUL, 1931 01:12:30,162 --> 01:12:32,097 DEPARTMENT OF DEFENSE WILL PONY 1932 01:12:32,097 --> 01:12:33,432 UP LOTS OF MONEY TO BE THE 1933 01:12:33,432 --> 01:12:34,833 DOWNSTREAM ADVANCE DEVELOPER TO 1934 01:12:34,833 --> 01:12:36,535 MAKE THESE A REALITY. IF I 1935 01:12:36,535 --> 01:12:39,672 DEVELOP A SATELLITE AT DARPA DOD 1936 01:12:39,672 --> 01:12:40,806 WILL MAKE THAT AND PRODUCE IT 1937 01:12:40,806 --> 01:12:43,175 LONG TERM. WE DON'T HAVE THAT IN 1938 01:12:43,175 --> 01:12:45,177 THE HEALTH ECOSYSTEM. WE HAVE 1939 01:12:45,177 --> 01:12:47,079 HHS THAT EXISTS BUT THEY ARE NOT 1940 01:12:47,079 --> 01:12:50,049 A MANUFACTURER, THEY ARE ALSO 1941 01:12:50,049 --> 01:12:52,951 NOT A CENTRAL BODY THAT FUNDS 1942 01:12:52,951 --> 01:12:54,787 HEALTHCARE IN AMERICA. WE HAVE A 1943 01:12:54,787 --> 01:12:56,822 FEDERATED SYSTEM THAT IS ACROSS 1944 01:12:56,822 --> 01:12:58,824 ALL 50 STATES, LOOKS DIFFERENT 1945 01:12:58,824 --> 01:13:03,095 DEPENDING THE STATE YOU ARE IN. 1946 01:13:03,095 --> 01:13:04,096 THIS OFTEN IN THIS IS TRYING TO 1947 01:13:04,096 --> 01:13:05,831 CREATE THE -- OFFICE SRI TRYING 1948 01:13:05,831 --> 01:13:08,267 TO CREATE THE ECOSYSTEM. WE WORK 1949 01:13:08,267 --> 01:13:10,102 WITH PROGRAM MANAGERS BEFORE 1950 01:13:10,102 --> 01:13:11,570 THEY LAUNCH PROGRAMS TO MARKET 1951 01:13:11,570 --> 01:13:13,272 ASSESSMENT WITH VENTURE 1952 01:13:13,272 --> 01:13:14,740 CAPITALISTS THAT ARE PART OF THE 1953 01:13:14,740 --> 01:13:16,975 PARTNERSHIP TEAM TO SAY OKAY 1954 01:13:16,975 --> 01:13:18,210 THERE IS A MARKET IN THIS PLACE 1955 01:13:18,210 --> 01:13:20,012 OR THERE IS NOT AND MAKE SURE WE 1956 01:13:20,012 --> 01:13:21,914 ARE BUYING DOWN THAT DOWNSTREAM 1957 01:13:21,914 --> 01:13:23,115 INVESTMENT RISK TOO SO WE WANT 1958 01:13:23,115 --> 01:13:25,284 TO DERISK THINGS NOT ONLY THE 1959 01:13:25,284 --> 01:13:26,719 TECHNOLOGY BUT WHAT DO INVESTORS 1960 01:13:26,719 --> 01:13:27,886 NEED TO SEE SO THEY WILL PICK 1961 01:13:27,886 --> 01:13:32,291 THIS UP. THIS IS ALL ALONG THE 1962 01:13:32,291 --> 01:13:33,759 COURSE OF PROGRAM, WE ARE 1963 01:13:33,759 --> 01:13:34,860 WORKING CLOSELY WITH TRANSITION 1964 01:13:34,860 --> 01:13:35,794 OFFICE BECAUSE WE DON'T WANT IT 1965 01:13:35,794 --> 01:13:37,596 TO BE A LAST DAY CONVERSATION. 1966 01:13:37,596 --> 01:13:38,931 WE NEED TO BE THINKING ABOUT IP, 1967 01:13:38,931 --> 01:13:41,600 ET CETERA. MAYBE EVEN SPINNING 1968 01:13:41,600 --> 01:13:43,302 OUT A COMPANY, WE WILL SUPPORT 1969 01:13:43,302 --> 01:13:45,738 THAT PROCESS AS WELL. OUR 1970 01:13:45,738 --> 01:13:47,539 PROGRAM MANAGERS DO COME TO THE 1971 01:13:47,539 --> 01:13:50,042 TABLE WITH AN IDEA OF A PROGRAM 1972 01:13:50,042 --> 01:13:51,376 THEY WANT TO FUND AND MOVE 1973 01:13:51,376 --> 01:13:53,378 FORWARD WITH. I HAVE IDENTIFIED 1974 01:13:53,378 --> 01:13:58,250 FOUR AREAS IN HEALTH. FOCUS 1975 01:13:58,250 --> 01:14:03,222 AREAS WE ARE TRYING TO CREATE 1976 01:14:03,222 --> 01:14:05,557 BUCKETS OF IDEA OR UMBRELLAS WE 1977 01:14:05,557 --> 01:14:06,692 OPERATE. THESE ARE BECOMING 1978 01:14:06,692 --> 01:14:08,460 MISSION OFFICE IT IS PROGRAM 1979 01:14:08,460 --> 01:14:11,130 MANAGER TEAMS DEVELOP UNDER. 1980 01:14:11,130 --> 01:14:11,797 HEALTH SCIENCE NEURO, EXPANDING 1981 01:14:11,797 --> 01:14:13,398 WHAT IS TECHNICALLY POSSIBLE, 1982 01:14:13,398 --> 01:14:16,769 ONE RECENT ANNOUNCEMENTS THE 1983 01:14:16,769 --> 01:14:18,237 CARROT PROJECT, REALLY DIRECT 1984 01:14:18,237 --> 01:14:21,507 MODULATION OF THE IMMUNE SYSTEM, 1985 01:14:21,507 --> 01:14:25,711 YOU SAYING DEAD CAST MODULATORS 1986 01:14:25,711 --> 01:14:27,312 THAT UP AND DOWN REGULATE GENES 1987 01:14:27,312 --> 01:14:28,680 INVOLVED IN IMMUNE RESPONSE. WE 1988 01:14:28,680 --> 01:14:32,618 HAVE THREE APPLICATIONS FOR 1989 01:14:32,618 --> 01:14:34,419 CANCER, LONG COVID AND FOR 1990 01:14:34,419 --> 01:14:36,388 LUPULUPUS. SO THOSE ARE THREE 1991 01:14:36,388 --> 01:14:37,523 DIFFERENT DISEASES RAISING A 1992 01:14:37,523 --> 01:14:38,624 PLATFORM TECHNOLOGY TO 1993 01:14:38,624 --> 01:14:40,025 DEMONSTRATE THAT. SO THIS IS THE 1994 01:14:40,025 --> 01:14:42,227 OFFICE IS THE ONE THAT WILL 1995 01:14:42,227 --> 01:14:44,530 BRING THOSE PLATFORMS FORWARD. 1996 01:14:44,530 --> 01:14:46,431 SCALABLE SOLUTIONS. THIS IS NOT 1997 01:14:46,431 --> 01:14:48,233 JUST MANUFACTURING AT SCALE, BUT 1998 01:14:48,233 --> 01:14:51,003 MEETING THE SCALE OF MEETING 1999 01:14:51,003 --> 01:14:51,904 AMERICANS WHERE THEY ARE AT IN 2000 01:14:51,904 --> 01:14:54,473 THEIR HOMES THAT LAST MILE OF 2001 01:14:54,473 --> 01:14:56,041 GETTING SOMETHING OUT OF THE LAB 2002 01:14:56,041 --> 01:14:57,543 INTO THE REAL WORLD BUT THEN 2003 01:14:57,543 --> 01:14:58,710 INTO A RURAL SETTING THAT IS 2004 01:14:58,710 --> 01:15:00,746 HUNDREDS OF MILES FROM 2005 01:15:00,746 --> 01:15:02,981 CENTRALIZED LOCATION. THESE ARE 2006 01:15:02,981 --> 01:15:05,017 TYPES OF INNOVATIONS WE LIKE TO 2007 01:15:05,017 --> 01:15:06,785 ADDRESS WITH SCALABLE SOLUTIONS 2008 01:15:06,785 --> 01:15:07,820 PROACTIVE HEALTH IS KEEPING 2009 01:15:07,820 --> 01:15:09,621 PEOPLE FROM BECOMING PATIENTS IN 2010 01:15:09,621 --> 01:15:12,324 THE FIRST PLACE. DIAGNOSTIC, 2011 01:15:12,324 --> 01:15:12,991 DETECTION, BEHAVE I DON'T RECALL 2012 01:15:12,991 --> 01:15:15,260 MENTAL HEALTH. ALL FALL UNDER 2013 01:15:15,260 --> 01:15:17,496 THIS OFFICE. THEN LAST BUT NOT 2014 01:15:17,496 --> 01:15:19,965 LEAST RESILIENT SYSTEMS IS WE 2015 01:15:19,965 --> 01:15:21,567 JUST SHOWED LAST THREE YEARS WE 2016 01:15:21,567 --> 01:15:23,001 DON'T HAVE A RESILIENT 2017 01:15:23,001 --> 01:15:23,936 HEALTHCARE SYSTEM, WHAT ARE THE 2018 01:15:23,936 --> 01:15:28,040 INVESTMENTS WE ARE MAKING NO NON 2019 01:15:28,040 --> 01:15:30,008 DIGITAL SOLUTIONS INNOVATION 2020 01:15:30,008 --> 01:15:30,843 THAT WE CAN BRING FORWARD. WHAT 2021 01:15:30,843 --> 01:15:32,311 IS GREAT ABOUT BEING NEW 2022 01:15:32,311 --> 01:15:34,746 GOVERNMENT AGENCY IS WE DON'T 2023 01:15:34,746 --> 01:15:37,149 HAVE TO TAKE ON ANY LEGACY DATA 2024 01:15:37,149 --> 01:15:39,551 SYSTEMS. WE CAN CREATE OUR OWN 2025 01:15:39,551 --> 01:15:42,020 AND MAKE IT RELEVANT TO MOVE AT 2026 01:15:42,020 --> 01:15:44,156 SPEED OF PRIVATE SECTOR, ALSO 2027 01:15:44,156 --> 01:15:45,424 SOMETHING WE ARE CRYING TO 2028 01:15:45,424 --> 01:15:46,558 CREATE. OUR FIRST PROGRAM WE 2029 01:15:46,558 --> 01:15:49,695 LAUNCHED IS CALLED NITRO. FROM 2030 01:15:49,695 --> 01:15:50,495 ROSS, THE SURGEON THAT I 2031 01:15:50,495 --> 01:15:52,764 MENTIONED. AND SO THIS IS JUST 2032 01:15:52,764 --> 01:15:54,132 TO GIVE YOU AN IDEA HOW YOU CAN 2033 01:15:54,132 --> 01:15:55,934 GET REALLY ULTRA FOCUSED ON 2034 01:15:55,934 --> 01:15:57,502 SOLVING A PROBLEM. SOL HE IS 2035 01:15:57,502 --> 01:15:59,571 ASKING QUESTIONS, WHAT IF OUR 2036 01:15:59,571 --> 01:16:01,440 JOINTS COULD HEAL THEMSELVES? 2037 01:16:01,440 --> 01:16:03,108 THIS IS A DEEPLY TECHNICAL FIVE 2038 01:16:03,108 --> 01:16:05,277 YEAR PROGRAM FOCUSED ON NO, 2039 01:16:05,277 --> 01:16:06,545 MA'AM MALL BASE BONE AND 2040 01:16:06,545 --> 01:16:08,780 CARTILAGE REGENERATION BUT 2041 01:16:08,780 --> 01:16:10,716 REPLACEMENT OF JOINTS FROM HUMAN 2042 01:16:10,716 --> 01:16:11,783 CELLS COMPLETELY GROWN IN 2043 01:16:11,783 --> 01:16:13,018 LABORATORY. OVER THE COURSE OF 2044 01:16:13,018 --> 01:16:14,953 THE PROGRAM THIS POO FOCUSES ON 2045 01:16:14,953 --> 01:16:16,088 NOT JUST DEMONSTRATING 2046 01:16:16,088 --> 01:16:18,724 MANUFACTURING OF THOSE CELLS BUT 2047 01:16:18,724 --> 01:16:19,725 PRE-CLINICAL WORK AND CLINICAL 2048 01:16:19,725 --> 01:16:22,527 WORK THAT WILL BE REQUIRED HERE 2049 01:16:22,527 --> 01:16:23,862 IMPORTANTLY WE HAVE A STRONG 2050 01:16:23,862 --> 01:16:27,366 LEVER AS A FUNDER WHERE THAT WE 2051 01:16:27,366 --> 01:16:29,234 CAN REQUIRE THIS CLINICAL TRIAL 2052 01:16:29,234 --> 01:16:30,402 ASSOCIATED WITH THIS PROGRAM 2053 01:16:30,402 --> 01:16:33,438 REFLECTS THE DEMOGRAPHICS OF 2054 01:16:33,438 --> 01:16:34,806 DISEASE OF THOSE THAT ARE 2055 01:16:34,806 --> 01:16:36,375 AFFLICTED. SO THIS IS A HARD 2056 01:16:36,375 --> 01:16:37,976 METRIC TO MEET BUT I WILL TALK 2057 01:16:37,976 --> 01:16:40,579 ABOUT ARPA H, THE NEW NETWORK WE 2058 01:16:40,579 --> 01:16:42,614 TRYING TO CREATE TO ACCELERATE 2059 01:16:42,614 --> 01:16:44,016 CLINICAL TRIALS AND GET THAT 2060 01:16:44,016 --> 01:16:46,385 ENROLLMENT UP AND RUNNING FASTER 2061 01:16:46,385 --> 01:16:47,753 THAN WE NORMALLY WOULD. IF YOU 2062 01:16:47,753 --> 01:16:49,821 HAVE BEEN TRACKING 2063 01:16:49,821 --> 01:16:50,522 ANNOUNCEMENTS, WE HAVE HAD NOW 2064 01:16:50,522 --> 01:16:52,858 QUITE A FAINEANCESMENTS IN THE 2065 01:16:52,858 --> 01:16:55,861 MOON SHOT REALM -- QUITE A FEW 2066 01:16:55,861 --> 01:16:56,895 ANNOUNCEMENTS IN THE CANCER 2067 01:16:56,895 --> 01:16:58,463 REALM WE ARE NOT MANDATED TO 2068 01:16:58,463 --> 01:17:00,065 WORK ON IT BUT FELT COMPELD BY 2069 01:17:00,065 --> 01:17:01,767 SOME OF THE APPLICATIONS THAT 2070 01:17:01,767 --> 01:17:03,135 HAVE COME IN AROUND MOON SHOT WE 2071 01:17:03,135 --> 01:17:05,404 THINK WE CAN START TO DELIVER ON 2072 01:17:05,404 --> 01:17:06,438 WHAT THE PRESIDENT HAS 2073 01:17:06,438 --> 01:17:10,642 CHALLENGED OUR NATION TO DO. TO 2074 01:17:10,642 --> 01:17:12,544 ADVANCE SO CANCER MOON SHOT 2075 01:17:12,544 --> 01:17:15,781 GOALS. PROGRAMS LIKE PRECISION 2076 01:17:15,781 --> 01:17:17,683 SURGICAL INTERVENTION TO ALLOW A 2077 01:17:17,683 --> 01:17:19,151 DOCK IN THE OPERATING ROOM TO BE 2078 01:17:19,151 --> 01:17:20,652 ABLE TO LOOK INTO THE SURGICAL 2079 01:17:20,652 --> 01:17:22,955 CAVITY AND SEE THE MARGINS OF 2080 01:17:22,955 --> 01:17:25,891 TUMOR NO LONGER PATHOLOGIST CUT 2081 01:17:25,891 --> 01:17:28,160 TUMORS RUN DOWN THE HALL AND 2082 01:17:28,160 --> 01:17:30,262 SAY, THESE ARE ONE AND DONE 2083 01:17:30,262 --> 01:17:33,298 SURGERIES, IN THIS PROGRAM. AND 2084 01:17:33,298 --> 01:17:34,132 BIOMEDICAL DATA FABRIC. THIS IS 2085 01:17:34,132 --> 01:17:36,201 TRYING TO BREAK DOWN SOME OF THE 2086 01:17:36,201 --> 01:17:37,903 SILOS OF THOUSANDS OF RESEARCH 2087 01:17:37,903 --> 01:17:39,004 CLINICAL INSTITUTES AROUND THE 2088 01:17:39,004 --> 01:17:40,605 COUNTRY WHERE DATA IS HOUSED 2089 01:17:40,605 --> 01:17:41,940 TODAY IN DIFFICULT TO ACCESS. SO 2090 01:17:41,940 --> 01:17:44,710 HOW DO WE CREATE A ROSETTA STONE 2091 01:17:44,710 --> 01:17:46,979 OF THE NETWORK THAT ALLOW US US 2092 01:17:46,979 --> 01:17:51,483 TO POOL AND LEARN ACROSS THOSE 2093 01:17:51,483 --> 01:17:53,719 DATA STREAMS TO ADDRESS DISEASE 2094 01:17:53,719 --> 01:17:55,087 LIKE CANCER BUT TO BE PLATFORM 2095 01:17:55,087 --> 01:17:57,089 FOR OTHER DISEASES. I MENTION 2096 01:17:57,089 --> 01:17:58,857 THE AMINO GENE PROGRAMMING AT 2097 01:17:58,857 --> 01:18:01,126 CURE IT. AND I WILL LET YOU READ 2098 01:18:01,126 --> 01:18:02,361 THE OTHERS BUT THIS IS AN 2099 01:18:02,361 --> 01:18:04,296 EXAMPLE OF VERY, VERY DIVERSE 2100 01:18:04,296 --> 01:18:05,831 PROJECTS TO ADDRESS SOME OF 2101 01:18:05,831 --> 01:18:07,666 THESE TOUGH CHALLENGES THAT ARPA 2102 01:18:07,666 --> 01:18:09,034 H WILL MAKE AN INVESTMENT IN, 2103 01:18:09,034 --> 01:18:11,470 DERISK THESE AREAS AND THEN 2104 01:18:11,470 --> 01:18:12,738 TRANSITION THOSE OUT OF THE 2105 01:18:12,738 --> 01:18:19,344 AGENCY. (INAUDIBLE) ANNOUNCED 2106 01:18:19,344 --> 01:18:21,613 ARPA H AS WELL THIS IS A NOD TO 2107 01:18:21,613 --> 01:18:25,317 DARPA HISTORY. ARPA NET STARTED 2108 01:18:25,317 --> 01:18:28,987 AT DARPA AS A FOUR NODE NETWORK 2109 01:18:28,987 --> 01:18:33,091 TO PRECURSOR TO WHAT BECAME 2110 01:18:33,091 --> 01:18:34,760 KNOWN AS THE INTERNET. SO 2111 01:18:34,760 --> 01:18:36,028 LOOKING AT THAT INSPIRATION WE 2112 01:18:36,028 --> 01:18:38,397 ARE STARTING OUR OWN ARPA NE NE. 2113 01:18:38,397 --> 01:18:40,098 WE WANT TO E CREATE 2114 01:18:40,098 --> 01:18:40,799 INTERCONNECTED HEALTHCARE 2115 01:18:40,799 --> 01:18:42,701 INNOVATION NETWORK FOR THE 2116 01:18:42,701 --> 01:18:46,471 UNITED STATES TO DO THINGS LIKE 2117 01:18:46,471 --> 01:18:49,007 BRING PEOPLE CLOSE TOGETHER AND 2118 01:18:49,007 --> 01:18:50,375 THESE ARE STATUTORY REQUIREMENT 2119 01:18:50,375 --> 01:18:52,711 THAT CONGRESS GAVE US TO BE IN 3 2120 01:18:52,711 --> 01:18:53,578 GEOGRAPHIC SITES AROUND THE 2121 01:18:53,578 --> 01:18:55,514 COUNTRY. SO THIS IS OUR ATTEMPT 2122 01:18:55,514 --> 01:18:57,215 AT RECOGNIZING THAT THERE AREN'T 2123 01:18:57,215 --> 01:18:58,683 THREE GEOGRAPHIES IN THE COUNTRY 2124 01:18:58,683 --> 01:18:59,751 THAT REPRESENT ALL AMERICAN 2125 01:18:59,751 --> 01:19:00,986 POPULATIONS SO WE WANT TO USE 2126 01:19:00,986 --> 01:19:03,255 THIS AS HUB AND SPOKE NETWORK TO 2127 01:19:03,255 --> 01:19:04,823 RECRUIT ALL 50 STATES TO BE PART 2128 01:19:04,823 --> 01:19:07,025 OF THIS NETWORK. THIS IS 2129 01:19:07,025 --> 01:19:07,959 INCREDIBLE CONVENING POWER OF 2130 01:19:07,959 --> 01:19:09,828 HAVING A NETWORK TO BRING 2131 01:19:09,828 --> 01:19:12,497 INVESTORS INDUSTRY ACADEMIC 2132 01:19:12,497 --> 01:19:14,132 GROUPS, COMMUNITIES TOGETHER IN 2133 01:19:14,132 --> 01:19:16,168 ORDER TO SOLVE HARD PROBLEMS. TO 2134 01:19:16,168 --> 01:19:21,406 DO SO IN INCLUSIVE WAY. ARPA NET 2135 01:19:21,406 --> 01:19:23,308 H THIS NETWORK CREATING ANYONE 2136 01:19:23,308 --> 01:19:26,778 CAN PARTICIPATE, NO PAY TO PLAY. 2137 01:19:26,778 --> 01:19:28,447 TO GET FUNDED THROUGH THIS 2138 01:19:28,447 --> 01:19:29,448 NETWORK FIRST PART OF THE 2139 01:19:29,448 --> 01:19:31,383 COMMUNITY IS THE LAYER BUT TO BE 2140 01:19:31,383 --> 01:19:32,918 FUNDED ALL THIS WORK IS DONE 2141 01:19:32,918 --> 01:19:34,586 THROUGH OTHER TRANSACTIONS WITH 2142 01:19:34,586 --> 01:19:37,756 THE SEVEN DAY TARGET. SO IMAGINE 2143 01:19:37,756 --> 01:19:39,091 YOU A COMMUNITY HOSPITAL THAT 2144 01:19:39,091 --> 01:19:40,759 DOESN'T KNOW HOW TO WORK WITH 2145 01:19:40,759 --> 01:19:42,561 THE FEDERAL GOVERNMENT. WE WANT 2146 01:19:42,561 --> 01:19:43,829 TICK MA IT SUPER SIMPLE. WE WANT 2147 01:19:43,829 --> 01:19:45,564 TO WORK WITH YOU AND WE DON'T 2148 01:19:45,564 --> 01:19:46,665 WANT US BEING THE GOVERNMENT TO 2149 01:19:46,665 --> 01:19:47,999 HINDER THAT. SO THIS IS A 2150 01:19:47,999 --> 01:19:51,103 RESOURCE FOR ALL DARPA ARPA H 2151 01:19:51,103 --> 01:19:53,138 PROGRAMS BUT ALSO FOR NCATS AND 2152 01:19:53,138 --> 01:19:56,441 NIH AND OTHER HHS BROTHER AND 2153 01:19:56,441 --> 01:19:58,376 SISTER AGENCIES. IMPORTANTLY, 2154 01:19:58,376 --> 01:19:59,377 THESE CONNECTIONS WILL ALLOW US 2155 01:19:59,377 --> 01:20:01,046 TO GET CLOSER TO THOSE CUSTOMERS 2156 01:20:01,046 --> 01:20:03,815 AND TRANSITION THINGS OUT OF 2157 01:20:03,815 --> 01:20:06,418 ARPA H AND THEY THEMSELVES 2158 01:20:06,418 --> 01:20:07,486 MENTIONED ROSS HAS DIVERSE 2159 01:20:07,486 --> 01:20:11,223 CLINICAL TRIAL HE IS TRYING TO E 2160 01:20:11,223 --> 01:20:12,657 ENROLL TO HELP US DO THAT. SO 2161 01:20:12,657 --> 01:20:15,460 BIG ANNOUNCEMENTS THIS WEEK OUR 2162 01:20:15,460 --> 01:20:16,561 STAKEHOLDER OPERATIONS HUB IN 2163 01:20:16,561 --> 01:20:17,863 THE NATIONAL CAPITAL REGION WE 2164 01:20:17,863 --> 01:20:19,998 NEED TO STAY CLOSE TO CMS FDA TO 2165 01:20:19,998 --> 01:20:22,100 TRANSITION CAPABILITIES. BUT 2166 01:20:22,100 --> 01:20:23,735 DALLAS AND GREATER TEXAS IS 2167 01:20:23,735 --> 01:20:25,804 GOING TO SERVE AS CUSTOMER 2168 01:20:25,804 --> 01:20:28,340 EXPERIENCE HUB. THERE IS 2169 01:20:28,340 --> 01:20:29,941 PROBABLY 25 DIFFERENT TOWNS AND 2170 01:20:29,941 --> 01:20:32,144 CITIES IN TEXAS REPRESENTED 2171 01:20:32,144 --> 01:20:34,613 HERE, POPULATIONS ALL ACROSS 2172 01:20:34,613 --> 01:20:36,214 URBAN AND RURAL SETTINGS BUT 2173 01:20:36,214 --> 01:20:38,016 IMPORTANTLY RECRUITING IN 50 2174 01:20:38,016 --> 01:20:41,987 STATES AS WELL. OUR LAST HUB 2175 01:20:41,987 --> 01:20:43,889 INVESTOR CATALYST HUB TO HELP 2176 01:20:43,889 --> 01:20:45,790 GET TO INVESTORS WHO WILL BRING 2177 01:20:45,790 --> 01:20:48,260 CAPITAL DOWNSTREAM TO ADVANCE 2178 01:20:48,260 --> 01:20:49,828 ARPA H PROGRAMS WILL BE BASED 2179 01:20:49,828 --> 01:20:55,066 OUT OF GREATER BOSTON AREA. THEN 2180 01:20:55,066 --> 01:20:56,434 LAST BUT NOT LEAST FOR THIS 2181 01:20:56,434 --> 01:20:58,336 GROUP, THINKING ABOUT WAYS TO 2182 01:20:58,336 --> 01:21:00,405 WORK WITH THIS, I WILL MENTION 2183 01:21:00,405 --> 01:21:01,706 BECOMING PROGRAM MANAGER, YOU 2184 01:21:01,706 --> 01:21:05,177 CAN TWO TO OUR WEB FORM NOT USA 2185 01:21:05,177 --> 01:21:06,912 JOBS IS A NICE GOOGLE FORM ON 2186 01:21:06,912 --> 01:21:10,916 THE WEBSITE TO APPLY AND OPEN 2187 01:21:10,916 --> 01:21:12,617 BROAD AGENCY ANNOUNCEMENTS SO 2188 01:21:12,617 --> 01:21:14,219 WHILE MOST EFFORTS ARE PROGRAMS 2189 01:21:14,219 --> 01:21:15,420 LAUNCHED BY PROGRAM MANAGERS WE 2190 01:21:15,420 --> 01:21:17,255 HAVE A WAY, IF YOU HAVE A GREAT 2191 01:21:17,255 --> 01:21:18,490 IDEA THAT MAYBE WE HAVEN'T 2192 01:21:18,490 --> 01:21:19,791 THOUGHT OF WE WANT TO HEAR FROM 2193 01:21:19,791 --> 01:21:23,228 YOU. WE MADE IT A THREE PAGER 2194 01:21:23,228 --> 01:21:24,596 THAT WHICH WANT TO HEAR THE 2195 01:21:24,596 --> 01:21:25,864 IDEAS BUT -- WE WANT TO HEAR 2196 01:21:25,864 --> 01:21:27,232 THOSE IDEAS BUT NOT SPEND A LOT 2197 01:21:27,232 --> 01:21:30,368 OF TIME TO GET FEEDBACK AND SEND 2198 01:21:30,368 --> 01:21:32,537 THOSE IDEAS TO THE OPEN BAA. I 2199 01:21:32,537 --> 01:21:34,372 LIKE TO END ON THIS I FEEL LIKE 2200 01:21:34,372 --> 01:21:37,175 EVERY WEEK AT ARPA H WE 2201 01:21:37,175 --> 01:21:38,210 ACCOMPLISH SO MUCH MORE THAN THE 2202 01:21:38,210 --> 01:21:41,413 WEEK BEFORE, WE HAD BIG 2203 01:21:41,413 --> 01:21:42,214 ANNOUNCEMENTS GROWING OUR 2204 01:21:42,214 --> 01:21:43,615 NETWORK. THE FUTURE WE WANT TO 2205 01:21:43,615 --> 01:21:45,517 CREATE IS HARD TO IMAGINE NOW IN 2206 01:21:45,517 --> 01:21:47,152 HEALTH AND ONE OF THE GROUP THAT 2207 01:21:47,152 --> 01:21:48,420 IS REALLY RESPONSIBLE FOR 2208 01:21:48,420 --> 01:21:50,455 LEADING THE CHARGE THERE. WITH 2209 01:21:50,455 --> 01:21:51,623 THAT I WILL STOP THE SCREEN 2210 01:21:51,623 --> 01:21:53,825 SHARE. HAPPY TO TAKE ANY 2211 01:21:53,825 --> 01:21:56,361 QUESTIONS AND AGAIN, LOTS OF 2212 01:21:56,361 --> 01:21:58,630 GRATITUDE TO JONI AND TEAM FOR 2213 01:21:58,630 --> 01:22:02,701 INVITING ME HERE TODAY. 2214 01:22:02,701 --> 01:22:04,502 >> RENEE, THANK YOU SO MUCH, 2215 01:22:04,502 --> 01:22:05,737 WONDERFUL OVERVIEW, I WOULD LIKE 2216 01:22:05,737 --> 01:22:07,639 TO OPEN UP TO ANY QUESTIONS FROM 2217 01:22:07,639 --> 01:22:13,378 OUR COUNCIL MEMBERS. 2218 01:22:13,378 --> 01:22:14,813 >> CONGRATULATIONS AND EXCITED 2219 01:22:14,813 --> 01:22:17,983 TO SEE THE SPEED WHICH YOU 2220 01:22:17,983 --> 01:22:20,485 LAUNCHED OFF NOT EXCITED TO SEE 2221 01:22:20,485 --> 01:22:23,588 THE FIRST PROGRAM MANAGER COME 2222 01:22:23,588 --> 01:22:26,391 ON. AS YOU MENTIONED IN THE LAST 2223 01:22:26,391 --> 01:22:28,560 SENTENCE SIX OUT OF EIGHT ARE 2224 01:22:28,560 --> 01:22:30,795 WHITE MEN AND SPEAKING AS WHITE 2225 01:22:30,795 --> 01:22:32,464 MAN MYSELF I BENEFIT A LOT FROM 2226 01:22:32,464 --> 01:22:36,001 DIVERSITY AND LEADERSHIP WHO 2227 01:22:36,001 --> 01:22:37,269 THINKS DIFFERENT INCOMES FROM A 2228 01:22:37,269 --> 01:22:38,837 DIFFERENT HISTORY AND DISRUPTIVE 2229 01:22:38,837 --> 01:22:42,607 INSIGHT WHOSE HAVE LEVELS OF 2230 01:22:42,607 --> 01:22:43,408 DIVERSITY HERE IN THE US. 2231 01:22:43,408 --> 01:22:44,876 THAT'S ONE OF THE REASONS I CAME 2232 01:22:44,876 --> 01:22:46,811 AND VERY HAPPY TO CONTRIBUTE TO 2233 01:22:46,811 --> 01:22:48,546 THE PROGRESS IN THIS GREAT 2234 01:22:48,546 --> 01:22:53,985 NATION OF OURS. SECOND COMMENT, 2235 01:22:53,985 --> 01:22:56,521 DARPA IS VERY SUCCESSFUL BECAUSE 2236 01:22:56,521 --> 01:22:58,423 AS YOU MENTIONED THIS IS A 2237 01:22:58,423 --> 01:22:59,691 FANTASTIC KITCHEN OF GREAT IDEAS 2238 01:22:59,691 --> 01:23:03,628 AND DOD TAKES IT AND PUSH IT 2239 01:23:03,628 --> 01:23:05,130 THROUGH WITH FORCE. HERE IN THE 2240 01:23:05,130 --> 01:23:05,797 HEALTHCARE SECTOR WE DON'T HAVE 2241 01:23:05,797 --> 01:23:10,201 THAT. AND VENTURE CAPITAL IS THE 2242 01:23:10,201 --> 01:23:12,771 SOURCE OF FINANCE TO BRING IN. 2243 01:23:12,771 --> 01:23:14,839 BUT VENTURE CAPITAL FINANCES 2244 01:23:14,839 --> 01:23:16,708 HAVE SERVED THOSE RESOURCE WELL 2245 01:23:16,708 --> 01:23:20,445 IN OUR COUNTRY. AND NOT ALWAYS 2246 01:23:20,445 --> 01:23:21,880 NOT WELL RESOURCED AND 2247 01:23:21,880 --> 01:23:24,115 UNDERSERVED POPULATIONS IS A LOT 2248 01:23:24,115 --> 01:23:26,618 OF WHERE DISEASE BURDEN IS. SO A 2249 01:23:26,618 --> 01:23:30,455 MAJOR CONCERN IF ARPA H RELIES 2250 01:23:30,455 --> 01:23:32,123 ON FINANCING TO MOVE FORWARD, 2251 01:23:32,123 --> 01:23:34,993 THAT MIGHT INADVERTENTLY RESULT 2252 01:23:34,993 --> 01:23:38,663 IN YOUR INVESTMENTS AGAIN GOING 2253 01:23:38,663 --> 01:23:42,033 TO THOSE WHO ARE IN NEED. I 2254 01:23:42,033 --> 01:23:43,401 DON'T HAVE A SOLUTION TO THAT 2255 01:23:43,401 --> 01:23:48,440 BUT THAT MIGHT IN ITSELF BE A 2256 01:23:48,440 --> 01:23:50,075 PROBLEM FOR -- TO PUT IN FRONT 2257 01:23:50,075 --> 01:23:50,241 OF. 2258 01:23:50,241 --> 01:23:51,943 >> YOU HIGHLIGHT A REALLY 2259 01:23:51,943 --> 01:23:54,612 IMPORTANT PROBLEM WHICH IS GOING 2260 01:23:54,612 --> 01:23:56,748 BACK TO THE HOW AM I RIGHT FROM 2261 01:23:56,748 --> 01:23:58,783 THE GET GO SAY DRESSING THAT 2262 01:23:58,783 --> 01:24:00,618 COST AND ACCESSIBILITY. EVEN IN 2263 01:24:00,618 --> 01:24:03,254 THE DESIGN OF OUR PROGRAMS, IF 2264 01:24:03,254 --> 01:24:06,324 ROSS MAKING SURE HIS CLINICAL 2265 01:24:06,324 --> 01:24:07,692 TRIAL REPRESENTS RAPID DISEASE 2266 01:24:07,692 --> 01:24:11,196 IS ACTUALLY IMPACTED BY 2267 01:24:11,196 --> 01:24:12,330 OSTEOARTHRITIS, THE SIDE 2268 01:24:12,330 --> 01:24:13,798 PROGRAM, PRECISION SURGICAL 2269 01:24:13,798 --> 01:24:14,933 INTERVENTIONS, THE PROGRAM 2270 01:24:14,933 --> 01:24:16,034 MANAGER IS REQUIRING THAT 2271 01:24:16,034 --> 01:24:17,602 SURGICAL DEMONSTRATION TO NOT 2272 01:24:17,602 --> 01:24:18,770 ONLY BE CENTER OF EXCELLENCE, 2273 01:24:18,770 --> 01:24:20,905 SURE WE WILL GET THOSE, BUT IN A 2274 01:24:20,905 --> 01:24:22,374 RURAL SETTING WHERE YOU DON'T 2275 01:24:22,374 --> 01:24:24,509 HAVE 5G, HOW DO YOU START TO 2276 01:24:24,509 --> 01:24:27,712 ACTUALLY APPLY THAT THERE. L SO 2277 01:24:27,712 --> 01:24:29,214 IT IS VERY INTENTIONAL AND A 2278 01:24:29,214 --> 01:24:32,550 REQUIREMENT OF OUR PROGRAMS. 2279 01:24:32,550 --> 01:24:35,220 FOR VCs WITH OUR INVESTOR 2280 01:24:35,220 --> 01:24:36,755 CATALYST HUB IT IS NOT JUST YOUR 2281 01:24:36,755 --> 01:24:38,089 TYPICAL, NOT GOING TO NAME 2282 01:24:38,089 --> 01:24:39,758 ANYBODY BUT YOU CAN PROBABLY TOP 2283 01:24:39,758 --> 01:24:42,794 TEN THINK OF YOUR VC AND HEALTH 2284 01:24:42,794 --> 01:24:44,696 NAMES. SURE THOSE FOLKS COME 2285 01:24:44,696 --> 01:24:45,797 AROUND THEY HAVE NO TROUBLE 2286 01:24:45,797 --> 01:24:47,265 FINDING INVESTMENTS. WHAT WE ARE 2287 01:24:47,265 --> 01:24:50,435 LOOKING FOR ARE INVESTORS THAT 2288 01:24:50,435 --> 01:24:51,703 HAVE RETURN INVESTMENT NOT ONLY 2289 01:24:51,703 --> 01:24:53,505 IN FINANCING BUT IN THE 2290 01:24:53,505 --> 01:24:56,074 COMMUNITIES THEY SERVE. SO OUR 2291 01:24:56,074 --> 01:24:58,710 PRIME FOR THAT EFFORT IS VENTURE 2292 01:24:58,710 --> 01:25:00,412 WEALTH WHO HAS REALLY GREAT 2293 01:25:00,412 --> 01:25:02,280 TRACK RECORD OF DELIVERING 2294 01:25:02,280 --> 01:25:03,381 SOLUTIONS TO UNDERSERVED 2295 01:25:03,381 --> 01:25:05,550 COMMUNITIES AND BEYOND. POINT 2296 01:25:05,550 --> 01:25:07,585 TAKEN, WE ARE NOT -- WE 2297 01:25:07,585 --> 01:25:08,820 DEFINITELY ARE NOT CREATING A 2298 01:25:08,820 --> 01:25:11,022 PIPELINE TO GO TO VC FUNDING 2299 01:25:11,022 --> 01:25:12,357 THAT IS NOT THE POINT BUT WE 2300 01:25:12,357 --> 01:25:13,391 KNOW THEY HAVE TO HAVE A SEAT AT 2301 01:25:13,391 --> 01:25:14,626 THE TABLE AND WE ARE TRYING TO 2302 01:25:14,626 --> 01:25:16,294 GUIDE THEM DOWN A PATH THAT 2303 01:25:16,294 --> 01:25:20,064 LOOKS AT THAT EQUITY AND ACCESS. 2304 01:25:20,064 --> 01:25:21,533 THE OTHER THING I WILL MENTION, 2305 01:25:21,533 --> 01:25:23,668 WE HAVE ONE UNIQUE AUTHORITY I 2306 01:25:23,668 --> 01:25:25,236 THINK NCATS MAY HAVE THIS AS 2307 01:25:25,236 --> 01:25:27,205 WELL BUT DON'T QUOTE ME, I 2308 01:25:27,205 --> 01:25:29,474 BELIEVE THAT'S JONI. WE CAN -- 2309 01:25:29,474 --> 01:25:31,409 WE HAVE TO SORT OF REIMBURSE FDA 2310 01:25:31,409 --> 01:25:32,343 DIRECTLY. AND WE HAVE BEEN 2311 01:25:32,343 --> 01:25:33,578 WORKING WITH THE COMMISSIONERS 2312 01:25:33,578 --> 01:25:35,580 OFFICE, WE PUT AN RFI OUT TO THE 2313 01:25:35,580 --> 01:25:37,615 PUBLIC AND TO GET IDEAS AS WELL. 2314 01:25:37,615 --> 01:25:39,184 HOW CAN WE USE THIS AUTHORITY? 2315 01:25:39,184 --> 01:25:40,885 LET'S BE CREATIVE ABOUT IT. AND 2316 01:25:40,885 --> 01:25:42,253 SOME OF THE THINGS THAT HAVE 2317 01:25:42,253 --> 01:25:44,889 COME UP ARE FOR EXAMPLE, IF WE 2318 01:25:44,889 --> 01:25:49,294 HELP DEVELOP A DRUG MAYBE 2319 01:25:49,294 --> 01:25:51,529 IMMUNOMODULATOR, COULD WE, IF WE 2320 01:25:51,529 --> 01:25:54,933 ENSURE A COST AT A CERTAIN LEVEL 2321 01:25:54,933 --> 01:25:56,768 OR ACCESS TO COMMUNITIES OF 2322 01:25:56,768 --> 01:25:58,102 NEED, WE COULD GIVE THE PERSON 2323 01:25:58,102 --> 01:26:01,473 THAT IS APPLYING FOR THE 2324 01:26:01,473 --> 01:26:03,274 REGULATORY APPROVAL PRIORITY 2325 01:26:03,274 --> 01:26:05,310 ACCESS TO THE MARKETPLACE OR 2326 01:26:05,310 --> 01:26:07,445 FIRST ACROSS THE FINISH LINE FOR 2327 01:26:07,445 --> 01:26:09,914 THAT REGULATION BUT TO MEET 2328 01:26:09,914 --> 01:26:11,416 THOSE GOVERNMENT NEEDS OR HAVE 2329 01:26:11,416 --> 01:26:12,450 PRECOMPETITIVE DATA SHARING SO 2330 01:26:12,450 --> 01:26:14,385 TRYING TO USE TOOLS BESIDES 2331 01:26:14,385 --> 01:26:16,054 MONEY TO INCENTIVIZE GOOD 2332 01:26:16,054 --> 01:26:17,922 BEHAVIOR. IF THIS GROUP 2333 01:26:17,922 --> 01:26:19,090 ESPECIALLY RARE DISEASE SIDE 2334 01:26:19,090 --> 01:26:20,425 UNDERSERVED COMMUNITIES IF 2335 01:26:20,425 --> 01:26:21,059 THERE'S OTHER THINGS YOU CAN 2336 01:26:21,059 --> 01:26:23,595 THINK OF THAT WE CAN TRY LIKE WE 2337 01:26:23,595 --> 01:26:24,963 WANT TO BE A PLACE TO EXPERIMENT 2338 01:26:24,963 --> 01:26:28,166 IN THAT WAY AS WELL. SORRY, 2339 01:26:28,166 --> 01:26:29,567 LONG WIND BUD REALLY PASSIONATE 2340 01:26:29,567 --> 01:26:30,768 ABOUT IT AND CARE A LOT ABOUT 2341 01:26:30,768 --> 01:26:34,472 IT. BUT TO YOUR POINT, NOT AN E 2342 01:26:34,472 --> 01:26:37,375 SE QUESTION TO WANT TO BRING THE 2343 01:26:37,375 --> 01:26:40,712 MOST CREATIVE IDEAS THERE. 2344 01:26:40,712 --> 01:26:42,547 >> PAULA, DID YOU HAVE A 2345 01:26:42,547 --> 01:26:45,049 QUESTION? PAULA AND ANNIE THEN 2346 01:26:45,049 --> 01:26:49,721 MAYBE WE'LL STOP AFTER AND IN A. 2347 01:26:49,721 --> 01:26:52,557 >> VERY EXCITI EXCITING. YOU TAT 2348 01:26:52,557 --> 01:26:54,125 HAVING A RURAL HOSPITAL. HOW DO 2349 01:26:54,125 --> 01:26:56,461 YOU ENVISION TAKING THE 2350 01:26:56,461 --> 01:26:59,030 TREATMENTS TO THOSE RURAL 2351 01:26:59,030 --> 01:27:00,298 COMMUNITIES THAT MAKE UP TO A 2352 01:27:00,298 --> 01:27:01,432 FIFTH OF THE POPULATION BUT VERY 2353 01:27:01,432 --> 01:27:05,003 UNDERSERVED? 2354 01:27:05,003 --> 01:27:06,804 >> YEAH. THIS IS LIKE WE 2355 01:27:06,804 --> 01:27:08,406 PRESCRIBED THAT IT HAS TO BE IN 2356 01:27:08,406 --> 01:27:10,842 A RURAL SETTING AND WE ARE 2357 01:27:10,842 --> 01:27:12,510 REQUIRING PERFORMERS TO BRING US 2358 01:27:12,510 --> 01:27:14,078 THEIR SOLUTION. O SO THIS IS A 2359 01:27:14,078 --> 01:27:16,915 PLACE WE WILL SET A BAR THEN 2360 01:27:16,915 --> 01:27:18,116 EXPECT THE COMMUNITY TO COME TO 2361 01:27:18,116 --> 01:27:21,553 THAT. THAT IS AN ACTIVE PROPOSAL 2362 01:27:21,553 --> 01:27:22,887 PROCESS RIGHT NOW WE HAVEN'T 2363 01:27:22,887 --> 01:27:25,657 SELECTED THE TEAMS YET BUT WHEN 2364 01:27:25,657 --> 01:27:27,458 WE ANNOUNCE THE PROJECTS AND 2365 01:27:27,458 --> 01:27:28,459 NAME WHERE THOSE HOSPITALS ARE, 2366 01:27:28,459 --> 01:27:29,827 SO THE TEAMS CAN BRING THEM AND 2367 01:27:29,827 --> 01:27:33,565 WE CAN LEAN ON ARPANET H TO DO 2368 01:27:33,565 --> 01:27:35,900 THAT FOR SURE. WE WILL HAVE IT 2369 01:27:35,900 --> 01:27:38,169 AN ADVISORY BOARD OF SURGEONS IN 2370 01:27:38,169 --> 01:27:39,537 THE SEATS THE PROGRAM MANAGER 2371 01:27:39,537 --> 01:27:41,673 HAS ASSIGNED ON THAT BOARD. MANY 2372 01:27:41,673 --> 01:27:43,141 OF THOSE SEATS ARE RURAL AND 2373 01:27:43,141 --> 01:27:44,709 UNDERSERVED SURGEONS. BECAUSE 2374 01:27:44,709 --> 01:27:46,311 THEY WOULD BE THE END USERS, WE 2375 01:27:46,311 --> 01:27:48,179 WANT TO MAKE SURE THEY ARE 2376 01:27:48,179 --> 01:27:50,348 WILLING TO ADAPT TO TECHNOLOGIES 2377 01:27:50,348 --> 01:27:51,549 SO THERE WILL BE A KEY PLACE SO 2378 01:27:51,549 --> 01:27:53,751 IF YOU KNOW FOLKS THAT FIT THAT 2379 01:27:53,751 --> 01:27:56,387 BILL LOVE TO HEAR FROM THEM AS 2380 01:27:56,387 --> 01:28:00,625 WELL AS WE -- THOSE ON THE 2381 01:28:00,625 --> 01:28:01,960 ADVISORY BOARD. 2382 01:28:01,960 --> 01:28:03,127 >> ANNIE. 2383 01:28:03,127 --> 01:28:04,529 >> THANK YOU SO MUCH FOR BEING 2384 01:28:04,529 --> 01:28:08,433 HERE WITH US TODA TODAY. I HAVEE 2385 01:28:08,433 --> 01:28:10,034 PLEASURE AND PRIVILEGE OF 2386 01:28:10,034 --> 01:28:11,936 WORKING ON A CROSS STAKEHOLDER 2387 01:28:11,936 --> 01:28:13,071 GROUP THAT WORKED ON THE 2388 01:28:13,071 --> 01:28:17,041 AUTHORIZING LANGUAGE FOR HR AND 2389 01:28:17,041 --> 01:28:19,911 WE WORKED VERY HARD TO BE SURE 2390 01:28:19,911 --> 01:28:24,449 WE AVOIDED ANY TYPE OF WHAT WE 2391 01:28:24,449 --> 01:28:26,017 CALL DISEASE WARDS SO WE DIDN'T 2392 01:28:26,017 --> 01:28:27,151 MENTION ANY PARTICULAR DISEASES 2393 01:28:27,151 --> 01:28:29,454 BUT WE WORKED TO MAKE SURE THE 2394 01:28:29,454 --> 01:28:31,022 AUTHORIZING LANGUAGE USED 2395 01:28:31,022 --> 01:28:34,125 TERMINOLOGY THAT WOULD BE 2396 01:28:34,125 --> 01:28:36,594 DISEASE BASED AGNOSTIC TO USE 2397 01:28:36,594 --> 01:28:37,395 THE TOOLS TO DRIVE THE 2398 01:28:37,395 --> 01:28:40,098 INNOVATION. SO THE TERMS THAT WE 2399 01:28:40,098 --> 01:28:41,933 LANDED ON AND ENDED UNDERSTOOD 2400 01:28:41,933 --> 01:28:43,468 ENDING UP BEING IN THE OPERATING 2401 01:28:43,468 --> 01:28:45,470 LANGUAGE WERE TO LOOK FOR 2402 01:28:45,470 --> 01:28:46,504 PROJECTS THAT WOULD HAVE EFFECT 2403 01:28:46,504 --> 01:28:50,808 ON DISEASE BURDEN, UNMET PATIENT 2404 01:28:50,808 --> 01:28:52,810 NEED, DRIVE DECISIONS AND 2405 01:28:52,810 --> 01:28:54,612 POTENTIAL TO PREEMPT PROGRESSION 2406 01:28:54,612 --> 01:28:58,583 OF SERIOUS DISEASE. ONE OF THE 2407 01:28:58,583 --> 01:29:00,151 THINGS WE ARE INTERESTED IN 2408 01:29:00,151 --> 01:29:01,819 SINCE WE ARE HERE AT NCATS I'M 2409 01:29:01,819 --> 01:29:03,921 INTERESTED IN, I GUESS I'M 2410 01:29:03,921 --> 01:29:05,823 ALWAYS SURPRISED WHEN I SEE 2411 01:29:05,823 --> 01:29:08,493 DESCRIPTIONS OF ARPA H AND ONE 2412 01:29:08,493 --> 01:29:11,696 OF YOUR FIRST SLIDES DESCRIBE 2413 01:29:11,696 --> 01:29:14,465 ARPA H FOCUSED ON CANCER 2414 01:29:14,465 --> 01:29:15,600 ALZHEIMERS AND DIABETES. I 2415 01:29:15,600 --> 01:29:17,502 ABSOLUTELY UNDERSTAND AND 2416 01:29:17,502 --> 01:29:18,670 APPRECIATE YOUR DESCRIPTION HERE 2417 01:29:18,670 --> 01:29:21,673 TALKING EMPHASIS ON RARE DISEASE 2418 01:29:21,673 --> 01:29:23,541 BUT WITHIN THE AUTHORIZING 2419 01:29:23,541 --> 01:29:24,876 LANGUAGE WE WERE SUPER 2420 01:29:24,876 --> 01:29:26,577 INTENTIONAL TALKING ABOUT UNMET 2421 01:29:26,577 --> 01:29:28,146 NEEDS AND DISEASE BURDEN. SO I 2422 01:29:28,146 --> 01:29:29,514 GUESS I'M WONDERING CAN YOU TALK 2423 01:29:29,514 --> 01:29:32,016 A LITTLE BIT ABOUT AS YOU THINK 2424 01:29:32,016 --> 01:29:33,918 ABOUT THE PRIORITIZATION OF 2425 01:29:33,918 --> 01:29:35,253 RESOURCES AND RESOURCE 2426 01:29:35,253 --> 01:29:37,188 ALLOCATION, HAS THERE BEEN ANY 2427 01:29:37,188 --> 01:29:40,525 THOUGHT ABOUT HOW YOU ENSURE 2428 01:29:40,525 --> 01:29:43,795 INDEED WE ARE MAKING SURE WE 2429 01:29:43,795 --> 01:29:44,929 ACCELERATE BETTER HEALTH 2430 01:29:44,929 --> 01:29:45,730 OUTCOMES FOR EVERYONE AND ALL 2431 01:29:45,730 --> 01:29:47,165 THE MAJOR RESOURCES AREN'T GOING 2432 01:29:47,165 --> 01:29:50,034 TO COMMUNITIES WHO ARGUABLY ARE 2433 01:29:50,034 --> 01:29:50,968 RECEIVING SIGNIFICANT AMOUNT OF 2434 01:29:50,968 --> 01:29:51,803 RESOURCES FROM OTHER PROJECTS 2435 01:29:51,803 --> 01:29:55,773 ALREADY. AND MAKE THEM SAY WE 2436 01:29:55,773 --> 01:29:57,775 DO, I CARE DEEPLY, WE ALL CARE 2437 01:29:57,775 --> 01:30:00,178 DEEPLY ABOUT CANCER DIABETES AND 2438 01:30:00,178 --> 01:30:01,412 ALZHEIMER'S BUT THE RARE DISEASE 2439 01:30:01,412 --> 01:30:03,748 COMMUNITY IS NOT RECEIVING A 2440 01:30:03,748 --> 01:30:06,651 SIGNIFICANT PORTION OF RESOURCES 2441 01:30:06,651 --> 01:30:08,219 ALREADY AND WE VERY MUCH WOULD 2442 01:30:08,219 --> 01:30:09,587 LAKE TO SEA SIGNIFICANT PORTION 2443 01:30:09,587 --> 01:30:14,325 OF RESOURCES COME FROM ARP H BE 2444 01:30:14,325 --> 01:30:15,460 DEDICATED TO THOSE PROJECTS. 2445 01:30:15,460 --> 01:30:18,796 >> LET ME TRY TO UNPACK. SO I AM 2446 01:30:18,796 --> 01:30:20,131 FIRST THANK YOU FOR THE WORK 2447 01:30:20,131 --> 01:30:21,265 THAT YOU DID TO PUT THAT 2448 01:30:21,265 --> 01:30:22,500 AUTHORIZING LANGUAGE IN PLACE. 2449 01:30:22,500 --> 01:30:25,770 IT WAS ONE OF THE THINGS THAT I 2450 01:30:25,770 --> 01:30:26,904 MENTIONED EARLY ON THAT I WENT 2451 01:30:26,904 --> 01:30:28,940 ON THE HILL AND TALKED TO 2452 01:30:28,940 --> 01:30:29,841 MEMBERS OF THE CONGRESS ABOUT 2453 01:30:29,841 --> 01:30:32,043 THINGS UNCOMPROMISING ON. THE 2454 01:30:32,043 --> 01:30:34,378 THING I WAS INSISTENT WE WERE 2455 01:30:34,378 --> 01:30:35,847 UNCOMPROMISING ON WAS NOT A 2456 01:30:35,847 --> 01:30:38,716 SINGLE DOLLAR OF ARPA H DOLLAR 2457 01:30:38,716 --> 01:30:40,618 COULD BE LINKED TO SPECIFIC 2458 01:30:40,618 --> 01:30:41,986 DISEASE. WE HAVE TO HAVE TOTAL 2459 01:30:41,986 --> 01:30:43,654 FREEDOM OF WHAT TO FUND FROM THE 2460 01:30:43,654 --> 01:30:44,822 DISEASE PERSPECTIVE TO THE 2461 01:30:44,822 --> 01:30:46,357 TECHNOLOGY TO THE STATE, YOU 2462 01:30:46,357 --> 01:30:48,526 NAME IT, IT IS UP TO US TO 2463 01:30:48,526 --> 01:30:50,762 DECIDE. WE HAVE THAT AUTHORITY. 2464 01:30:50,762 --> 01:30:52,630 AND I WILL DEFEND THAT DURING 2465 01:30:52,630 --> 01:30:54,098 ALL OF MY TIME HERE AS DIRECTOR. 2466 01:30:54,098 --> 01:30:57,301 SO THERE IS NO LANGUAGE AROUND 2467 01:30:57,301 --> 01:30:58,936 ALZHEIMER'S OR CANCER OR 2468 01:30:58,936 --> 01:31:00,204 DIABETES. I KNOW THAT HAS 2469 01:31:00,204 --> 01:31:01,773 FLOATED OUT THERE. WE DON'T USE 2470 01:31:01,773 --> 01:31:06,210 THAT INTERNALLYLY. BUT TO SAY IF 2471 01:31:06,210 --> 01:31:08,813 WE HAVE A PROPOSAL OR PROGRAM 2472 01:31:08,813 --> 01:31:11,282 THAT PROGRAM MANAGER IDENTIFIES 2473 01:31:11,282 --> 01:31:13,584 A GAP THAT IS T NOT BEING 2474 01:31:13,584 --> 01:31:15,153 ADDRESSED WE DO THAT ON MARKET 2475 01:31:15,153 --> 01:31:16,287 ANALYSIS TO MAKE SURE THE 2476 01:31:16,287 --> 01:31:17,955 PRIVATE SECTOR IS NOT ALREADY 2477 01:31:17,955 --> 01:31:20,892 ADDRESSING IT INTERNAL AT NIH WE 2478 01:31:20,892 --> 01:31:22,493 HAVE A DECONFLICTING PROCESS TO 2479 01:31:22,493 --> 01:31:23,828 MAKE SURE THERE IS NOT PROJECTS 2480 01:31:23,828 --> 01:31:27,498 ALREADY FUNDED. WE DO THAT 2481 01:31:27,498 --> 01:31:28,399 DIGITALLY, 88,000 PROPOSAL AS 2482 01:31:28,399 --> 01:31:30,034 YEAR, WE LOOK THROUGH THOSE AND 2483 01:31:30,034 --> 01:31:32,703 WORK WITH PEOPLE AT NCATS OR THE 2484 01:31:32,703 --> 01:31:34,739 RELEVANT INSTITUTES TO ENSURE 2485 01:31:34,739 --> 01:31:36,741 OUR INVESTMENTS TRULY ARE UNIQUE 2486 01:31:36,741 --> 01:31:40,378 AND ONLY RELEVANT FOR ARPA H. 2487 01:31:40,378 --> 01:31:44,248 THEN ONCE WE DO ALL THOSE 2488 01:31:44,248 --> 01:31:47,451 THINGS, WE TRY TO MAP A 2489 01:31:47,451 --> 01:31:49,153 PORTFOLIO. WE DON'T SAY I CAN'T 2490 01:31:49,153 --> 01:31:51,155 TELL YOU WHAT WE ARE GOING TO 2491 01:31:51,155 --> 01:31:52,590 FUND THREE YEARS FROM NOW 2492 01:31:52,590 --> 01:31:53,491 BECAUSE I HAVEN'T MET THE 2493 01:31:53,491 --> 01:31:54,559 PROGRAM MANAGERS WHERE ET IN 2494 01:31:54,559 --> 01:31:55,793 MANY CASES SO WE DON'T HAVE A 2495 01:31:55,793 --> 01:31:57,595 PLAN THE NEXT TEN YEARS. BUT WE 2496 01:31:57,595 --> 01:31:59,897 DO HAVE THE PORTFOLIO MAP TO 2497 01:31:59,897 --> 01:32:01,365 MAKE SURE WHERE WE IDENTIFY 2498 01:32:01,365 --> 01:32:03,234 WHITE SPACE, I WILL GIVE COUPLE 2499 01:32:03,234 --> 01:32:05,903 OF EXAMPLES, WE HAVE WHITE SPACE 2500 01:32:05,903 --> 01:32:07,572 IN RARE DISEASE, WHITE SPACE IN 2501 01:32:07,572 --> 01:32:08,573 MATERNAL HEALTH AND WE HAVE 2502 01:32:08,573 --> 01:32:10,474 WHITE SPACE IN PEDIATRICS. 2503 01:32:10,474 --> 01:32:11,843 THESE ARE AREAS WE HAVE 2504 01:32:11,843 --> 01:32:13,811 IDENTIFIED AS A GAP THAT WE 2505 01:32:13,811 --> 01:32:16,280 THINK OUR INVESTMENT CAN MAKE AN 2506 01:32:16,280 --> 01:32:17,448 ASYMMETRICAL TO MANAGE. BUT THE 2507 01:32:17,448 --> 01:32:19,784 TRICK TO ARPA IS YOU NEED TO 2508 01:32:19,784 --> 01:32:23,654 CHAMPION TO COME IN AND BE THAT 2509 01:32:23,654 --> 01:32:25,756 PROGRAMS MANAGER IN PROJECTS 2510 01:32:25,756 --> 01:32:28,426 AROUND THAT AREA,S THAT MY POINT 2511 01:32:28,426 --> 01:32:30,228 AROUND THE FLY WHEEL. THE 2512 01:32:30,228 --> 01:32:31,796 PORTFOLIO THIS YEAR SHOULD LOOK 2513 01:32:31,796 --> 01:32:32,830 TOTALLY DIFFERENT THAN FIVE 2514 01:32:32,830 --> 01:32:34,732 YEARS FROM NOW. IF YOU LOOK AT 2515 01:32:34,732 --> 01:32:37,034 DARPA THAT IS EXACTLY THE CASE. 2516 01:32:37,034 --> 01:32:38,502 WHILE TODAY WE DON'T HAVE A RARE 2517 01:32:38,502 --> 01:32:40,071 DISEASE PROJECT I CERTAINLY HOPE 2518 01:32:40,071 --> 01:32:41,639 SEVERAL MONTHS FROM NOW WE WILL. 2519 01:32:41,639 --> 01:32:43,307 T THIS IS WHERE YOU BRING IN 2520 01:32:43,307 --> 01:32:45,509 YOUR COMMUNITY AND HELPING US 2521 01:32:45,509 --> 01:32:46,844 IDENTIFY THOSE CHAMPIONS WHO CAN 2522 01:32:46,844 --> 01:32:49,447 BE HERE FOR THREE YEARS OF A 2523 01:32:49,447 --> 01:32:52,984 TERM TO BE FULL CHAMPION EFFORT 2524 01:32:52,984 --> 01:32:55,086 THEN THEY WILL VACATE, LEAVE THE 2525 01:32:55,086 --> 01:32:56,554 SLOT OPEN FOR THE NEXT PERSON IS 2526 01:32:56,554 --> 01:32:57,488 WHAT IS IMPORTANT ABOUT THIS 2527 01:32:57,488 --> 01:32:59,156 AGENCY. I HOPE THAT MAKES SENSE 2528 01:32:59,156 --> 01:33:02,193 AND ANSWERS YOUR QUESTION. 2529 01:33:02,193 --> 01:33:04,061 >> IT DOES, HELPFUL TO 2530 01:33:04,061 --> 01:33:06,264 UNDERSTAND YOU IDENTIFYING THE 2531 01:33:06,264 --> 01:33:07,732 WHITE SPACES AND NOT FILLING ALL 2532 01:33:07,732 --> 01:33:09,634 THE FUNDING WITH WHATEVER THE 2533 01:33:09,634 --> 01:33:11,936 OTHER SPACE, SO THANK YOU VERY 2534 01:33:11,936 --> 01:33:12,803 MUCH. 2535 01:33:12,803 --> 01:33:15,873 >> I CAN MEET AFTERWARDS TO 2536 01:33:15,873 --> 01:33:18,109 SHARE OUT BUT IF YOU GO TO BROAD 2537 01:33:18,109 --> 01:33:20,378 AGENCY ANNOUNCEMENT, OPEN BAA 2538 01:33:20,378 --> 01:33:23,047 THE FOUR FOCUS AREAS THE HEALTH 2539 01:33:23,047 --> 01:33:24,749 SCIENCE SCALABLE SOLUTIONS UNDER 2540 01:33:24,749 --> 01:33:26,984 EACH IS ABOUT TEN EXAMPLES OF 2541 01:33:26,984 --> 01:33:29,687 AREAS WE THINK WE COULD HAVE A 2542 01:33:29,687 --> 01:33:31,722 OUTSIDE IMPACT. LIKE PEDIATRICS, 2543 01:33:31,722 --> 01:33:32,957 MATERNAL HEALTH, ADOLESCENT 2544 01:33:32,957 --> 01:33:34,725 MENTAL HEALTH. THESE ARE AREAS 2545 01:33:34,725 --> 01:33:36,093 WE THINK WE CAN MAKE IMPACT. SO 2546 01:33:36,093 --> 01:33:38,129 WE ARE FLAGGING TO THE COMMUNITY 2547 01:33:38,129 --> 01:33:40,197 HEY, WE NEED THOSE IDEAS BUT 2548 01:33:40,197 --> 01:33:41,699 AGAIN THOSE IDEAS COME FROM THE 2549 01:33:41,699 --> 01:33:43,401 OUTSIDE IN. IT IS -- IT DOESN'T 2550 01:33:43,401 --> 01:33:51,042 COME FROM US TOP DOWN. 2551 01:33:51,042 --> 01:33:54,745 >> RENEE, THANK YOU SO MUCH FOR 2552 01:33:54,745 --> 01:33:56,814 JOINING US TODAY. AND SPENDING 2553 01:33:56,814 --> 01:33:58,449 TIME WAS. I KNOW YOU HAVE BEEN 2554 01:33:58,449 --> 01:34:00,084 INCREDIBLY BUSY OVER THE LAST 2555 01:34:00,084 --> 01:34:01,819 FEW WEEKS, SEEN THE 2556 01:34:01,819 --> 01:34:02,653 ANNOUNCEMENTS SO APPRECIATE YOUR 2557 01:34:02,653 --> 01:34:03,421 TIME AND THANK YOU FOR THE 2558 01:34:03,421 --> 01:34:03,721 DISCUSSION. 2559 01:34:03,721 --> 01:34:08,125 >> THANK YOU ALL. APPRECIATE IT 2560 01:34:08,125 --> 01:34:09,961 APPRECIATE YOU JONI. BYE-BYE. 2561 01:34:09,961 --> 01:34:11,529 >> ALL RIGHT. TAKE CARE. SO WITH 2562 01:34:11,529 --> 01:34:11,646 THAT I THINK WE ARE TEN MINUTE BREAK. 2563 01:34:11,646 --> 01:34:13,113 I THINK WE ARE READY TO 2564 01:34:13,113 --> 01:34:16,050 RESUME. THANK YOU, EVERYONE, 2565 01:34:16,050 --> 01:34:19,820 WELCOME BACK. WE WILL START OUR 2566 01:34:19,820 --> 01:34:21,321 CONCEPT CLEARANCES NOW. SO LET'S 2567 01:34:21,321 --> 01:34:23,991 GO AHEAD AND MOVE FORWARD WITH 2568 01:34:23,991 --> 01:34:25,859 DR. DAN TAGLY WHO WILL TALK 2569 01:34:25,859 --> 01:34:30,664 ABOUT TISSUE CHIPS IN SPACE -- 2570 01:34:30,664 --> 01:34:32,633 DR. TAGLE WHO WILL TALK TISSUE 2571 01:34:32,633 --> 01:34:33,667 CHIPS IN SPACE AND BEYOND. 2572 01:34:33,667 --> 01:34:34,968 >> GOOD AFTERNOON, THANK YOU, 2573 01:34:34,968 --> 01:34:38,172 JONI. I WILL BE TALKING THE 2574 01:34:38,172 --> 01:34:41,809 FIRST OF CONCEPT CLEARANCES FROM 2575 01:34:41,809 --> 01:34:45,746 NCATS, FIRST OFF WOULD BE TO 2576 01:34:45,746 --> 01:34:47,948 INTRODUCE OFFICE OF SPECIALTY 2577 01:34:47,948 --> 01:34:49,383 INITIATIVES AND TELL YOU MORE 2578 01:34:49,383 --> 01:34:53,854 ABOUT WHAT WE DO AS AN OFFICE. 2579 01:34:53,854 --> 01:34:56,623 SO OFFICE SPECIALIST SERVES 2580 01:34:56,623 --> 01:34:58,625 WITHIN NCATS ADDRESSES 2581 01:34:58,625 --> 01:35:01,528 TRANSLATIONAL PROBLEMS TO 2582 01:35:01,528 --> 01:35:03,397 CREATIVE SOLUTIONS BY INNOVATING 2583 01:35:03,397 --> 01:35:05,632 AND CREATING DISRUPTIVE 2584 01:35:05,632 --> 01:35:07,434 TECHNOLOGIES THROUGH NOVEL 2585 01:35:07,434 --> 01:35:08,402 PARTNERSHIPS THAT RESULTS IN 2586 01:35:08,402 --> 01:35:12,539 PARADIGM SHIFT. IN THE FIELD. 2587 01:35:12,539 --> 01:35:13,674 SO WE HAVE A NUMBER OF PROGRAMS 2588 01:35:13,674 --> 01:35:14,775 AND ACTIVITIES WITHIN OUR 2589 01:35:14,775 --> 01:35:18,278 OFFICE. AS YOU CAN SEE HERE IN 2590 01:35:18,278 --> 01:35:20,748 THIS SLIDE OUR TECHNOLOGIES SPAN 2591 01:35:20,748 --> 01:35:22,216 THE RANGE FROM FUNDAMENTAL 2592 01:35:22,216 --> 01:35:26,220 RESEARCH ALL THE WAY THROUGH 2593 01:35:26,220 --> 01:35:28,355 PRE-CLINICAL THROUGH REGULATORY 2594 01:35:28,355 --> 01:35:30,357 ACCEPTANCE. ALL THE PROGRAMS WE 2595 01:35:30,357 --> 01:35:33,460 DO PRIMARILY ADHERE TO THE NCATS 2596 01:35:33,460 --> 01:35:36,029 3-D PRINCIPLES OF DEVELOPING 2597 01:35:36,029 --> 01:35:36,864 TECHNOLOGY, DEMON INVESTIGATING 2598 01:35:36,864 --> 01:35:39,199 THE UTILITY OF THE TECHNOLOGY, 2599 01:35:39,199 --> 01:35:40,968 AND ULTIMATELY BEING ABLE TO 2600 01:35:40,968 --> 01:35:42,970 DISSEMINATE THE TECHNOLOGY FOR 2601 01:35:42,970 --> 01:35:46,340 PUBLIC USE. SO WE HAVE A NUMBER 2602 01:35:46,340 --> 01:35:47,608 OF DIFFERENT PROGRAMS, WITHIN 2603 01:35:47,608 --> 01:35:49,943 THE OFFICE HIGHLIGHTED IN BLUE 2604 01:35:49,943 --> 01:35:52,012 ARE TECHNOLOGIES THAT ARE 2605 01:35:52,012 --> 01:35:55,883 PRIMARILY AI DRIVEN, ARTIFICIAL 2606 01:35:55,883 --> 01:35:56,917 INTELLIGENCE OR INTELLIGENCE 2607 01:35:56,917 --> 01:36:01,088 MOSTLY AREA OF MANUFACTURING. Z 2608 01:36:01,088 --> 01:36:02,956 WHERE WILL CHEMISTRY, AUTOMATED 2609 01:36:02,956 --> 01:36:04,291 CHEMISTRY OR SIP THETIC BIOLOGY, 2610 01:36:04,291 --> 01:36:08,028 SHOWN IN PURPLE ARE DIAGNOSTIC 2611 01:36:08,028 --> 01:36:09,396 TECHNOLOGIES AS WELL AS 2612 01:36:09,396 --> 01:36:12,800 DETECTION TECHNOLOGIES SHOWN 2613 01:36:12,800 --> 01:36:15,135 THERE WOULD BE USING ELECTRONIC 2614 01:36:15,135 --> 01:36:19,740 NODE TECHNOLOGY AND WE HAVE ALSO 2615 01:36:19,740 --> 01:36:21,742 PRIVILEGED TO WORK IN ERA OF 2616 01:36:21,742 --> 01:36:23,443 COVID FOR RAPID ACCELERATION OF 2617 01:36:23,443 --> 01:36:26,480 DIAGNOSTICS. SHOWN IN PINK WOULD 2618 01:36:26,480 --> 01:36:28,749 BE NEW AREA IN TERMS OF QUANTUM 2619 01:36:28,749 --> 01:36:30,851 INFORMATION SCIENCES USING 2620 01:36:30,851 --> 01:36:32,653 QUANTUM COMPUTATIONAL AND 2621 01:36:32,653 --> 01:36:35,088 QUANTUM BIOSENSING TECHNOLOGIES. 2622 01:36:35,088 --> 01:36:39,793 IN YELLOW WOULD BE A PROGRAM OF 2623 01:36:39,793 --> 01:36:41,161 REGENERATIVE MEDICINE TISSUE 2624 01:36:41,161 --> 01:36:44,264 REPAIR AND WOUND HEALING. THEN 2625 01:36:44,264 --> 01:36:46,500 THE LIGHT BLUE WOULD BE NIH 2626 01:36:46,500 --> 01:36:49,036 COMMON FUND AREAS IN TERMS OF 2627 01:36:49,036 --> 01:36:52,573 EXOSOMES AND EXTRA CELLULAR RNA 2628 01:36:52,573 --> 01:36:55,042 AS WELL AS NEUROMODULATION. WE 2629 01:36:55,042 --> 01:36:57,010 ALSO HAVE PARTNERSHIPS WITH 2630 01:36:57,010 --> 01:37:00,013 ANOTHER AGENCY OUTSIDE OF NIH, 2631 01:37:00,013 --> 01:37:02,149 NSF LOOKING AT CYBER PHYSICAL 2632 01:37:02,149 --> 01:37:05,319 SYSTEMS AND ROBOTICS. THEN THE 2633 01:37:05,319 --> 01:37:07,287 LAST CATEGORY OF ACTIVITIES WE 2634 01:37:07,287 --> 01:37:09,890 HAVE IS SHOWN IN GREEN, MOSTLY 2635 01:37:09,890 --> 01:37:14,328 IN TERMS OF MICROFABRICATED 2636 01:37:14,328 --> 01:37:16,230 TISSUES, 3-D BIOPRINTING AND 2637 01:37:16,230 --> 01:37:18,599 TISSUE CHIPS. SO THE CONCEPT I 2638 01:37:18,599 --> 01:37:19,867 WILL BRING FORWARD TODAY WOULD 2639 01:37:19,867 --> 01:37:21,902 BE RELATED TO THE TISSUE CHIP 2640 01:37:21,902 --> 01:37:23,136 TECHNOLOGY THAT NCATS INVESTED 2641 01:37:23,136 --> 01:37:28,308 IN OVER THE PAST DECADE OR SO. 2642 01:37:28,308 --> 01:37:30,177 SO THE TITLE OF CONCEPT IS 2643 01:37:30,177 --> 01:37:33,814 TISSUE CHIPS IN SPACE 2.0. 2644 01:37:33,814 --> 01:37:35,182 CLDs AND BEYOND. I WILL GO 2645 01:37:35,182 --> 01:37:39,253 INTO DETAIL ABOUT THIS CONCEPT. 2646 01:37:39,253 --> 01:37:41,288 SO TISSUE CHIPS IN SPACE 2.0 IS 2647 01:37:41,288 --> 01:37:44,825 ESSENTIALLY A RENEWAL SO THIS 2648 01:37:44,825 --> 01:37:45,959 HAS BEEN PREVIOUSLY CONCEPT 2649 01:37:45,959 --> 01:37:47,728 CLEARED AND WE DID RUN A PROGRAM 2650 01:37:47,728 --> 01:37:49,096 OVER THE COURSE OF THE LAST FIVE 2651 01:37:49,096 --> 01:37:52,733 YEARS OR SO. SO INDUSTRY 2652 01:37:52,733 --> 01:37:54,534 RENEWAL OF TISSUE CHIP AND 2653 01:37:54,534 --> 01:37:56,737 PROGRAM WILL BE FOCUS ON 2654 01:37:56,737 --> 01:37:59,172 CONNECTIVITY AND INTEGRATION OF 2655 01:37:59,172 --> 01:38:01,275 MULTI--- MULTIPLE ORGAN SYSTEMS 2656 01:38:01,275 --> 01:38:02,509 AND TISSUE CHIPS THAT 2657 01:38:02,509 --> 01:38:04,544 APPROXIMATE MATE A HUMAN BODY ON 2658 01:38:04,544 --> 01:38:06,346 A CHIP SYSTEM. WE ALSO WANT TO 2659 01:38:06,346 --> 01:38:09,650 ESTABLISH THE USE OF IPS STEM 2660 01:38:09,650 --> 01:38:12,653 CELL DERIVED MATERIALS FROM 2661 01:38:12,653 --> 01:38:16,323 DIVERSE GROUP OF INDIVIDUALS, 2662 01:38:16,323 --> 01:38:19,593 THAT REPRESENTS SEX AND VARIOUS 2663 01:38:19,593 --> 01:38:22,162 ETHNICITIES AS WELL AS 2664 01:38:22,162 --> 01:38:23,330 DEVELOPMENTAL AGE. AND WE ARE 2665 01:38:23,330 --> 01:38:26,500 PRIMARILY LOOKING IN TERMS OF 2666 01:38:26,500 --> 01:38:28,068 INITIALLY LOOKING AT NASA AND 2667 01:38:28,068 --> 01:38:29,636 COMMERCIAL ASTRONAUTS PRIMARILY 2668 01:38:29,636 --> 01:38:31,438 TO SERVE AS THEIR OWN TISSUE 2669 01:38:31,438 --> 01:38:35,709 CHIP AVENUE TARS. AVATARS AND 2670 01:38:35,709 --> 01:38:36,510 BEING TRANSLATED FOR USE ON 2671 01:38:36,510 --> 01:38:37,945 EARTH TO HAVE PERSONALIZED CHIPS 2672 01:38:37,945 --> 01:38:41,615 FOR INDIVIDUALS. WE ALSO WANT TO 2673 01:38:41,615 --> 01:38:43,517 IN THIS RENEWAL INCORPORATE 2674 01:38:43,517 --> 01:38:45,519 ADVANCEMENTS THAT WE HAVE MADE 2675 01:38:45,519 --> 01:38:48,255 IN TERMS OF 3-D MICROFABRICATION 2676 01:38:48,255 --> 01:38:49,723 TISSUE CHIP TECHNOLOGY SUCH AS 2677 01:38:49,723 --> 01:38:51,959 BEING ABLE TO EXPAND CULTURE 2678 01:38:51,959 --> 01:38:53,493 LIFE BEYOND SIX MONTHS AS WELL 2679 01:38:53,493 --> 01:38:55,462 AS AUTOMATE AND MINIATURIZED 2680 01:38:55,462 --> 01:38:57,731 PLATFORMS. SO IN THIS 2681 01:38:57,731 --> 01:39:00,734 PARTICULAR RENEWAL, THE OFFICE 2682 01:39:00,734 --> 01:39:04,004 OF SPECIAL INITIATIVES PRIMARILY 2683 01:39:04,004 --> 01:39:06,006 WANTS TO IMPROVE DISEASE 2684 01:39:06,006 --> 01:39:07,674 OUTCOMES BY TRANSLATING 2685 01:39:07,674 --> 01:39:08,909 OBSERVATIONS FROM BIOMEDICAL 2686 01:39:08,909 --> 01:39:12,112 RESEARCH EXPERIMENTS IN SPACE 2687 01:39:12,112 --> 01:39:13,880 INTERVENTIONS THAT BENEFIT THE 2688 01:39:13,880 --> 01:39:17,551 HEALTH OF INDIVIDUALS AND PUBLIC 2689 01:39:17,551 --> 01:39:19,052 HERE ON EARTH. SO WHAT DOES THAT 2690 01:39:19,052 --> 01:39:25,993 LOOK LIKE? SO IN TERMS OF THE 2691 01:39:25,993 --> 01:39:26,760 BIOMEDICAL RESEARCH 2692 01:39:26,760 --> 01:39:27,961 OPPORTUNITIES, AS YOU CAN SEE 2693 01:39:27,961 --> 01:39:29,963 HERE BOTH IN TERMS OF LOW EARTH 2694 01:39:29,963 --> 01:39:33,433 ORBIT AND SPACE, THERE ARE 2695 01:39:33,433 --> 01:39:35,402 OPPORTUNITIES TO MODEL DISEASES 2696 01:39:35,402 --> 01:39:37,404 IN HUMAN CONDITIONS THAT MAY BE 2697 01:39:37,404 --> 01:39:39,906 DIFFICULT OR TAKE LONGER ON 2698 01:39:39,906 --> 01:39:41,942 EARTH. IN ONE PARTICULAR AREA 2699 01:39:41,942 --> 01:39:45,479 WOULD BE ON AGING. IT TAKES 2700 01:39:45,479 --> 01:39:47,814 OBVIOUSLY YEARS IF NOT DECADES 2701 01:39:47,814 --> 01:39:51,418 TO MODEL HUMAN AGING BUT UNDER 2702 01:39:51,418 --> 01:39:53,186 INFLUENCE OF MICROGRAVITY AS 2703 01:39:53,186 --> 01:39:54,621 TURNS OUT WE CAN DO SO IN A 2704 01:39:54,621 --> 01:39:57,424 MATTER OF WEEKS OR MONTHS. 2705 01:39:57,424 --> 01:40:00,160 THERE'S ALSO OPPORTUNITIES TO 2706 01:40:00,160 --> 01:40:01,395 BETTER UNDERSTAND EFFECT OF 2707 01:40:01,395 --> 01:40:03,997 COSMIC RADIATION, MICROGRAVITY, 2708 01:40:03,997 --> 01:40:07,200 AND PHYSICAL ISOLATION THAT 2709 01:40:07,200 --> 01:40:09,302 COULD DEVELOP EFFECTIVE 2710 01:40:09,302 --> 01:40:10,937 INTERVENTIONS AND COUNTER 2711 01:40:10,937 --> 01:40:13,140 MEASURES. OPPORTUNITIES ALSO 2712 01:40:13,140 --> 01:40:16,109 REST ON BIOMANUFACTURING, 2713 01:40:16,109 --> 01:40:19,679 ABILITY TO CRYSTALLIZE PROTEINS, 2714 01:40:19,679 --> 01:40:22,282 AS WELL AS BIOPRINT ORGAN 2715 01:40:22,282 --> 01:40:23,917 SYSTEMS UNDER MICROGRAVITY THAT 2716 01:40:23,917 --> 01:40:25,852 COULD BE HELPFUL FOR 2717 01:40:25,852 --> 01:40:27,220 REGENERATIVE MEDICINE. WE ARE 2718 01:40:27,220 --> 01:40:29,856 ALSO LOOKING AT OPPORTUNITIES 2719 01:40:29,856 --> 01:40:33,093 FOR TELEMETRY AND OTHER ROBOTIC 2720 01:40:33,093 --> 01:40:34,428 AND OTHER AUTONOMOUS SYSTEMS 2721 01:40:34,428 --> 01:40:37,097 THAT LEND ITSELF FOR UNDERSOURCE 2722 01:40:37,097 --> 01:40:40,834 OR UNDERSERVE AREAS IN TERMS OF 2723 01:40:40,834 --> 01:40:42,636 HEALTHCARE DELIVERY. THEN 2724 01:40:42,636 --> 01:40:46,339 LASTLY, WE ARE LOOKING TO ENABLE 2725 01:40:46,339 --> 01:40:48,141 POSSIBILITY OF CREATING LONG 2726 01:40:48,141 --> 01:40:51,144 SHELF LIFE PHARMACEUTICALS 2727 01:40:51,144 --> 01:40:53,847 AND/OR ON DEMAND PHARMACOLOGY 2728 01:40:53,847 --> 01:40:55,182 CAPABILITIES. SO WHAT HAS BEEN 2729 01:40:55,182 --> 01:40:59,719 DONE SO FAR? IN TERMS HOW HAS 2730 01:40:59,719 --> 01:41:00,954 THIS OPPORTUNITY BEEN TRANSLATED 2731 01:41:00,954 --> 01:41:02,389 FOR USE HERE ON EARTH? HERE ARE 2732 01:41:02,389 --> 01:41:08,328 JUST A FEW EXAMPLES WHERE NIH 2733 01:41:08,328 --> 01:41:11,565 HAVE MORE RECENTLY TRIED TO 2734 01:41:11,565 --> 01:41:15,435 CRYSTALLIZE KRAS, A ONCOPROTEIN 2735 01:41:15,435 --> 01:41:17,871 AS A WHOLE PROTEIN IT'S BEEN 2736 01:41:17,871 --> 01:41:20,440 DIFFICULT TO CRYSTALLIZE 2737 01:41:20,440 --> 01:41:21,641 ESPECIALLY WITH HYPERVARIABLE 2738 01:41:21,641 --> 01:41:25,278 REGION BEING INCORPORATED INTO 2739 01:41:25,278 --> 01:41:29,015 THE G DOMAIN. THAT HAS BEEN 2740 01:41:29,015 --> 01:41:32,152 POSSIBLE UNDER MICROGRAVITY. A 2741 01:41:32,152 --> 01:41:33,854 SECOND AREA THAT HAS COME OUT IN 2742 01:41:33,854 --> 01:41:36,556 TERMS OF BIOMEDICAL RESEARCH IN 2743 01:41:36,556 --> 01:41:38,458 SPACE IS TO IMPROVE PRODUCTION 2744 01:41:38,458 --> 01:41:41,027 PROCESSES FOR MONOCLONAL 2745 01:41:41,027 --> 01:41:43,897 ANTIBODY KETRUDO. IN THE PAST 2746 01:41:43,897 --> 01:41:47,300 DELIVERED BY IV INFUSION WHICH 2747 01:41:47,300 --> 01:41:49,236 TAKES SEVERAL HOURS AND REQUIRES 2748 01:41:49,236 --> 01:41:51,371 HOSPITALIZATION, BUT UNDER 2749 01:41:51,371 --> 01:41:54,975 MICROGRAVITY THIS IS UNIFORM 2750 01:41:54,975 --> 01:41:56,877 CRYSTALS IN SIMILAR THAN 2751 01:41:56,877 --> 01:41:58,578 TRANSLATED THAT PROCESS INTO 2752 01:41:58,578 --> 01:42:01,348 BEING ABLE TO MANUFACTURE 2753 01:42:01,348 --> 01:42:03,116 KEYTRUDA INTO HOMOGENOUS 2754 01:42:03,116 --> 01:42:05,819 CRYSTALS THAT HAVE BEEN ABLE SUB 2755 01:42:05,819 --> 01:42:09,890 Q INEX SOMEWHERE. MORE RELATED 2756 01:42:09,890 --> 01:42:13,760 DOWN TO EARTH IN TERMS OF HOW WE 2757 01:42:13,760 --> 01:42:16,630 HAVE ENABLED TISSUE CHIP 2758 01:42:16,630 --> 01:42:19,166 TECHNOLOGY TO INFORM BIOMEDICAL 2759 01:42:19,166 --> 01:42:21,735 RESEARCH OVER THE LAST FOUR OR 2760 01:42:21,735 --> 01:42:23,203 FIVE YEARS OR SO OF THE PROGRAM, 2761 01:42:23,203 --> 01:42:24,971 THAT'S BEEN RUNNING, WE HAVE 2762 01:42:24,971 --> 01:42:28,508 BEEN ABLE TO UNDERSTAND HOW 2763 01:42:28,508 --> 01:42:30,076 CARDIOVASCULAR DIP AND CHIP -- 2764 01:42:30,076 --> 01:42:31,878 DECONDITIONING HAPPENS TO OUR 2765 01:42:31,878 --> 01:42:34,981 CARDIO MYSELFCYTES AND CHIPS, 2766 01:42:34,981 --> 01:42:36,249 SHOWN THAT SIX MONTHS OF 2767 01:42:36,249 --> 01:42:38,618 EXPOSURE UNDER MICROGRAVITY IS 2768 01:42:38,618 --> 01:42:40,086 EQUIVALENT TO TEN YEARS OF 2769 01:42:40,086 --> 01:42:41,621 BIOLOGICAL AGING SO YOU CAN 2770 01:42:41,621 --> 01:42:45,592 DEFINITELY STUDY THIS KIND OF 2771 01:42:45,592 --> 01:42:46,927 PROCESSES, PHYSIOLOGICAL 2772 01:42:46,927 --> 01:42:48,128 PROCESSES IN A MUCH MORE 2773 01:42:48,128 --> 01:42:50,630 ACCELERATED TIME LINE. WE HAVE 2774 01:42:50,630 --> 01:42:53,934 ALSO SHOWN DECREASE FORCE 2775 01:42:53,934 --> 01:42:55,969 CONTRACTILITY AS WELL AS SWITCH 2776 01:42:55,969 --> 01:42:57,437 FORCE NOT ONLY CARDIAC BUT 2777 01:42:57,437 --> 01:42:58,805 SKELETAL MUSCLE SO EFFECTIVELY 2778 01:42:58,805 --> 01:43:01,908 BEING ABLE TO USE THIS 2779 01:43:01,908 --> 01:43:04,244 INFORMATION TO STUDY SARCOPENIA 2780 01:43:04,244 --> 01:43:09,549 OR MUSCLE WASTING. AGAIN, THAT 2781 01:43:09,549 --> 01:43:13,220 IS SHOWN, MUSCLE LOSS IS 2782 01:43:13,220 --> 01:43:14,621 ACCELERATED FROM ONE PERCENT 2783 01:43:14,621 --> 01:43:17,123 NORMALLY HERE ON EARTH TO ABOUT 2784 01:43:17,123 --> 01:43:20,860 3% MUSCLE LOSS IN SPACE. WE 2785 01:43:20,860 --> 01:43:25,065 HAVE ALSO SHOWN BIOMARKER 2786 01:43:25,065 --> 01:43:26,066 CHANGES THAT ARE SIMILAR TO 2787 01:43:26,066 --> 01:43:28,735 THOSE OBSERVED FOR AGING OF THE 2788 01:43:28,735 --> 01:43:30,303 IMMUNE CELLS SUCH AS 2789 01:43:30,303 --> 01:43:34,107 IMMUNOSENESCENCE. LASTLY, WHAT 2790 01:43:34,107 --> 01:43:37,978 WE ARE TRYING TO DO IS MAKE 2791 01:43:37,978 --> 01:43:39,212 TECHNOLOGY THAT SUPPORTS AND 2792 01:43:39,212 --> 01:43:42,782 RUNS TISSUE CHIP TO BE AUTOMATED 2793 01:43:42,782 --> 01:43:46,953 AND TRANSFERABLE SO ALLOWING 2794 01:43:46,953 --> 01:43:50,257 ACCESS TO LOW INCOME AND MIDDLE 2795 01:43:50,257 --> 01:43:55,528 INCOME COUNTRIES. SO WHAT HAS 2796 01:43:55,528 --> 01:43:58,498 BEEN SHOWN AS I MENTION 2797 01:43:58,498 --> 01:44:00,533 MICROGRAVITY EXPOSURE INDUCES 2798 01:44:00,533 --> 01:44:04,838 AGING RELATED CHANGES. LIKE 2799 01:44:04,838 --> 01:44:05,939 SARCOPENIA, BONE DENSITY LOSS, 2800 01:44:05,939 --> 01:44:08,508 CARD YES VASCULAR 2801 01:44:08,508 --> 01:44:11,278 DECONDITIONING, GI DISTURBANCE, 2802 01:44:11,278 --> 01:44:12,946 CHANGES IN BLOOD CELLS, 2803 01:44:12,946 --> 01:44:18,385 DECLINING IMMUNI IMMUNITY. AND L 2804 01:44:18,385 --> 01:44:20,654 STONE INFLAMMATION. TISSUE CHIPS 2805 01:44:20,654 --> 01:44:21,888 AN SPACE PROGRAM WAS A 2806 01:44:21,888 --> 01:44:23,256 PARTNERSHIP WITH NCATS, NASA, 2807 01:44:23,256 --> 01:44:24,591 THE CENTER FOR ADVANCEMENT OF 2808 01:44:24,591 --> 01:44:26,793 SCIENCE IN SPACE AND 2809 01:44:26,793 --> 01:44:29,029 INTERNATIONAL SPACE STATION 2810 01:44:29,029 --> 01:44:30,697 NATIONAL LABORATORY. WE HAD TO 2811 01:44:30,697 --> 01:44:32,299 GO MODELING AGE RELATED DISEASE 2812 01:44:32,299 --> 01:44:36,836 UNDER MICROGRAVITY TO BE ABLE TO 2813 01:44:36,836 --> 01:44:38,071 TRANSLATE THE OPPORTUNITIES THAT 2814 01:44:38,071 --> 01:44:41,408 WE LEARNED FOR IMPROVEMENTS HERE 2815 01:44:41,408 --> 01:44:43,610 ON EFFORT. ONE OF THE THINGS 2816 01:44:43,610 --> 01:44:45,178 THAT CAME OUT OF THIS 2817 01:44:45,178 --> 01:44:46,513 PARTNERSHIP, NOVEL PARTNERSHIP 2818 01:44:46,513 --> 01:44:50,283 WAS WORKING WITH PAYLOAD 2819 01:44:50,283 --> 01:44:51,418 DEVELOPERS AN SPACE ENGINEERS 2820 01:44:51,418 --> 01:44:53,386 WITH ABILITY TO AUTOMATE AND 2821 01:44:53,386 --> 01:44:54,621 MINIATURIZE THE PLATFORM. SO 2822 01:44:54,621 --> 01:44:56,656 SHOWN HERE IS AN EXAMPLE HOW 2823 01:44:56,656 --> 01:45:00,827 THIS HAS HAPPENED. IN LOOKING AT 2824 01:45:00,827 --> 01:45:03,496 THIS AS A PROJECT BY JONATHAN 2825 01:45:03,496 --> 01:45:05,899 (INAUDIBLE) KIDNEY ON A CHIP SO 2826 01:45:05,899 --> 01:45:09,035 IN ORDER TO RUN 24 KIDNEY CHIPS 2827 01:45:09,035 --> 01:45:12,539 REQUIRES INCUBATOR SPACE ALONG 2828 01:45:12,539 --> 01:45:16,443 WITH THE CONTROLLERS, VALVES AND 2829 01:45:16,443 --> 01:45:17,977 TUBINGS, 48 CUBIC FEET THE SIZE 2830 01:45:17,977 --> 01:45:20,113 OF YOUR AVERAGE KITCHEN 2831 01:45:20,113 --> 01:45:20,947 REFRIGERATOR BUT CERTAINLY 2832 01:45:20,947 --> 01:45:25,985 WORKING WITH SPACEX AND NASA AND 2833 01:45:25,985 --> 01:45:30,557 BEING ABLE TO REALIZE THAT THE 2834 01:45:30,557 --> 01:45:32,325 PAYLOAD HAS TO BE REDUCED THE 2835 01:45:32,325 --> 01:45:37,263 SIZE OF A SHOE BOX. SO WE WORK 2836 01:45:37,263 --> 01:45:40,800 EFFECTIVELY WITH SPACE TANGO AND 2837 01:45:40,800 --> 01:45:42,969 BIOSERVE, SPACE IMPLEMENTATION 2838 01:45:42,969 --> 01:45:44,537 PARTNERS THAT BRING DOWN TO 2839 01:45:44,537 --> 01:45:46,005 PRACTICE AND BE ABLE TO 2840 01:45:46,005 --> 01:45:48,341 MINIATURIZE AND AUTOMATE 2841 01:45:48,341 --> 01:45:49,776 TECHNOLOGIES. SO THIS IS NOW IN 2842 01:45:49,776 --> 01:45:53,213 THE PROCESS OF TRYING TO TAKE 2843 01:45:53,213 --> 01:45:54,948 THIS TECHNOLOGICAL ADVANCEMENT 2844 01:45:54,948 --> 01:46:01,554 FOR USE HERE ON EARTH. SO THIS 2845 01:46:01,554 --> 01:46:04,491 SHOWS WE HAVE BEEN SUCCESSFUL IN 2846 01:46:04,491 --> 01:46:05,291 MINIMIZING THE TECHNOLOGY AND 2847 01:46:05,291 --> 01:46:07,060 AUTOMATING IT SO WE HAVE HAD A 2848 01:46:07,060 --> 01:46:10,597 HAD A TOTAL OF NINE LAUNCHES 2849 01:46:10,597 --> 01:46:15,101 EACH FIRST SET WAS TO SHOW 2850 01:46:15,101 --> 01:46:17,003 TECHNOLOGY CAN PERFORM UNDER 2851 01:46:17,003 --> 01:46:18,571 PRESSURE OF LAUNCH OPERATIONS 2852 01:46:18,571 --> 01:46:20,273 UNDER MICRO GRAVITY AND BRINGING 2853 01:46:20,273 --> 01:46:22,175 BACK THE SAMPLES HERE ON EARTH 2854 01:46:22,175 --> 01:46:27,914 FOR ANALYSIS. THE SECOND LAUNCH 2855 01:46:27,914 --> 01:46:29,749 WAS THEN TO LOOK AT THE 2856 01:46:29,749 --> 01:46:33,420 BIOMARKERS IDENTIFIED THAT WOULD 2857 01:46:33,420 --> 01:46:35,755 INDICATE ACCELERATED AGING AND 2858 01:46:35,755 --> 01:46:37,290 TO TEST COUNTER MEASURES OR 2859 01:46:37,290 --> 01:46:39,292 INTERVENTIONS THAT WILL SLOW 2860 01:46:39,292 --> 01:46:44,497 DOWN EFFECTS OF AGING SO IT CAN 2861 01:46:44,497 --> 01:46:46,966 BE MARKETED TO EVENTUAL USE HERE 2862 01:46:46,966 --> 01:46:50,470 ON EARTH. SO WHAT ARE WE LOOKING 2863 01:46:50,470 --> 01:46:58,578 FOR IN -- DURING RENEWAL, TISSUE 2864 01:46:58,578 --> 01:46:59,579 CHIPS 2.0. OBJECTIVES ARE 2865 01:46:59,579 --> 01:47:02,081 LOOKING AT DEPLOYMENT OF TISSUE 2866 01:47:02,081 --> 01:47:04,117 CHIPS AS GREATER MODELS OF 2867 01:47:04,117 --> 01:47:05,585 ACCELERATED AGING TO DEVELOP 2868 01:47:05,585 --> 01:47:07,020 INTERVENTIONS AND COUNTER 2869 01:47:07,020 --> 01:47:08,388 MEASURES TO MITIGATE AGING 2870 01:47:08,388 --> 01:47:10,924 EFFECTS HERE ON EARTH, DEPLOY 2871 01:47:10,924 --> 01:47:12,725 MULTI-ORGAN INTEGRATED PLATFORMS 2872 01:47:12,725 --> 01:47:14,594 THAT CLOSELY APPROXIMATE HUMAN 2873 01:47:14,594 --> 01:47:16,062 BODY IN A CHIP SYSTEM, TO BE 2874 01:47:16,062 --> 01:47:18,264 ABLE TO SEE THIS TISSUE CHIPS 2875 01:47:18,264 --> 01:47:20,266 WITH ORGAN SPECIFIC CELL TYPES 2876 01:47:20,266 --> 01:47:23,069 AND DIVERSE GROUPS OF PEOPLE FOR 2877 01:47:23,069 --> 01:47:24,270 PRECISION MEDICINE TO 2878 01:47:24,270 --> 01:47:25,738 INCORPORATE ADVANCEMENT IN 2879 01:47:25,738 --> 01:47:27,607 TISSUE CHIP TECHNOLOGY SUCH AS 2880 01:47:27,607 --> 01:47:29,275 CULTURE LIFE BEYOND SIX MONTHS 2881 01:47:29,275 --> 01:47:31,411 AND AUTOMATED AND MINIATURIZED 2882 01:47:31,411 --> 01:47:34,080 PLATFORMS TO BE ABLE TO ACCESS 2883 01:47:34,080 --> 01:47:36,516 -- ASSESS QUALITY AND INTEGRITY 2884 01:47:36,516 --> 01:47:38,318 OF STEM CELLS SUITABLE FOR IN 2885 01:47:38,318 --> 01:47:40,220 SPACE BIOMANUFACTURING INCLUDING 2886 01:47:40,220 --> 01:47:42,121 THE PRODUCTION OF THERAPEUTIC 2887 01:47:42,121 --> 01:47:44,357 EXOSOMES FOR REGENERATIVE 2888 01:47:44,357 --> 01:47:47,126 MEDICINE. AND THEN ENABLE 4D 2889 01:47:47,126 --> 01:47:49,562 BUYER PRINTING CAPABILITIES 2890 01:47:49,562 --> 01:47:51,998 UNDER MICROGRAVITY TO ALLOW FREE 2891 01:47:51,998 --> 01:47:54,467 FORM VOLUME METRIC PRINTING OF 2892 01:47:54,467 --> 01:47:57,937 COMPLEXION ORGAN CONSTRUCTS. SO 2893 01:47:57,937 --> 01:48:01,007 THE KEY AREAS OF EMPHASIS IN 2894 01:48:01,007 --> 01:48:03,109 THIS RENEWAL WOULD BE 2895 01:48:03,109 --> 01:48:04,911 PARTNERSHIP AGAIN WITH NASA AND 2896 01:48:04,911 --> 01:48:08,548 POSSIBLY WORKING OUT AGREEMENTS 2897 01:48:08,548 --> 01:48:10,650 WITH SPACE AGENCY AS WELL AS 2898 01:48:10,650 --> 01:48:11,818 CURRENT INTERNATIONAL SPACE 2899 01:48:11,818 --> 01:48:14,587 STATION NATIONAL LABORATORY AND 2900 01:48:14,587 --> 01:48:16,556 AS YOU KNOW THE CURRENT SPACE 2901 01:48:16,556 --> 01:48:18,691 STATION IS SCHEDULED TO BE 2902 01:48:18,691 --> 01:48:22,629 DECOMMISSIONED STARTING IN 2025. 2903 01:48:22,629 --> 01:48:24,364 SO THERE ARE NOW EFFORTS TO 2904 01:48:24,364 --> 01:48:28,334 BRING UP CLDs OR COMMERCIAL 2905 01:48:28,334 --> 01:48:30,470 LEGAL DESTINATIONS, THERE ARE 2906 01:48:30,470 --> 01:48:32,906 FOUR FROM ACTION SPACE, FROM 2907 01:48:32,906 --> 01:48:38,211 ORBITAL REEF WHICH IS FUNDED BY 2908 01:48:38,211 --> 01:48:43,283 BLUE ORIGIN AND ALSO LOOKING AT 2909 01:48:43,283 --> 01:48:50,523 LOCKHEED MARTIN AND NORTHRUP 2910 01:48:50,523 --> 01:48:51,424 GRUM MIRKSN. WE ARE WORKING WITH 2911 01:48:51,424 --> 01:48:52,425 INSTITUTES AN CENTERS AT THE NIH 2912 01:48:52,425 --> 01:48:54,460 TO PROVIDE FUNDING SUCH AS THE 2913 01:48:54,460 --> 01:48:57,230 NATIONAL INSTITUTE FOR AGING. 2914 01:48:57,230 --> 01:49:03,336 AND LOOKING AT ABILITY TO 2915 01:49:03,336 --> 01:49:05,338 POSITION TISSUE CHIPS TO BE 2916 01:49:05,338 --> 01:49:07,273 BIOMEDICAL EXPERIMENT OF CHOICE 2917 01:49:07,273 --> 01:49:09,842 BEYOND LOW EARTH ORBIT. THERE IS 2918 01:49:09,842 --> 01:49:11,945 NOW DISCUSSIONS IN TERMS OF 2919 01:49:11,945 --> 01:49:13,146 MISSION TO MOON AND MISSION TO 2920 01:49:13,146 --> 01:49:14,914 MARS. WE STILL DON'T KNOW WHAT 2921 01:49:14,914 --> 01:49:16,683 THE HEALTH HAZARDS THAT WE ARE 2922 01:49:16,683 --> 01:49:18,885 GOING TO BE EXPOSING THE 2923 01:49:18,885 --> 01:49:23,056 ASTRONAUTS AND EVENTUALLY SPACE 2924 01:49:23,056 --> 01:49:25,725 COLONIZERS, SO TALKING ABOUT 2925 01:49:25,725 --> 01:49:29,062 POSSIBILITIES OF USING TISSUE 2926 01:49:29,062 --> 01:49:32,498 CHIPS, TO BE PART OF THE MISSION 2927 01:49:32,498 --> 01:49:35,602 OF ARTEMIS III OR THE MISSION O 2928 01:49:35,602 --> 01:49:37,804 TO MARS WHERE TISSUE CHIPS WILL 2929 01:49:37,804 --> 01:49:40,306 BE POSITIONED TO ANTICIPATE WHAT 2930 01:49:40,306 --> 01:49:43,242 THE EXPOSURE HAZARDS WOULD BE 2931 01:49:43,242 --> 01:49:49,482 FOR FUTURE SPACE COLONIZERS. SO 2932 01:49:49,482 --> 01:49:53,419 WHY NCATS? CERTAINLY NCATS HAS 2933 01:49:53,419 --> 01:49:54,687 BEEN -- OCCURRED IN PREVIOUS 2934 01:49:54,687 --> 01:49:57,223 DISCUSSION, LEADER IN TISSUE 2935 01:49:57,223 --> 01:49:57,991 CHIP TECHNOLOGY HERE IN THE 2936 01:49:57,991 --> 01:50:00,460 UNITED STATES AS WELL AS 2937 01:50:00,460 --> 01:50:03,229 INTERNATIONALLY. WE ALSO SERVE 2938 01:50:03,229 --> 01:50:06,432 AS THE DR. JONI ROGERS SERVES AS 2939 01:50:06,432 --> 01:50:10,169 THE HHS AND NIH LIAISON TO NASA 2940 01:50:10,169 --> 01:50:11,904 IN TERMS OF INTERFACING AND 2941 01:50:11,904 --> 01:50:13,506 PARTNERING WITH THEM IN TERMS OF 2942 01:50:13,506 --> 01:50:14,941 BIOMEDICAL RESEARCH IN SPACE. 2943 01:50:14,941 --> 01:50:17,377 AND LOOKING AT WHAT ARE THE 2944 01:50:17,377 --> 01:50:19,178 EXPECTED OUTCOMES AND IMPACT OF 2945 01:50:19,178 --> 01:50:22,482 THIS NEW CONCEPT, WE SHOULD BE 2946 01:50:22,482 --> 01:50:23,583 IN A POSITION TO UNDERSTAND 2947 01:50:23,583 --> 01:50:25,585 HUMAN CELLULAR RESPONSES, SPACE 2948 01:50:25,585 --> 01:50:30,189 FLIGHT. AND BE ABLE TO 2949 01:50:30,189 --> 01:50:30,990 UNDERSTAND AND DEVELOP MODEL 2950 01:50:30,990 --> 01:50:33,893 SYSTEMS TO STUDY AGING EFFECTS. 2951 01:50:33,893 --> 01:50:35,995 PROVIDE KEY INSIGHTS O THE 2952 01:50:35,995 --> 01:50:37,997 CONTROL AND OPTIMIZATION OF STEM 2953 01:50:37,997 --> 01:50:41,100 CELL DIFFERENTIATION, SUCH AS 2954 01:50:41,100 --> 01:50:43,736 PLURIPOTENCY, MULTI-POTENCY. AS 2955 01:50:43,736 --> 01:50:45,204 WELL AS STEM CELLS TO 2956 01:50:45,204 --> 01:50:47,407 PROLIFERATE AND EXPAND UNDER 2957 01:50:47,407 --> 01:50:48,508 MICROGRAVITY, HOW WE CAN 2958 01:50:48,508 --> 01:50:49,409 ACCELERATE THE MATURATION 2959 01:50:49,409 --> 01:50:51,944 PROCESS UNDER MICROGRAVITY. 2960 01:50:51,944 --> 01:50:53,646 INCREASE USE OF EXOSOME BASED 2961 01:50:53,646 --> 01:50:55,214 THERAPIES FOR TISSUE REPAIR AND 2962 01:50:55,214 --> 01:50:58,051 WOUND HEALING. AND THEN BE ABLE 2963 01:50:58,051 --> 01:50:59,218 TO DEVELOP THERAPEUTICS AND 2964 01:50:59,218 --> 01:51:01,587 COUNTER MEASURES FOR 2965 01:51:01,587 --> 01:51:02,321 PHYSIOLOGICAL CHANGES. 2966 01:51:02,321 --> 01:51:04,157 ASSOCIATED WITH THE AGING 2967 01:51:04,157 --> 01:51:08,327 PROCESS. AND LASTLY BE ABLE TO 2968 01:51:08,327 --> 01:51:10,296 ENABLE TISSUE CHIP CORE 2969 01:51:10,296 --> 01:51:12,899 PRECISION MEDICINE TISSUE ON A 2970 01:51:12,899 --> 01:51:15,535 CHIP SYSTEM AND BUILD UP 2971 01:51:15,535 --> 01:51:17,003 CAPABILITIES FOR 4D BIOPRINTING 2972 01:51:17,003 --> 01:51:19,572 OR ORGAN PRODUCTION UNDER 2973 01:51:19,572 --> 01:51:20,807 MICROGRAVITY FOR USE IN 2974 01:51:20,807 --> 01:51:21,674 REGENERATIVE MEDICINE HERE ON 2975 01:51:21,674 --> 01:51:26,512 EARTH. IN TERMS OF WHAT WE 2976 01:51:26,512 --> 01:51:28,948 ANTICIPATE SUCCESS OF THIS 2977 01:51:28,948 --> 01:51:32,251 PROGRAM, WE WOULD LIKE AGAIN TO 2978 01:51:32,251 --> 01:51:34,954 REITERATE WE WILL BE -- TO MODEL 2979 01:51:34,954 --> 01:51:38,124 ACCELERATED AGING, 30% DIVERSE 2980 01:51:38,124 --> 01:51:40,059 POPULATIONS IN CHIPS TO DEVELOP 2981 01:51:40,059 --> 01:51:42,261 TISSUE CHIP AVATARS FOR USE IN 2982 01:51:42,261 --> 01:51:45,364 PRECISION MEDICINE. WE WOULD 2983 01:51:45,364 --> 01:51:47,133 LIKE TO ALSO LOOK AT DEVELOPMENT 2984 01:51:47,133 --> 01:51:49,902 OF COUNTER MEASURES AGAINST 2985 01:51:49,902 --> 01:51:54,574 AGING RADIATION EXPOSURE DUE TO 2986 01:51:54,574 --> 01:51:57,677 COSMIC RADIATION AN EVENTUALLY 2987 01:51:57,677 --> 01:51:58,778 TO HAVE A BETTER UNDERSTANDING 2988 01:51:58,778 --> 01:52:03,015 OF HUMAN BIOLOGY RELATES TO 2989 01:52:03,015 --> 01:52:05,885 CHRONIC EXPOSURE TO HAZARDS AND 2990 01:52:05,885 --> 01:52:08,588 RISKS ASSOCIATED WITH SPACE 2991 01:52:08,588 --> 01:52:12,291 FLIGHFLIGHT IN SUMMARY MAIN GOAF 2992 01:52:12,291 --> 01:52:14,927 TISSUE CHIPS 2.0 PUTTING FORTH 2993 01:52:14,927 --> 01:52:15,962 FOR COUNCIL FOR CONSIDERATION OF 2994 01:52:15,962 --> 01:52:17,663 RENEWAL IS TO BE ABLE TO IMPROVE 2995 01:52:17,663 --> 01:52:19,866 DISEASE OUTCOMES BY TRANSLATING 2996 01:52:19,866 --> 01:52:21,567 OBSERVATIONS FROM BIOMEDICAL 2997 01:52:21,567 --> 01:52:24,270 RESEARCH IN SPACE, INTO 2998 01:52:24,270 --> 01:52:25,772 INTERVENTIONS THAT BENEFIT 2999 01:52:25,772 --> 01:52:29,008 HEALTH OF INDIVIDUALS AND PUBLIC 3000 01:52:29,008 --> 01:52:32,111 ON EARTH. THIS WILL BE A CONCEPT 3001 01:52:32,111 --> 01:52:34,347 BUILT UPON ALREADY BY SUCCESSFUL 3002 01:52:34,347 --> 01:52:37,049 PARTNERSHIPS THAT NCATS HAD WITH 3003 01:52:37,049 --> 01:52:40,586 NASA, THE ISS AND PURSUING OTHER 3004 01:52:40,586 --> 01:52:42,588 PARTNERSHIPS. POTENTIALLY WITH 3005 01:52:42,588 --> 01:52:45,158 ARPA H AND COMMERCIAL VIDEO 3006 01:52:45,158 --> 01:52:46,492 DESTINATION AS WELL AS OTHER 3007 01:52:46,492 --> 01:52:47,126 INSTITUTES AND CENTERS AT THE 3008 01:52:47,126 --> 01:52:50,830 NIH. THIS INITIATIVE WILL 3009 01:52:50,830 --> 01:52:53,699 ADVANCE MULTIPLE OTHER RELATED 3010 01:52:53,699 --> 01:52:55,601 FIELDS RELATED TO TISSUE CHIPS 3011 01:52:55,601 --> 01:52:57,870 SUCH AS TISSUE ENGINEERING 3012 01:52:57,870 --> 01:52:59,338 MECHANIC KNOW BIOLOGY, 3013 01:52:59,338 --> 01:53:00,239 REGENERATIVE DISEASE MODELING 3014 01:53:00,239 --> 01:53:05,178 AND SPACE MEDICINE. SO IN THIS 3015 01:53:05,178 --> 01:53:06,612 LAST SLIDE JUST A FEW QUESTIONS 3016 01:53:06,612 --> 01:53:08,681 FOR COUNCIL FOR CONSIDERATION 3017 01:53:08,681 --> 01:53:10,016 AND COMMENTS IN TERMS OF WHAT 3018 01:53:10,016 --> 01:53:12,118 MIGHT IMPROVE THIS INITIATIVE 3019 01:53:12,118 --> 01:53:13,452 FROM PREVIOUS VERSION OR 3020 01:53:13,452 --> 01:53:15,588 PREVIOUS ITERATION. WHAT ARE 3021 01:53:15,588 --> 01:53:18,491 THE KEY POINTS TO CONSIDER THAT 3022 01:53:18,491 --> 01:53:20,893 I MAY HAVE MISSD IN THIS 3023 01:53:20,893 --> 01:53:24,330 RENEWAL. SPECIFIC QUESTIONS FOR 3024 01:53:24,330 --> 01:53:27,667 COUNCIL JUST TO PARAPHRASE 3025 01:53:27,667 --> 01:53:29,702 CAPTAIN JAMES KIRK FROM THE USS 3026 01:53:29,702 --> 01:53:31,704 ENTERPRISE, HOW CAN NCATS BEST 3027 01:53:31,704 --> 01:53:34,140 LEVERAGE TISSUE AVATARS TO GO 3028 01:53:34,140 --> 01:53:35,608 BOLDLY WHERE NO MAN HAS GONE 3029 01:53:35,608 --> 01:53:37,710 BEFORE. THANK YOU. HAPPY TO 3030 01:53:37,710 --> 01:53:41,280 ENTERTAIN ANY QUESTIONS. 3031 01:53:41,280 --> 01:53:43,716 >> THANK YOU, DAN. I BELIEVE WE 3032 01:53:43,716 --> 01:53:48,020 DO HAVE SOME DISCUSSION. I HAVE 3033 01:53:48,020 --> 01:53:51,958 MATTHIAS AND PAULA TO GO FIRST. 3034 01:53:51,958 --> 01:53:52,892 MATTHIAS, FIRST ON MY LIST, DO 3035 01:53:52,892 --> 01:53:54,427 YOU WANT TO START? 3036 01:53:54,427 --> 01:53:59,332 >> DAN, AS ALWAYS AS YOU HAVE 3037 01:53:59,332 --> 01:54:01,234 FOR THE LAST TWO DECADES, VERY 3038 01:54:01,234 --> 01:54:03,636 EXCITED TO SEE THIS CONTINUE AND 3039 01:54:03,636 --> 01:54:05,705 I WOULD SOLUTIONS DEVELOP IN 3040 01:54:05,705 --> 01:54:08,174 SPACE FOR US DOWN HERE ON EARTH. 3041 01:54:08,174 --> 01:54:09,842 THAT IS WELL ALIGNED WITH THE 3042 01:54:09,842 --> 01:54:11,744 NCATS MISSION BUT ALSO BE AWARE 3043 01:54:11,744 --> 01:54:14,947 SOLUTION DEVELOPED IN SPACE FOR 3044 01:54:14,947 --> 01:54:16,649 SPACE, THAT SHOULD BE PAID FOR 3045 01:54:16,649 --> 01:54:20,186 BY NASA. SO CONTINUE YOUR VERY 3046 01:54:20,186 --> 01:54:22,154 EFFECTIVE DISCUSSIONS, THIS CORE 3047 01:54:22,154 --> 01:54:24,724 FUNDING BECAUSE I DON'T THINK 3048 01:54:24,724 --> 01:54:26,058 NCATS FUNDING SHOULD TEACH US 3049 01:54:26,058 --> 01:54:29,195 HOW WE KEEP OUR PEOPLE ALIVE IN 3050 01:54:29,195 --> 01:54:33,232 SPACE. THAT IS A BIG ASK. I 3051 01:54:33,232 --> 01:54:35,034 SERVED ON VERY SUCCESSFUL MANY 3052 01:54:35,034 --> 01:54:37,003 THE PAST KEEP CORE FUNDINGS 3053 01:54:37,003 --> 01:54:38,671 MOVING FORWARD BECAUSE NASA 3054 01:54:38,671 --> 01:54:40,239 BENEFITED TREMENDOUSLY FROM ALL 3055 01:54:40,239 --> 01:54:41,974 THE INVESTMENTS N CATS HAS MADE 3056 01:54:41,974 --> 01:54:47,546 >> THANK Y THANK YOU. MATTHIAS.K 3057 01:54:47,546 --> 01:54:49,081 TO CONTINUE THAT PARTNERSHIP, AS 3058 01:54:49,081 --> 01:54:50,750 I POINTED OUT WE ARE ALSO 3059 01:54:50,750 --> 01:54:54,186 ENTERING A ERA IN SPACE MEDICINE 3060 01:54:54,186 --> 01:54:56,188 AND SPACE EXPLORATION BECAUSE 3061 01:54:56,188 --> 01:54:57,290 NASA HAS BEEN LOOKING IN TERMS 3062 01:54:57,290 --> 01:55:00,826 OF HOW TO COMMERCIALIZE SPACE. 3063 01:55:00,826 --> 01:55:02,929 THE REPLACEMENTS FOR 3064 01:55:02,929 --> 01:55:05,531 INTERNATIONAL SPACE STATION WILL 3065 01:55:05,531 --> 01:55:07,867 HAVE TO BE -- WILL BE PRIMARILY 3066 01:55:07,867 --> 01:55:09,835 PRIVATE FUNDING SO NAVIGATING IN 3067 01:55:09,835 --> 01:55:13,739 TERMS OF HOW WE PARTNER WITH 3068 01:55:13,739 --> 01:55:16,575 PRIVATE CORPORATIONS RIGHT NOW 3069 01:55:16,575 --> 01:55:19,612 SUCH AS ORBITAL REEF, AGAIN, 3070 01:55:19,612 --> 01:55:23,783 FUNDED BY JEFF BEZOS, BLUE 3071 01:55:23,783 --> 01:55:27,553 ORIGIN COMPANY, NOR THEREUPON 3072 01:55:27,553 --> 01:55:28,554 GRUMMIN LOCKHEED MARTIN, THOSE 3073 01:55:28,554 --> 01:55:29,855 ARE ALL NEW TERRITORYS WE ARE IN 3074 01:55:29,855 --> 01:55:30,823 THE PROCESS OF TRYING TO 3075 01:55:30,823 --> 01:55:33,159 DETERMINE WHAT THE BEST 3076 01:55:33,159 --> 01:55:36,395 PARTNERSHIP OPPORTUNITIES MAY 3077 01:55:36,395 --> 01:55:37,863 ARISE. 3078 01:55:37,863 --> 01:55:41,801 >> EXCELLENT KEY. GOOD LUCK. 3079 01:55:41,801 --> 01:55:44,136 WHAT WE CAN OFFER TO THOSE IS 3080 01:55:44,136 --> 01:55:49,108 THESE ARE KEY ASSETS WHO WILL 3081 01:55:49,108 --> 01:55:50,476 HELP TO DEVELOP PROGRAMS ALSO 3082 01:55:50,476 --> 01:55:54,113 FROM THE COMMERCIAL SIDE TO KEEP 3083 01:55:54,113 --> 01:55:57,016 PEOPLE SAFE. I THINK FROM THE 3084 01:55:57,016 --> 01:56:00,486 CONCEPT THE MAIN SUCCESS FROM MY 3085 01:56:00,486 --> 01:56:02,388 VANTAGE POINT WAS OF THE CURRENT 3086 01:56:02,388 --> 01:56:06,592 PROGRAMS THAT YOU REALLY FORCE 3087 01:56:06,592 --> 01:56:09,028 INVESTIGATORS TO DEVELOP 3088 01:56:09,028 --> 01:56:11,797 ULTIMATE SOLUTIONS FOR THEIR 3089 01:56:11,797 --> 01:56:13,299 PLATFORMS. THAT IS FOR ME ONE 3090 01:56:13,299 --> 01:56:16,969 OF THE MAIN DELIVERABLES AND 3091 01:56:16,969 --> 01:56:18,571 PROBABLY ONE OF THE CONSEQUENCES 3092 01:56:18,571 --> 01:56:19,939 WHY FDA NOW CONSIDERS THESE 3093 01:56:19,939 --> 01:56:22,842 PLATFORMS TO BE READY FOR 3094 01:56:22,842 --> 01:56:25,511 THERAPEUTIC USE. YOU SHOULD 3095 01:56:25,511 --> 01:56:29,382 ABSOLUTELY TAKE THA THA THAT. 3096 01:56:29,382 --> 01:56:31,050 >> THANK YOU FOR POINTING THAT 3097 01:56:31,050 --> 01:56:32,618 OUT. THAT IS PROBABLY IN SOME 3098 01:56:32,618 --> 01:56:34,653 WAYS THE MORE TANGIBLE EVIDENCE 3099 01:56:34,653 --> 01:56:35,988 OF THIS PRODUCTIVE PARTNERSHIP 3100 01:56:35,988 --> 01:56:40,760 WITH NASA IS THE CAPABILITY TO 3101 01:56:40,760 --> 01:56:43,262 DEMOCRATIZE TISSUE CHIP PLATFORM 3102 01:56:43,262 --> 01:56:44,830 BECAUSE EVEN NOW AS SHOWN ON THE 3103 01:56:44,830 --> 01:56:46,499 SLIDE, THE TECHNOLOGY IS VERY 3104 01:56:46,499 --> 01:56:48,834 PROMISING BUT THE SUPPORTING 3105 01:56:48,834 --> 01:56:53,005 INSTRUMENTATION CAN STILL BE 3106 01:56:53,005 --> 01:56:54,240 TECHNICALLY HARD AND WOULD 3107 01:56:54,240 --> 01:56:56,675 REQUIRE BIOMEDICAL ENGINEERS TO 3108 01:56:56,675 --> 01:56:59,211 RUN SUCH A SYSTEM. BUT WITH 3109 01:56:59,211 --> 01:57:00,679 AUTOMATION AND CERTAINLY WITH 3110 01:57:00,679 --> 01:57:04,116 MINIATURIZATION OF SMALLER FOOD 3111 01:57:04,116 --> 01:57:07,086 PRINT, I HARKEN BACK TO DAYS 3112 01:57:07,086 --> 01:57:09,755 WHEN I WAS WORKING EARLY DAYS OF 3113 01:57:09,755 --> 01:57:11,857 PCR WHEN YOU WOULD BE DUNKING 3114 01:57:11,857 --> 01:57:13,659 EPITOPES INTO WATER BATHS AND 3115 01:57:13,659 --> 01:57:15,428 YOU HAVE TO BE BABY SIT IT. THE 3116 01:57:15,428 --> 01:57:18,097 ASTRONAUTS DON'T HAVE THE TIME 3117 01:57:18,097 --> 01:57:19,565 TO BABY SIT EXPERIMENTS IN SPACE 3118 01:57:19,565 --> 01:57:20,900 SO AUTOMATION IS A KEY FEATURE 3119 01:57:20,900 --> 01:57:22,768 IN TERMS OF STANDING BIOMEDICAL 3120 01:57:22,768 --> 01:57:25,538 RESEARCH IN SPACE, SO I THINK 3121 01:57:25,538 --> 01:57:27,306 THE AUTOMATION AND 3122 01:57:27,306 --> 01:57:28,340 MINIATURIZATION CAPABILITIES 3123 01:57:28,340 --> 01:57:32,211 THAT WE HAVE LEARNED WILL THEN 3124 01:57:32,211 --> 01:57:34,513 LEND ITSELF TO ALMOST LIKE A PCR 3125 01:57:34,513 --> 01:57:36,382 TYPE MACHINE INSTRUMENTATION FOR 3126 01:57:36,382 --> 01:57:37,616 TISSUE CHIPS WHERE YOU CAN PLUG 3127 01:57:37,616 --> 01:57:39,919 IN YOUR CHIPS, WALK AWAY, AND 3128 01:57:39,919 --> 01:57:43,789 COME BACK AND BE ABLE TO LOOK AT 3129 01:57:43,789 --> 01:57:45,491 THE DATA AS IT IS ALSO BEING 3130 01:57:45,491 --> 01:57:47,359 COLLECTED. SO I THINK THAT THAT 3131 01:57:47,359 --> 01:57:49,995 WOULD CERTAINLY LEND ITSELF FOR 3132 01:57:49,995 --> 01:57:51,263 WIDESPREAD ADOPTION NOT ONLY 3133 01:57:51,263 --> 01:57:54,133 WILL IT MAKE IT EASIER TO 3134 01:57:54,133 --> 01:57:57,837 OPERATE BUT IT ALSO MAKE IT 3135 01:57:57,837 --> 01:58:00,706 SUFFICIENT TO REQUIRE SUCH 3136 01:58:00,706 --> 01:58:07,446 TECHNOLOGICAL CAPABILITIES. 3137 01:58:07,446 --> 01:58:11,117 WHICH LEADS TO NEXT CASE HOW DO 3138 01:58:11,117 --> 01:58:12,685 YOU (INAUDIBLE) KELLY TWINS ONE 3139 01:58:12,685 --> 01:58:14,253 UP THERE AND ONE DOWN HERE WHICH 3140 01:58:14,253 --> 01:58:17,590 REALLY PROVIDED LOT OF HARD 3141 01:58:17,590 --> 01:58:21,227 EVIDENCE OF THE ACCELERATED 3142 01:58:21,227 --> 01:58:21,994 AGENING SPAC SPACE. 3143 01:58:21,994 --> 01:58:24,964 >> THAT WAS A KEY INSIGHT IN 3144 01:58:24,964 --> 01:58:29,602 TERMS OF HOW SCOTT (INAUDIBLE) 3145 01:58:29,602 --> 01:58:30,836 CHANGED PHYSIOLOGICALLY BUT IN 3146 01:58:30,836 --> 01:58:33,606 SOME WAYS SURPRISINGLY TOO THAT 3147 01:58:33,606 --> 01:58:35,274 MOST OF THE FUZZ OWE LOGICAL 3148 01:58:35,274 --> 01:58:37,143 CHANGES REVERTED BACK 3149 01:58:37,143 --> 01:58:38,677 UNFORTUNATELY FOR HIM REVERTED 3150 01:58:38,677 --> 01:58:40,146 BACK TO NORMAL WHEN HE RETURNED 3151 01:58:40,146 --> 01:58:41,714 BACK TO EARTH BUT THAT GIVES US 3152 01:58:41,714 --> 01:58:42,948 OPPORTUNITY TO THEN WHAT ARE THE 3153 01:58:42,948 --> 01:58:44,183 MOLECULAR SIGNATURES THAT 3154 01:58:44,183 --> 01:58:46,485 CHANGES WHEN YOU ARE EXPOSED TO 3155 01:58:46,485 --> 01:58:47,620 MICROGRAVITY THAT INSTITUTE THIS 3156 01:58:47,620 --> 01:58:49,722 -- ALL THE PHYSIOLOGICAL CHANGES 3157 01:58:49,722 --> 01:58:51,524 UNDER MICROGRAVITY RELATED TO 3158 01:58:51,524 --> 01:58:53,859 AGING. AND THEN LOOKING BACK AT 3159 01:58:53,859 --> 01:58:56,428 THE SIGNATURES THEN RETURNING TO 3160 01:58:56,428 --> 01:58:58,330 EARTH, SO THAT WE CAN BETTER 3161 01:58:58,330 --> 01:59:00,032 UNDERSTAND HOW WE CAN REVERSE OR 3162 01:59:00,032 --> 01:59:04,203 SLOW DOWN EFFECTS OF AGING. WE 3163 01:59:04,203 --> 01:59:06,105 ONLY HAVE ONE IDENTICAL TWINS 3164 01:59:06,105 --> 01:59:07,673 WHO ARE ASTRONAUTS SO THAT IS 3165 01:59:07,673 --> 01:59:10,776 OUR GOAL TO CREATE TISSUE CHIP 3166 01:59:10,776 --> 01:59:12,077 AVATARS INSTEAD OF HAVING 3167 01:59:12,077 --> 01:59:13,812 GENETIC TWINS WE WILL HAVE 3168 01:59:13,812 --> 01:59:16,582 TISSUE CHIPS WITH EVERYONE WHO 3169 01:59:16,582 --> 01:59:19,485 MIGHT BE CANDIDATE TO GO OUT THE 3170 01:59:19,485 --> 01:59:22,421 SPACE TO GO ALONG TISSUE CHIP 3171 01:59:22,421 --> 01:59:25,391 AVATAR TO IN DEPTH PROBING OF 3172 01:59:25,391 --> 01:59:26,091 PHYSIOLOGICAL CHANGES THAT MIGHT 3173 01:59:26,091 --> 01:59:27,493 BE HAPPENING TO THEM. SO THAT 3174 01:59:27,493 --> 01:59:30,062 GIVES US ALSO THE CAPABILITY 3175 01:59:30,062 --> 01:59:32,932 HERE ON EARTH TO CREATE TISSUE 3176 01:59:32,932 --> 01:59:35,968 CHIP AVATARS FOR DIAGNOSTICS AS 3177 01:59:35,968 --> 01:59:37,303 WELL AS PRECISION MEDICINE 3178 01:59:37,303 --> 01:59:37,703 APPLICATION. 3179 01:59:37,703 --> 01:59:40,172 >> I THIS I THAT IS MY FINAL 3180 01:59:40,172 --> 01:59:43,075 COMMENT, BENCHMARKING THOSE 3181 01:59:43,075 --> 01:59:44,510 SYSTEMS WILL AGAINST IN VIVO 3182 01:59:44,510 --> 01:59:48,247 STATE OBVIOUSLY YOU HAVE BEEN 3183 01:59:48,247 --> 01:59:49,281 DOING THROUGHOUT YOUR WILL BE 3184 01:59:49,281 --> 01:59:50,749 MORE RELEVANT AND WILL BE 3185 01:59:50,749 --> 01:59:53,085 PARTICULARLY RELEVANT TO MAKE 3186 01:59:53,085 --> 01:59:56,589 SURE THAT THE INSIDE OF THE 3187 01:59:56,589 --> 01:59:57,790 ACCELERATED AGING POLICIES WE 3188 01:59:57,790 --> 02:00:00,359 HAVE A FEW IDEAS WHAT 3189 02:00:00,359 --> 02:00:01,026 ACCELERATES BUT I DON'T THINK WE 3190 02:00:01,026 --> 02:00:02,494 HAVE ALL ANSWERS YET, IS 3191 02:00:02,494 --> 02:00:06,932 BECOMING AVAILABLE SO YOU KNOW 3192 02:00:06,932 --> 02:00:08,867 WHICH PROCESSES ACCELERATED OF 3193 02:00:08,867 --> 02:00:11,470 IT AND WHICH ONES ARE MAINTAINED 3194 02:00:11,470 --> 02:00:14,406 TO THE STATE WE HAVE FOUND HERE. 3195 02:00:14,406 --> 02:00:18,611 SO TECHNOLOGIES HAVE RAPIDLY 3196 02:00:18,611 --> 02:00:21,947 MATURED TO DO THAT, THIS 3197 02:00:21,947 --> 02:00:23,782 GENOMICS DATA STRUCTURE AND FROM 3198 02:00:23,782 --> 02:00:25,718 VERY MINDED ELEMENTS BUT 3199 02:00:25,718 --> 02:00:27,152 BENCHMARKING AGAINST THE 3200 02:00:27,152 --> 02:00:29,421 INDIVIDUALS WHERE YOU HAVE THE 3201 02:00:29,421 --> 02:00:33,425 IPC MODEST TISSUE SAFE, CREATIVE 3202 02:00:33,425 --> 02:00:36,495 SOLUTIONS NOW ALSO BECOMING 3203 02:00:36,495 --> 02:00:37,229 AVAILABLE MIGHT BE ONE ASPECT TO 3204 02:00:37,229 --> 02:00:37,796 CONSIDER. 3205 02:00:37,796 --> 02:00:40,466 >> THANK YOU. CERTAINLY WILL BE 3206 02:00:40,466 --> 02:00:41,800 CAREFUL TO HAVE THOSE 3207 02:00:41,800 --> 02:00:42,434 BENCHMARKS. 3208 02:00:42,434 --> 02:00:45,070 >> AND WE ARE A RESULT OVER TIME 3209 02:00:45,070 --> 02:00:49,208 SO WE MOVE US -- A LITTLE OVER 3210 02:00:49,208 --> 02:00:50,409 TIME SO MOVE TO NEXT QUESTION. 3211 02:00:50,409 --> 02:00:52,778 >> I'M INCREDIBLY ENTHUSIASTIC 3212 02:00:52,778 --> 02:00:54,446 ABOUT THIS PROGRAM. I DO BELIEVE 3213 02:00:54,446 --> 02:00:55,748 OUR NEXT GENERATION IS GOING TO 3214 02:00:55,748 --> 02:00:57,683 BE SPENDING LOTS OF TIME IN 3215 02:00:57,683 --> 02:00:59,885 SPACE AND THAT IS JUST GOING TO 3216 02:00:59,885 --> 02:01:01,520 BE YET ANOTHER TRANSLATIONAL 3217 02:01:01,520 --> 02:01:05,791 ISSUE FOR NCATS TO DEAL WITH AND 3218 02:01:05,791 --> 02:01:08,227 TO ACCELERATE NOT ONLY WHAT IS 3219 02:01:08,227 --> 02:01:11,363 GOING TO BE THE BENEFITS HERE ON 3220 02:01:11,363 --> 02:01:13,165 EARTH BUT ALSO HOW YOU KEEP 3221 02:01:13,165 --> 02:01:16,268 PEOPLE SAFE IN SPACE. I THINK IF 3222 02:01:16,268 --> 02:01:18,804 YOU CAN DO SOME OF THESE THINGS 3223 02:01:18,804 --> 02:01:20,806 IN SPACE WITH ASTRONAUTS WHO 3224 02:01:20,806 --> 02:01:22,908 AREN'T BIOLOGISTS YOU CAN DO 3225 02:01:22,908 --> 02:01:24,710 THEM IN RURAL AMERICA AND IN 3226 02:01:24,710 --> 02:01:28,047 UNDERSERVED PLACES AS WELL. SO I 3227 02:01:28,047 --> 02:01:30,382 AM VERY ENTHUSIASTIC ABOUT THE 3228 02:01:30,382 --> 02:01:32,584 PARTNERSHIP BECAUSE NO ONE 3229 02:01:32,584 --> 02:01:33,552 FUNDING STREAM WILL BE ABLE TO 3230 02:01:33,552 --> 02:01:36,121 DO THIS ALONE, IT WILL TAKE 3231 02:01:36,121 --> 02:01:37,790 MULTIPLE FEDERAL PRIVATE AND 3232 02:01:37,790 --> 02:01:39,425 ACADEMIC AND MANY, MANY OTHERS 3233 02:01:39,425 --> 02:01:42,194 TO TRY TO MAKE THIS WORK AND TO 3234 02:01:42,194 --> 02:01:46,298 MAKE THIS GO. I DO THINK THAT 3235 02:01:46,298 --> 02:01:48,033 HELPING PERHAPS THE ACADEMICS 3236 02:01:48,033 --> 02:01:54,306 AND HELPING THE OTHERS IN HOW TO 3237 02:01:54,306 --> 02:01:56,475 DESIGN CHIPS, AND NCATS IS A 3238 02:01:56,475 --> 02:01:57,910 WORLD LEADER IN THIS AND WE 3239 02:01:57,910 --> 02:01:59,144 DISCUSSED A LITTLE BIT HOW CHIPS 3240 02:01:59,144 --> 02:02:02,014 THAT WORK ON EARTH MAY NOT WORK 3241 02:02:02,014 --> 02:02:05,984 IN REMOTE EARTH ORBIT OR OTHER 3242 02:02:05,984 --> 02:02:09,421 ATMOSPHERES SO THAT HELPING THE 3243 02:02:09,421 --> 02:02:12,291 COMMUNITY THAT DOES HAVE DEEP 3244 02:02:12,291 --> 02:02:13,892 EXPERTISE IN DIFFERENT ASPECTS 3245 02:02:13,892 --> 02:02:15,994 OF AGING AND BONE LOSS AND 3246 02:02:15,994 --> 02:02:18,597 MUSCLE AND HOW YOU DEAL WITH 3247 02:02:18,597 --> 02:02:20,466 THESE CHIPS AND HOW PROGRAMS IN 3248 02:02:20,466 --> 02:02:22,000 ADDITION TO WORK WITH THAT 3249 02:02:22,000 --> 02:02:23,769 PUBLIC PRIVATE ACADEMIC 3250 02:02:23,769 --> 02:02:26,338 PARTNERSHIP SO WE CAN DESIGN 3251 02:02:26,338 --> 02:02:28,107 THESE CHIPS THAT CAN BE USED NOT 3252 02:02:28,107 --> 02:02:29,675 ONLY IN SPACE BUT ULTIMATELY IN 3253 02:02:29,675 --> 02:02:32,544 OTHER PLACES. ONCE AGAIN, VERY, 3254 02:02:32,544 --> 02:02:34,513 VERY THRILLED ABOUT THIS 3255 02:02:34,513 --> 02:02:35,781 PROGRAM. KEEP UP THE GREAT WORK. 3256 02:02:35,781 --> 02:02:38,016 >> THANK YOU, DR. SHIREMAN. 3257 02:02:38,016 --> 02:02:41,653 >> THANK YOU SO MUCH FOR THAT 3258 02:02:41,653 --> 02:02:42,921 INPUT AND NOW I WILL TURN IT 3259 02:02:42,921 --> 02:02:46,158 OVER TO YOU. 3260 02:02:46,158 --> 02:02:47,626 >> IF THERE IS NO FURTHER 3261 02:02:47,626 --> 02:02:48,627 DISCUSSION ON THIS CONCEPT, 3262 02:02:48,627 --> 02:02:49,995 MOTION TO APPROVE THE TISSUE 3263 02:02:49,995 --> 02:02:52,431 CHIPS CONCEPT? MOVED. SECOND? 3264 02:02:52,431 --> 02:02:53,098 >> HE COULD IS. 3265 02:02:53,098 --> 02:02:55,134 >> ALL IN FAVOR? 3266 02:02:55,134 --> 02:02:55,734 >> AYE. 3267 02:02:55,734 --> 02:03:00,305 >> ANY OPPOSED? ANY ABSTENTIONS 3268 02:03:00,305 --> 02:03:02,074 WITH THAT, THE TISSUE CHIP 3269 02:03:02,074 --> 02:03:04,576 CONCEPT IS APPROVED. NEXT. 3270 02:03:04,576 --> 02:03:07,946 >> THANK YOU. ALL RIGHT NEXT WE 3271 02:03:07,946 --> 02:03:10,616 HAVE A PROGRAMMATIC UPDATE FROM 3272 02:03:10,616 --> 02:03:12,184 THE DIVISION OF CLINICAL 3273 02:03:12,184 --> 02:03:13,318 INNOVATIONS WITH DR. MIKE 3274 02:03:13,318 --> 02:03:21,193 KURILLA. SO MIKE, OVER TO YOU. 3275 02:03:21,193 --> 02:03:23,896 >> ALL RIGHT. IT IS A PLEASURE. 3276 02:03:23,896 --> 02:03:26,799 I'M GOING TO GIVE YOU A -- AM I 3277 02:03:26,799 --> 02:03:34,506 ADVANCING SLIDES I? THE CO-BOAR. 3278 02:03:34,506 --> 02:03:38,577 OKAY. -- KEYBOARD. I'M GOING TO 3279 02:03:38,577 --> 02:03:41,613 GIVE YOU A WHIRLWIND TOUR OF THE 3280 02:03:41,613 --> 02:03:44,383 CTSA PROGRAM, VERY HIGH-LEVEL, 3281 02:03:44,383 --> 02:03:46,819 VERY SELECTIVE. I WISH WE HAD 3282 02:03:46,819 --> 02:03:48,921 THE OPPORTUNITY TO RUN THROUGH 3283 02:03:48,921 --> 02:03:51,723 LOT MORE DETAIL BUT WE ONLY HAVE 3284 02:03:51,723 --> 02:03:53,792 SO MUCH TIME SO WE WILL TRY TO 3285 02:03:53,792 --> 02:03:55,761 GET THROUGH THIS. I SHOWED THIS 3286 02:03:55,761 --> 02:03:58,797 EARLIER, CTSA PROGRAM. THIS IS 3287 02:03:58,797 --> 02:04:02,234 REALLY THE FOCUS. I COULD 3288 02:04:02,234 --> 02:04:03,469 PROBABLY PICK ANY ONE OF THESE 3289 02:04:03,469 --> 02:04:04,770 AND SPEND THE REST OF THE 3290 02:04:04,770 --> 02:04:05,571 AFTERNOON TALKING ABOUT THE 3291 02:04:05,571 --> 02:04:07,105 ACTIVITIES SO I WILL TRY TO DO 3292 02:04:07,105 --> 02:04:08,941 AN OVERVIEW. JONI SHOWED THIS 3293 02:04:08,941 --> 02:04:11,076 EARLIER, THIS IS JUST TO SAY 3294 02:04:11,076 --> 02:04:12,711 THAT UNFORTUNATELY WITH REGARD 3295 02:04:12,711 --> 02:04:15,681 TO BUDGET WE ARE LIVING, WE -- 3296 02:04:15,681 --> 02:04:17,783 THE BEST CASE SCENARIO TO END UP 3297 02:04:17,783 --> 02:04:19,151 NEXT YEAR WITH WHAT WE HAD THIS 3298 02:04:19,151 --> 02:04:21,153 PAST YEAR. SO THAT IS WHERE WE 3299 02:04:21,153 --> 02:04:28,727 ARE. THE FY 23 CTSA PROGRAM H 3300 02:04:28,727 --> 02:04:30,329 CURRENT HUBS AS YOU CAN SEE WE 3301 02:04:30,329 --> 02:04:34,333 HAVE A TOTAL OF 64, THERE WERE 3302 02:04:34,333 --> 02:04:39,538 16 UM 1 AWARDS INDICATED BY THE 3303 02:04:39,538 --> 02:04:42,808 RED DIAMONDS. SO IT IS A PRETTY 3304 02:04:42,808 --> 02:04:45,711 -- WE FEEL PRETTY SUCCESSFUL 3305 02:04:45,711 --> 02:04:46,812 PRETTY SATISFIED WITH THE 3306 02:04:46,812 --> 02:04:47,980 SUCCESS OF WHAT THIS PAST YEAR 3307 02:04:47,980 --> 02:04:54,219 HAS BEEN IN TERMS OF NEW FOAs. 3308 02:04:54,219 --> 02:04:56,388 I WANT TO SHARE, NOT TOO MUCH 3309 02:04:56,388 --> 02:04:57,723 DETAIL BUT THERE WAS SOME 3310 02:04:57,723 --> 02:04:59,358 CONCERN EXPRESSED BY THE 3311 02:04:59,358 --> 02:05:03,428 COMMUNITY INITIALLY AS WELL AS 3312 02:05:03,428 --> 02:05:05,564 CONGRESS THAT THE CHANGES WERE 3313 02:05:05,564 --> 02:05:06,798 GOING TO REDUCE THE SUPPORT TO 3314 02:05:06,798 --> 02:05:10,435 HUBS OVERALL. SO WE DID A 3315 02:05:10,435 --> 02:05:13,238 CAREFUL ANALYSIS, ALL 16 FOR THE 3316 02:05:13,238 --> 02:05:15,707 ENTIRE YEAR, WE WERE TOLD 3317 02:05:15,707 --> 02:05:20,679 EVERYONE HAD TO BE AT LEAST 95%. 3318 02:05:20,679 --> 02:05:22,881 AS YOU CAN SEE ONLY 2 OUT OF 16 3319 02:05:22,881 --> 02:05:24,449 SHOWED ANY DECLINE. ONE WAS 3320 02:05:24,449 --> 02:05:26,251 PRETTY INSIGNIFICANT, ONE ONLY A 3321 02:05:26,251 --> 02:05:29,655 DECLINE OF 3%. BUT OVERALL THE 3322 02:05:29,655 --> 02:05:32,758 AVERAGE INCREASE FOR THE 3323 02:05:32,758 --> 02:05:33,792 CTSAs, THERE WAS A 14% 3324 02:05:33,792 --> 02:05:35,060 INCREASES IN TOTAL AMOUNT GOING 3325 02:05:35,060 --> 02:05:36,728 IN TERMS OF THE UM 1s RELATIVE 3326 02:05:36,728 --> 02:05:40,766 TO THE UL-1s AT THE SAME HUBS 3327 02:05:40,766 --> 02:05:42,834 THE PREVIOUS YEAR. SO YOU CAN 3328 02:05:42,834 --> 02:05:46,038 SEE IT WAS A RATHER SIZABLE 3329 02:05:46,038 --> 02:05:49,875 INCREASE OF NEARLY $14 MILLION 3330 02:05:49,875 --> 02:05:51,476 FOR THOSE 16 INSTITUTIONS, I 3331 02:05:51,476 --> 02:05:55,013 HAVE TO GIVE CREDIT TO ANDY 3332 02:05:55,013 --> 02:05:57,916 KELLY AN TEAM IN TERMS OF THE 3333 02:05:57,916 --> 02:05:59,484 MODELING AND FORECASTING THEY 3334 02:05:59,484 --> 02:06:01,019 DID, THEY WERE VERY MUCH ON 3335 02:06:01,019 --> 02:06:02,688 TARGET. THIS IS WHAT WE 3336 02:06:02,688 --> 02:06:04,022 ANTICIPATED AND THIS IS HOW 3337 02:06:04,022 --> 02:06:06,558 THINGS TURNED OUT. WITH REGARD 3338 02:06:06,558 --> 02:06:09,661 TO THE K PROGRAM, 12 OF THE 16 3339 02:06:09,661 --> 02:06:12,431 DID RECEIVE Ks. NOT ALL OF 3340 02:06:12,431 --> 02:06:13,699 THEM DID, THERE WERE A FEW THAT 3341 02:06:13,699 --> 02:06:16,702 DIDN'T DO AS WELL IN REVIEW, 3342 02:06:16,702 --> 02:06:18,570 WHICH IS NOT A BAD THING BECAUSE 3343 02:06:18,570 --> 02:06:23,041 IF WE HAD BEEN UNDER THE OLD 3344 02:06:23,041 --> 02:06:24,643 U-54, THAT POOR K APPLICATION 3345 02:06:24,643 --> 02:06:26,311 MIGHT HAVE TANKED THE OVERALL 3346 02:06:26,311 --> 02:06:27,412 AND WOULD HAVE LOST THE U 3347 02:06:27,412 --> 02:06:30,182 PORTION AS WELL. BUT WE ALSO 3348 02:06:30,182 --> 02:06:32,284 HAVE IN INSTANCES WHERE 3349 02:06:32,284 --> 02:06:33,619 INSTITUTIONS WISH TO DEFER AWARD 3350 02:06:33,619 --> 02:06:37,723 OF THEIR K, TO LATER IN THE NEXT 3351 02:06:37,723 --> 02:06:38,857 YEAR IN ORDER TO BETTER ALIGN IT 3352 02:06:38,857 --> 02:06:42,027 TO THE ACADEMIC CALENDAR, THAT 3353 02:06:42,027 --> 02:06:44,463 HAS BEEN A RECOMMENDATION BY 3354 02:06:44,463 --> 02:06:45,897 SEVERAL, WE HAD SEEN THAT 3355 02:06:45,897 --> 02:06:47,232 SEVERAL TIMES IN TERMS OF 3356 02:06:47,232 --> 02:06:49,768 PREVIOUS RFIs THAT SOME 3357 02:06:49,768 --> 02:06:51,436 INSTITUTIONS ACTUALLY WANTED A 3358 02:06:51,436 --> 02:06:53,872 SEPARATION OF THE Us AND THE 3359 02:06:53,872 --> 02:06:57,309 Ks SO THEY COULD HAVE BETTER 3360 02:06:57,309 --> 02:06:59,244 ALIGNMENT TO THEIR ACADEMIC 3361 02:06:59,244 --> 02:07:00,245 CALENDAR SO THEY HAVE TAKEN 3362 02:07:00,245 --> 02:07:01,713 ADVANTAGE OF THAT. AS YOU CAN 3363 02:07:01,713 --> 02:07:06,018 SEE OUR MODELING ANDY'S CREW WAS 3364 02:07:06,018 --> 02:07:07,786 REALLY RIGHT ON, YOU CAN SEE 3365 02:07:07,786 --> 02:07:09,254 THERE IS A TOTAL INCREASE IN 3366 02:07:09,254 --> 02:07:11,056 AMOUNT OF SUPPORT GOING TO THE 3367 02:07:11,056 --> 02:07:13,425 Ks. WE DID FIND IN OUR 3368 02:07:13,425 --> 02:07:15,627 ANALYSIS OF THE Ks THAT THERE 3369 02:07:15,627 --> 02:07:18,330 WAS QUITE BIT OF, I WILL BE NICE 3370 02:07:18,330 --> 02:07:21,667 AND SAY THERE IS QUITE A BIT OF 3371 02:07:21,667 --> 02:07:26,605 CREATIVITY WHO PEOPLE INSTITUTED 3372 02:07:26,605 --> 02:07:28,173 THEIR K PROGRAMS WHICH CREATED 3373 02:07:28,173 --> 02:07:29,941 DIVERSITY. THIS CREATES SOME 3374 02:07:29,941 --> 02:07:31,977 DOWNSTREAM PROBLEMS IN TERMS OF 3375 02:07:31,977 --> 02:07:33,311 REPORTING. , COMPLIANCE 3376 02:07:33,311 --> 02:07:35,313 FOLLOW-UP FROM THE GRANTS 3377 02:07:35,313 --> 02:07:38,083 MANAGEMENT SIDE, SO INJECTING A 3378 02:07:38,083 --> 02:07:39,618 LITTLE UNIFORMITY, WE KNEW THERE 3379 02:07:39,618 --> 02:07:42,954 WERE GOING TO BE MAYBE A FEW NOT 3380 02:07:42,954 --> 02:07:46,324 EVERYONE COME OUT ON TOP BUT 3381 02:07:46,324 --> 02:07:47,592 OVERALL AS YOU CAN SEE IN TERMS 3382 02:07:47,592 --> 02:07:49,294 OF SLOT NUMBER, THE OVERALL SLOT 3383 02:07:49,294 --> 02:07:54,099 NUMBERS ACTUALLY WENT UP AN ONLY 3384 02:07:54,099 --> 02:07:56,735 1 OF 12 SAW DECLINE ONLY IN ONE 3385 02:07:56,735 --> 02:07:58,303 SLOT SO OVERALL THE MODELING HAS 3386 02:07:58,303 --> 02:08:02,941 HELD UP PRETTY WELL AND WE ANDY 3387 02:08:02,941 --> 02:08:04,776 AN CREW NAILED IT AS FAR AS I'M 3388 02:08:04,776 --> 02:08:09,981 CONCERNED. STAFF UPDATES, WE 3389 02:08:09,981 --> 02:08:11,483 HAVE HAD A NUMBER OF NEW PEOPLE 3390 02:08:11,483 --> 02:08:13,685 IN PARTICULAR, YOU WILL SEE AT 3391 02:08:13,685 --> 02:08:15,687 THE FAR RIGHT ROBIN WAGNER IS 3392 02:08:15,687 --> 02:08:17,355 THE DIRECTOR OF OUR OFFICE OF 3393 02:08:17,355 --> 02:08:20,025 PROGRAM EVALUATION ANALYSIS AND 3394 02:08:20,025 --> 02:08:22,928 RECORDING. WE CALL IT OPARE. 3395 02:08:22,928 --> 02:08:25,564 AND WE HOPE TO BE ABLE TO HAVE 3396 02:08:25,564 --> 02:08:27,933 BETTER COORDINATION AND 3397 02:08:27,933 --> 02:08:29,167 HARMONIZATION ACROSS THE 3398 02:08:29,167 --> 02:08:30,869 DIVISION IN TERMS OF ACTIVITIES 3399 02:08:30,869 --> 02:08:35,707 GOING ON IN THE HUB, ACROSS THE 3400 02:08:35,707 --> 02:08:40,846 CTSA PROGRAMS. CONGRATULATIONS 3401 02:08:40,846 --> 02:08:42,414 ARE IN ORDER. JONI SHOWED THIS 3402 02:08:42,414 --> 02:08:46,017 EARLIER, I WANT TO SAY THAT N 3C 3403 02:08:46,017 --> 02:08:47,085 I WON'T TALK TOO MUCH ABOUT IT I 3404 02:08:47,085 --> 02:08:48,754 HAVE TALKED ABOUT IT EXTENSIVELY 3405 02:08:48,754 --> 02:08:51,523 IN THE PAST. THIS AWARD 3406 02:08:51,523 --> 02:08:54,693 HIGHLIGHTS THE CONTRIBUTIONS 3407 02:08:54,693 --> 02:08:58,330 THEY HAVE MADE TO THAT I WILL 3408 02:08:58,330 --> 02:08:59,765 HIGHLIGHT WERE INSTITUTED BY 3409 02:08:59,765 --> 02:09:02,534 QUESTIONS COMING FROM THE WHITE 3410 02:09:02,534 --> 02:09:04,302 HOUSE. AT ONE POINT THERE WAS 3411 02:09:04,302 --> 02:09:08,306 CONCERN INITIALLY DURING THE 3412 02:09:08,306 --> 02:09:09,407 PAXLOVID ROLL OUT, THERE WAS A 3413 02:09:09,407 --> 02:09:10,976 LOT OF QUESTIONS AND N 3C 3414 02:09:10,976 --> 02:09:13,879 STEPPED UP AND ADDRESSED 3415 02:09:13,879 --> 02:09:15,113 PAXLOVID REBOUND. WHEN WE FIRST 3416 02:09:15,113 --> 02:09:17,115 ASKED ABOUT THIS, IT WAS SAID 3417 02:09:17,115 --> 02:09:20,085 NO, YES NOT ABLE TO TELL ABOUT 3418 02:09:20,085 --> 02:09:22,854 PAXLOVID REBOUND IN N 3C BECAUSE 3419 02:09:22,854 --> 02:09:24,823 IT IS NOT DIAGNOSED THAT WAY. 3420 02:09:24,823 --> 02:09:27,492 BUT THE ISSUE WE RECOGNIZED WAS 3421 02:09:27,492 --> 02:09:30,128 THAT IT WASN'T PAXLOVID REBOUND 3422 02:09:30,128 --> 02:09:32,164 PER SE BUT THERE WAS THAT 3423 02:09:32,164 --> 02:09:35,700 REBOUND HAVING SOME CLINICAL 3424 02:09:35,700 --> 02:09:37,369 IMPLICATIONS SO N 3C ADDRESSED 3425 02:09:37,369 --> 02:09:38,270 THE FACT THAT INDIVIDUALS WHO 3426 02:09:38,270 --> 02:09:40,839 RECEIVED PAXLOVID WERE NOT 3427 02:09:40,839 --> 02:09:42,707 HAVING ANY SUBSTANTIAL INCREASES 3428 02:09:42,707 --> 02:09:44,709 IN TOUCHES WITH THE HEALTHCARE 3429 02:09:44,709 --> 02:09:48,146 SYSTEM AFTER PAXLOVID, 3430 02:09:48,146 --> 02:09:49,748 SUGGESTING IT WAS NOT A MAJOR 3431 02:09:49,748 --> 02:09:51,650 CONCERN. THAT ALLAYED A LOT OF 3432 02:09:51,650 --> 02:09:52,884 CONCERNS AND FEARS THAT PEOPLE 3433 02:09:52,884 --> 02:09:54,386 HAD THAT WE WERE SITTING ON A 3434 02:09:54,386 --> 02:09:57,489 TICKING TIME BOMB INITIALLY. AS 3435 02:09:57,489 --> 02:09:59,291 TURNS OUTS THAT'S BORNE OUT 3436 02:09:59,291 --> 02:10:00,926 WELL, WITH REBOUND MAY OCCUR BUT 3437 02:10:00,926 --> 02:10:02,160 NOT LEADING TO REPEAT 3438 02:10:02,160 --> 02:10:03,195 HOSPITALIZATIONS INCREASED 3439 02:10:03,195 --> 02:10:06,631 MORTALITY OR THINGS LIKE THAT. 3440 02:10:06,631 --> 02:10:08,767 THE OTHER ONE, LAST ONE WAS ONE 3441 02:10:08,767 --> 02:10:11,736 OF THE LAST THINGS AJIJ BEFORE 3442 02:10:11,736 --> 02:10:13,405 HE LEFT THE WHITE HOUSE ASKED US 3443 02:10:13,405 --> 02:10:17,943 ABOUT PAXLOVID UTILIZATION AND N 3444 02:10:17,943 --> 02:10:19,277 3C WAS ABLE TO DO A NICE 3445 02:10:19,277 --> 02:10:21,780 DETAILED ANALYSIS LOOKING AT 3446 02:10:21,780 --> 02:10:23,048 FROM ELIGIBILITY REQUIREMENTS 3447 02:10:23,048 --> 02:10:25,250 WHO WAS ELIGIBLE FOR PAXLOVID, 3448 02:10:25,250 --> 02:10:26,985 WHO WAS GETTING IT AND HOW IT 3449 02:10:26,985 --> 02:10:29,020 VARIED ACROSS INSTITUTION, IT 3450 02:10:29,020 --> 02:10:31,489 WAS VERY INTERESTING IN TERMS OF 3451 02:10:31,489 --> 02:10:33,058 RESULTS BECAUSE IT WAS FAR 3452 02:10:33,058 --> 02:10:35,193 UNDERUTILIZATION OF PAXLOVID 3453 02:10:35,193 --> 02:10:38,296 THAT I THINK PEOPLE APPRECIATED 3454 02:10:38,296 --> 02:10:40,432 AN ESTIMATING THE TENS OF 3455 02:10:40,432 --> 02:10:41,366 THOUSANDS OF LIVES THAT COULD 3456 02:10:41,366 --> 02:10:45,103 HAVE BEEN SAVED IF PAXLOVID HAS 3457 02:10:45,103 --> 02:10:47,005 BEEN ADMINISTERED BY THE 3458 02:10:47,005 --> 02:10:49,007 ELIGIBILITY REQUIREMENTS BUT IN 3459 02:10:49,007 --> 02:10:51,309 SOME CASES, THERE WAS ZERO 3460 02:10:51,309 --> 02:10:53,979 UTILIZATION BY INSTITUTIONS FOR 3461 02:10:53,979 --> 02:10:55,213 PAXLOVID SO WE JUST FOUND THERE 3462 02:10:55,213 --> 02:10:57,515 WAS A LOT OF UNEVENNESS ACROSS 3463 02:10:57,515 --> 02:10:59,251 THE COUNTRY. REMAINS TO BE SEEN 3464 02:10:59,251 --> 02:11:00,418 HOW WE CAN ADDRESS THAT IN THE 3465 02:11:00,418 --> 02:11:03,955 FUTURE. WE SEE THIS EVERY YEAR, 3466 02:11:03,955 --> 02:11:05,624 THE NUMBER OF NEW MEMBERS TO THE 3467 02:11:05,624 --> 02:11:07,058 NATIONAL ACADEMY OF SCIENCES 3468 02:11:07,058 --> 02:11:09,661 THAT HAVE AFFILIATIONS WITH THE 3469 02:11:09,661 --> 02:11:11,229 CTSA. CONTINUES TO BE QUITE 3470 02:11:11,229 --> 02:11:15,367 STRONG AND I THINK THIS REALLY 3471 02:11:15,367 --> 02:11:16,635 IS INDICATOR OF THE QUALITY OF 3472 02:11:16,635 --> 02:11:21,706 THE CTSA LEADERSHIP AND QUALITY 3473 02:11:21,706 --> 02:11:23,608 OF THE TYPES OF INDIVIDUALS THAT 3474 02:11:23,608 --> 02:11:25,410 ARE BEING SELECTED AND PROMOTED 3475 02:11:25,410 --> 02:11:31,149 WITHIN THE CTSA PROGRAM. PEOPLE 3476 02:11:31,149 --> 02:11:35,120 MAY RECALL THAT ONE OF OUR CTSA 3477 02:11:35,120 --> 02:11:35,754 PIs, BECK CAN YOU JACKSON 3478 02:11:35,754 --> 02:11:39,858 PASSED AWAY AND ACTS INSTITUTED 3479 02:11:39,858 --> 02:11:42,661 THE DISTINGUISHED EDUCATOR 3480 02:11:42,661 --> 02:11:44,663 RESEARCH DISTINGUISHED EDUCATOR 3481 02:11:44,663 --> 02:11:46,865 AWARD, RUN BY CYNTHIA MORRIS, A 3482 02:11:46,865 --> 02:11:51,403 PI, CTSA PI AT OREGON AND THEN 3483 02:11:51,403 --> 02:11:55,140 STEVE DUBINETT FROM UCLA MOVED 3484 02:11:55,140 --> 02:11:56,708 UP TO BECOME DEAN. SO HE'S 3485 02:11:56,708 --> 02:12:00,512 TURNED THE REIGNS OVER TO ARLENE 3486 02:12:00,512 --> 02:12:04,382 BROWN AT UCLA. I ALWAYS LIKE TO 3487 02:12:04,382 --> 02:12:07,519 SEE THESE, CTSA PEOPLE WHO ARE 3488 02:12:07,519 --> 02:12:09,054 BRILLIANT NEW INVESTIGATORS AN 3489 02:12:09,054 --> 02:12:10,922 BREAK THROUGH IS ALWAYS NICE TO 3490 02:12:10,922 --> 02:12:14,726 BE RECOGNIZED FOR THESE TYPES OF 3491 02:12:14,726 --> 02:12:16,728 SPECIAL AWARDS. THEN FOR THE 3492 02:12:16,728 --> 02:12:18,430 YOUNGER CROWD, THERE IS A NUMBER 3493 02:12:18,430 --> 02:12:22,801 OF THESE NATIONAL 40 UNDER 40 3494 02:12:22,801 --> 02:12:25,670 HONOREES. YOU CAN SEE FORMER TL 3495 02:12:25,670 --> 02:12:28,206 1, FORMER KL 2 SCHOLAR WHICH 3496 02:12:28,206 --> 02:12:31,176 INDICATES THE CTS ASAs ARE 3497 02:12:31,176 --> 02:12:32,944 DOING A GOOD JOB IDENTIFYING 3498 02:12:32,944 --> 02:12:34,045 PEOPLE WHO GO ON TO BE 3499 02:12:34,045 --> 02:12:36,281 RECOGNIZED BEYOND THEIR 3500 02:12:36,281 --> 02:12:37,582 INSTITUTION, FOR THE SIGNIFICANT 3501 02:12:37,582 --> 02:12:40,318 CONTRIBUTIONS. SO THERE'S A LOT 3502 02:12:40,318 --> 02:12:41,553 MORE BUT I DON'T HAVE ENOUGH 3503 02:12:41,553 --> 02:12:44,289 TIME TO GO INTO THAT. WANTED TO 3504 02:12:44,289 --> 02:12:47,392 JUST HIGHLIGHT THE RO 3 AS I 3505 02:12:47,392 --> 02:12:48,760 SAID BEFORE WE ARE DIPPING OUR 3506 02:12:48,760 --> 02:12:50,528 TOE IN THE WATER IN TERMS OF 3507 02:12:50,528 --> 02:12:53,098 MOVING TOWARDS AN R PROGRAM. AND 3508 02:12:53,098 --> 02:12:54,566 THE -- THIS SMALL GRANT PROGRAM 3509 02:12:54,566 --> 02:12:57,969 IS REALLY GEARED TOWARDS THE K 3510 02:12:57,969 --> 02:13:00,405 SCHOLARS TRYING TO HELP THEM 3511 02:13:00,405 --> 02:13:03,108 ALONG THE GRANTS PATHWAY AND I 3512 02:13:03,108 --> 02:13:08,847 THINK THIS IS A VERY BROAD GROUP 3513 02:13:08,847 --> 02:13:10,815 HERE, ONE OF THE ONES THAT 3514 02:13:10,815 --> 02:13:11,816 REALLY I FIND VERY INTERESTING 3515 02:13:11,816 --> 02:13:13,518 WHICH I'M GLAD TO SEE SOME FOCUS 3516 02:13:13,518 --> 02:13:15,620 ON, IF YOU LOOK AT THE FIRST ONE 3517 02:13:15,620 --> 02:13:17,522 BY ELIZABETH WOLF, IT'S LOOKING 3518 02:13:17,522 --> 02:13:19,224 AT BARRIERS TO DEIMPLEMENTATION 3519 02:13:19,224 --> 02:13:21,059 WE PUT EFFORT INTO 3520 02:13:21,059 --> 02:13:22,660 IMPLEMENTATION SCIENCE, DON'T AS 3521 02:13:22,660 --> 02:13:24,062 MUCH FOCUS ON DEIMPLEMENTATION 3522 02:13:24,062 --> 02:13:25,430 WHEN WE KNOW SOMETHING DOESN'T 3523 02:13:25,430 --> 02:13:26,898 WORK, HOW DO WE GET PEOPLE TO 3524 02:13:26,898 --> 02:13:29,768 STOP DOING THE STUFF THAT 3525 02:13:29,768 --> 02:13:32,303 DOESN'T WORK? IT IS ACTUALLY NOT 3526 02:13:32,303 --> 02:13:34,539 A TRIVIAL TASK. SO THAT IS WHAT 3527 02:13:34,539 --> 02:13:36,975 HER FOCUS WILL BE. AND HEN THE 3528 02:13:36,975 --> 02:13:39,711 NEXT ONE I LIKE INTERESTINGLY 3529 02:13:39,711 --> 02:13:42,247 BECAUSE IT DEALS WITH ADVANCED 3530 02:13:42,247 --> 02:13:44,816 CHRONIC EYE DISEASE TREATMENT. 3531 02:13:44,816 --> 02:13:46,051 BESIDES THE FACT I'M GETTING TO 3532 02:13:46,051 --> 02:13:47,352 THE POINT WHERE I NEED TWO SETS 3533 02:13:47,352 --> 02:13:49,654 OF READING GLASSES NOW WHICH IS 3534 02:13:49,654 --> 02:13:50,822 VERY FRUSTRATING BUT MORE 3535 02:13:50,822 --> 02:13:52,490 IMPORTANTLY I THINK TO ME IT 3536 02:13:52,490 --> 02:13:53,925 UNDERSCORE IT IS FACT THAT WE 3537 02:13:53,925 --> 02:13:56,594 PUT EFFORT INTO TALKING ABOUT 3538 02:13:56,594 --> 02:13:58,630 NIH AND PUT A LOT OF EFFORT 3539 02:13:58,630 --> 02:13:59,864 TALKING ABOUT SAVING LIVES. 3540 02:13:59,864 --> 02:14:01,866 NOBODY REALLY DIES OF EYE 3541 02:14:01,866 --> 02:14:04,602 DISEASE PER SE UNLESS YOU HAVE 3542 02:14:04,602 --> 02:14:05,336 OCULAR ROTE KNOW BLAST TOE MANY 3543 02:14:05,336 --> 02:14:07,072 OR SOMETHING LIKE THAT OR OCULAR 3544 02:14:07,072 --> 02:14:08,973 MELANOMA. BUT IN GENERAL I THINK 3545 02:14:08,973 --> 02:14:13,378 WE DON'T ALWAYS FOCUS AS MUCH ON 3546 02:14:13,378 --> 02:14:15,480 QUALITY OF LIFE ISSUES.S. 3547 02:14:15,480 --> 02:14:16,815 MAINTAINING VISION, HEARING, 3548 02:14:16,815 --> 02:14:18,083 MOBILITY, ARE VERY, VERY 3549 02:14:18,083 --> 02:14:19,984 IMPORTANT AND MAY NOT KILL 3550 02:14:19,984 --> 02:14:21,886 PEOPLE BUT I THINK IMPACTING THE 3551 02:14:21,886 --> 02:14:23,988 QUALITY OF PEOPLE'S LIVES IS 3552 02:14:23,988 --> 02:14:25,557 EQUALLY IMPORTANT, IF NOT MORE 3553 02:14:25,557 --> 02:14:26,858 IMPORTANT THAN SIMPLY EXTENDING 3554 02:14:26,858 --> 02:14:32,130 LIFE. WE ONLY HAD ONE CCIA AWARD 3555 02:14:32,130 --> 02:14:33,465 THIS YEAR THAT WAS GIVEN. THIS 3556 02:14:33,465 --> 02:14:34,933 IS INTEGRATION AN 3557 02:14:34,933 --> 02:14:36,000 INTEROPERABILITY OF COMPLEX DATA 3558 02:14:36,000 --> 02:14:37,969 AND TISSUE THE HUMAN BRAIN. I 3559 02:14:37,969 --> 02:14:39,871 THINK THIS IS A CONSEQUENCE OF 3560 02:14:39,871 --> 02:14:42,540 COMING OFF COVID, THERE WAS A 3561 02:14:42,540 --> 02:14:45,643 REAL SORT OF INTERRUPTION IN 3562 02:14:45,643 --> 02:14:47,412 THESE SORTS OF TYPES OF 3563 02:14:47,412 --> 02:14:49,380 PARTICULARLY CCIAs WERE 3564 02:14:49,380 --> 02:14:50,949 INVOLVED IN COLLABORATION AMONG 3565 02:14:50,949 --> 02:14:53,785 MULTIPLE CTSAs. I'M HOPING AS 3566 02:14:53,785 --> 02:14:55,987 WE ARE IN OUR WIND DOWN FROM THE 3567 02:14:55,987 --> 02:14:59,224 COVID PHASE, THAT COLLABORATIONS 3568 02:14:59,224 --> 02:15:00,792 ACROSS INSTITUTIONS WILL 3569 02:15:00,792 --> 02:15:04,129 INCREASE BUT I THINK THIS IS -- 3570 02:15:04,129 --> 02:15:05,597 THIS KIND OF WORK I THINK IS 3571 02:15:05,597 --> 02:15:07,365 VERY INDICATIVE WHERE I SEE A 3572 02:15:07,365 --> 02:15:09,901 LOT OF FOCUS OF THE CTSAs 3573 02:15:09,901 --> 02:15:11,102 MOVING FORWARD BECAUSE THIS IS 3574 02:15:11,102 --> 02:15:14,205 REALLY LOOKING AT THE 3575 02:15:14,205 --> 02:15:16,107 INTEGRATION OF MULTIPLE TYPES OF 3576 02:15:16,107 --> 02:15:17,575 DATA TYPES, IF YOU LOOK HERE 3577 02:15:17,575 --> 02:15:21,212 LOOKING INCLUDING EEGs, MRI, 3578 02:15:21,212 --> 02:15:22,914 GENOMICS BLOOD SAMPLES 3579 02:15:22,914 --> 02:15:23,715 ELECTRONIC HEALTH RECORDS 3580 02:15:23,715 --> 02:15:24,949 BRINGING TOGETHER THE MASSIVE 3581 02:15:24,949 --> 02:15:27,051 AMOUNTS OF DATA IN A PRODUCTIVE 3582 02:15:27,051 --> 02:15:30,188 MANNER THAT REALLY IDENTIFIES 3583 02:15:30,188 --> 02:15:33,725 FUTURE AREAS OF INVESTIGATION I 3584 02:15:33,725 --> 02:15:36,494 THINK IS A KEY FOCUS ON WHAT WE 3585 02:15:36,494 --> 02:15:37,529 IMMEDIATE TO BE THINKING ABOUT 3586 02:15:37,529 --> 02:15:42,033 WHEN WE TALK 3587 02:15:42,033 --> 02:15:45,537 I LIKE TO POINT OUT TO PEOPLE 3588 02:15:45,537 --> 02:15:47,872 THAT IT'S NOT SIMPLY A MATTER OF 3589 02:15:47,872 --> 02:15:49,941 DOING THINGS FASTER. 3590 02:15:49,941 --> 02:15:51,276 WE SHOULD THINK ABOUT DOING 3591 02:15:51,276 --> 02:15:52,243 THINGS DIFFERENTLY, AND NEW 3592 02:15:52,243 --> 02:15:53,545 THINGS WE HAVEN'T THOUGHT TO DO 3593 02:15:53,545 --> 02:15:54,012 BEFORE. 3594 02:15:54,012 --> 02:15:55,313 AND THIS TYPE OF ANALYSIS I 3595 02:15:55,313 --> 02:15:57,382 THINK IS GOING TO PROMOTE THAT. 3596 02:15:57,382 --> 02:15:59,450 ONE OF THE THINGS I'M GOING 3597 02:15:59,450 --> 02:16:01,653 TO -- I'VE BEEN PUTTING MORE 3598 02:16:01,653 --> 02:16:02,353 ATTENTION INTO RECENTLY, 3599 02:16:02,353 --> 02:16:04,923 PARTICULARLY WITH REGARD TO THE 3600 02:16:04,923 --> 02:16:06,224 CCIAs, IS WHAT HAPPENS WITH 3601 02:16:06,224 --> 02:16:06,591 THESE. 3602 02:16:06,591 --> 02:16:10,094 I TELL YOU ABOUT MAKING THE 3603 02:16:10,094 --> 02:16:12,397 AWARDS BUT THERE'S NOT A 3604 02:16:12,397 --> 02:16:12,664 FOLLOW-UP. 3605 02:16:12,664 --> 02:16:15,133 UNLESS IT'S BROUGHT TO MY 3606 02:16:15,133 --> 02:16:19,070 ATTENTION BY THE INVESTIGATORS 3607 02:16:19,070 --> 02:16:21,239 WHICH IT WAS, OR BY MY STAFF OR 3608 02:16:21,239 --> 02:16:23,541 IN SOME CASES THE MEDIA. 3609 02:16:23,541 --> 02:16:29,347 THIS IS ONE SUCH CCIA THAT HAS 3610 02:16:29,347 --> 02:16:34,819 RATHER HERCULEAN TITLE OF HAR 3611 02:16:34,819 --> 02:16:35,653 HARNESSING THE POWER USING 3612 02:16:35,653 --> 02:16:37,455 SOCIAL DETERMINANTS OF HEALTH, 3613 02:16:37,455 --> 02:16:39,724 FRAILTY, FUNCTIONAL STATUS TO 3614 02:16:39,724 --> 02:16:41,793 IDENTIFY AT-RISK PATIENTS AND 3615 02:16:41,793 --> 02:16:42,594 IMPROVE RISK ADJUSTMENT, AWARDED 3616 02:16:42,594 --> 02:16:43,261 IN 2018. 3617 02:16:43,261 --> 02:16:44,896 SO IT'S JUST ABOUT COMING TO THE 3618 02:16:44,896 --> 02:16:47,832 END, YOU CAN SEE THE 3619 02:16:47,832 --> 02:16:48,533 COLLABORATING INSTITUTION, 3620 02:16:48,533 --> 02:16:51,102 UNIVERSITY OF TEXAS AT AUSTIN, 3621 02:16:51,102 --> 02:16:53,204 TEXAS HEALTH SCIENCE CENTER, 3622 02:16:53,204 --> 02:16:53,671 HOUSTON, UNIVERSITY OF 3623 02:16:53,671 --> 02:16:55,840 PITTSBURGH, YOU SEE THREE 3624 02:16:55,840 --> 02:16:57,242 PUBLICATIONS, THAT'S THREE OF 3625 02:16:57,242 --> 02:16:58,443 37, STILL COUNTING. 3626 02:16:58,443 --> 02:17:00,111 THIS IS A VERY, VERY IMPRESSIVE 3627 02:17:00,111 --> 02:17:03,748 PIECE OF WORK THAT REALLY 3628 02:17:03,748 --> 02:17:07,652 BROUGHT TOGETHER I THINK AND 3629 02:17:07,652 --> 02:17:09,654 ADVANCING A CONCEPT THAT I THINK 3630 02:17:09,654 --> 02:17:11,089 NEEDS MORE ATTENTION, THE 3631 02:17:11,089 --> 02:17:13,091 CONCEPT OF FRAILTY. 3632 02:17:13,091 --> 02:17:14,392 MEDICINE DOES A LOT OF THINGS 3633 02:17:14,392 --> 02:17:17,095 BECAUSE IT'S EASY TO DO. 3634 02:17:17,095 --> 02:17:19,464 AGE IS A VERY EASY THING TO DO. 3635 02:17:19,464 --> 02:17:21,933 IF YOU'RE OVER 65 YOU'RE AT 3636 02:17:21,933 --> 02:17:22,200 SOMETHING. 3637 02:17:22,200 --> 02:17:23,768 IF YOU'RE UNDER 65 YOU'RE NOT AT 3638 02:17:23,768 --> 02:17:24,969 RISK. 3639 02:17:24,969 --> 02:17:28,806 AGE IS ACTUALLY A PRETTY POOR 3640 02:17:28,806 --> 02:17:29,107 STRATIFIER. 3641 02:17:29,107 --> 02:17:30,608 IT DOESN'T REALLY WORK THAT 3642 02:17:30,608 --> 02:17:30,908 WELL. 3643 02:17:30,908 --> 02:17:32,110 WHAT WE REALLY ARE TALKING ABOUT 3644 02:17:32,110 --> 02:17:34,979 WHEN WE TALK ABOUT AGE IS WE'RE 3645 02:17:34,979 --> 02:17:36,814 FOCUSED ON FRAILTY AND BEING 3646 02:17:36,814 --> 02:17:38,249 ABLE TO QUANTIFY AND QUANTITATE 3647 02:17:38,249 --> 02:17:38,783 THAT. 3648 02:17:38,783 --> 02:17:40,318 IT'S INTERESTING BECAUSE WHEN 3649 02:17:40,318 --> 02:17:43,154 PEOPLE FIRST STARTED TO CONSIDER 3650 02:17:43,154 --> 02:17:46,758 THE POSSIBILITY OF ANTI-AGING 3651 02:17:46,758 --> 02:17:52,230 INTERVENTIONS, THE FDA SAID WE 3652 02:17:52,230 --> 02:17:53,331 CAN'T DEAL WITH THAT. 3653 02:17:53,331 --> 02:17:55,633 AGING IS NOT A DISEASE. 3654 02:17:55,633 --> 02:17:57,035 YOU CAN'T HAVE A DRUG AGAINST 3655 02:17:57,035 --> 02:18:01,306 SOMETHING THAT'S NOT A DISEASE. 3656 02:18:01,306 --> 02:18:03,174 CONCEPT OF FRAILTY WAS THOUGHT 3657 02:18:03,174 --> 02:18:08,846 TO BE AN APPROPRIATE SURROGATE, 3658 02:18:08,846 --> 02:18:09,614 UNDERSTANDING FRAILTY AND HOW 3659 02:18:09,614 --> 02:18:11,149 WOE MEASURE THAT AND HOW THAT 3660 02:18:11,149 --> 02:18:13,117 PREDICTS RISK FOR OTHER THINGS I 3661 02:18:13,117 --> 02:18:14,452 THINK IS CRITICAL. 3662 02:18:14,452 --> 02:18:17,288 THAT'S WHAT A LOT OF THIS CCIA 3663 02:18:17,288 --> 02:18:18,256 HAS REALLY BEEN INVOLVED WITH, 3664 02:18:18,256 --> 02:18:22,560 REALLY LOOKING AT A LOT OF 3665 02:18:22,560 --> 02:18:23,094 FACTORS AS WELL AS SOCIAL 3666 02:18:23,094 --> 02:18:27,899 DETERMINANTS OF HEALTH WHICH IS 3667 02:18:27,899 --> 02:18:29,233 CLEARLY ANOTHER UNDER UTILIZED 3668 02:18:29,233 --> 02:18:31,969 ACTIVITY OR AREA WE NEED TO 3669 02:18:31,969 --> 02:18:32,937 EXPLOIT MUCH MORE. 3670 02:18:32,937 --> 02:18:37,508 ONE OF THE OTHER THINGS WE DID 3671 02:18:37,508 --> 02:18:39,811 IN 23 WAS RECOMPETED THE TIN, 3672 02:18:39,811 --> 02:18:41,679 TIN 2.0. 3673 02:18:41,679 --> 02:18:43,014 I WANTED TO HIGHLIGHT EFFORTS 3674 02:18:43,014 --> 02:18:46,484 OVER THE LAST 7 YEARS, IN 3675 02:18:46,484 --> 02:18:47,685 PARTICULAR, PARTICULARLY WITH 3676 02:18:47,685 --> 02:18:48,986 COVID, THE TIN REALLY SHOWED 3677 02:18:48,986 --> 02:18:52,757 WHAT IT'S CAPABLE OF BUT I THINK 3678 02:18:52,757 --> 02:18:54,058 WE DON'T NECESSARILY RECOGNIZE 3679 02:18:54,058 --> 02:18:55,793 THE TOTALITY OF WHAT THE TIN HAS 3680 02:18:55,793 --> 02:18:57,028 BEEN ABLE TO DO. 3681 02:18:57,028 --> 02:19:00,732 ONE OF THE IMPRESSIVE NUMBERS 3682 02:19:00,732 --> 02:19:04,569 HERE FOR ME IS THAT 20 NIH 3683 02:19:04,569 --> 02:19:07,638 I.C.s HAVE ENGAGED THE TIN, 3684 02:19:07,638 --> 02:19:11,776 THAT'S IMPRESSIVE IN TERMS OF 3685 02:19:11,776 --> 02:19:12,243 CROSS-NIH RECOGNIZING 3686 02:19:12,243 --> 02:19:16,080 FUNCTIONALITY AND CAPABILITY AND 3687 02:19:16,080 --> 02:19:18,116 FUNCTIONALITY OF THE TIN. 3688 02:19:18,116 --> 02:19:21,419 THERE WERE 400 REQUESTS FOR 3689 02:19:21,419 --> 02:19:23,454 SUPPORT, 95% OF CTSAs 3690 02:19:23,454 --> 02:19:26,758 SUBMITTED PROPOSALS TO THE TIN 3691 02:19:26,758 --> 02:19:31,396 SO IT'S GOTTEN QUITE A BIT OF 3692 02:19:31,396 --> 02:19:35,199 ATTENTION AND UTILIZATION AND 3693 02:19:35,199 --> 02:19:36,167 RECOGNITION. 3694 02:19:36,167 --> 02:19:40,905 WE CAN THINK ABOUT RECRUITMENT, 3695 02:19:40,905 --> 02:19:42,874 ONE SMALL COMPONENT FROM 3696 02:19:42,874 --> 02:19:45,042 AWARENESS THROUGH TO RETURN OF 3697 02:19:45,042 --> 02:19:46,244 VALUE. 3698 02:19:46,244 --> 02:19:51,482 ONE OF THE INTERESTING ASPECTS 3699 02:19:51,482 --> 02:19:56,654 I'VE BEEN INVOLVED WITH CITY, 3700 02:19:56,654 --> 02:19:57,288 PRE-COVID HAD DISCUSSIONS OF 3701 02:19:57,288 --> 02:19:59,690 EUROPEAN POSITION OF RETURN OF 3702 02:19:59,690 --> 02:20:00,458 INFORMATION, RETURN OF RESULTS 3703 02:20:00,458 --> 02:20:01,893 OF CLINICAL TRIALS, AND THAT WAS 3704 02:20:01,893 --> 02:20:04,862 GOING TO HAVE AN IMPACT ON THE 3705 02:20:04,862 --> 02:20:06,597 U.S. AND COVID HIT, SO THAT 3706 02:20:06,597 --> 02:20:07,031 DISCUSSION STOPPED. 3707 02:20:07,031 --> 02:20:08,699 BUT UNDERSTANDING HOW WE DO THAT 3708 02:20:08,699 --> 02:20:10,435 AND RETURN VALUE BACK TO THE 3709 02:20:10,435 --> 02:20:11,636 PATIENTS WHO HAVE BEEN IN THE 3710 02:20:11,636 --> 02:20:17,341 CLINICAL TRIALS I THINK IS VERY 3711 02:20:17,341 --> 02:20:17,608 IMPORTANT. 3712 02:20:17,608 --> 02:20:22,613 THE RIC HAS REALLY PIONEERED A 3713 02:20:22,613 --> 02:20:23,481 NUMBER OF FEATURES, REDCap 3714 02:20:23,481 --> 02:20:28,486 CLEARLY IS ONE OF THE WELL 3715 02:20:28,486 --> 02:20:29,420 INTERNATIONALLY RESPONSIVE AND 3716 02:20:29,420 --> 02:20:31,355 UTILIZED COMPONENTS BUT THE 3717 02:20:31,355 --> 02:20:33,224 COMMUNITY ENGAGEMENT STUDIOS HAS 3718 02:20:33,224 --> 02:20:35,526 BEEN WILDLY SUCCESSFUL, AND 3719 02:20:35,526 --> 02:20:37,962 DURING COVID WAS HIGHLY, HIGHLY 3720 02:20:37,962 --> 02:20:40,131 UTILIZED IN TERMS OF ASSISTING 3721 02:20:40,131 --> 02:20:42,633 WITH THOSE. 3722 02:20:42,633 --> 02:20:44,001 I WANTED TO HIGHLIGHT ONE RIC 3723 02:20:44,001 --> 02:20:45,036 SUCCESS STORY. 3724 02:20:45,036 --> 02:20:51,175 THIS WAS THE TARGET TRIAL. 3725 02:20:51,175 --> 02:20:56,414 THIS IS ONE, FORMER NIAMS TOLD 3726 02:20:56,414 --> 02:20:58,616 ME THE RIC WAS RESPONSIBLE FOR 3727 02:20:58,616 --> 02:20:59,717 SALVAGING THIS TRIAL BECAUSE 3728 02:20:59,717 --> 02:21:04,388 AFTER THEY HAD INITIATED THE 3729 02:21:04,388 --> 02:21:06,357 TRIAL ON THEIR OWN, AFTER THREE 3730 02:21:06,357 --> 02:21:08,226 YEARS HAD 30 PEOPLE, AND THEY 3731 02:21:08,226 --> 02:21:11,195 WERE SHOOTING FOR 300. 3732 02:21:11,195 --> 02:21:12,797 THE PROGRAM OFFICER OVER AT 3733 02:21:12,797 --> 02:21:14,565 NIAMS WAS LOOKING AT A 30-YEAR 3734 02:21:14,565 --> 02:21:16,334 TRIAL AND KNEW THAT WASN'T GOING 3735 02:21:16,334 --> 02:21:18,503 TO WORK AND ACTUALLY REACHED OUT 3736 02:21:18,503 --> 02:21:19,871 AND DIRECTLY CONTACTED THE RIC 3737 02:21:19,871 --> 02:21:20,838 ABOUT THIS. 3738 02:21:20,838 --> 02:21:24,242 THE RIC WAS ABLE TO DO A NUMBER 3739 02:21:24,242 --> 02:21:26,511 OF REALLY -- REALLY SALVAGED 3740 02:21:26,511 --> 02:21:28,312 THIS WITH REFINEMENT OF 3741 02:21:28,312 --> 02:21:29,280 RECRUITMENT MATERIALS, IT WAS 3742 02:21:29,280 --> 02:21:31,382 PASSED OUT TO PATIENTS. 3743 02:21:31,382 --> 02:21:33,184 THE ORIGINAL RECRUITMENT 3744 02:21:33,184 --> 02:21:34,519 MATERIAL THAT THEY PROVIDED THE 3745 02:21:34,519 --> 02:21:38,589 PATIENTS ACTUALLY SPENT HALF OF 3746 02:21:38,589 --> 02:21:39,657 THE BROCHURE OUTLINING THE 3747 02:21:39,657 --> 02:21:40,858 CLEVER ACRONYM THEY HAD COME UP 3748 02:21:40,858 --> 02:21:43,928 WITH FOR CALLING IT THE TARGET 3749 02:21:43,928 --> 02:21:44,128 TRIAL. 3750 02:21:44,128 --> 02:21:46,430 WHICH I DON'T THINK PATIENTS 3751 02:21:46,430 --> 02:21:48,533 WERE MUCH INTERESTED IN. 3752 02:21:48,533 --> 02:21:50,034 THEY PRODUCED A STUDY APP THAT 3753 02:21:50,034 --> 02:21:51,769 WAS VERY EASY FOR A HEALTH CARE 3754 02:21:51,769 --> 02:21:53,638 PROVIDER TO PUT ON THEIR PHONE 3755 02:21:53,638 --> 02:21:55,840 AND PUT IN A FEW PARTICULARS 3756 02:21:55,840 --> 02:21:58,576 ABOUT THEIR PARTICULAR PATIENT 3757 02:21:58,576 --> 02:22:02,280 THEY WERE SEARING AND DETERMINED 3758 02:22:02,280 --> 02:22:05,016 IMMEDIATELY WHETHER OR NOT THAT 3759 02:22:05,016 --> 02:22:06,183 PATIENT WAS ELIGIBLE. 3760 02:22:06,183 --> 02:22:08,753 THE OUTCOME WAS THEY WERE ABLE 3761 02:22:08,753 --> 02:22:09,620 TO COMPLETE THE ENROLLMENT 3762 02:22:09,620 --> 02:22:11,489 WITHIN THE ORIGINAL TIME FRAME 3763 02:22:11,489 --> 02:22:12,690 SO THE RIC CAME THROUGH. 3764 02:22:12,690 --> 02:22:14,458 THE THE GROUP HAS COME BACK TO 3765 02:22:14,458 --> 02:22:16,961 THE RIC WITH A NEW GRANT 3766 02:22:16,961 --> 02:22:18,162 SUBMISSION, HELP WE'RE PLEASED 3767 02:22:18,162 --> 02:22:20,364 WITH THIS, AND THE END RESULT 3768 02:22:20,364 --> 02:22:22,934 THIS WAS A SALVAGED TRIAL THAT 3769 02:22:22,934 --> 02:22:23,834 WAS DETERMINING WHETHER OR NOT 3770 02:22:23,834 --> 02:22:26,137 FOR PEOPLE WHO WERE NOT DOING 3771 02:22:26,137 --> 02:22:29,874 WELL WITH THEIR RHEUMATOID 3772 02:22:29,874 --> 02:22:32,743 ARTHRITIS TREATMENT ON TWO DRUGS 3773 02:22:32,743 --> 02:22:40,484 WHETHER ADDING THIRD DRUG OR TNF 3774 02:22:40,484 --> 02:22:46,524 INHIBITOR WAS AN ADVANTAGE, SO 3775 02:22:46,524 --> 02:22:49,460 THIS IS HAS HAD A DIRECT IMPACT 3776 02:22:49,460 --> 02:22:52,797 ON PATIENT CLINICAL GUIDANCE. 3777 02:22:52,797 --> 02:22:57,034 SO THE TIN 2.0, WE HAVE TWO, ONE 3778 02:22:57,034 --> 02:22:59,670 AT VANDERBILT, ONE AT HOPKINS. 3779 02:22:59,670 --> 02:23:02,740 THE RISK RISK SUCCESSFULLY 3780 02:23:02,740 --> 02:23:06,243 COMPETED WITH THE VANDERBILT 3781 02:23:06,243 --> 02:23:08,079 MEHARRY GOING ON, AWARDED THIS 3782 02:23:08,079 --> 02:23:11,716 PAST SUMMER. 3783 02:23:11,716 --> 02:23:14,785 I THINK WE'RE PLANNING ON OUR 3784 02:23:14,785 --> 02:23:15,920 FIRST IN-PERSON MEETING SOMETIME 3785 02:23:15,920 --> 02:23:17,989 IN LATE NOVEMBER, I BELIEVE, 3786 02:23:17,989 --> 02:23:18,756 BEING SCHEDULED. 3787 02:23:18,756 --> 02:23:20,791 BUT THESE ARE SOME OF THE THEMES 3788 02:23:20,791 --> 02:23:23,661 THAT TIN 2.0 IS WORKING ON, 3789 02:23:23,661 --> 02:23:25,663 EXPANDING PARTICIPATION, 3790 02:23:25,663 --> 02:23:29,266 OUTREACH MORE TO HBCUs, 3791 02:23:29,266 --> 02:23:30,067 MINORITY-SERVING INSTITUTIONS, 3792 02:23:30,067 --> 02:23:31,335 RURAL ORGANIZATIONS TRYING TO 3793 02:23:31,335 --> 02:23:34,171 GET THEM MORE FOCUSED. 3794 02:23:34,171 --> 02:23:35,606 REALLY LOOKING AT 3795 02:23:35,606 --> 02:23:36,440 INCLUSION/EXCLUSION CRITERIA, 3796 02:23:36,440 --> 02:23:39,210 THIS IS ONE OF THE BIG ISSUES, 3797 02:23:39,210 --> 02:23:41,245 IT'S ONE OF THESE DIRTY LITTLE 3798 02:23:41,245 --> 02:23:46,217 SECRETS NIH DOESN'T WANT TO TALK 3799 02:23:46,217 --> 02:23:52,757 ABOUT. 3800 02:23:52,757 --> 02:23:54,191 SOMETIMES INCLUSION/EXCLUSION 3801 02:23:54,191 --> 02:23:55,259 CRITERIA PRODUCES LIMITATIONS, 3802 02:23:55,259 --> 02:23:58,362 WE DON'T RECOGNIZE FULLY GOING 3803 02:23:58,362 --> 02:24:00,031 IN HOW RESTRICTIVE THAT CAN BE. 3804 02:24:00,031 --> 02:24:04,502 WE HAD AN RFI OUT THIS YEAR 3805 02:24:04,502 --> 02:24:06,170 REGARDING DECENTRALIZED TRIAL 3806 02:24:06,170 --> 02:24:08,105 SUPPORT, AN ENORMOUS AMOUNT OF 3807 02:24:08,105 --> 02:24:10,107 DESIRE AND INTEREST IN NOT ONLY 3808 02:24:10,107 --> 02:24:13,611 BY THE ACADEMIC COMMUNITY BUT 3809 02:24:13,611 --> 02:24:14,679 PHARMACEUTICAL COMMUNITY FOR 3810 02:24:14,679 --> 02:24:18,115 UTILIZATION OF DECENTRALIZED 3811 02:24:18,115 --> 02:24:19,550 TRIALS, ABILITY TO DO LOW TOUCH 3812 02:24:19,550 --> 02:24:21,052 OR NO TOUCH TRIALS. 3813 02:24:21,052 --> 02:24:22,720 WE'VE HAD CONTACT WITH THE FDA 3814 02:24:22,720 --> 02:24:25,322 VERY MUCH INTERESTED IN THE 3815 02:24:25,322 --> 02:24:28,626 ABILITY TO VALIDATE USE OF MORE 3816 02:24:28,626 --> 02:24:31,228 CLINICAL ENDPOINTS FROM DIGITAL 3817 02:24:31,228 --> 02:24:32,029 ANT MOBILE TECHNOLOGIES BECAUSE 3818 02:24:32,029 --> 02:24:34,665 THEY FEEL THIS WOULD GREATLY 3819 02:24:34,665 --> 02:24:37,501 IMPROVE ENROLLMENT AND DIVERSITY 3820 02:24:37,501 --> 02:24:38,269 RECRUITMENT AFTER ITS ACROSS. 3821 02:24:38,269 --> 02:24:40,571 THERE'S A LOT OF INTEREST IN 3822 02:24:40,571 --> 02:24:41,539 THIS AREA MOVING FORWARD. 3823 02:24:41,539 --> 02:24:46,277 AND I THINK SOME OF THE THINGS 3824 02:24:46,277 --> 02:24:47,344 WE'VE SEEN REALLY OFFER 3825 02:24:47,344 --> 02:24:51,282 OPPORTUNITIES FOR HOW WE CAN 3826 02:24:51,282 --> 02:24:53,250 REALLY ADVANCE THIS AREA. 3827 02:24:53,250 --> 02:24:54,685 CONSENT AND REGULATORY BURDEN 3828 02:24:54,685 --> 02:24:56,854 REDUCTION IS SOMETHING WE CAN'T 3829 02:24:56,854 --> 02:24:58,856 BE GIVING PEOPLE 50-PAGE 3830 02:24:58,856 --> 02:25:00,157 INFORMED CONSENTS. 3831 02:25:00,157 --> 02:25:02,593 IT JUST DOESN'T WORK. 3832 02:25:02,593 --> 02:25:03,894 AND THEN, YOU KNOW, OBVIOUSLY 3833 02:25:03,894 --> 02:25:08,132 SOME OF THE STANDARD THINGS, 3834 02:25:08,132 --> 02:25:10,768 TESTING TOOLS FOR TRAINING, 3835 02:25:10,768 --> 02:25:12,103 DISSEMINATION, CONTINUING WITH 3836 02:25:12,103 --> 02:25:15,706 THE TIN 1.0, WHICH WAS 3837 02:25:15,706 --> 02:25:17,141 MULTI-CENTER TRIAL SUPPORT 3838 02:25:17,141 --> 02:25:17,975 ACROSS TIN SERVICE ACTIVITIES 3839 02:25:17,975 --> 02:25:20,411 AND A LOT OF WORKING MORE 3840 02:25:20,411 --> 02:25:23,814 CLOSELY WITH CTSAs TO BETTER 3841 02:25:23,814 --> 02:25:25,015 UTILIZE THOSE. 3842 02:25:25,015 --> 02:25:26,650 YOU KNOW, I HIGHLIGHTED -- THIS 3843 02:25:26,650 --> 02:25:31,455 WAS HIGHLIGHTED IN THE 3844 02:25:31,455 --> 02:25:32,723 SUPPLEMENTS, ADMINISTRATIVE 3845 02:25:32,723 --> 02:25:35,392 SUPPLEMENTS THIS MORNING. 3846 02:25:35,392 --> 02:25:37,261 THIS IS RECOGNITION BEYOND 3847 02:25:37,261 --> 02:25:40,865 NCATS, PLACES ACROSS NIH THAT 3848 02:25:40,865 --> 02:25:42,166 CAME TO NCATS TO PROVIDE MONEY 3849 02:25:42,166 --> 02:25:45,770 FOR ACTIVITIES THAT CAN BE 3850 02:25:45,770 --> 02:25:48,839 UTILIZED THROUGH THE CTSA 3851 02:25:48,839 --> 02:25:50,608 PROGRAM, INCLUDING "HEAL." 3852 02:25:50,608 --> 02:25:53,677 AND TRAINING PROGRAMS AS WELL AS 3853 02:25:53,677 --> 02:25:55,846 BIOETHICS, AS WELL AS A FEW 3854 02:25:55,846 --> 02:25:56,180 OTHER TOPICS. 3855 02:25:56,180 --> 02:25:57,648 SO, I WANT TO TALK ABOUT SOME OF 3856 02:25:57,648 --> 02:26:00,317 OUR WHAT I CONSIDER OUR MOST 3857 02:26:00,317 --> 02:26:01,185 VALUABLE PLAYERS. 3858 02:26:01,185 --> 02:26:06,624 SO, I HIGHLIGHT A COUPLE KL2 3859 02:26:06,624 --> 02:26:10,060 SCHOLARS, H. 3860 02:26:10,060 --> 02:26:11,028 THIS IS AN INTERESTING ACTIVITY 3861 02:26:11,028 --> 02:26:12,163 IN ARKANSAS. 3862 02:26:12,163 --> 02:26:15,432 ARC 3863 02:26:15,432 --> 02:26:16,734 ARKANSAS IS UNIQUE. 3864 02:26:16,734 --> 02:26:18,936 MOST PEOPLE ARE PROBABLY NOT AS 3865 02:26:18,936 --> 02:26:21,806 OLD AS I AM, SO, DURING -- 3866 02:26:21,806 --> 02:26:26,577 SHORTLY AFTER WORLD WAR II WHEN 3867 02:26:26,577 --> 02:26:32,483 THE U.S. WAS TESTING ABOVE AT 3868 02:26:32,483 --> 02:26:33,484 ATMOSPHERIC NUCLEAR BOMB TESTING 3869 02:26:33,484 --> 02:26:35,152 WE BLEW UP THINGS IN THE PACIFIC 3870 02:26:35,152 --> 02:26:36,754 AND RELOCATED PEOPLE FROM THE 3871 02:26:36,754 --> 02:26:38,956 MARSHALL ISLANDS WHERE WE BLEW 3872 02:26:38,956 --> 02:26:42,693 UP SOME ATOLLS IN THAT REGION. 3873 02:26:42,693 --> 02:26:44,461 AND WE RELOCATED THEM TO 3874 02:26:44,461 --> 02:26:45,129 NORTHWEST ARKANSAS. 3875 02:26:45,129 --> 02:26:47,364 AND SO THE UNIVERSITY OF 3876 02:26:47,364 --> 02:26:51,001 ARKANSAS CTSA HAS HAD AN 3877 02:26:51,001 --> 02:26:53,204 OUTREACH AND A LONGSTANDING 3878 02:26:53,204 --> 02:27:03,714 COMMUNITY ENGAGEMENT WITH THAT 3879 02:27:04,081 --> 02:27:04,648 MARSHALESE POPULATION, REACHING 3880 02:27:04,648 --> 02:27:08,619 OUT TO THE REPUBLIC OF THE 3881 02:27:08,619 --> 02:27:11,055 MARSHALL ISLANDS THROUGH THE 3882 02:27:11,055 --> 02:27:13,991 CHURCH CONNECTION, FAITH-BASED 3883 02:27:13,991 --> 02:27:14,692 ORGANIZATIONS, IN NORTHWEST 3884 02:27:14,692 --> 02:27:16,961 ARKANSAS AND THERE, TO LOOK AT 3885 02:27:16,961 --> 02:27:21,332 SOME -- WHAT AMOUNTS TO SOME 3886 02:27:21,332 --> 02:27:24,168 STRIKING HEALTH DISPARITIES THEY 3887 02:27:24,168 --> 02:27:29,006 HAVE SOME OF THE HIGHEST AGE 3888 02:27:29,006 --> 02:27:30,074 ADJUSTED TYPE 2 DIABETES 3889 02:27:30,074 --> 02:27:33,143 MELLITUS IN THE WORLD, OFFERING 3890 02:27:33,143 --> 02:27:36,080 POTENTIAL INSIGHT INTO DISEASE 3891 02:27:36,080 --> 02:27:37,114 ETIOLOGY AND PATHOGENESIS. 3892 02:27:37,114 --> 02:27:39,049 AND SO SHE'S DONE A GREAT JOB IN 3893 02:27:39,049 --> 02:27:43,988 TERMS OF MOVING THAT EFFORT 3894 02:27:43,988 --> 02:27:44,221 FORWARD. 3895 02:27:44,221 --> 02:27:48,559 GREGORY PECK, WHO IS AT THE 3896 02:27:48,559 --> 02:27:49,894 RUTGERS CTSA, I'M PARTICULARLY 3897 02:27:49,894 --> 02:27:52,162 FOND OF THIS BECAUSE WE DON'T 3898 02:27:52,162 --> 02:27:54,598 ALWAYS SEE SOMEBODY ACTUALLY 3899 02:27:54,598 --> 02:27:55,766 DOING PREVENTIVE CARE. 3900 02:27:55,766 --> 02:27:56,467 I THINK IT'S SOMETHING THAT CAME 3901 02:27:56,467 --> 02:27:59,270 OUT IN MANY OF THE STAKEHOLDER 3902 02:27:59,270 --> 02:28:00,804 ENGAGEMENTS, THAT REALLY NEED TO 3903 02:28:00,804 --> 02:28:02,072 FOCUS MORE IN PREVENTING DISEASE 3904 02:28:02,072 --> 02:28:08,078 RATHER THAN JUST THINKING ABOUT 3905 02:28:08,078 --> 02:28:09,380 TREATING IT AFTER OCCURS. 3906 02:28:09,380 --> 02:28:12,683 HE'S PUT QUITE A BIT OF EFFORTS 3907 02:28:12,683 --> 02:28:14,018 INTO PREVENTIVE CARE TO DECREASE 3908 02:28:14,018 --> 02:28:15,619 RISK FACTORS FOR CHRONIC DISEASE 3909 02:28:15,619 --> 02:28:20,557 BEFORE THE NEED FOR 3910 02:28:20,557 --> 02:28:21,058 HOSPITAL-BASED TREATMENT 3911 02:28:21,058 --> 02:28:21,859 ACTUALLY ARISING. 3912 02:28:21,859 --> 02:28:27,431 I LIKE TO TALK ABOUT FORMER K 3913 02:28:27,431 --> 02:28:29,066 SCHOLARS, CAROLYN IS BECOMING A 3914 02:28:29,066 --> 02:28:30,267 ROCK STAR. 3915 02:28:30,267 --> 02:28:35,205 SHE IS THE LEAD INVESTIGATOR ON 3916 02:28:35,205 --> 02:28:37,608 THE COVID-OUT TRIAL LEADING TO 3917 02:28:37,608 --> 02:28:39,710 POSITIVE RESULTS FOR METFORMIN 3918 02:28:39,710 --> 02:28:42,446 FOR ACUTE COVID AND ALSO 3919 02:28:42,446 --> 02:28:44,381 DISPLAYED INTERESTINGLY ENOUGH A 3920 02:28:44,381 --> 02:28:48,352 42% REDUCTION IN THE DEVELOPMENT 3921 02:28:48,352 --> 02:28:50,521 OF LONG COVID FOLLOWING ACUTE -- 3922 02:28:50,521 --> 02:28:53,057 FOLLOWING TREATMENT FOR ACUTE 3923 02:28:53,057 --> 02:28:55,459 COVID, WHICH IS IMPRESSIVE, AND 3924 02:28:55,459 --> 02:28:57,561 ONE OF THE REASONS THAT ACTIV 6 3925 02:28:57,561 --> 02:29:00,464 IS FOLLOWING ON TO SEE IF WE CAN 3926 02:29:00,464 --> 02:29:01,799 REPEAT THERE'S, THERE'S QUITE A 3927 02:29:01,799 --> 02:29:04,201 BIT OF INTEREST GIVEN THE 3928 02:29:04,201 --> 02:29:07,371 COMPLETE LACK OF ANY SPECIFIC 3929 02:29:07,371 --> 02:29:08,706 INTERVENTIONS TO ADDRESS LONG 3930 02:29:08,706 --> 02:29:12,943 COVID AT THIS POINT. 3931 02:29:12,943 --> 02:29:15,813 SO, SHE'S JUST REALLY TAKEN OFF 3932 02:29:15,813 --> 02:29:19,216 AND DONE QUITE IMPRESSIVE WORK 3933 02:29:19,216 --> 02:29:22,920 IN THIS AREA. 3934 02:29:22,920 --> 02:29:24,888 SO FOR TL1s, ANDREW RAINEY, 3935 02:29:24,888 --> 02:29:28,525 TALKED ABOUT THIS BEFORE, BUT I 3936 02:29:28,525 --> 02:29:29,927 THINK THE UTILIZATION OF 3937 02:29:29,927 --> 02:29:37,601 WASTEWATER AS A PUBLIC HEALTH 3938 02:29:37,601 --> 02:29:41,772 MEASURE I THINK PRE-COVID PEOPLE 3939 02:29:41,772 --> 02:29:42,773 WOULD HAVE RECOMMENDED A PSYCH 3940 02:29:42,773 --> 02:29:44,408 EVALUATION IF YOU REQUESTED THIS 3941 02:29:44,408 --> 02:29:45,709 BUT IT'S CLEARLY SHOWN, THE 3942 02:29:45,709 --> 02:29:49,980 ABILITY TO USE THIS IN A 3943 02:29:49,980 --> 02:29:51,081 COMPREHENSIVE MANNER REQUIRES 3944 02:29:51,081 --> 02:29:56,887 THE ABILITY TO UNDERSTAND HOW WE 3945 02:29:56,887 --> 02:30:00,257 GO ABOUT DOING THIS AND 3946 02:30:00,257 --> 02:30:05,963 NORMALIZATION FACTORS FOR 3947 02:30:05,963 --> 02:30:07,164 EPIHERE, ANALYZING DATASETS OF 3948 02:30:07,164 --> 02:30:10,601 182 COMMUNITIES ACROSS MULTIPLE 3949 02:30:10,601 --> 02:30:10,834 STATES. 3950 02:30:10,834 --> 02:30:11,902 IT IS -- THIS IS REALLY GETTING 3951 02:30:11,902 --> 02:30:16,807 AT THE BEGINNINGS OF HOW WE CAN 3952 02:30:16,807 --> 02:30:19,977 REALLY BEGIN TO UTILIZE THIS 3953 02:30:19,977 --> 02:30:21,612 INFORMATION FOR VERY EFFECTIVE 3954 02:30:21,612 --> 02:30:22,379 PUBLIC HEALTH GUIDANCE. 3955 02:30:22,379 --> 02:30:23,614 YOU'LL HEAR MORE ABOUT ANOTHER 3956 02:30:23,614 --> 02:30:29,053 PUBLIC HEALTH PROJECT RELATED TO 3957 02:30:29,053 --> 02:30:30,287 THIS LATER ON. 3958 02:30:30,287 --> 02:30:31,989 SALLY EAGLETON, LOOKING AT 3959 02:30:31,989 --> 02:30:33,257 IMPROVING SCREENING AND 3960 02:30:33,257 --> 02:30:35,225 REFERRALS FOR FEDERAL NUTRITION 3961 02:30:35,225 --> 02:30:36,193 PROGRAMS PARTICIPATION, USING 3962 02:30:36,193 --> 02:30:37,461 ELECTRONIC HEALTH RECORDS. 3963 02:30:37,461 --> 02:30:40,898 KEEP IN MIND THAT THIS IS THE 3964 02:30:40,898 --> 02:30:42,800 WIC -- WE HAD THE PROBLEM WITH 3965 02:30:42,800 --> 02:30:44,301 THE BABY FORMULA, WIC IS ONE OF 3966 02:30:44,301 --> 02:30:47,071 THE MAIN DRIVERS OF THAT. 3967 02:30:47,071 --> 02:30:50,274 SO THIS REALLY HAS A BIG IMPACT. 3968 02:30:50,274 --> 02:30:52,609 BUT THE ABILITY TO INTEGRATE A 3969 02:30:52,609 --> 02:30:53,877 LOT OF ELECTRONIC HEALTH RECORD 3970 02:30:53,877 --> 02:30:55,512 DATA INTO THIS ANALYSIS I THINK 3971 02:30:55,512 --> 02:30:58,282 IS SOMETHING THAT'S BEEN SORELY 3972 02:30:58,282 --> 02:30:59,683 LACKING AND GREATLY NEEDED. 3973 02:30:59,683 --> 02:31:02,319 SO WHERE DO THESE GO ON TO? 3974 02:31:02,319 --> 02:31:04,488 WELL, THIS INDIVIDUAL QUITE 3975 02:31:04,488 --> 02:31:09,093 IMPRESSED ME, ZAK DYER IS A 3976 02:31:09,093 --> 02:31:10,060 FORMER TL1 TRAINEE FROM LAST 3977 02:31:10,060 --> 02:31:14,498 YEAR, WENT ON TO GET A 3978 02:31:14,498 --> 02:31:15,799 SUBSEQUENT T32 PRE-DOCTORAL 3979 02:31:15,799 --> 02:31:18,635 FELLOWSHIP FROM NIMHD, FOCUSED 3980 02:31:18,635 --> 02:31:23,373 ON A -- LOOKING AT A LARGE 3981 02:31:23,373 --> 02:31:24,842 NUMBER, 40 DATA ELEMENTS, 3982 02:31:24,842 --> 02:31:26,410 MEASURES SOCIAL DETERMINANTS OF 3983 02:31:26,410 --> 02:31:29,246 HEALTH TO PROVIDE SUPPORT FOR A 3984 02:31:29,246 --> 02:31:30,447 STRUCTURAL RACISM EFFECT INDEX 3985 02:31:30,447 --> 02:31:32,883 WHICH PEOPLE ARE ACTUALLY QUITE 3986 02:31:32,883 --> 02:31:34,418 INTERESTED IN. 3987 02:31:34,418 --> 02:31:36,386 BUT HE'S AN MD/PHD STUDENT AT 3988 02:31:36,386 --> 02:31:39,123 THE UNIVERSITY OF MASSACHUSETTS. 3989 02:31:39,123 --> 02:31:41,391 BUT HE'S TEMPORARILY ON LEAVE 3990 02:31:41,391 --> 02:31:42,960 BECAUSE AS A STUDENT HE'S BECOME 3991 02:31:42,960 --> 02:31:44,461 THE ACTING DIRECTOR OF THE 3992 02:31:44,461 --> 02:31:46,663 WORCESTER DEPARTMENT OF PUBLIC 3993 02:31:46,663 --> 02:31:52,669 HEALTH, SO I THINK IT'S PRETTY 3994 02:31:52,669 --> 02:31:54,638 IMPRESSIVE WHAT HE'S DOING SO 3995 02:31:54,638 --> 02:31:57,374 FAR, AND HOPEFULLY HE WILL 3996 02:31:57,374 --> 02:31:58,809 COMPLETE HIS Ph.D. AND HIS 3997 02:31:58,809 --> 02:32:02,412 WORK WITH A LOT OF PEOPLE 3998 02:32:02,412 --> 02:32:04,915 LOOKING FORWARD IT. 3999 02:32:04,915 --> 02:32:08,318 WITH REGARD TO OUR DIVERSITY AND 4000 02:32:08,318 --> 02:32:09,186 REENTRY SUPPLEMENT AWARDEES WE 4001 02:32:09,186 --> 02:32:14,158 HAD SEVEN THIS PAST YEAR, NICE 4002 02:32:14,158 --> 02:32:15,993 RANGE FROM GEOGRAPHICALLY ACROSS 4003 02:32:15,993 --> 02:32:17,194 THE COUNTRY. 4004 02:32:17,194 --> 02:32:20,831 AND JUST TO HIGHLIGHT TWO, LAIKA 4005 02:32:20,831 --> 02:32:24,201 IS ASSISTANT PROFESSOR OF 4006 02:32:24,201 --> 02:32:32,075 PSYCHIATRY AT UCSD, AND SHE IS 4007 02:32:32,075 --> 02:32:33,710 LEVERAGING MACHINE LEARNING, 4008 02:32:33,710 --> 02:32:36,446 PREDICTORS FOR EMERGENCE OF 4009 02:32:36,446 --> 02:32:37,748 SUBSTANCE ABUSE WHICH IS 4010 02:32:37,748 --> 02:32:40,717 PROBABLY A FRUITFUL AREA OF 4011 02:32:40,717 --> 02:32:41,051 INVESTIGATION. 4012 02:32:41,051 --> 02:32:51,562 AND THEN CATRELL, ASSISTANT 4013 02:32:53,197 --> 02:32:55,465 PROFESSOR OF EPIDEMIOLOGY, 4014 02:32:55,465 --> 02:32:57,901 UNIVERSITY OF KENTUCKY, SLEEP IN 4015 02:32:57,901 --> 02:32:59,836 APPALACHIAN CHILDREN. 4016 02:32:59,836 --> 02:33:02,339 WHEN I VISITED KENTUCKY THEY 4017 02:33:02,339 --> 02:33:03,006 TOLD ME EASTERN KENTUCKY, THEY 4018 02:33:03,006 --> 02:33:05,676 ARE ON THE EDGE OF, IS VERY MUCH 4019 02:33:05,676 --> 02:33:07,311 LIKE WEST VIRGINIA. 4020 02:33:07,311 --> 02:33:08,712 SO IT'S A SIGNIFICANT POPULATION 4021 02:33:08,712 --> 02:33:10,280 WHEN YOU THINK ABOUT WHAT GOES 4022 02:33:10,280 --> 02:33:13,550 ON IN WEST VIRGINIA, EASTERN 4023 02:33:13,550 --> 02:33:16,486 KENTUCKY IS SUFFERING VERY 4024 02:33:16,486 --> 02:33:16,720 SIMILAR. 4025 02:33:16,720 --> 02:33:20,190 AND SO THERE ARE A LOT OF 4026 02:33:20,190 --> 02:33:21,758 ISSUES, BODY MASS INDEX, 4027 02:33:21,758 --> 02:33:23,160 SECONDHAND SMOKE. 4028 02:33:23,160 --> 02:33:24,928 THIS IS REALLY IMPACTING THE 4029 02:33:24,928 --> 02:33:26,330 PEDIATRIC COHORT QUITE 4030 02:33:26,330 --> 02:33:26,997 SIGNIFICANTLY THERE. 4031 02:33:26,997 --> 02:33:33,036 AND SO WHERE ARE THEY NOW? 4032 02:33:33,036 --> 02:33:34,271 DMITRY IS NOW ASSISTANT 4033 02:33:34,271 --> 02:33:39,176 PROFESSOR OF MEDICINE, ASSOCIATE 4034 02:33:39,176 --> 02:33:39,743 DIRECTOR OF HEALTH EQUITY, 4035 02:33:39,743 --> 02:33:43,247 UNIVERSITY OF COLORADO. 4036 02:33:43,247 --> 02:33:46,083 HER FOCUS IS ON PERIPHERAL 4037 02:33:46,083 --> 02:33:49,620 ARTERY DISEASE IN AFRICAN 4038 02:33:49,620 --> 02:33:49,987 AMERICANS. 4039 02:33:49,987 --> 02:33:54,658 SO, I'LL RUN THROUGH A COUPLE 4040 02:33:54,658 --> 02:33:55,525 LITTLE HIGHLIGHTS HERE. 4041 02:33:55,525 --> 02:33:56,193 NEWS HIGHLIGHTS. 4042 02:33:56,193 --> 02:33:59,563 WE'LL BE SEEING MORE AND MORE OF 4043 02:33:59,563 --> 02:34:00,230 THIS. 4044 02:34:00,230 --> 02:34:01,999 A.I. APPLICATIONS, WHAT WE'RE 4045 02:34:01,999 --> 02:34:04,401 LOOKING AT IS INFORMATION 4046 02:34:04,401 --> 02:34:06,136 EVERYWHERE, SO THIS IS WHAT MAY 4047 02:34:06,136 --> 02:34:08,171 BE CONSIDERED A SLIGHTLY OBSCURE 4048 02:34:08,171 --> 02:34:08,372 STUDY. 4049 02:34:08,372 --> 02:34:11,942 I DON'T KNOW THAT PEOPLE ARE 4050 02:34:11,942 --> 02:34:13,577 REGULARLY READING WHATEVER THIS 4051 02:34:13,577 --> 02:34:14,144 JOURNAL IS. 4052 02:34:14,144 --> 02:34:17,180 BUT WHAT THEY WERE ABLE TO DO, 4053 02:34:17,180 --> 02:34:20,284 THIS GROUP AT VANDERBILT, WAS TO 4054 02:34:20,284 --> 02:34:22,119 ACTUALLY TAKE ROUTINE CHEST 4055 02:34:22,119 --> 02:34:25,455 CTs, AS YOU CAN SEE HERE, AND 4056 02:34:25,455 --> 02:34:32,362 THEY WERE ABLE TO ACTUALLY 4057 02:34:32,362 --> 02:34:37,034 EVALUATE IT, CHEST CTs, 4058 02:34:37,034 --> 02:34:38,468 SUBCUTANEOUS ADIPOSE TISSUE, 4059 02:34:38,468 --> 02:34:40,404 MUSCLE MASS, BONE, IF YOU HAVE 4060 02:34:40,404 --> 02:34:42,072 TO DISTINGUISH BETWEEN MEN AND 4061 02:34:42,072 --> 02:34:42,606 WOMEN OBVIOUSLY. 4062 02:34:42,606 --> 02:34:47,477 BUT THEY WERE ABLE TO DERIVE 4063 02:34:47,477 --> 02:34:49,112 OVERALL BODY COMPOSITION FROM 4064 02:34:49,112 --> 02:34:50,314 THESE. 4065 02:34:50,314 --> 02:34:51,715 WHICH IS PRETTY IMPRESSIVE. 4066 02:34:51,715 --> 02:34:53,817 SO WHAT IT MEANS IS IF YOU'RE 4067 02:34:53,817 --> 02:34:55,118 LOOKING AT A CHEST CT FOR THE 4068 02:34:55,118 --> 02:34:57,187 PURPOSE OF WHAT'S GOING ON IN 4069 02:34:57,187 --> 02:34:58,121 THE CHEST, YOU'RE LEAVING A LOT 4070 02:34:58,121 --> 02:34:59,823 OF INFORMATION ON THE TABLE. 4071 02:34:59,823 --> 02:35:00,924 THERE'S A LOT OF DIGITAL 4072 02:35:00,924 --> 02:35:02,559 INFORMATION THAT THE A.I. WAS 4073 02:35:02,559 --> 02:35:04,294 ABLE TO REALLY PULL OUT. 4074 02:35:04,294 --> 02:35:05,295 WHAT THEY HAVE SUBSEQUENTLY GONE 4075 02:35:05,295 --> 02:35:07,164 ON TO DO WITH THIS, WHICH IS 4076 02:35:07,164 --> 02:35:11,301 WHAT I WANTED TO HIGHLIGHT, WAS 4077 02:35:11,301 --> 02:35:19,409 THEY HAVE TAKEN THIS AND USING 4078 02:35:19,409 --> 02:35:21,144 LOW DOSE TOMOGRAPHY DATA, CHEST 4079 02:35:21,144 --> 02:35:24,414 CTs, THAT THE NCI HAS FUNDED 4080 02:35:24,414 --> 02:35:25,849 OVER DECADES FOR LOW-DOSE LUNG 4081 02:35:25,849 --> 02:35:27,651 SCREENINGS FOR PEOPLE AT HIGH 4082 02:35:27,651 --> 02:35:29,686 RISK FOR LUNG CANCER, HAVE TENS 4083 02:35:29,686 --> 02:35:31,421 OF THOUSANDS OF THESE CHEST 4084 02:35:31,421 --> 02:35:32,222 CTs THEY HAVE BEEN TRACKING 4085 02:35:32,222 --> 02:35:33,390 FOR YEARS AND YEARS AND YEARS. 4086 02:35:33,390 --> 02:35:37,127 THEY HAVE BEEN ABLE TO SHOW BY 4087 02:35:37,127 --> 02:35:39,663 STRATIFYING IN TERMS OF MUSCLE 4088 02:35:39,663 --> 02:35:43,266 MASS AND ADIPOSE TISSUE, 4089 02:35:43,266 --> 02:35:44,334 RELATIVE ADIPOSITY AND 4090 02:35:44,334 --> 02:35:46,436 SARCOPENIA, IF YOU STRATIFY YOU 4091 02:35:46,436 --> 02:35:49,373 CAN SHOW YOU SEE A CORRELATION 4092 02:35:49,373 --> 02:35:52,008 IN TERMS OF NOT ONLY WITH 4093 02:35:52,008 --> 02:35:54,511 MORTALITY FROM LUNG CANCER BUT 4094 02:35:54,511 --> 02:35:57,013 MORTALITY FROM CARDIOVASCULAR 4095 02:35:57,013 --> 02:35:59,316 DISEASE AND ALL-CAUSE MORTALITY. 4096 02:35:59,316 --> 02:36:01,184 SO, ONE SIMPLE LOW DOSE 4097 02:36:01,184 --> 02:36:04,921 SCREENING CAN ACTUALLY PROVIDE 4098 02:36:04,921 --> 02:36:06,456 SOME VERY INSIGHTFUL VALUE 4099 02:36:06,456 --> 02:36:08,191 BEYOND JUST LUNG CANCER 4100 02:36:08,191 --> 02:36:09,760 DETECTION AND LUNG CANCER 4101 02:36:09,760 --> 02:36:11,461 FOLLOW-UP HERE. 4102 02:36:11,461 --> 02:36:12,896 I THINK THIS HIGHLIGHTS TO ME 4103 02:36:12,896 --> 02:36:15,665 THAT IN A LOT OF OUR IMAGING 4104 02:36:15,665 --> 02:36:17,067 MODALITIES THERE'S A LOT OF 4105 02:36:17,067 --> 02:36:20,137 INFORMATION THAT WE'RE NOT 4106 02:36:20,137 --> 02:36:21,138 RECOGNIZING AS YET, AND 4107 02:36:21,138 --> 02:36:21,772 ARTIFICIAL INTELLIGENCE IS 4108 02:36:21,772 --> 02:36:23,407 PROBABLY ONE WAY WE'LL BE ABLE 4109 02:36:23,407 --> 02:36:25,809 TO BE TEASE SOME OF THESE 4110 02:36:25,809 --> 02:36:28,578 RELATIONSHIPS OUT AND DO USEFUL 4111 02:36:28,578 --> 02:36:30,447 THINGS IN THE FUTURE. 4112 02:36:30,447 --> 02:36:32,516 I THINK ANOTHER AREA RIPE FOR 4113 02:36:32,516 --> 02:36:35,685 A.I., THIS IS A PAPER THAT CAME 4114 02:36:35,685 --> 02:36:39,489 OUT OF THE UCLA CTSA. 4115 02:36:39,489 --> 02:36:40,824 SO LOOKING AT CONSENT DOCUMENT 4116 02:36:40,824 --> 02:36:41,258 TRANSLATION. 4117 02:36:41,258 --> 02:36:45,529 WHAT YOU CAN SEE IS THAT IF YOU 4118 02:36:45,529 --> 02:36:47,831 COMPARE INDUSTRY TRIALS, THIS IS 4119 02:36:47,831 --> 02:36:50,901 ALL THE TRIALS DONE AT UCLA, IF 4120 02:36:50,901 --> 02:36:53,970 YOU COMPARE INDUSTRY TRIALS WITH 4121 02:36:53,970 --> 02:36:55,739 NON-INDUSTRY, WHICH IS LARGELY 4122 02:36:55,739 --> 02:36:56,473 ALMOST EXCLUSIVELY NIH-FUNDED 4123 02:36:56,473 --> 02:36:59,543 TRIALS, WHAT YOU FIND IS THAT 4124 02:36:59,543 --> 02:37:04,381 THE NIH-FUNDED TRIALS ARE ONLY 4125 02:37:04,381 --> 02:37:05,282 PROVIDING TRANSLATED INFORMED 4126 02:37:05,282 --> 02:37:06,383 CONSENT AT HALF THE RATE 4127 02:37:06,383 --> 02:37:06,817 INDUSTRY IS. 4128 02:37:06,817 --> 02:37:08,218 NOW, WHEN WE THINK OF 4129 02:37:08,218 --> 02:37:11,521 TRANSLATION WE MAY BE THINKING 4130 02:37:11,521 --> 02:37:12,556 IT'S MOSTLY SPANISH TRANSLATION 4131 02:37:12,556 --> 02:37:13,590 BUT IN SOUTHERN CALIFORNIA 4132 02:37:13,590 --> 02:37:16,893 YOU'RE PROBABLY TALKING ABOUT 4133 02:37:16,893 --> 02:37:19,729 UPWARDS OF 70 DIFFERENT 4134 02:37:19,729 --> 02:37:20,597 LANGUAGES THAT ARE SPOKEN, IF 4135 02:37:20,597 --> 02:37:22,032 YOU WANT TO GET IN ALL THOSE 4136 02:37:22,032 --> 02:37:22,466 COMMUNITIES. 4137 02:37:22,466 --> 02:37:25,402 SO WHEN THEY LOOKED INTO WHY 4138 02:37:25,402 --> 02:37:28,505 THIS WAS OCCURRING, IT WAS CLEAR 4139 02:37:28,505 --> 02:37:31,007 THAT THE ABILITY TO DO THAT 4140 02:37:31,007 --> 02:37:32,709 TRANSLATION, THE FUNDING WAS 4141 02:37:32,709 --> 02:37:34,611 JUST NOT AVAILABLE IN THE NIH 4142 02:37:34,611 --> 02:37:36,480 GRANTS TO SUPPORT THOSE 4143 02:37:36,480 --> 02:37:37,013 TRANSLATIONS. 4144 02:37:37,013 --> 02:37:38,348 INDUSTRY, IF THEY WANTED TO GET 4145 02:37:38,348 --> 02:37:40,650 TO THOSE PEOPLE, IF THEY WANT TO 4146 02:37:40,650 --> 02:37:44,254 HIT ENROLLMENT TARGETS WILL DO 4147 02:37:44,254 --> 02:37:45,455 WHAT IT TAKES WERE WILLING TO 4148 02:37:45,455 --> 02:37:47,991 PAY FOR IT BUT FOR NIH TRIALS 4149 02:37:47,991 --> 02:37:52,329 THAT I WAS -- THIS WAS AN AREA 4150 02:37:52,329 --> 02:37:52,896 OF LIMITATION. 4151 02:37:52,896 --> 02:37:54,764 A.I. IS BEING USED FOR 4152 02:37:54,764 --> 02:37:56,833 TRANSLATION, NOT AS SIMPLE AS 4153 02:37:56,833 --> 02:37:57,934 TELLING A.I. TO TRANSLATE BUT 4154 02:37:57,934 --> 02:38:00,003 THIS IS ONE AREA WHERE WE REALLY 4155 02:38:00,003 --> 02:38:02,405 SHOULD BE ABLE TO EXPLOIT A.I. 4156 02:38:02,405 --> 02:38:03,940 TO REALLY BE ABLE -- AND THIS 4157 02:38:03,940 --> 02:38:06,243 WOULD BE A SIMPLE 4158 02:38:06,243 --> 02:38:09,312 STRAIGHTFORWARD ENHANCEMENT TO 4159 02:38:09,312 --> 02:38:10,614 RECRUITMENT EFFORTS. 4160 02:38:10,614 --> 02:38:12,015 SO I MENTIONED THE WASTE WATER 4161 02:38:12,015 --> 02:38:12,382 BEFORE. 4162 02:38:12,382 --> 02:38:13,350 THIS CAUGHT MY EYE. 4163 02:38:13,350 --> 02:38:15,318 THIS IS OUT OF DAVIS. 4164 02:38:15,318 --> 02:38:18,255 IT HAS THE GREAT TITLE WHICH 4165 02:38:18,255 --> 02:38:21,124 CATCHES ME, ANYTIME YOU USE 4166 02:38:21,124 --> 02:38:24,728 BAYESIAN I'M INTERESTED, BECAUSE 4167 02:38:24,728 --> 02:38:27,664 USUALLY WHEN SOMEBODY SAYS 4168 02:38:27,664 --> 02:38:29,766 BAYESIAN EVERYBODY ELSE SAYS AS 4169 02:38:29,766 --> 02:38:30,467 THEY ARE CROSSING ONIONS IN 4170 02:38:30,467 --> 02:38:34,604 FRONT OF THEM, THIS IS A 4171 02:38:34,604 --> 02:38:38,308 BAYESIAN SEQUENTIAL APPROACH TO 4172 02:38:38,308 --> 02:38:40,944 MONITOR COVID VARIANTS FROM 4173 02:38:40,944 --> 02:38:41,244 WASTEWATER. 4174 02:38:41,244 --> 02:38:43,914 THEY ACTUALLY DID AN ANALYSIS 4175 02:38:43,914 --> 02:38:46,082 THAT COULD PROVIDE STATISTICAL 4176 02:38:46,082 --> 02:38:48,285 METHOD TO QUANTITATE THRESHOLD 4177 02:38:48,285 --> 02:38:51,521 LEVELS FOR ACTUALLY ESTIMATING 4178 02:38:51,521 --> 02:38:52,222 COMMUNITY TRANSMISSION, 4179 02:38:52,222 --> 02:38:54,624 COMMUNITY TRANSMISSION RATES OF 4180 02:38:54,624 --> 02:38:56,493 COVID FROM THE WASTEWATER DATA. 4181 02:38:56,493 --> 02:38:57,694 THIS IS SOMETHING THAT IS -- 4182 02:38:57,694 --> 02:39:00,330 THIS IS REALLY NEWS YOU CAN USE 4183 02:39:00,330 --> 02:39:00,630 IMMEDIATELY. 4184 02:39:00,630 --> 02:39:03,500 WHAT'S QUITE IMPRESSIVE THOUGH 4185 02:39:03,500 --> 02:39:04,734 ABOUT THIS WAS THAT WHEN YOU 4186 02:39:04,734 --> 02:39:06,469 LOOK AT WHAT HAD TO BE BROUGHT 4187 02:39:06,469 --> 02:39:07,337 TOGETHER SO THESE WERE 4188 02:39:07,337 --> 02:39:10,941 DEPARTMENTS OF PUBLIC HEALTH 4189 02:39:10,941 --> 02:39:12,909 SCIENCES, MATHEMATICS, AND CIVIL 4190 02:39:12,909 --> 02:39:13,777 AND ENVIRONMENTAL ENGINEERING 4191 02:39:13,777 --> 02:39:15,779 GROUPS IN ORDER TO PULL THIS 4192 02:39:15,779 --> 02:39:16,212 OFF. 4193 02:39:16,212 --> 02:39:18,281 I THINK THIS IS, TO ME, 4194 02:39:18,281 --> 02:39:19,683 INDICATIVE OF WHERE THE FUTURE 4195 02:39:19,683 --> 02:39:22,218 WITH BIG DATA IS REALLY COMING 4196 02:39:22,218 --> 02:39:24,187 FROM THAT LOTS OF DIFFERENT 4197 02:39:24,187 --> 02:39:28,558 SPECIALTIES, LOTS OF EXPERTISE 4198 02:39:28,558 --> 02:39:30,327 AND DIVERSE SECTORS OF 4199 02:39:30,327 --> 02:39:31,194 SCIENTIFIC AND TECHNICAL 4200 02:39:31,194 --> 02:39:32,495 EXPERIENCE REALLY HAVE TO COME 4201 02:39:32,495 --> 02:39:36,232 TOGETHER IN SUCH A WAY TO BE 4202 02:39:36,232 --> 02:39:39,302 ABLE TO UTILIZE WHAT IS VERY 4203 02:39:39,302 --> 02:39:40,203 COMPLEX SCIENTIFIC AND MEDICAL 4204 02:39:40,203 --> 02:39:42,505 INFORMATION IN A PRODUCTIVE WAY 4205 02:39:42,505 --> 02:39:45,575 TO REALLY MAKE SOME -- COME UP 4206 02:39:45,575 --> 02:39:48,278 WITH VERY SPECIFIC GUIDANCE AND 4207 02:39:48,278 --> 02:39:49,713 RECOMMENDATIONS FOR PUBLIC 4208 02:39:49,713 --> 02:39:50,046 HEALTH. 4209 02:39:50,046 --> 02:39:56,419 AND SO I THINK THIS IS WHAT THE 4210 02:39:56,419 --> 02:39:59,656 CTSA ARE FACILE AT AND EMPHASIS 4211 02:39:59,656 --> 02:40:03,193 NEEDS TO BE EMPHASIZED FOR THE 4212 02:40:03,193 --> 02:40:03,793 FUTURE. 4213 02:40:03,793 --> 02:40:06,563 A FEW OTHERS, YOU KNOW, 4214 02:40:06,563 --> 02:40:07,230 SMARTPHONES, NEARLY EVERYONE 4215 02:40:07,230 --> 02:40:08,598 PROBABLY HAS ONE IN THEIR 4216 02:40:08,598 --> 02:40:11,401 POCKET, RIGHT IN FRONT OF THEM 4217 02:40:11,401 --> 02:40:12,936 RIGHT NOW. 4218 02:40:12,936 --> 02:40:15,338 AND SO I WAS REALLY IMPRESSED. 4219 02:40:15,338 --> 02:40:20,510 THIS IS OUT OF THE UCSD, THEY 4220 02:40:20,510 --> 02:40:25,548 HAVE A GEM PROGRAM WHICH IS AN 4221 02:40:25,548 --> 02:40:28,618 INTERESTING COMMUNITY WHERE THE 4222 02:40:28,618 --> 02:40:29,819 CTSA SPONSORS ABILITY TO BRING 4223 02:40:29,819 --> 02:40:31,621 TOGETHER MEMBERS OF SCHOOL OF 4224 02:40:31,621 --> 02:40:32,956 ENGINEERING FROM SCHOOL OF 4225 02:40:32,956 --> 02:40:33,990 MEDICINE AND THE SCHOOL OF 4226 02:40:33,990 --> 02:40:35,625 MEDICINE TALKS ABOUT THEIR 4227 02:40:35,625 --> 02:40:36,926 PROBLEMS OR ISSUES, AND THE 4228 02:40:36,926 --> 02:40:39,796 SCHOOL OF ENGINEERING COMES UP 4229 02:40:39,796 --> 02:40:41,231 WITH VERY INNOVATIVE SOLUTIONS. 4230 02:40:41,231 --> 02:40:43,566 AND SO WE MAY THINK BLOOD 4231 02:40:43,566 --> 02:40:44,868 PRESSURE TESTING IS PRETTY 4232 02:40:44,868 --> 02:40:48,204 ROUTINE, YOU CAN BUY SOMETHING 4233 02:40:48,204 --> 02:40:50,940 IN THE STORE, AT THE PHARMACY, 4234 02:40:50,940 --> 02:40:52,308 TO TAKE YOUR OWN BLOOD PRESSURE 4235 02:40:52,308 --> 02:40:53,943 BUT WE KNOW IT'S NOT TRIVIAL. 4236 02:40:53,943 --> 02:40:56,146 YOU HAVE TO BE CAREFUL ABOUT 4237 02:40:56,146 --> 02:40:57,247 TAKING THE MEASUREMENTS, GET THE 4238 02:40:57,247 --> 02:40:59,015 RIGHT CUFF SIZE, DO IT 4239 02:40:59,015 --> 02:41:01,518 CORRECTLY, ALL OF THIS. 4240 02:41:01,518 --> 02:41:03,553 BUT THIS WAS ACTUALLY A LITTLE 4241 02:41:03,553 --> 02:41:05,321 ATTACHMENT COSTING LESS THAN A 4242 02:41:05,321 --> 02:41:07,624 DOLLAR TO MANUFACTURE, THAT YOU 4243 02:41:07,624 --> 02:41:09,159 PLUG INTO A SMARTPHONE AND CAN 4244 02:41:09,159 --> 02:41:11,027 TAKE A BLOOD PRESSURE. 4245 02:41:11,027 --> 02:41:14,297 THIS REALLY THINK GOES A LONG 4246 02:41:14,297 --> 02:41:15,732 WAY IN TERMS OF DEMOCRATIZING 4247 02:41:15,732 --> 02:41:16,900 MONITORING OF BLOOD PRESSURE. 4248 02:41:16,900 --> 02:41:20,003 ONE CAN THINK NOT ONLY ABOUT 4249 02:41:20,003 --> 02:41:22,372 TAKING CARE OF PATIENTS IN THE 4250 02:41:22,372 --> 02:41:24,207 FUTURE BUT THE ABILITY TO DO 4251 02:41:24,207 --> 02:41:27,644 CERTAIN TYPES OF CLINICAL 4252 02:41:27,644 --> 02:41:28,745 TRIALS IN A VERY DECENTRALIZED 4253 02:41:28,745 --> 02:41:30,814 MANNER BECAUSE YOU DON'T HAVE TO 4254 02:41:30,814 --> 02:41:34,417 RELY ON DIFFERENT WAY TO RELY ON 4255 02:41:34,417 --> 02:41:35,118 OBTAINING INFORMATION SUCH AS 4256 02:41:35,118 --> 02:41:35,752 BLOOD PRESSURE. 4257 02:41:35,752 --> 02:41:37,053 I THINK WE'RE JUST AT THE 4258 02:41:37,053 --> 02:41:37,687 BEGINNING. 4259 02:41:37,687 --> 02:41:41,091 WE'RE ON THE CUSP OF WHERE 4260 02:41:41,091 --> 02:41:41,858 LITTLE TINY ATTACHMENTS 4261 02:41:41,858 --> 02:41:43,493 RELATIVELY CHEAP THAT CANNING 4262 02:41:43,493 --> 02:41:46,129 PLUGGED INTO SMARTPHONES WILL 4263 02:41:46,129 --> 02:41:46,996 EXPAND THE CAPABILITY, REALLY 4264 02:41:46,996 --> 02:41:48,965 PUTTING WHAT AMOUNTS TO A 4265 02:41:48,965 --> 02:41:51,601 CLINICAL LABORATORY IN THE PALM 4266 02:41:51,601 --> 02:41:54,003 OF YOUR HAND AND WILL REALLY 4267 02:41:54,003 --> 02:41:55,972 GIVE PEOPLE THE OPPORTUNITY TO 4268 02:41:55,972 --> 02:41:57,107 CONSIDER CERTAIN TYPES OF 4269 02:41:57,107 --> 02:41:59,676 CLINICAL STUDIES AND CLINICAL 4270 02:41:59,676 --> 02:42:03,279 TRIALS THAT WOULD HAVE BEEN 4271 02:42:03,279 --> 02:42:04,180 UNTENABLE PRIOR. 4272 02:42:04,180 --> 02:42:05,682 AND THEN THIS LAST ONE THAT I'LL 4273 02:42:05,682 --> 02:42:08,017 FOCUS ON, AGAIN, I THINK THIS IS 4274 02:42:08,017 --> 02:42:09,219 BRINGING TOGETHER DISPARATE 4275 02:42:09,219 --> 02:42:10,720 DATASETS, THIS IS FROM 4276 02:42:10,720 --> 02:42:13,690 UNIVERSITY OF NORTH CAROLINA. 4277 02:42:13,690 --> 02:42:15,692 SO, EVERYBODY I THINK WOULD WALK 4278 02:42:15,692 --> 02:42:17,193 AROUND AND CONSIDER THAT 4279 02:42:17,193 --> 02:42:20,697 POLLUTION IS NOT A GOOD THING. 4280 02:42:20,697 --> 02:42:25,068 AND BUT IT'S BEEN QUANTITATIVE 4281 02:42:25,068 --> 02:42:25,635 SO PARTICULATE MANNER 4282 02:42:25,635 --> 02:42:27,504 2.5-MICRON, WHAT THEY HAVE BEEN 4283 02:42:27,504 --> 02:42:29,339 ABLE TO SHOW, AGAIN I THINK THIS 4284 02:42:29,339 --> 02:42:30,940 IS WHERE BRINGING TOGETHER 4285 02:42:30,940 --> 02:42:32,742 DISPARATE DATASETS BUT THEY WERE 4286 02:42:32,742 --> 02:42:38,348 ABLE TO SHOW THAT THE PM2.5 4287 02:42:38,348 --> 02:42:41,084 EXPOSURE, THAT CREATED MORE 4288 02:42:41,084 --> 02:42:44,154 CARDIOVASCULAR MORTALITY AND 4289 02:42:44,154 --> 02:42:46,890 ENDED UP WITH MORE DIAGNOSTIC 4290 02:42:46,890 --> 02:42:47,423 TESTING PERFORMED, MORE 4291 02:42:47,423 --> 02:42:50,160 PROCEDURES AS A RESULT OF THAT. 4292 02:42:50,160 --> 02:42:53,763 AGAIN, THIS IS WHERE WE GET INTO 4293 02:42:53,763 --> 02:42:56,065 BIG DATA SO OVER 20,000 EHR 4294 02:42:56,065 --> 02:42:57,467 RECORDS WITH HEART FAILURE 4295 02:42:57,467 --> 02:42:58,701 SPECIFICALLY WERE EVALUATED. 4296 02:42:58,701 --> 02:43:02,539 AND THIS CAN ACTUALLY PROVIDE 4297 02:43:02,539 --> 02:43:03,640 SOME RECOMMENDATIONS AND 4298 02:43:03,640 --> 02:43:06,810 GUIDANCE, AND FOR BOTH 4299 02:43:06,810 --> 02:43:08,545 HEALTHCARE PROVIDERS AND 4300 02:43:08,545 --> 02:43:10,413 INDIVIDUALS, WITH PARTICULAR 4301 02:43:10,413 --> 02:43:11,014 CARDIOVASCULAR CONDITIONS. 4302 02:43:11,014 --> 02:43:12,182 AND I THINK THIS IS JUST -- 4303 02:43:12,182 --> 02:43:13,483 WE'RE JUST AT THE BEGINNING OF 4304 02:43:13,483 --> 02:43:15,885 BEING ABLE TO GET THINGS LIKE 4305 02:43:15,885 --> 02:43:16,085 THIS. 4306 02:43:16,085 --> 02:43:18,621 I'M GOING TO FINISH UP WITH A 4307 02:43:18,621 --> 02:43:20,623 COUPLE EXAMPLES OF SOMEWHAT I 4308 02:43:20,623 --> 02:43:23,660 THINK ARE CTSA IMPACTS. 4309 02:43:23,660 --> 02:43:26,496 SO, I PRESENTED THIS, THIS IS A 4310 02:43:26,496 --> 02:43:28,464 SLIDE I PRESENTED MANY YEARS 4311 02:43:28,464 --> 02:43:29,566 AGO, PRE-COVID, SO SORT OF LIKE 4312 02:43:29,566 --> 02:43:32,035 BACK IN THE DARK AGES AS FAR AS 4313 02:43:32,035 --> 02:43:32,502 I'M CONCERNED. 4314 02:43:32,502 --> 02:43:35,271 HARD TO REMEMBER EXACTLY WHEN. 4315 02:43:35,271 --> 02:43:38,107 BUT BACK IN AROUND AT THE END OF 4316 02:43:38,107 --> 02:43:42,679 2007, EARLY 2008, THERE WAS A 4317 02:43:42,679 --> 02:43:44,647 CTSA PILOT AWARD. 4318 02:43:44,647 --> 02:43:45,648 THIS IS AT CORNELL. 4319 02:43:45,648 --> 02:43:49,052 WAS GIVEN FOR A PRE-CLINICAL 4320 02:43:49,052 --> 02:43:57,060 MODEL USING ULTRA SMALL 4321 02:43:57,060 --> 02:43:57,694 T UMOR-TARGETING CORE-SHELL 4322 02:43:57,694 --> 02:43:58,027 NANOPARTICLES. 4323 02:43:58,027 --> 02:44:02,498 THIS IS IT ON THE RIGHT, A 4324 02:44:02,498 --> 02:44:04,367 FAIRLY MALLEABLE PLATFORM THAT 4325 02:44:04,367 --> 02:44:05,802 ALLOWS YOU TO ATTACH A NUMBER OF 4326 02:44:05,802 --> 02:44:06,569 DIFFERENT THINGS. 4327 02:44:06,569 --> 02:44:08,972 YOU CAN HAVE A TARGETING 4328 02:44:08,972 --> 02:44:11,274 MOLECULE HERE, AND THEN CAN YOU 4329 02:44:11,274 --> 02:44:12,909 HAVE A RADIO LABEL, STICK A DRUG 4330 02:44:12,909 --> 02:44:15,411 ON, A LOT OF THINGS. 4331 02:44:15,411 --> 02:44:16,646 YOU WOULD INJECT THESE. 4332 02:44:16,646 --> 02:44:18,281 THEY SHOWED QUITE A BIT OF 4333 02:44:18,281 --> 02:44:19,482 RELATIVE SAFETY. 4334 02:44:19,482 --> 02:44:23,019 THERE WAS JUST EFFICIENT URINARY 4335 02:44:23,019 --> 02:44:24,654 EXCRETION FOR THEM. 4336 02:44:24,654 --> 02:44:29,359 AND IN 2011 THEY GOT AN IND FOR 4337 02:44:29,359 --> 02:44:30,159 A MULTIMODAL PLATFORM. 4338 02:44:30,159 --> 02:44:34,597 2014 THEY GOT IT FROM AN OPTICAL 4339 02:44:34,597 --> 02:44:35,265 PARTICLE PROBE. 4340 02:44:35,265 --> 02:44:36,900 THIS HAS GONE ON THOUGH, I 4341 02:44:36,900 --> 02:44:38,768 DIDN'T CREATE THIS. 4342 02:44:38,768 --> 02:44:41,237 THIS IS FROM A MICHELLE 4343 02:44:41,237 --> 02:44:42,739 BRADBURY, BUT THIS IS THE 4344 02:44:42,739 --> 02:44:45,475 ORIGINAL AWARD THAT WAS GIVEN 4345 02:44:45,475 --> 02:44:47,210 LATE 2007, EARLY 2008. 4346 02:44:47,210 --> 02:44:49,412 THEY GOT A SUBSEQUENT SEED GRANT 4347 02:44:49,412 --> 02:44:51,814 FROM THE CTSA AWARD, BUT WHAT 4348 02:44:51,814 --> 02:44:53,850 YOU CAN SEE IS THIS HAS GONE ON, 4349 02:44:53,850 --> 02:44:55,752 THERE'S BEEN -- THE NUMBER OF 4350 02:44:55,752 --> 02:44:58,788 STUDIES FIRST IN HUMANS AS EARLY 4351 02:44:58,788 --> 02:45:01,758 AS THE 2011 ONE, BUT THIS HAS 4352 02:45:01,758 --> 02:45:02,859 BEEN COMMERCIALIZED, THERE'S A 4353 02:45:02,859 --> 02:45:04,594 CAN BE USING THIS 4354 02:45:04,594 --> 02:45:05,261 THERAPEUTICALLY AND IT'S BEING 4355 02:45:05,261 --> 02:45:08,865 USED IN A NUMBER OF DIAGNOSTIC 4356 02:45:08,865 --> 02:45:09,198 APPLICATIONS. 4357 02:45:09,198 --> 02:45:12,268 SO IT'S A RATHER 4358 02:45:12,268 --> 02:45:12,969 MULTI-FUNCTIONAL MULTI-MODAL 4359 02:45:12,969 --> 02:45:15,204 PLATFORM THAT REALLY GOT ITS 4360 02:45:15,204 --> 02:45:18,841 START FROM A CTSA PILOT AWARD. 4361 02:45:18,841 --> 02:45:20,476 AND I THINK IF THAT APPLICATION 4362 02:45:20,476 --> 02:45:22,779 HAD COME TO AN NIH STUDY SECTION 4363 02:45:22,779 --> 02:45:24,647 EARLY ON BACK IN 2007, IT 4364 02:45:24,647 --> 02:45:26,816 PROBABLY WOULD HAVE BEEN NOT 4365 02:45:26,816 --> 02:45:27,684 DISCUSSED AT ALL. 4366 02:45:27,684 --> 02:45:30,787 LAST ONE I WANT TO FINISH WITH 4367 02:45:30,787 --> 02:45:36,459 IS AN INTERESTING ANALYSIS. 4368 02:45:36,459 --> 02:45:38,628 THIS IS A BIBLIOMETRIC ANALYSIS 4369 02:45:38,628 --> 02:45:45,768 THAT WAS DONE BY A NUMBER OF 4370 02:45:45,768 --> 02:45:46,502 CTSA AWARDEES. 4371 02:45:46,502 --> 02:45:48,905 AND THEY LOOKED AT ALL THE 4372 02:45:48,905 --> 02:45:50,440 CTSAs, I COULDN'T HAVE TOLD 4373 02:45:50,440 --> 02:45:51,874 YOU THIS NUMBER BEFORE THEY TOLD 4374 02:45:51,874 --> 02:45:53,776 ME WHAT IT WAS. 4375 02:45:53,776 --> 02:45:56,279 BUT FROM 2006 WHEN THE PROGRAM 4376 02:45:56,279 --> 02:46:00,850 BEGAN THROUGH 2021, THERE'S OVER 4377 02:46:00,850 --> 02:46:01,617 118,000 PUBLICATIONS THAT LIST 4378 02:46:01,617 --> 02:46:03,920 CTSA FUNDING WHICH IS IMPRESSIVE 4379 02:46:03,920 --> 02:46:06,255 IN AND OF ITSELF. 4380 02:46:06,255 --> 02:46:08,758 WHAT'S INTERESTING IS 13% OF 4381 02:46:08,758 --> 02:46:10,827 THOSE PUBLICATIONS HAVE BEEN 4382 02:46:10,827 --> 02:46:12,895 FOUND TO BE REFERENCED IN POLICY 4383 02:46:12,895 --> 02:46:14,330 DOCUMENTS WHICH IS A PRETTY 4384 02:46:14,330 --> 02:46:15,531 IMPRESSIVE NUMBER. 4385 02:46:15,531 --> 02:46:20,003 AND BY DOING AN ANALYSIS FOR THE 4386 02:46:20,003 --> 02:46:21,337 TYPE OF HEALTH-RELATED 4387 02:46:21,337 --> 02:46:23,072 PUBLICATIONS THAT THEY HAD 4388 02:46:23,072 --> 02:46:29,345 DESCRIBED, THAT'S ABOUT A 30% 4389 02:46:29,345 --> 02:46:31,848 INCREASE OVER NON-CTSA 4390 02:46:31,848 --> 02:46:32,181 PUBLICATIONS. 4391 02:46:32,181 --> 02:46:35,351 SO THE CTSA IS REALLY PRODUCING 4392 02:46:35,351 --> 02:46:37,754 STUDIES THAT ARE BEING READ NOT 4393 02:46:37,754 --> 02:46:41,491 JUST BY THE ACADEMIC COMMUNITY 4394 02:46:41,491 --> 02:46:44,027 AND INTERESTED INVESTIGATORS BUT 4395 02:46:44,027 --> 02:46:47,597 IS BEING REVIEWED AND EVALUATED 4396 02:46:47,597 --> 02:46:51,167 BY POLICYMAKERS AND PEOPLE IN 4397 02:46:51,167 --> 02:46:52,902 CHARGE OF ASSEMBLING CLINICAL 4398 02:46:52,902 --> 02:46:55,371 GUIDANCE AND THE LIKE. 4399 02:46:55,371 --> 02:46:58,107 THE OTHER INTERESTING ASPECT IS 4400 02:46:58,107 --> 02:47:02,178 THERE'S THIS LITTLE -- THIS 4401 02:47:02,178 --> 02:47:05,448 NIH-DERIVED APT, WHICH STANDS 4402 02:47:05,448 --> 02:47:12,555 FOR -- IT'S BIZARRE, NIH 4403 02:47:12,555 --> 02:47:13,856 PUBLICATION, IT'S APPROXIMATE 4404 02:47:13,856 --> 02:47:16,392 POTENTIAL TO TRANSLATE, IT'S NIH 4405 02:47:16,392 --> 02:47:20,863 SO A BIZARRE SORT OF NAME. 4406 02:47:20,863 --> 02:47:23,066 IT'S AN ML PREDICTION ALGORITHM 4407 02:47:23,066 --> 02:47:26,903 THAT ESTIMATES THE ABILITY OF A 4408 02:47:26,903 --> 02:47:29,972 PUBLICATION TO BE SUBSEQUENTLY 4409 02:47:29,972 --> 02:47:32,041 CITED IN A FUTURE CLINICAL STUDY 4410 02:47:32,041 --> 02:47:33,376 OF SOME TYPE. 4411 02:47:33,376 --> 02:47:36,779 AND WHAT THEY SHOWED WAS THAT 4412 02:47:36,779 --> 02:47:39,515 THE CTSA PUBLICATIONS THAT WERE 4413 02:47:39,515 --> 02:47:42,652 REFERENCED IN POLICY DOCUMENTS 4414 02:47:42,652 --> 02:47:53,129 HAD A STATISTICALLY HIGHER 4415 02:47:56,099 --> 02:47:57,867 LIKELIHOOD OF APTITUDE. 4416 02:47:57,867 --> 02:47:59,335 YOU LOOK AT SIMPLE SCIENTIFIC 4417 02:47:59,335 --> 02:48:00,436 STUDY AND WONDER IS ANYBODY 4418 02:48:00,436 --> 02:48:02,505 GOING TO DO SOMETHING USEFUL 4419 02:48:02,505 --> 02:48:04,173 WITH THIS LATER ON, PARTICULARLY 4420 02:48:04,173 --> 02:48:06,342 IN A CLINICAL AS OPPOSED TO 4421 02:48:06,342 --> 02:48:11,147 FOLLOW-ON BASIC SCIENCE STUDY. 4422 02:48:11,147 --> 02:48:14,650 THE APT IS AN ATTEMPT TO DO 4423 02:48:14,650 --> 02:48:19,155 THAT. 4424 02:48:19,155 --> 02:48:22,592 CTSA PUBLICATIONS VALIDATE THE 4425 02:48:22,592 --> 02:48:24,861 UTILITY OF THAT APT MEASURE. 4426 02:48:24,861 --> 02:48:27,330 I WILL CLOSE AND HAPPY TO TAKE 4427 02:48:27,330 --> 02:48:27,797 QUESTIONS. 4428 02:48:27,797 --> 02:48:30,733 >> YOU'RE TEN MINUTES OVER SO WE 4429 02:48:30,733 --> 02:48:32,268 HAVE -- I'D LIKE TO MAKE SURE WE 4430 02:48:32,268 --> 02:48:33,469 HAVE AN OPPORTUNITY TO HAVE 4431 02:48:33,469 --> 02:48:34,570 MAYBE A QUESTION OR SO. 4432 02:48:34,570 --> 02:48:38,608 IF THERE IS A QUESTION PLEASE GO 4433 02:48:38,608 --> 02:48:38,875 AHEAD. 4434 02:48:38,875 --> 02:48:41,477 IF NOT WE'LL MOVE ON. 4435 02:48:41,477 --> 02:48:41,844 GO AHEAD, PAUL. 4436 02:48:41,844 --> 02:48:43,646 >> I DON'T HAVE A QUESTION BUT 4437 02:48:43,646 --> 02:48:45,148 THAT WAS A PHENOMENAL 4438 02:48:45,148 --> 02:48:46,082 PRESENTATION. 4439 02:48:46,082 --> 02:48:46,616 THANK YOU. 4440 02:48:46,616 --> 02:48:48,017 >> THANK YOU. 4441 02:48:48,017 --> 02:48:49,252 >> TOUR DU FORCE. 4442 02:48:49,252 --> 02:48:51,888 >> THANK YOU. 4443 02:48:51,888 --> 02:48:54,590 >> HEAR, HEAR. 4444 02:48:54,590 --> 02:48:56,058 4445 02:48:56,058 --> 02:48:59,662 >> A CURIOSITY QUESTION. 4446 02:48:59,662 --> 02:49:01,430 WHERE YOU ENDED ON POLICY I'M 4447 02:49:01,430 --> 02:49:05,701 CURIOUS HOW MANY OF THE COVID 4448 02:49:05,701 --> 02:49:09,739 POLICIES, YOU TALK ABOUT RAPID 4449 02:49:09,739 --> 02:49:13,075 RESPONSE, WE HAVE ALL -- 4450 02:49:13,075 --> 02:49:14,577 PROBABLY DON'T KNOW THE SUBSET 4451 02:49:14,577 --> 02:49:16,179 BUT INTERESTING TO SEE. 4452 02:49:16,179 --> 02:49:17,713 >> THIS ANALYSIS, I MEAN, I 4453 02:49:17,713 --> 02:49:20,049 THINK THIS PUBLICATION CAME OUT 4454 02:49:20,049 --> 02:49:21,350 IN 23, THINGS PUBLISHED THROUGH 4455 02:49:21,350 --> 02:49:22,652 21, SO THERE WOULD HAVE BEEN 4456 02:49:22,652 --> 02:49:23,953 VERY LITTLE OPPORTUNITY I THINK 4457 02:49:23,953 --> 02:49:24,854 FOR COVID. 4458 02:49:24,854 --> 02:49:28,324 I HAVE TO SAY IT IS NOT TRIVIAL. 4459 02:49:28,324 --> 02:49:30,626 WE'VE TRIED TO DO THIS AND 4460 02:49:30,626 --> 02:49:33,162 TRACKING WHAT APPEARS IN POLICY 4461 02:49:33,162 --> 02:49:37,533 DOCUMENTS IS NOT AN EASY TASK. 4462 02:49:37,533 --> 02:49:38,968 AND IT'S SOMETHING WE'RE TRYING 4463 02:49:38,968 --> 02:49:41,904 TO PUT MORE EFFORT INTO. 4464 02:49:41,904 --> 02:49:43,239 IT'S NOT STRAIGHTFORWARD, NOT 4465 02:49:43,239 --> 02:49:43,639 SIMPLE. 4466 02:49:43,639 --> 02:49:47,610 >> YOU CAN DO IT EASIER WITH 4467 02:49:47,610 --> 02:49:48,311 (INDISCERNIBLE) DOCKET. 4468 02:49:48,311 --> 02:49:49,912 >> THAT'S ONE -- YES. 4469 02:49:49,912 --> 02:49:52,181 BUT THERE'S AN -- I MEAN, YOU 4470 02:49:52,181 --> 02:49:55,017 KNOW, WE'VE SEEN EXAMPLES OF 4471 02:49:55,017 --> 02:49:57,220 WHERE, YOU KNOW, FINLAND HAS 4472 02:49:57,220 --> 02:49:58,321 CITED CTSA PUBLISHING 4473 02:49:58,321 --> 02:50:00,389 INDICATIONS IN THEIR POLICY 4474 02:50:00,389 --> 02:50:03,359 DOCUMENTS, SO W.H.O. 4475 02:50:03,359 --> 02:50:03,659 EXTENSIVELY. 4476 02:50:03,659 --> 02:50:05,428 IT'S NOT JUST U.S. 4477 02:50:05,428 --> 02:50:06,629 IT'S NOT JUST PROFESSIONAL 4478 02:50:06,629 --> 02:50:08,931 GUIDANCE OR CDC OR SOMETHING 4479 02:50:08,931 --> 02:50:09,198 LIKE THAT. 4480 02:50:09,198 --> 02:50:13,402 IT'S FAR MORE. 4481 02:50:13,402 --> 02:50:14,837 IT'S A BIG LIFT. 4482 02:50:14,837 --> 02:50:16,038 >> THERE HAS BEEN SOME 4483 02:50:16,038 --> 02:50:17,907 REFERENCES TO THINGS THAT HAVE 4484 02:50:17,907 --> 02:50:19,075 BEEN HAPPENING THROUGH COVID 4485 02:50:19,075 --> 02:50:23,913 LIKE LESSONS LEARNED FROM THE 4486 02:50:23,913 --> 02:50:26,782 PANDEMIC, ALSO CTSA PROGRAM 4487 02:50:26,782 --> 02:50:28,851 RELATED TO N3C FOR EXAMPLE, 4488 02:50:28,851 --> 02:50:31,020 THERE HAVE BEEN THOSE THINGS IN 4489 02:50:31,020 --> 02:50:32,321 TERMS OF DEVELOPING DOCUMENTS 4490 02:50:32,321 --> 02:50:33,222 FOR PREPAREDNESS FOR FUTURE 4491 02:50:33,222 --> 02:50:35,057 PANDEMICS, FROM THE WHITE HOUSE. 4492 02:50:35,057 --> 02:50:37,460 SO THERE ARE SOME ASPECTS OF 4493 02:50:37,460 --> 02:50:38,027 THOSE. 4494 02:50:38,027 --> 02:50:40,763 YEAH, PROBABLY MORE THAN WE 4495 02:50:40,763 --> 02:50:40,997 REALIZE. 4496 02:50:40,997 --> 02:50:41,631 ALL RIGHT. 4497 02:50:41,631 --> 02:50:42,732 THANK YOU. 4498 02:50:42,732 --> 02:50:45,601 AND WE HAVE ONE MORE PROGRAM 4499 02:50:45,601 --> 02:50:48,638 UPDATE FROM DR. CHRISTINE COLVIS 4500 02:50:48,638 --> 02:50:51,340 FROM OFFICE OF DRUG DEVELOPMENT 4501 02:50:51,340 --> 02:50:52,008 PARTNERSHIP PROGRAM. 4502 02:50:52,008 --> 02:50:55,511 AND SHE WILL GO AHEAD AND TAKE 4503 02:50:55,511 --> 02:50:55,711 OVER. 4504 02:50:55,711 --> 02:50:57,046 >> OKAY. 4505 02:50:57,046 --> 02:50:58,681 THANK YOU. 4506 02:50:58,681 --> 02:51:00,449 YEP, I'M CHRISTINE COLVIS, I'LL 4507 02:51:00,449 --> 02:51:02,585 GIVE AN UPDATE ON SOME OF THE 4508 02:51:02,585 --> 02:51:03,619 PROGRAMS THAT WE HAVE GOING 4509 02:51:03,619 --> 02:51:10,393 RIGHT NOW IN OUR OFFICE. 4510 02:51:10,393 --> 02:51:12,762 I'LL CEDE TIME TO DR. BECK FOR A 4511 02:51:12,762 --> 02:51:14,263 MORE DETAILED UPDATE ON THE 4512 02:51:14,263 --> 02:51:15,231 TRANSLATOR PROGRAM. 4513 02:51:15,231 --> 02:51:16,866 THIS IS SHOWING YOU AN OVERVIEW 4514 02:51:16,866 --> 02:51:21,904 OF THE DIFFERENT THINGS WE HAVE 4515 02:51:21,904 --> 02:51:25,941 GOING ON. 4516 02:51:25,941 --> 02:51:27,910 WE COVER PRE-CLINICAL 4517 02:51:27,910 --> 02:51:29,011 DEVELOPMENT AND INTO EARLY STAGE 4518 02:51:29,011 --> 02:51:32,114 CLINICAL TRIALS BUT WE ALSO HAVE 4519 02:51:32,114 --> 02:51:34,283 THINGS THAT SPAN THE ENTIRE 4520 02:51:34,283 --> 02:51:37,386 PIPELINE SO WE PRIMARILY ARE 4521 02:51:37,386 --> 02:51:38,821 FOCUSED ON EITHER DEVELOPING 4522 02:51:38,821 --> 02:51:42,058 MORE TREATMENTS OR MORE QUICKLY, 4523 02:51:42,058 --> 02:51:47,129 AND DON'T TOUCH SO MUCH ON ALL 4524 02:51:47,129 --> 02:51:48,898 PEOPLE EXCEPT CARLY DOES AND 4525 02:51:48,898 --> 02:51:50,966 SHE'LL TELL BUT A CONCEPT LATER 4526 02:51:50,966 --> 02:51:55,004 TODAY WHERE SHE TRIES TO ADDRESS 4527 02:51:55,004 --> 02:51:57,073 THE ALL-PEOPLE ASPECT OF OUR 4528 02:51:57,073 --> 02:51:58,040 MOTTO. 4529 02:51:58,040 --> 02:52:01,777 EXPANDING THE TARGET LANDSCAPE, 4530 02:52:01,777 --> 02:52:04,080 SO, THIS WAS REALLY INITIATED BY 4531 02:52:04,080 --> 02:52:05,848 AN NIH COMMON FUND PROGRAM 4532 02:52:05,848 --> 02:52:08,584 CALLED THE ILLUMINATING THE 4533 02:52:08,584 --> 02:52:10,586 DRUGGABLE GENOME PROGRAM. 4534 02:52:10,586 --> 02:52:14,590 AND WITH NIH COMMON FUND 4535 02:52:14,590 --> 02:52:20,963 PROGRAMS THEY INVOLVE LARGE 4536 02:52:20,963 --> 02:52:21,630 CENTERS, ADMINISTRATIVE CORE, 4537 02:52:21,630 --> 02:52:22,498 ALL THOSE THINGS. 4538 02:52:22,498 --> 02:52:23,699 THE PROGRAM MANAGED BY PROGRAM 4539 02:52:23,699 --> 02:52:25,634 STAFF FROM ACROSS THE NIH, 4540 02:52:25,634 --> 02:52:28,304 USUALLY WITH ONE OR TWO PROGRAM 4541 02:52:28,304 --> 02:52:30,306 PEOPLE WHO OVERSEE THE ENTIRE 4542 02:52:30,306 --> 02:52:32,041 THING FOR THE NIH. 4543 02:52:32,041 --> 02:52:34,610 KARLIE DOES THAT FOR 4544 02:52:34,610 --> 02:52:35,745 ILLUMINATING THE DRUGGABLE 4545 02:52:35,745 --> 02:52:36,612 GENOME PROJECT, OVERSEES THE 4546 02:52:36,612 --> 02:52:37,079 WHOLE THING. 4547 02:52:37,079 --> 02:52:38,914 I WON'T TELL YOU ABOUT THE LARGE 4548 02:52:38,914 --> 02:52:39,415 CENTERS AND EVERYTHING. 4549 02:52:39,415 --> 02:52:42,952 WHAT I WANT TO TELL BUT IS A 4550 02:52:42,952 --> 02:52:45,388 SMALL GRANT PROGRAM SHE STARTED 4551 02:52:45,388 --> 02:52:47,056 IN THE COMMON FUND ELIMINATING 4552 02:52:47,056 --> 02:52:48,958 THE DRUGGABLE GENOME PROGRAM. 4553 02:52:48,958 --> 02:52:53,062 FIRST LET ME REMIND YOU OF WHAT 4554 02:52:53,062 --> 02:52:54,063 THE IDG PROGRAM IS ABOUT. 4555 02:52:54,063 --> 02:52:56,565 THE GOAL TO UNDERSTAND THE 4556 02:52:56,565 --> 02:52:59,635 PROPERTIES AND FUNCTIONS OF 4557 02:52:59,635 --> 02:53:00,603 UNDERSTUDIED PROTEINS WITHIN 4558 02:53:00,603 --> 02:53:02,037 DRUGGABLE PROTEIN FAMILIES. 4559 02:53:02,037 --> 02:53:04,206 FOR BUDGETARY REASONS WE LIMITED 4560 02:53:04,206 --> 02:53:07,510 DRUGGABLE PROTEIN FAMILIES TO 4561 02:53:07,510 --> 02:53:08,711 ION CHANNELS, GPCRs, KINASES. 4562 02:53:08,711 --> 02:53:11,981 THERE ARE MANY MORE. 4563 02:53:11,981 --> 02:53:14,116 BUT AGAIN THAT WAS LIMITED. 4564 02:53:14,116 --> 02:53:16,786 WHEN WE TALK ABOUT UNDERSTUDIED 4565 02:53:16,786 --> 02:53:18,554 PROTEINS WE MEAN PROTEINS THAT 4566 02:53:18,554 --> 02:53:20,523 EITHER HAVE NO PUBLICATIONS OR 4567 02:53:20,523 --> 02:53:22,925 VERY FEW PUBLICATIONS AND ALSO 4568 02:53:22,925 --> 02:53:24,994 LACK R01 FUNDING. 4569 02:53:24,994 --> 02:53:27,763 THESE ARE LOW-HANGING FRUIT, 4570 02:53:27,763 --> 02:53:28,931 POTENTIALLY, FOR THERAPEUTIC 4571 02:53:28,931 --> 02:53:30,032 DEVELOPMENT. 4572 02:53:30,032 --> 02:53:33,436 YET NOBODY'S REALLY LOOKING. 4573 02:53:33,436 --> 02:53:39,108 THE IDEA HERE IS TO CEDE 4574 02:53:39,108 --> 02:53:41,510 RESEARCH ON THESE LOW-HANGING 4575 02:53:41,510 --> 02:53:42,511 FRUIT, UNDERSTUDIED PROTEINS, 4576 02:53:42,511 --> 02:53:46,782 THAT WILL EVENTUALLY LEAD ON TO 4577 02:53:46,782 --> 02:53:49,185 MORE INVESTIGATION IN THE 4578 02:53:49,185 --> 02:53:49,518 FUTURE. 4579 02:53:49,518 --> 02:53:52,121 SO WHAT KARLIE DID WAS DECIDED 4580 02:53:52,121 --> 02:53:55,791 TO START A SMALL GRANT PROGRAM, 4581 02:53:55,791 --> 02:53:56,859 R03 PROGRAM, JUST $100,000 A 4582 02:53:56,859 --> 02:54:00,229 YEAR DIRECT COST FOR JUST ONE 4583 02:54:00,229 --> 02:54:00,463 YEAR. 4584 02:54:00,463 --> 02:54:01,997 THE IDEA JUST TO SEED AND 4585 02:54:01,997 --> 02:54:04,400 PROVIDE ENOUGH INFORMATION FOR 4586 02:54:04,400 --> 02:54:06,068 SOMEBODY TO GATHER PRELIMINARY 4587 02:54:06,068 --> 02:54:08,804 DATA, DECIDE WHETHER IT'S WORTH 4588 02:54:08,804 --> 02:54:10,105 PURSUING AND SUBMIT AN 4589 02:54:10,105 --> 02:54:12,074 APPLICATION FOR A LARGER AWARD. 4590 02:54:12,074 --> 02:54:13,609 THIS HAS BEEN VERY SUCCESSFUL. 4591 02:54:13,609 --> 02:54:16,979 THE FIRST AWARDS WERE MADE IN 4592 02:54:16,979 --> 02:54:18,347 2019. 4593 02:54:18,347 --> 02:54:22,251 SHE'S MADE OVER -- ALMOST 100 4594 02:54:22,251 --> 02:54:24,420 AWARDS THUS FAR, AND ABOUT A 4595 02:54:24,420 --> 02:54:26,956 THIRD OF THESE ACTUALLY END UP 4596 02:54:26,956 --> 02:54:28,257 BEING AWARDED TO EARLY-STAGE 4597 02:54:28,257 --> 02:54:29,124 INVESTIGATORS AND NEW 4598 02:54:29,124 --> 02:54:30,226 INVESTIGATORS, THIS IS A 4599 02:54:30,226 --> 02:54:32,394 BY-PRODUCT OF HAVING THIS 4600 02:54:32,394 --> 02:54:34,230 SMALLER AWARD PROGRAM AND SO 4601 02:54:34,230 --> 02:54:37,433 THIS IS REALLY ATTRACTIVE TO 4602 02:54:37,433 --> 02:54:39,301 EMERGING SCIENTISTS IN THE 4603 02:54:39,301 --> 02:54:40,102 COMMUNITY AND HELPING HOPEFULLY 4604 02:54:40,102 --> 02:54:42,404 TO ALSO BUILD THAT WORKFORCE AND 4605 02:54:42,404 --> 02:54:45,474 GIVE THEM A NICHE TO SORT OF 4606 02:54:45,474 --> 02:54:48,744 BUILD ON AND HAVE AS THEIR OWN 4607 02:54:48,744 --> 02:54:48,944 SPACE. 4608 02:54:48,944 --> 02:54:53,482 THE REAL PROOF IN THE PUDDING IS 4609 02:54:53,482 --> 02:54:55,784 IN WHETHER OR NOT THIS SEED GETS 4610 02:54:55,784 --> 02:55:01,924 NURTURED AND GROWS AND DOES GO 4611 02:55:01,924 --> 02:55:04,026 ON TO LARGER AWARDS, R01s, 4612 02:55:04,026 --> 02:55:05,094 R21s, THAT TYPE OF THING. 4613 02:55:05,094 --> 02:55:06,061 WE DO SEE THAT. 4614 02:55:06,061 --> 02:55:07,596 IT TAKES OF COURSE A LITTLE BIT 4615 02:55:07,596 --> 02:55:11,367 OF TIME BUT IF WE LOOK AT, YOU 4616 02:55:11,367 --> 02:55:13,869 KNOW, THREE TO FOUR YEARS AFTER 4617 02:55:13,869 --> 02:55:18,340 THE INITIAL R03 AWARD IS MADE, 4618 02:55:18,340 --> 02:55:21,744 WE SEE 40 TO 50% RECEIVE AN R01 4619 02:55:21,744 --> 02:55:23,078 AND R21, COOPERATIVE AGREEMENT 4620 02:55:23,078 --> 02:55:24,947 AWARD OR SOMETIMES AN AWARD 4621 02:55:24,947 --> 02:55:27,550 THAT'S OUTSIDE OF THE NIH EVEN. 4622 02:55:27,550 --> 02:55:29,752 BUT IN THIS RESPECT WE FEEL LIKE 4623 02:55:29,752 --> 02:55:31,620 WE ARE STARTING TO EXPAND THE 4624 02:55:31,620 --> 02:55:33,255 CAR GET LANDSCAPE, WE'RE GIVING 4625 02:55:33,255 --> 02:55:36,191 PEOPLE NEW TARGETS TO GO AFTER 4626 02:55:36,191 --> 02:55:38,160 FOR DEVELOPING DRUGS. 4627 02:55:38,160 --> 02:55:40,796 AND WITH VERY, VERY MODEST 4628 02:55:40,796 --> 02:55:42,331 SUPPORT. 4629 02:55:42,331 --> 02:55:43,632 SO, SEEING THAT SUPPORT, THAT 4630 02:55:43,632 --> 02:55:46,068 WAS NIH COMMON FUND MONEY, NIH 4631 02:55:46,068 --> 02:55:47,036 O.D. MONEY. 4632 02:55:47,036 --> 02:55:49,004 SEEING THAT SUPPORT WE THOUGHT 4633 02:55:49,004 --> 02:55:51,073 MAYBE WE SHOULD DO SOMETHING FOR 4634 02:55:51,073 --> 02:55:52,174 RARE DISEASES AND ACTUALLY DO 4635 02:55:52,174 --> 02:55:54,476 SOMETHING, YOU KNOW, USING NCATS 4636 02:55:54,476 --> 02:55:55,144 MONEY. 4637 02:55:55,144 --> 02:56:01,684 SO WE ESTABLISHED A SIMILAR 4638 02:56:01,684 --> 02:56:03,118 PROGRAM WHERE THE APPLICATIONS 4639 02:56:03,118 --> 02:56:05,955 HAVE TO BE FOCUSED ON AN 4640 02:56:05,955 --> 02:56:07,423 UNDERSTUDIED PROTEIN, WE PROVIDE 4641 02:56:07,423 --> 02:56:09,592 A LIST OF THE QUALIFYING 4642 02:56:09,592 --> 02:56:10,259 PROTEINS. 4643 02:56:10,259 --> 02:56:12,561 THESE ARE AGAIN DRUGGABLE 4644 02:56:12,561 --> 02:56:13,529 PROTEINS THAT ARE ASSOCIATED 4645 02:56:13,529 --> 02:56:14,530 WITH A RARE DISEASE. 4646 02:56:14,530 --> 02:56:16,498 SO IT'S UP TO THE INVESTIGATOR 4647 02:56:16,498 --> 02:56:19,234 TO MAKE THAT ASSOCIATION. 4648 02:56:19,234 --> 02:56:22,037 AGAIN, STILL ONLY PROVIDING 4649 02:56:22,037 --> 02:56:23,372 $100,000 FOR JUST ONE YEAR, 4650 02:56:23,372 --> 02:56:26,008 KARLIE MANAGED TO GARNER SUPPORT 4651 02:56:26,008 --> 02:56:28,744 FROM ALSO OTHER INSTITUTES 4652 02:56:28,744 --> 02:56:30,379 ACROSS THE NIH AND IN THIS PAST 4653 02:56:30,379 --> 02:56:32,982 YEAR WHICH IS OUR FIRST YEAR OF 4654 02:56:32,982 --> 02:56:35,751 ACTUALLY HAVING THESE AWARDS, 21 4655 02:56:35,751 --> 02:56:41,557 AWARDS WERE MADE, THIS FISCAL 4656 02:56:41,557 --> 02:56:41,757 YEAR. 4657 02:56:41,757 --> 02:56:47,696 WE HAVE UPCOMING RECEIPT DATE IN 4658 02:56:47,696 --> 02:56:50,099 A COUPLE WEEKS, ONE IN JANUARY 4659 02:56:50,099 --> 02:56:50,866 AND JULY. 4660 02:56:50,866 --> 02:56:51,834 WE ENCOURAGE PEOPLE TO TAKE A 4661 02:56:51,834 --> 02:56:53,035 LOOK IF THERE'S A RARE DISEASE 4662 02:56:53,035 --> 02:56:54,136 THEY ARE INTERESTED IN. 4663 02:56:54,136 --> 02:56:56,438 I WANT TO TELL YOU ABOUT A 4664 02:56:56,438 --> 02:56:57,539 PROGRAM ADDRESSING THE MORE 4665 02:56:57,539 --> 02:56:59,608 QUICKLY PART OF OUR MOTTO, THE 4666 02:56:59,608 --> 02:57:02,211 ASSETS PROGRAM BEING LED BY DR. 4667 02:57:02,211 --> 02:57:06,715 CONGRESS. 4668 02:57:06,715 --> 02:57:07,683 DR. KANG. 4669 02:57:07,683 --> 02:57:13,455 THIS IS A SMALL AWARD PROGRAM, 4670 02:57:13,455 --> 02:57:15,257 R21s TO SUPPORT EARLY STAGE 4671 02:57:15,257 --> 02:57:16,392 TECHNOLOGY DEVELOPMENT TO 4672 02:57:16,392 --> 02:57:20,529 IMPROVE EFFICIENCY ALONG THE 4673 02:57:20,529 --> 02:57:21,196 TRANSLATIONAL PIPELINE, WE WANT 4674 02:57:21,196 --> 02:57:28,737 TO DOUGH THIS -- DO THIS IN A 4675 02:57:28,737 --> 02:57:29,705 DISEAS AGNOSTIC WAY BECAUSE 4676 02:57:29,705 --> 02:57:30,472 WE'RE NCATS. 4677 02:57:30,472 --> 02:57:33,776 WE WANT A FUTURE PLAN FROM 4678 02:57:33,776 --> 02:57:34,376 INVESTIGATORS, WE WANT THEM 4679 02:57:34,376 --> 02:57:35,411 THINKING ABOUT HOW IS THIS 4680 02:57:35,411 --> 02:57:37,713 TECHNOLOGY GOING TO BE USED IN 4681 02:57:37,713 --> 02:57:39,448 THE REAL WORLD, HOW IS IT GOING 4682 02:57:39,448 --> 02:57:41,316 TO GET TO THE REAL WORLD AND GET 4683 02:57:41,316 --> 02:57:43,819 TO THAT POINT. 4684 02:57:43,819 --> 02:57:45,054 IT'S NOT QUITE A 4685 02:57:45,054 --> 02:57:46,121 COMMERCIALIZATION PLAN LIKE SBIR 4686 02:57:46,121 --> 02:57:47,222 BECAUSE THESE ARE VERY EARLY 4687 02:57:47,222 --> 02:57:47,456 STAGES. 4688 02:57:47,456 --> 02:57:50,859 WE DON'T THINK AFTER TWO YEARS 4689 02:57:50,859 --> 02:57:54,563 OF AN R21 SUPPORT THEY WILL HAVE 4690 02:57:54,563 --> 02:57:55,964 SOMETHING COMMERCIALIZABLE BUT 4691 02:57:55,964 --> 02:57:57,533 WE ASKED FOR THAT FUTURE PLAN. 4692 02:57:57,533 --> 02:57:59,401 THE FIRST RECEIPT DATE WAS JUST 4693 02:57:59,401 --> 02:58:00,502 THIS PAST JULY. 4694 02:58:00,502 --> 02:58:01,704 IT'S REALLY, REALLY EARLY DAYS. 4695 02:58:01,704 --> 02:58:03,672 THERE'S NOT A LOT I CAN TELL 4696 02:58:03,672 --> 02:58:06,575 YOU, BUT I CAN SHOW YOU SORT OF 4697 02:58:06,575 --> 02:58:07,843 WHAT THE CHARACTERISTICS ARE OF 4698 02:58:07,843 --> 02:58:09,144 THE APPLICATIONS WE RECEIVED. 4699 02:58:09,144 --> 02:58:11,680 WE SEE A REALLY NICE 4700 02:58:11,680 --> 02:58:12,448 DISTRIBUTION OF TECHNOLOGIES, 4701 02:58:12,448 --> 02:58:15,284 AND WE ALSO SEE A NICE 4702 02:58:15,284 --> 02:58:17,052 DISTRIBUTION ACROSS THE STAGES 4703 02:58:17,052 --> 02:58:19,354 ALONG THE TRANSLATIONAL PIPELINE 4704 02:58:19,354 --> 02:58:22,524 THAT WE'RE SEEING. 4705 02:58:22,524 --> 02:58:25,794 I'LL TELL YOU, WE HAD - TO SAY A 4706 02:58:25,794 --> 02:58:27,296 ROBUST RESPONSE IS AN 4707 02:58:27,296 --> 02:58:27,763 UNDERSTATEMENT. 4708 02:58:27,763 --> 02:58:29,298 WE HAD A VERY, VERY STRONG 4709 02:58:29,298 --> 02:58:32,334 RESPONSE TO THIS, THIS FUNDING 4710 02:58:32,334 --> 02:58:32,668 OPPORTUNITY. 4711 02:58:32,668 --> 02:58:33,869 THAT'S A REALLY GOOD THING 4712 02:58:33,869 --> 02:58:35,504 BECAUSE IT MEANS WE'VE ACTUALLY 4713 02:58:35,504 --> 02:58:37,940 HIT ON SOMETHING WHERE THERE WAS 4714 02:58:37,940 --> 02:58:42,945 A REAL NEED, BUT WE ARE 4715 02:58:42,945 --> 02:58:44,046 CONCERNED THAT GIVEN NCATS' 4716 02:58:44,046 --> 02:58:45,380 BUDGET RIGHT NOW WE WOULDN'T BE 4717 02:58:45,380 --> 02:58:47,549 ABLE TO SUPPORT AS MANY AS WE 4718 02:58:47,549 --> 02:58:49,718 WOULD LIKE TO SO WE MAY BE 4719 02:58:49,718 --> 02:58:52,154 NARROWING THE SCOPE OF THIS 4720 02:58:52,154 --> 02:58:53,155 ANNOUNCEMENT GOING FORWARD IN 4721 02:58:53,155 --> 02:58:59,995 FAIRNESS TOP APPLICANTS, WE 4722 02:58:59,995 --> 02:59:01,864 DON'T WANT IT SO COMPETITIVE THE 4723 02:59:01,864 --> 02:59:03,098 CHANCE OF GETTING AN AWARD ARE 4724 02:59:03,098 --> 02:59:03,866 TOO SLIM. 4725 02:59:03,866 --> 02:59:05,934 THAT SAID, WE DID HAVE TWO MORE 4726 02:59:05,934 --> 02:59:06,468 RECEIPT DATES. 4727 02:59:06,468 --> 02:59:08,003 KEEP AN EYE ON THIS. 4728 02:59:08,003 --> 02:59:09,538 WE MIGHT BE TWEAKING THINGS. 4729 02:59:09,538 --> 02:59:11,607 BUT AS OF RIGHT NOW WE HAVE 4730 02:59:11,607 --> 02:59:15,144 RECEIPT DATE ONCE A YEAR, JUNE 4731 02:59:15,144 --> 02:59:18,547 19, OF BOTH 2024 AND 2025, AGAIN 4732 02:59:18,547 --> 02:59:19,882 BUDGETS ARE STANDARD. 4733 02:59:19,882 --> 02:59:25,187 IN TERMS OF R01 -- SORRY, 4734 02:59:25,187 --> 02:59:25,988 R21-TYPE AWARDS. 4735 02:59:25,988 --> 02:59:27,289 NOW, ANOTHER PROGRAM THAT I WANT 4736 02:59:27,289 --> 02:59:31,994 TO TELL BUT VERY QUICKLY IS THE 4737 02:59:31,994 --> 02:59:32,761 LITCOIN PROGRAM. 4738 02:59:32,761 --> 02:59:36,265 THE MAIN GOALS OF THIS PROGRAM 4739 02:59:36,265 --> 02:59:40,102 WITH TO INCENTIVIZE DATA AND 4740 02:59:40,102 --> 02:59:41,637 KNOWLEDGE SHAKER, THAT'S THE 4741 02:59:41,637 --> 02:59:42,404 LITCOIN PROPER. 4742 02:59:42,404 --> 02:59:45,207 THE SECOND BULLET HERE IS TO 4743 02:59:45,207 --> 02:59:47,476 BUILD MACHINE READABLE 4744 02:59:47,476 --> 02:59:48,944 A.I.-READY KNOWLEDGE FROM FREE 4745 02:59:48,944 --> 02:59:52,514 TEXT AT THE TIME OF THE 4746 02:59:52,514 --> 02:59:53,148 MANUSCRIPT SUBMISSION. 4747 02:59:53,148 --> 02:59:56,084 AND I WANT TO FOCUS ON THAT 4748 02:59:56,084 --> 02:59:56,552 SECOND BULLET. 4749 02:59:56,552 --> 02:59:58,220 SO THAT SECOND BULLET IS MUCH 4750 02:59:58,220 --> 02:59:59,721 BROADER THAN JUST A LITCOIN. 4751 02:59:59,721 --> 03:00:03,425 A LITCOIN AS YOU MAY RECALL IS 4752 03:00:03,425 --> 03:00:04,993 SOMETHING VERY -- A SPECIFIC 4753 03:00:04,993 --> 03:00:07,830 TYPE OF PUBLICATION LIKE A 4754 03:00:07,830 --> 03:00:09,031 MICROPUBLICATION, BUT THE SECOND 4755 03:00:09,031 --> 03:00:10,299 BULLET IS SOMETHING THAT WE SEE 4756 03:00:10,299 --> 03:00:14,069 AS SOMETHING THAT CAN BE 4757 03:00:14,069 --> 03:00:17,906 APPLIED TO ANY PUBLICATION GOING 4758 03:00:17,906 --> 03:00:18,974 FORWARD. 4759 03:00:18,974 --> 03:00:21,710 THE AUTHOR WOULD SUBMIT TO A 4760 03:00:21,710 --> 03:00:24,179 LITCOIN PORTAL YET TO BE BUILT, 4761 03:00:24,179 --> 03:00:26,114 WOULD SUBMIT THEIR ABSTRACT FOR 4762 03:00:26,114 --> 03:00:30,819 THE PAPER, TO THE PORTAL, THE 4763 03:00:30,819 --> 03:00:34,823 PORTAL RUNS NATURAL LANGUAGE 4764 03:00:34,823 --> 03:00:35,991 PROCESSING AND GENERATES A 4765 03:00:35,991 --> 03:00:38,493 MACHINE READABLE KNOWLEDGE GRAPH 4766 03:00:38,493 --> 03:00:39,328 OR NETWORK THAT REPRESENTS THE 4767 03:00:39,328 --> 03:00:41,663 TEXT THAT WAS IN THE ABSTRACT. 4768 03:00:41,663 --> 03:00:44,066 THE REASON YOU WANT TO DO THAT 4769 03:00:44,066 --> 03:00:46,501 IS BECAUSE THAT GRAPHICAL 4770 03:00:46,501 --> 03:00:47,135 REPRESENTATION, THAT NETWORK 4771 03:00:47,135 --> 03:00:48,237 REPRESENTATION, IS MUCH EASIER 4772 03:00:48,237 --> 03:00:49,972 FOR THE COMPUTER TO ACTUALLY 4773 03:00:49,972 --> 03:00:52,174 UNDERSTAND AND EXTRACT KNOWLEDGE 4774 03:00:52,174 --> 03:00:52,941 FROM. 4775 03:00:52,941 --> 03:00:54,142 WHEN THEY SUBMIT THEIR 4776 03:00:54,142 --> 03:00:57,012 MANUSCRIPT TO THE PUBLISHER THEY 4777 03:00:57,012 --> 03:01:02,584 WOULD ALSO SUBMIT THIS GRAPH. 4778 03:01:02,584 --> 03:01:04,987 THE PUBLISHER THEN WOULD TAKE 4779 03:01:04,987 --> 03:01:08,523 THAT AND PASS IT ON TO THE PEER 4780 03:01:08,523 --> 03:01:10,259 REVIEWERS, ALONG WITH THE 4781 03:01:10,259 --> 03:01:10,692 MANUSCRIPT. 4782 03:01:10,692 --> 03:01:12,027 THEY ARE ALSO GOING TO LOOK AT 4783 03:01:12,027 --> 03:01:12,895 THIS GRAPH. 4784 03:01:12,895 --> 03:01:15,731 I SHOULD SAY THE AUTHOR WHEN THE 4785 03:01:15,731 --> 03:01:16,932 GRAPH IS GENERATED, THE AUTHOR 4786 03:01:16,932 --> 03:01:21,770 HAS AN OPPORTUNITY TO MAKE 4787 03:01:21,770 --> 03:01:24,940 CORRECTIONS, TO SAY, NO, THE 4788 03:01:24,940 --> 03:01:27,476 ARROW HAS TO BE TURNED AROUND. 4789 03:01:27,476 --> 03:01:29,211 THE REVIEWERS THEN HAVE AN 4790 03:01:29,211 --> 03:01:31,146 OPPORTUNITY TO CONFIRM THAT, 4791 03:01:31,146 --> 03:01:33,916 YES, THIS GRAPH, CORRECTED 4792 03:01:33,916 --> 03:01:35,484 GRAPH, DOES REPRESENT WHAT IS 4793 03:01:35,484 --> 03:01:37,085 BEING SAID IN THE TEXT OF THE 4794 03:01:37,085 --> 03:01:38,220 PAPER. 4795 03:01:38,220 --> 03:01:41,256 SO WHEN THE MANUSCRIPT IS 4796 03:01:41,256 --> 03:01:43,091 ACCEPTED FOR PUBLICATION, THAT 4797 03:01:43,091 --> 03:01:46,161 GRAPH GETS SENT BACK TO THE 4798 03:01:46,161 --> 03:01:48,297 LITCOIN PORTAL. 4799 03:01:48,297 --> 03:01:52,334 AND IT GETS INCORPORATED INTO 4800 03:01:52,334 --> 03:01:53,769 THIS MACHINE READABLE 4801 03:01:53,769 --> 03:01:54,436 FOUNDATIONAL GRAPH WHICH 4802 03:01:54,436 --> 03:01:55,304 REPRESENTS THE CORPUS OF 4803 03:01:55,304 --> 03:01:56,505 KNOWLEDGE THAT WE ALREADY HAVE 4804 03:01:56,505 --> 03:01:58,373 THAT'S IN THIS MACHINE READABLE 4805 03:01:58,373 --> 03:01:58,674 FORM. 4806 03:01:58,674 --> 03:02:00,709 AND SO AS YOU CAN SEE OVER TIME 4807 03:02:00,709 --> 03:02:02,010 YOU JUST BEGIN TO BUILD THIS. 4808 03:02:02,010 --> 03:02:04,313 SO THIS IS SOMETHING THAT WE 4809 03:02:04,313 --> 03:02:06,515 WANT TO SEE HAPPEN WITH ALL 4810 03:02:06,515 --> 03:02:06,949 PUBLICATIONS. 4811 03:02:06,949 --> 03:02:09,918 WE WERE ADVISED WE SHOULD PILOT 4812 03:02:09,918 --> 03:02:11,086 THIS FIRST. 4813 03:02:11,086 --> 03:02:11,987 SO WE'RE PILOTING IT. 4814 03:02:11,987 --> 03:02:13,388 I'LL SAY MORE IN A SECOND. 4815 03:02:13,388 --> 03:02:15,691 AS YOU CAN SEE THIS PROCESS IS 4816 03:02:15,691 --> 03:02:19,528 VERY NEW, A NEW CONCEPT. 4817 03:02:19,528 --> 03:02:23,365 WE PUT OUT A PRIZE COMPETITION, 4818 03:02:23,365 --> 03:02:25,233 A CHALLENGE, TO HEAR WHAT 4819 03:02:25,233 --> 03:02:26,969 PEOPLE'S IDEAS WERE IN TERMS OF 4820 03:02:26,969 --> 03:02:29,071 HOW YOU WOULD DESIGN THE SYSTEM 4821 03:02:29,071 --> 03:02:31,106 THAT WOULD ACTUALLY ALLOW THIS 4822 03:02:31,106 --> 03:02:33,275 TO HAPPEN, AND TO GIVE US THE 4823 03:02:33,275 --> 03:02:33,976 TECHNICAL REQUIREMENTS THAT 4824 03:02:33,976 --> 03:02:35,644 WOULD BE NEEDED IN ORDER FOR 4825 03:02:35,644 --> 03:02:36,611 THIS TO ACTUALLY WORK. 4826 03:02:36,611 --> 03:02:38,347 WE HAVE A VISION BUT WE NEED TO 4827 03:02:38,347 --> 03:02:40,449 KNOW WHAT ARE GOING TO BE OUR 4828 03:02:40,449 --> 03:02:41,450 TECHNICAL REQUIREMENTS IF WE 4829 03:02:41,450 --> 03:02:43,185 WANT TO MAKE THIS HAPPEN. 4830 03:02:43,185 --> 03:02:45,721 WE ENDED UP AWARDING TWO FIRST 4831 03:02:45,721 --> 03:02:46,922 PRIZES AND SECOND PRIZE, ALL 4832 03:02:46,922 --> 03:02:49,858 THREE GREAT BUT WE WENT WITH TWO 4833 03:02:49,858 --> 03:02:52,060 FIRST PRIZEs INSTEAD OF FIRST, 4834 03:02:52,060 --> 03:02:54,596 SECOND, THIRD, BECAUSE THE FIRST 4835 03:02:54,596 --> 03:02:55,664 TEAM YOU'RE SEEING WAS VERY 4836 03:02:55,664 --> 03:02:57,833 FOCUSED ON THE NEEDS OF THE 4837 03:02:57,833 --> 03:02:58,100 PUBLISHER. 4838 03:02:58,100 --> 03:03:01,136 THE SECOND TEAM WAS VERY FOCUSED 4839 03:03:01,136 --> 03:03:02,938 ON THE NEEDS OF THE AUTHORS. 4840 03:03:02,938 --> 03:03:04,840 AND ONE OF THE ADVANTAGES OF 4841 03:03:04,840 --> 03:03:06,375 USING THE PRIZE MECHANISM IS NOW 4842 03:03:06,375 --> 03:03:08,343 WE CAN ACTUALLY TAKE THE BEST OF 4843 03:03:08,343 --> 03:03:11,079 BOTH WORLDS AND DESIGN A SYSTEM 4844 03:03:11,079 --> 03:03:11,880 THAT'S REALLY HOPEFULLY GOING TO 4845 03:03:11,880 --> 03:03:16,118 BE, YOU KNOW, WORK FOR 4846 03:03:16,118 --> 03:03:17,519 EVERYBODY. 4847 03:03:17,519 --> 03:03:19,054 AND THEN THE OTHER PIECE THAT'S 4848 03:03:19,054 --> 03:03:21,590 IMPORTANT FOR US TO DO EARLY ON 4849 03:03:21,590 --> 03:03:23,692 IS ESTABLISH THAT FOUNDATIONAL 4850 03:03:23,692 --> 03:03:26,061 KNOWLEDGE GRAPH, AND WE'RE DOING 4851 03:03:26,061 --> 03:03:28,163 THAT WITH FINANCIAL SUPPORT FROM 4852 03:03:28,163 --> 03:03:29,564 THE HEAL PROGRAM, HELPING END 4853 03:03:29,564 --> 03:03:31,533 ADDICTION LONG TERM. 4854 03:03:31,533 --> 03:03:33,935 WE'LL FOCUS OUR FOUNDATIONAL 4855 03:03:33,935 --> 03:03:36,138 GRAPH IN THAT SPACE, SO IN PAIN 4856 03:03:36,138 --> 03:03:37,439 AND ADDICTION. 4857 03:03:37,439 --> 03:03:39,307 AND WE AWARDED CONTRACT JUST 4858 03:03:39,307 --> 03:03:41,510 LAST WEEK TO THE RTI 4859 03:03:41,510 --> 03:03:43,478 INTERNATIONAL TO HELP US TO 4860 03:03:43,478 --> 03:03:44,246 BUILD THAT. 4861 03:03:44,246 --> 03:03:46,214 THE LAST BIT OF UPDATE FOR 4862 03:03:46,214 --> 03:03:48,283 LITCOIN IS THAT WITH SUPPORT 4863 03:03:48,283 --> 03:03:51,153 FROM "HEAL," AND FROM THE 4864 03:03:51,153 --> 03:03:52,654 OFFICES OF DATA SCIENCE STRATEGY 4865 03:03:52,654 --> 03:03:54,723 WE'RE GETTING SUPPORT FOR DR. 4866 03:03:54,723 --> 03:03:57,726 AARON BERNSTEIN TO WORK WITH US 4867 03:03:57,726 --> 03:04:00,662 AS AN ODSS DATA SCHOLAR, AARON 4868 03:04:00,662 --> 03:04:02,764 IS A NEWLY MINTED PhD and just 4869 03:04:02,764 --> 03:04:03,999 started on Monday but he's 4870 03:04:03,999 --> 03:04:05,934 really hitting the ground 4871 03:04:05,934 --> 03:04:06,168 running. 4872 03:04:06,168 --> 03:04:07,803 WE'RE VERY EXCITED TO HAVE HIM. 4873 03:04:07,803 --> 03:04:08,904 THE ONE OTHER THING I WANTED TO 4874 03:04:08,904 --> 03:04:12,074 TELL YOU ABOUT BEFORE I HAND 4875 03:04:12,074 --> 03:04:15,243 THIS OFF TO TYLER IS A 4876 03:04:15,243 --> 03:04:18,080 COLLABORATION THAT KARLIE 4877 03:04:18,080 --> 03:04:19,081 ESTABLISHED WITH CHRISTINE 4878 03:04:19,081 --> 03:04:20,549 COTILLO IN THE NCATS O.D. AND 4879 03:04:20,549 --> 03:04:23,351 HAS GONE ON TO THE OFFICE OF 4880 03:04:23,351 --> 03:04:25,854 DATA SCIENCE STRATEGY, NIH O.D., 4881 03:04:25,854 --> 03:04:28,156 WE'RE HAPPY FOR HER, SAD FOR US. 4882 03:04:28,156 --> 03:04:32,761 BUT BEFORE SHE LEFT SHE AND 4883 03:04:32,761 --> 03:04:35,063 KARLIE ISSUED A CHALLENGE, PRIZE 4884 03:04:35,063 --> 03:04:36,598 COMPETITION, FOCUSED ON 4885 03:04:36,598 --> 03:04:38,767 MINIMIZING BIAS, MAXIMIZING 4886 03:04:38,767 --> 03:04:40,836 LONG-TERM ACCURACY OF PREDICTIVE 4887 03:04:40,836 --> 03:04:43,038 ALGORITHMS AND HEALTH CARE, AND 4888 03:04:43,038 --> 03:04:44,673 I WANTED TO ACKNOWLEDGE THE 4889 03:04:44,673 --> 03:04:50,745 FIRST PLACE TEAM, TEAM INTERFAIR 4890 03:04:50,745 --> 03:04:52,114 THAT WON, WITH THE MOST 4891 03:04:52,114 --> 03:04:54,583 COMPREHENSIVE SOLUTION FOR THIS 4892 03:04:54,583 --> 03:04:56,618 AND VERY EXCITED FOR THEM. 4893 03:04:56,618 --> 03:04:57,219 OKAY. 4894 03:04:57,219 --> 03:04:59,354 WITH THAT, I'M GOING TO INVITE 4895 03:04:59,354 --> 03:05:01,957 TYLER TO COME UP TO GIVE YOU AN 4896 03:05:01,957 --> 03:05:03,058 UPDATE ON TRANSLATOR AND I'M 4897 03:05:03,058 --> 03:05:04,759 GOING TO INVITE OUR PANELISTS TO 4898 03:05:04,759 --> 03:05:06,995 COME AND SIT AT THE TABLE. 4899 03:05:06,995 --> 03:05:09,764 AFTER TYLER'S UPDATE, HE'S GOING 4900 03:05:09,764 --> 03:05:12,801 TO GO STRAIGHT INTO THE CONCEPT 4901 03:05:12,801 --> 03:05:15,203 CLEARANCE THAT HE HAS FOR THAT. 4902 03:05:15,203 --> 03:05:17,405 MAYBE WE'LL WANT TO PAUSE FOR 4903 03:05:17,405 --> 03:05:19,307 QUESTIONS BEFORE HE GOES TO THE 4904 03:05:19,307 --> 03:05:21,810 CONCEPT CLEARANCE. 4905 03:05:21,810 --> 03:05:23,545 >> WE SHOULD HAVE AN OPPORTUNITY 4906 03:05:23,545 --> 03:05:24,312 FOR QUESTIONS. 4907 03:05:24,312 --> 03:05:24,880 >> OKAY. 4908 03:05:24,880 --> 03:05:31,653 WE'LL PAUSE FOR QUESTIONS. 4909 03:05:31,653 --> 03:05:33,622 >> IF YOU HAVE A POSITIVE 4910 03:05:33,622 --> 03:05:34,389 RESPONSE DON'T SHUT THAT 4911 03:05:34,389 --> 03:05:36,024 RESPONSE DOWN. 4912 03:05:36,024 --> 03:05:38,860 WHAT YOU DO IS EVEN DON'T TELL 4913 03:05:38,860 --> 03:05:41,029 YOU, YOU PANEL, THEY CAN ONLY 4914 03:05:41,029 --> 03:05:46,334 FUND 5% BECAUSE THEY WILL BE 4915 03:05:46,334 --> 03:05:48,970 EXTRA CRUEL TO THE GRANTS COMING 4916 03:05:48,970 --> 03:05:50,372 IN BECAUSE THEY HAVE TO BE 4917 03:05:50,372 --> 03:05:53,208 REALLY (INDISCERNIBLE). 4918 03:05:53,208 --> 03:05:54,009 DON'T DO THAT. 4919 03:05:54,009 --> 03:05:55,744 TAKE THOSE SCORES TO THE 4920 03:05:55,744 --> 03:05:58,380 DIRECTOR OF THE INSTITUTE AND 4921 03:05:58,380 --> 03:06:00,448 SHE WILL HAVE THE FUN JOB TO 4922 03:06:00,448 --> 03:06:03,185 DECIDE WHAT HAS TO HAPPEN. 4923 03:06:03,185 --> 03:06:04,186 I'M SERIOUS. 4924 03:06:04,186 --> 03:06:07,255 OTHER INSTITUTES ARE DOING THAT. 4925 03:06:07,255 --> 03:06:08,890 IF YOU HAVE A BRANCH IN YOUR 4926 03:06:08,890 --> 03:06:13,895 INSTITUTE WHO IS ABLE TO 4927 03:06:13,895 --> 03:06:16,865 MOBILIZE RESEARCH COMMUNITY, I 4928 03:06:16,865 --> 03:06:18,066 TELL MY MENTEES NOT TO, BECAUSE 4929 03:06:18,066 --> 03:06:20,035 THEY ARE AS MUCH WORK AS AN R01 4930 03:06:20,035 --> 03:06:21,937 AND YOU GET TWO YEARS OF 4931 03:06:21,937 --> 03:06:24,539 FUNDING, SO IT'S A FACT YOU'VE 4932 03:06:24,539 --> 03:06:28,043 GOT SUCH AN OVERWHELMING 4933 03:06:28,043 --> 03:06:30,011 RESPONSE REALLY TELLS YOU 4934 03:06:30,011 --> 03:06:31,346 (INDISCERNIBLE) SO PLEASE DON'T 4935 03:06:31,346 --> 03:06:33,848 SHUT IT DOWN. 4936 03:06:33,848 --> 03:06:38,887 FIND CREATIVE WAYS LIKE 4937 03:06:38,887 --> 03:06:39,888 REALLOCATING FUNDS, LOOKING AT 4938 03:06:39,888 --> 03:06:41,957 FOUNDATIONAL FUNDS TO SEE WHERE 4939 03:06:41,957 --> 03:06:42,357 CAN YOU LEVERAGE. 4940 03:06:42,357 --> 03:06:43,491 >> YEAH, THANK YOU. 4941 03:06:43,491 --> 03:06:43,825 THANK YOU. 4942 03:06:43,825 --> 03:06:45,160 >> ALL RIGHT. 4943 03:06:45,160 --> 03:06:46,127 I'M TYLER BECK. 4944 03:06:46,127 --> 03:06:48,196 I'M GOING TO TALK ABOUT THE 4945 03:06:48,196 --> 03:06:49,331 PROGRAM THAT I'VE BEEN WORKING 4946 03:06:49,331 --> 03:06:53,602 ON SINCE I STARTED NCATS FIVE 4947 03:06:53,602 --> 03:06:54,336 YEARS AGO NOW. 4948 03:06:54,336 --> 03:06:58,840 AND SO THIS IS THE BIOMEDICAL 4949 03:06:58,840 --> 03:06:59,374 DATA TRANSLATOR. 4950 03:06:59,374 --> 03:07:01,910 I KNOW SEVERAL OF YOU HAVE SEEN 4951 03:07:01,910 --> 03:07:02,911 PRESENTATIONS ON THIS BEFORE BUT 4952 03:07:02,911 --> 03:07:05,847 I WANT TO GIVE A BACKGROUND ON 4953 03:07:05,847 --> 03:07:06,615 IT. 4954 03:07:06,615 --> 03:07:07,716 SO, TRANSLATOR IS DESIGN TO HELP 4955 03:07:07,716 --> 03:07:09,351 SURFACE KNOWLEDGE FROM A VAST 4956 03:07:09,351 --> 03:07:18,760 ARRAY OF BIOMEDICAL DATA. 4957 03:07:18,760 --> 03:07:21,830 AUGMENTING THROUGH THE USE OF 4958 03:07:21,830 --> 03:07:25,000 KNOWLEDGE GRAPHS, HUGE GROUPS OF 4959 03:07:25,000 --> 03:07:29,070 DATA POINTS CONNECTED THROUGH 4960 03:07:29,070 --> 03:07:30,338 RELATIONSHIPS. 4961 03:07:30,338 --> 03:07:32,574 THESE ARE ENCODED INTO THIS 4962 03:07:32,574 --> 03:07:35,076 LARGE CLOUD, INFORMATION LIKE 4963 03:07:35,076 --> 03:07:36,511 THIS TRAVERSES DATA AND PRESENTS 4964 03:07:36,511 --> 03:07:38,713 RELATIVE CONNECTIONS BETWEEN THE 4965 03:07:38,713 --> 03:07:40,448 PIECES OF INFORMATION. 4966 03:07:40,448 --> 03:07:42,417 THESE CONNECTIONS REPRESENT 4967 03:07:42,417 --> 03:07:43,618 RELATIONSHIPS FOUND IN MANY 4968 03:07:43,618 --> 03:07:44,853 SOURCES INCLUDING THOSE 4969 03:07:44,853 --> 03:07:47,489 SUPPORTED BY NIH LIKE PubMed 4970 03:07:47,489 --> 03:07:50,191 AND GUARD AND PubChem, ALONG 4971 03:07:50,191 --> 03:07:52,961 WITH PUBLIC DATABASES NOT 4972 03:07:52,961 --> 03:07:54,696 SUPPORTED DIRECTLY BY NIH SUCH 4973 03:07:54,696 --> 03:07:56,564 AS SNOMED AND MANY OTHERS. 4974 03:07:56,564 --> 03:07:59,401 IT'S WORTH NOTING GETTING THESE 4975 03:07:59,401 --> 03:08:00,268 DISPARATE DATA SOURCES TO 4976 03:08:00,268 --> 03:08:03,805 INTERACT WITH EACH OTHER IN A 4977 03:08:03,805 --> 03:08:05,640 COHERENT WAY WAS A HUGE TASK 4978 03:08:05,640 --> 03:08:07,509 TRIED BY MANY OTHER GROUPS 4979 03:08:07,509 --> 03:08:08,943 BEFORE WITH LITTLE SUCCESS. 4980 03:08:08,943 --> 03:08:11,346 HAVING A SINGLE LANGUAGE TO 4981 03:08:11,346 --> 03:08:12,414 DESCRIBE CONCEPTS ACROSS ALL OF 4982 03:08:12,414 --> 03:08:14,716 BIOMEDICAL SCIENCE IS A HUGE 4983 03:08:14,716 --> 03:08:15,583 UNDERTAKING. 4984 03:08:15,583 --> 03:08:16,251 WE'VE CREATED SEVERAL STANDARDS 4985 03:08:16,251 --> 03:08:17,686 AS PART OF THIS CONSORTIUM OVER 4986 03:08:17,686 --> 03:08:18,887 THE LAST FEW YEARS. 4987 03:08:18,887 --> 03:08:21,289 SOME OF WHICH ARE USED IN OTHER 4988 03:08:21,289 --> 03:08:24,459 LARGE DATA SCIENCE PROGRAMS AS 4989 03:08:24,459 --> 03:08:25,060 WELL. 4990 03:08:25,060 --> 03:08:26,761 SO AS YOU'RE PROBABLY AWARE 4991 03:08:26,761 --> 03:08:31,733 TRANSLATOR IS A SYSTEM SOFTWARE 4992 03:08:31,733 --> 03:08:33,335 TOOLS BUILT BY 14 TEAMS. 4993 03:08:33,335 --> 03:08:38,340 WE HAVE SEVERAL TYPES OF TEAMS 4994 03:08:38,340 --> 03:08:39,574 WITH DIFFERENT FUNCTIONALITY. 4995 03:08:39,574 --> 03:08:41,743 FIRST OFF WE HAVE KNOWLEDGE 4996 03:08:41,743 --> 03:08:42,944 PROVIDER TEAM, TASKED WITH 4997 03:08:42,944 --> 03:08:44,379 SEARCHING FOR AND COLLECTING 4998 03:08:44,379 --> 03:08:48,516 DATA FROM DATABASES AROUND THE 4999 03:08:48,516 --> 03:08:49,084 WEB. 5000 03:08:49,084 --> 03:08:53,021 DATABASES CAN ANSWER THE LOWEST 5001 03:08:53,021 --> 03:08:53,888 COMPLEXITY QUESTIONS THAT USERS 5002 03:08:53,888 --> 03:08:56,291 MIGHT HAVE FOR A SYSTEM ON THEIR 5003 03:08:56,291 --> 03:08:59,060 OWN SUCH AS WHAT CELL TYPE A 5004 03:08:59,060 --> 03:09:07,135 GENE IS HIGHLY EXPRESSED IN. 5005 03:09:07,135 --> 03:09:08,870 THEY BUILD KNOWLEDGE GRAPHS AND 5006 03:09:08,870 --> 03:09:10,071 SERVE AS EXPERT SOURCE FOR THAT 5007 03:09:10,071 --> 03:09:11,840 TYPE OF KNOWLEDGE. 5008 03:09:11,840 --> 03:09:15,210 WE HAVE GENOMICS DATA PROVIDER, 5009 03:09:15,210 --> 03:09:18,480 CLINICAL DATA PROVIDER, CHEMICAL 5010 03:09:18,480 --> 03:09:24,853 DATA PROVIDER AND SEVERAL 5011 03:09:24,853 --> 03:09:25,086 OTHERS. 5012 03:09:25,086 --> 03:09:27,455 WE HAVE ARAs WHICH ACCESS 5013 03:09:27,455 --> 03:09:29,224 GRAPHS, REQUESTING SPECIFIC 5014 03:09:29,224 --> 03:09:30,425 PARTS OF THE UNDERLYING 5015 03:09:30,425 --> 03:09:31,526 KNOWLEDGE GRAPHS BASED ON WHAT 5016 03:09:31,526 --> 03:09:33,495 THE USER ASKED. 5017 03:09:33,495 --> 03:09:35,463 THEY COMBINE THESE RESULTS INTO 5018 03:09:35,463 --> 03:09:39,734 A NEW GRAPH WHICH INCLUDES 5019 03:09:39,734 --> 03:09:41,603 KNOWLEDGE FROM MANY DOMAINS 5020 03:09:41,603 --> 03:09:42,470 CONNECTED TOGETHER. 5021 03:09:42,470 --> 03:09:44,406 ARA WILL FIND A PATH THAT MAY 5022 03:09:44,406 --> 03:09:46,541 SATISFY THE CRITERIA OF THE 5023 03:09:46,541 --> 03:09:47,409 QUESTION ASKED. 5024 03:09:47,409 --> 03:09:48,710 SO THESE RESULTS ARE RANKED 5025 03:09:48,710 --> 03:09:52,547 BASED ON THINGS LINING 5026 03:09:52,547 --> 03:09:53,648 CONFIDENCE SCORES AND METRICS 5027 03:09:53,648 --> 03:09:59,788 AND EACH HAS A DIFFERENT WAY OF 5028 03:09:59,788 --> 03:10:01,322 RANKING THEIR RESULTS. 5029 03:10:01,322 --> 03:10:04,392 EACH OF THESE ARE THEN SENT TO 5030 03:10:04,392 --> 03:10:05,894 THE AUTONOMOUS RELAY SYSTEM 5031 03:10:05,894 --> 03:10:07,095 WHICH THE INTRAMURAL TEAM BUILT 5032 03:10:07,095 --> 03:10:08,196 FOR US. 5033 03:10:08,196 --> 03:10:09,931 ALL THESE POTENTIAL RESULTS ARE 5034 03:10:09,931 --> 03:10:12,033 SORTED AND COMBINED AS NECESSARY 5035 03:10:12,033 --> 03:10:16,438 INTO A SET OF POTENTIAL ANSWERS 5036 03:10:16,438 --> 03:10:18,606 FOR THE USER. 5037 03:10:18,606 --> 03:10:20,475 OVER THE COURSE, WE'VE MADE 5038 03:10:20,475 --> 03:10:22,510 STRIDES TOWARDS MAKING THE 5039 03:10:22,510 --> 03:10:25,380 SYSTEM A REALITY AND NOW AN 5040 03:10:25,380 --> 03:10:27,348 ALPHA VERSION OF USER INTERFACE, 5041 03:10:27,348 --> 03:10:30,084 INTERACTING WITH THE ARAS TO 5042 03:10:30,084 --> 03:10:33,588 DISPLAY RULEDS TO EXPLORE 5043 03:10:33,588 --> 03:10:34,889 EVIDENCE AND SOURCE OF RESULTS, 5044 03:10:34,889 --> 03:10:37,091 BUILT THROUGH A CONTRACT WITH A 5045 03:10:37,091 --> 03:10:38,526 COMPANY CALLED DMI WHO WORKED 5046 03:10:38,526 --> 03:10:40,695 WITH TRANSLATOR TEAMS AND USER 5047 03:10:40,695 --> 03:10:43,431 GROUPS TO DESIGN FRONT END FOR 5048 03:10:43,431 --> 03:10:43,731 TRANSLATOR. 5049 03:10:43,731 --> 03:10:54,042 WE'LL LOOK AT INTERFACE IN A FEW 5050 03:10:54,042 --> 03:10:54,275 MOMENTS. 5051 03:10:54,275 --> 03:10:56,478 THEY HAVE TO TALK TO EACH OTHER. 5052 03:10:56,478 --> 03:11:00,515 THIS IS THE DIAGRAM FROM THE 5053 03:11:00,515 --> 03:11:02,817 JUNE HACKATHON MEETING. 5054 03:11:02,817 --> 03:11:05,320 YOU CAN SEE SOMETHING THAT'S 5055 03:11:05,320 --> 03:11:06,221 COMPLICATED WHICH DOESN'T 5056 03:11:06,221 --> 03:11:08,056 ACCOUNT FOR ACCESSING AND 5057 03:11:08,056 --> 03:11:10,124 UPDATING KNOWLEDGE GRAPHS 5058 03:11:10,124 --> 03:11:10,758 KNOWLEDGE PROVIDERS THEMSELVES 5059 03:11:10,758 --> 03:11:10,959 STORE. 5060 03:11:10,959 --> 03:11:11,860 THIS IS JUST THE INFORMATION 5061 03:11:11,860 --> 03:11:14,095 THAT NEEDS TO FLOW BETWEEN OUR 5062 03:11:14,095 --> 03:11:15,930 TOOLS WHEN A QUERY IS MADE. 5063 03:11:15,930 --> 03:11:17,365 THIS GIVES A TASTE OF HOW MUCH 5064 03:11:17,365 --> 03:11:19,000 WORK HAS GONE INTO THE 5065 03:11:19,000 --> 03:11:19,934 ARCHITECTURE AND DEVELOPMENT OF 5066 03:11:19,934 --> 03:11:23,805 THE SYSTEM UP TO THIS POINT. 5067 03:11:23,805 --> 03:11:25,707 A LITTLE HISTORY ON THE PROJECT, 5068 03:11:25,707 --> 03:11:27,775 I KNOW SOME OF YOU ARE FAMILIAR 5069 03:11:27,775 --> 03:11:30,378 WITH IT. 5070 03:11:30,378 --> 03:11:31,145 FEASIBILITY WAS ACHIEVED IN 5071 03:11:31,145 --> 03:11:31,746 2019. 5072 03:11:31,746 --> 03:11:33,047 WE BEGAN THE CURRENT DEVELOPMENT 5073 03:11:33,047 --> 03:11:35,116 PHASE OF THE PROGRAM. 5074 03:11:35,116 --> 03:11:36,651 WE BEGAN WITH COMPETITIVE 5075 03:11:36,651 --> 03:11:38,286 PROTOTYPING PHASE, IN JANUARY OF 5076 03:11:38,286 --> 03:11:40,021 2020, PART OF THE FINAL 5077 03:11:40,021 --> 03:11:41,256 APPLICATION PROCESS FOR THIS 5078 03:11:41,256 --> 03:11:41,456 PHASE. 5079 03:11:41,456 --> 03:11:43,124 AND ONCE WE CHOSE OUR WINNERS 5080 03:11:43,124 --> 03:11:44,192 BEGAN FULL DEVELOPMENT OF THE 5081 03:11:44,192 --> 03:11:46,294 SYSTEM IN MAY OF THAT YEAR. 5082 03:11:46,294 --> 03:11:48,029 THAT MEANS RIGHT NOW WE'RE JUST 5083 03:11:48,029 --> 03:11:50,198 OVER 3 YEARS INTO DEVELOPMENT OF 5084 03:11:50,198 --> 03:11:51,299 THE SYSTEM. 5085 03:11:51,299 --> 03:11:52,300 IN ADDITION TO DEVELOPMENT 5086 03:11:52,300 --> 03:11:55,503 RESEARCH TEAMS WE HAVE THE USER 5087 03:11:55,503 --> 03:11:56,638 INTERFACE DEVELOPMENT TEAM, AND 5088 03:11:56,638 --> 03:11:59,974 THEY ARE TWO YEARS INTO A 5089 03:11:59,974 --> 03:12:03,478 THREE-YEAR FUNDING PERIOD. 5090 03:12:03,478 --> 03:12:03,711 SORRY. 5091 03:12:03,711 --> 03:12:04,679 GO BACK. 5092 03:12:04,679 --> 03:12:05,780 THERE WE GO. 5093 03:12:05,780 --> 03:12:07,882 WE WERE ABLE TO BUILD UPON THE 5094 03:12:07,882 --> 03:12:09,417 STANDARDS AND SOME GRAPHS 5095 03:12:09,417 --> 03:12:10,485 CREATED DURING FEASIBILITY BUT 5096 03:12:10,485 --> 03:12:12,654 FOR THE MOST PART THE 5097 03:12:12,654 --> 03:12:13,421 DEVELOPMENT PHASE OF TRANSLATOR 5098 03:12:13,421 --> 03:12:15,323 REPRESENTED BRAND NEW START FOR 5099 03:12:15,323 --> 03:12:15,957 THE CONSORTIUM. 5100 03:12:15,957 --> 03:12:18,359 WITH SEVERAL BRAND NEW TEAMS AND 5101 03:12:18,359 --> 03:12:22,597 MANY OF THE PREVIOUS TEAMS 5102 03:12:22,597 --> 03:12:23,097 SELF-REORGANIZING INTO 5103 03:12:23,097 --> 03:12:25,400 COLLABORATIONS DURING THE 5104 03:12:25,400 --> 03:12:26,200 PROCESS. 5105 03:12:26,200 --> 03:12:28,436 WE'VE BEEN HOLDING HACKATHON 5106 03:12:28,436 --> 03:12:29,837 TYPE MEETINGS, UP UNTIL RECENTLY 5107 03:12:29,837 --> 03:12:31,406 HAD BEEN VIRTUAL BECAUSE OF 5108 03:12:31,406 --> 03:12:33,474 COVID CONCERNS BUT IN JUNE WE 5109 03:12:33,474 --> 03:12:34,676 HELD OUR FIRST IN-PERSON 5110 03:12:34,676 --> 03:12:36,544 HACKATHON IN OVER FOUR YEARS. 5111 03:12:36,544 --> 03:12:38,713 AT THE BEGINNING OF THIS MONTH 5112 03:12:38,713 --> 03:12:39,714 WE RELEASED OUR FIRST PUBLIC 5113 03:12:39,714 --> 03:12:42,216 ALPHA VERSION OF THE TRANSLATOR 5114 03:12:42,216 --> 03:12:43,651 SYSTEM AND CURRENT VERSION 5115 03:12:43,651 --> 03:12:44,852 INCLUDES FUNCTIONALITY FOR USERS 5116 03:12:44,852 --> 03:12:47,021 TO ASK A SET OF SPECIFIC 5117 03:12:47,021 --> 03:12:48,923 QUESTIONS OF THE SYSTEM AND GET 5118 03:12:48,923 --> 03:12:49,991 BACK POTENTIAL ANSWERS TO THESE 5119 03:12:49,991 --> 03:12:53,828 QUESTIONS ALONG WITH THE 5120 03:12:53,828 --> 03:12:54,929 EVIDENCE AND PROVENANCE 5121 03:12:54,929 --> 03:12:57,532 ASSOCIATED WITH EACH ONE. 5122 03:12:57,532 --> 03:13:04,973 WE'VE BEEN HOLDING HACKATHONS, 5123 03:13:04,973 --> 03:13:06,107 RELAY MEETINGS, TWO TO THREE 5124 03:13:06,107 --> 03:13:11,579 TIMES A YEAR, TRUE WORKING 5125 03:13:11,579 --> 03:13:12,080 MEETINGS. 5126 03:13:12,080 --> 03:13:13,247 EVERY SESSION HAS TO HAVE 5127 03:13:13,247 --> 03:13:15,016 DELIVERABLES TO FIND SO WE CAN 5128 03:13:15,016 --> 03:13:16,618 KEEP TRACK OF ALL THAT WORK. 5129 03:13:16,618 --> 03:13:17,619 MEETINGS WERE VIRTUAL FOR 5130 03:13:17,619 --> 03:13:18,953 SEVERAL YEARS BECAUSE OF COVID 5131 03:13:18,953 --> 03:13:21,122 BUT NOW WE STARTED HAVING 5132 03:13:21,122 --> 03:13:23,524 IN-PERSON COMPONENT TO MEETINGS 5133 03:13:23,524 --> 03:13:25,193 WHEN POSSIBLE. 5134 03:13:25,193 --> 03:13:27,261 WE'VE PERFECTED VIRTUAL MEETINGS 5135 03:13:27,261 --> 03:13:29,797 AS NECESSITY IN TRANSLATOR 5136 03:13:29,797 --> 03:13:30,965 PROGRAM, IN-PERSON MEETING STILL 5137 03:13:30,965 --> 03:13:31,332 HAS ADVANTAGES. 5138 03:13:31,332 --> 03:13:33,167 ONE OF WHICH IS OUR TEAMS ARE 5139 03:13:33,167 --> 03:13:34,802 HIGHLY MOTIVATED AND YOU CAN 5140 03:13:34,802 --> 03:13:36,337 OFTEN FIND AT LEAST A SMALL 5141 03:13:36,337 --> 03:13:38,072 GROUP WORKING LATE INTO THE 5142 03:13:38,072 --> 03:13:40,041 NIGHT IN THE HOTEL LOBBY ON SOME 5143 03:13:40,041 --> 03:13:41,376 IDEA THEY CAME UP WITH, AND 5144 03:13:41,376 --> 03:13:43,645 THAT'S HARD IF NOT IMPOSSIBLE TO 5145 03:13:43,645 --> 03:13:46,247 REPLICATE IN AN ALL-VIRTUAL 5146 03:13:46,247 --> 03:13:49,584 SETTING. 5147 03:13:49,584 --> 03:13:52,854 ON THE TOP RIGHT SHOWS A GROUP 5148 03:13:52,854 --> 03:13:55,089 WORKING ON SOFTWARE AT MIDNIGHT. 5149 03:13:55,089 --> 03:13:56,457 BELOW THAT IS PRESENTATION ABOUT 5150 03:13:56,457 --> 03:13:59,093 IT THE NEXT DAY TO THE FULL 5151 03:13:59,093 --> 03:13:59,961 GROUP. 5152 03:13:59,961 --> 03:14:02,263 MOST RECENT MEETING IN POTOMAC 5153 03:14:02,263 --> 03:14:04,065 LAST WEEK TESTED THE IDEA 5154 03:14:04,065 --> 03:14:05,767 ALLOWING FOR AD HOC WORKING 5155 03:14:05,767 --> 03:14:07,301 SESSION WAS BREAKOUT ROOMS 5156 03:14:07,301 --> 03:14:08,102 ESSENTIALLY AVAILABLE WHENEVER 5157 03:14:08,102 --> 03:14:10,238 THEY WEREN'T BEING USED FOR 5158 03:14:10,238 --> 03:14:12,540 SCHEDULED SESSION, AND THIS 5159 03:14:12,540 --> 03:14:13,641 ALLOWED SMALL GROUPS, WORKING 5160 03:14:13,641 --> 03:14:17,912 SESSIONS IN A MORE FORMALIZED 5161 03:14:17,912 --> 03:14:18,112 WAY. 5162 03:14:18,112 --> 03:14:20,114 SO LET'S TALK ABOUT WHO WE'RE 5163 03:14:20,114 --> 03:14:21,649 BUILDING THE SYSTEM FOR. 5164 03:14:21,649 --> 03:14:25,253 WE EXPECT MAIN USER BASE WILL BE 5165 03:14:25,253 --> 03:14:26,254 TRANSLATIONAL RESEARCHERS, 5166 03:14:26,254 --> 03:14:27,355 PARTICULARLY RARE DISEASE 5167 03:14:27,355 --> 03:14:27,822 RESEARCHERS. 5168 03:14:27,822 --> 03:14:29,891 IT MAY BE THAT THEY ARE IN THE 5169 03:14:29,891 --> 03:14:32,026 LAB AND OBSERVED SOMETHING 5170 03:14:32,026 --> 03:14:33,661 INTERESTED, LOOKING FOR 5171 03:14:33,661 --> 03:14:34,462 POTENTIAL EXPLANATIONS OR 5172 03:14:34,462 --> 03:14:35,863 SUPPORT BEFORE THEY PURSUE IT 5173 03:14:35,863 --> 03:14:36,931 FURTHER. 5174 03:14:36,931 --> 03:14:39,367 OR MAY BE THESE ARE EARLY CAREER 5175 03:14:39,367 --> 03:14:41,135 RESEARCHERS WITH EXCITING NEW 5176 03:14:41,135 --> 03:14:42,970 IDEAS, LOOKING FOR MECHANISMS 5177 03:14:42,970 --> 03:14:44,272 THAT MIGHT SUPPORT THEIR 5178 03:14:44,272 --> 03:14:44,839 HYPOTHESES. 5179 03:14:44,839 --> 03:14:46,507 WE HAVE A BUILT-IN GROUP OF 5180 03:14:46,507 --> 03:14:49,343 USERS WHO HAVE GIVEN US FEEDBACK 5181 03:14:49,343 --> 03:14:50,945 DURING THIS INITIAL STAGE, 5182 03:14:50,945 --> 03:14:52,213 ANALYSTS WORKING AT THE 5183 03:14:52,213 --> 03:14:53,181 PRECISION MEDICINE INSTITUTE AT 5184 03:14:53,181 --> 03:14:56,017 THE UNIVERSITY OF ALABAMA 5185 03:14:56,017 --> 03:14:56,317 BIRMINGHAM. 5186 03:14:56,317 --> 03:14:57,719 THESE WORKED DIRECTLY WITH 5187 03:14:57,719 --> 03:14:59,187 CLINICAL RESEARCHERS LOOKING FOR 5188 03:14:59,187 --> 03:15:02,023 NEW POTENTIAL TREATMENTS FOR 5189 03:15:02,023 --> 03:15:03,458 VERY RARE OR REFRACTORY 5190 03:15:03,458 --> 03:15:03,925 CONDITIONS. 5191 03:15:03,925 --> 03:15:05,126 I'LL TALK MORE ABOUT HOW THAT 5192 03:15:05,126 --> 03:15:06,728 PROCESS WORKS IN A BIT. 5193 03:15:06,728 --> 03:15:08,696 WE HAVE ONE MORE VERY DIFFERENT 5194 03:15:08,696 --> 03:15:11,966 GROUP OF USERS FOR TRANSLATOR, 5195 03:15:11,966 --> 03:15:14,102 DATA SCIENTISTS COLLABORATOR WHO 5196 03:15:14,102 --> 03:15:18,539 WISH TO CONTRIBUTE DATA AND USE 5197 03:15:18,539 --> 03:15:21,409 KNOWLEDGE GRAPHS THROUGH APIs 5198 03:15:21,409 --> 03:15:22,944 AND MECHANISMS OF INTERACTING 5199 03:15:22,944 --> 03:15:25,113 WITH THE GRAPHS. 5200 03:15:25,113 --> 03:15:28,082 I MENTIONED ON THE TIMELINE 5201 03:15:28,082 --> 03:15:30,051 SLIDE WE JUST HAD OUR ALPHA 5202 03:15:30,051 --> 03:15:30,384 RELEASE. 5203 03:15:30,384 --> 03:15:32,453 I WANTED TO MAKE IT CLEAR WHAT 5204 03:15:32,453 --> 03:15:33,821 WE MEAN BY ALPHA RELEASE. 5205 03:15:33,821 --> 03:15:37,492 THIS IS A TERM USED FOR EARLY 5206 03:15:37,492 --> 03:15:38,025 INVESTIGATORS OF SOFTWARE, 5207 03:15:38,025 --> 03:15:39,894 UNSTABLE, USEFUL TO SHOW WHAT 5208 03:15:39,894 --> 03:15:41,095 THE SOFTWARE WILL DO. 5209 03:15:41,095 --> 03:15:42,830 THAT'S THE POINT WE'RE AT WITH 5210 03:15:42,830 --> 03:15:43,164 TRANSLATOR. 5211 03:15:43,164 --> 03:15:46,467 I WANT YOU TO KEEP THAT IN MIND 5212 03:15:46,467 --> 03:15:48,703 AS WE MOVE FORWARD. 5213 03:15:48,703 --> 03:15:50,972 OUR SYSTEM CAN SUPPORT ALMOST 5214 03:15:50,972 --> 03:15:52,640 ANY QUERY THROUGH THE API. 5215 03:15:52,640 --> 03:15:54,909 WE MADE THE DECISION TO START 5216 03:15:54,909 --> 03:15:56,677 WITH TEMPLATED QUERIES TO MAKE 5217 03:15:56,677 --> 03:15:58,746 SURE THE RESULTS ARE TAILORED TO 5218 03:15:58,746 --> 03:16:00,181 REPRESENT INFORMATION THAT USERS 5219 03:16:00,181 --> 03:16:01,582 REALLY WANT TO SEE. 5220 03:16:01,582 --> 03:16:03,551 AT THIS TIME A USER CAN ASK 5221 03:16:03,551 --> 03:16:04,652 THREE QUERIES. 5222 03:16:04,652 --> 03:16:06,187 WHAT DRUGS OR CHEMICALS MAY 5223 03:16:06,187 --> 03:16:07,655 TREAT A DISEASE OF INTEREST? 5224 03:16:07,655 --> 03:16:09,991 WHAT GENES MAY BE UP OR 5225 03:16:09,991 --> 03:16:10,658 DOWNREGULATED BY DRUG OR 5226 03:16:10,658 --> 03:16:11,859 CHEMICAL OF INTEREST? 5227 03:16:11,859 --> 03:16:15,496 AND WHAT DRUGS OR CHEMICALS MAY 5228 03:16:15,496 --> 03:16:17,331 UPOR DOWNREGULATE THEIR GENE OF 5229 03:16:17,331 --> 03:16:17,865 INTEREST? 5230 03:16:17,865 --> 03:16:19,534 I WANT TO MAKE THE NOTE HERE 5231 03:16:19,534 --> 03:16:22,703 THAT THE TERM DRUG IS USED 5232 03:16:22,703 --> 03:16:23,871 LOOSELY AND ANY CHEMICAL WHICH 5233 03:16:23,871 --> 03:16:26,207 MAY OR MAY NOT HAVE ANY KIND OF 5234 03:16:26,207 --> 03:16:28,176 FDA APPROVAL STATUS CAN BE 5235 03:16:28,176 --> 03:16:29,277 RETURNED IN THESE RESULTS ARE 5236 03:16:29,277 --> 03:16:36,717 OFTEN THE RESULTS THAT THE USERS 5237 03:16:36,717 --> 03:16:39,320 ARE REALLY LOOKING FOR. 5238 03:16:39,320 --> 03:16:41,823 WE USE A COMPLEX SYSTEM AND HAVE 5239 03:16:41,823 --> 03:16:43,357 A COMPLEX SCORING SCHEME THAT 5240 03:16:43,357 --> 03:16:44,926 HAD TO BE IMPLEMENTED, WE'RE 5241 03:16:44,926 --> 03:16:46,227 WORKING ON IMPROVEMENTS TO THE 5242 03:16:46,227 --> 03:16:47,762 SCORING SCHEME NOW. 5243 03:16:47,762 --> 03:16:49,397 AT THE MOMENT UTILIZES 5244 03:16:49,397 --> 03:16:50,164 COMBINATION OF WEIGHTED SCORES 5245 03:16:50,164 --> 03:16:51,699 COMING FROM EACH OF THE 5246 03:16:51,699 --> 03:16:52,900 REASONING AGENTS THAT RETURNED A 5247 03:16:52,900 --> 03:16:53,434 GIVEN RESULT. 5248 03:16:53,434 --> 03:16:55,436 WE'RE IN THE PROCESS OF 5249 03:16:55,436 --> 03:16:57,371 IMPLEMENTING ADDITIONAL SCORING 5250 03:16:57,371 --> 03:16:58,806 METRICS SUCH AS ASSESSMENT OF 5251 03:16:58,806 --> 03:17:00,975 NOVELTY OF A GIVEN ANSWER AND 5252 03:17:00,975 --> 03:17:03,644 INCLUDING DIRECT CLINICAL 5253 03:17:03,644 --> 03:17:04,612 EVIDENCE WHERE IT EXISTS. 5254 03:17:04,612 --> 03:17:06,480 SO THIS IS WHAT CURRENT USER 5255 03:17:06,480 --> 03:17:07,381 INTERFACE LOOKS LIKE, IMPORTANT 5256 03:17:07,381 --> 03:17:12,053 TO NOTE AT THE TOP OF THE PAGE 5257 03:17:12,053 --> 03:17:15,656 WE ALWAYS SHOW A BANNER THAT 5258 03:17:15,656 --> 03:17:16,858 IT'S FOR RESEARCH ONLY, NOT AS 5259 03:17:16,858 --> 03:17:19,193 DECISION SUPPORT IN THE COURSE 5260 03:17:19,193 --> 03:17:20,461 OF TREATMENT OF PATIENTS. 5261 03:17:20,461 --> 03:17:22,563 I'LL WALK YOU THROUGH A QUERY TO 5262 03:17:22,563 --> 03:17:24,532 SEE THE PROCESS FOR YOURSELVES. 5263 03:17:24,532 --> 03:17:26,934 I'LL USE GENES TO CHEMICALS 5264 03:17:26,934 --> 03:17:29,904 QUERY ON THE RIGHT SIDE GIVING 5265 03:17:29,904 --> 03:17:32,840 INFORMATION ON EFFECTS ON GENE 5266 03:17:32,840 --> 03:17:33,140 REGULATION. 5267 03:17:33,140 --> 03:17:34,475 WE EXPECT THIS WILL OFTEN BE 5268 03:17:34,475 --> 03:17:36,777 USED BY RESEARCHES LIKE THOSE IN 5269 03:17:36,777 --> 03:17:42,783 OUR OWN DPI, PRE-CLINICAL 5270 03:17:42,783 --> 03:17:46,087 DEVELOPMENT, USEFUL TO RESEARCH 5271 03:17:46,087 --> 03:17:49,690 RESEARCH TEAMS TO HELP NARROW 5272 03:17:49,690 --> 03:17:51,659 DOWN CHEMICALS TO SCREEN DURING 5273 03:17:51,659 --> 03:17:53,294 EARLY DEVELOPMENT. 5274 03:17:53,294 --> 03:17:58,432 WE NEED TO SPECIFY WE WANT 5275 03:17:58,432 --> 03:18:01,602 CHEMICALS CAN REGULATE A GENE. 5276 03:18:01,602 --> 03:18:05,773 WE'LL USE UPREGULATORS IN THIS 5277 03:18:05,773 --> 03:18:05,973 CASE. 5278 03:18:05,973 --> 03:18:14,115 A SEARCH BAR LETS THE USER KNOW 5279 03:18:14,115 --> 03:18:16,350 IT NEEDS AN ENTRY, WE'LL USE 5280 03:18:16,350 --> 03:18:17,818 FRAG 1. 5281 03:18:17,818 --> 03:18:22,523 WHEN YOU START TYPING THE NAME 5282 03:18:22,523 --> 03:18:23,858 THE SEARCH BAR WILL SHOW 5283 03:18:23,858 --> 03:18:24,425 OPTIONS. 5284 03:18:24,425 --> 03:18:26,794 CLICK ON ONE TO CONFIRM WHICH 5285 03:18:26,794 --> 03:18:30,731 GENE THEY ARE INTERESTED IN. 5286 03:18:30,731 --> 03:18:32,366 WHILE YOU'RE WAITING FOR 5287 03:18:32,366 --> 03:18:33,267 RESULTS, SYSTEM GIVES 5288 03:18:33,267 --> 03:18:35,770 INFORMATION ABOUT THE ENTITY YOU 5289 03:18:35,770 --> 03:18:46,314 SEARCHED FOR, THE IN THIS CASE 5290 03:18:47,248 --> 03:18:47,515 FRAS1 GENE. 5291 03:18:47,515 --> 03:18:51,552 WE'LL LOOK AT PATHS IN A MOMENT. 5292 03:18:51,552 --> 03:18:54,488 EVIDENCE THAT SUPPORTS IT 5293 03:18:54,488 --> 03:18:58,359 INCLUDING PUBLICATIONS AND 5294 03:18:58,359 --> 03:18:58,759 SCORE. 5295 03:18:58,759 --> 03:19:02,096 WE'LL TAKE A LOOK AT ONE 5296 03:19:02,096 --> 03:19:09,837 SPECIFIC RESULT, SODIUM 5297 03:19:09,837 --> 03:19:10,104 VALPROATE. 5298 03:19:10,104 --> 03:19:12,473 THIS SHOWS MORE INFORMATION ON 5299 03:19:12,473 --> 03:19:13,240 THAT RESULT. 5300 03:19:13,240 --> 03:19:14,976 THIS INCLUDES GRAPH VIEW WHICH 5301 03:19:14,976 --> 03:19:20,581 SHOWS ALL THE CONNECTIONS FOUND 5302 03:19:20,581 --> 03:19:22,116 BETWEEN POTENTIAL TREATMENT AND 5303 03:19:22,116 --> 03:19:23,084 FRAS1 GENE. 5304 03:19:23,084 --> 03:19:25,186 YOU CAN SEE THE PATH VIEW 5305 03:19:25,186 --> 03:19:26,721 SHOWING ALL PATHWAYS THAT 5306 03:19:26,721 --> 03:19:29,123 CONNECT THE TWO IN A TABLE VIEW. 5307 03:19:29,123 --> 03:19:31,559 THIS CAN GIVE A GOOD SENSE OF 5308 03:19:31,559 --> 03:19:33,527 WHAT KINDS OF RELATIONSHIPS ARE 5309 03:19:33,527 --> 03:19:38,699 REPRESENTED IN THE GRAPH ABOVE. 5310 03:19:38,699 --> 03:19:42,636 SO IN THIS CASE, FOR EXAMPLE, 5311 03:19:42,636 --> 03:19:44,038 VALPROATE CAUSES INCREASED 5312 03:19:44,038 --> 03:19:44,805 EXPRESSION OF FRAS1. 5313 03:19:44,805 --> 03:19:47,108 IF YOU CLICK ON A GREEN BUTTON, 5314 03:19:47,108 --> 03:19:49,410 A SCREEN SHOWS EVIDENCE FOR THIS 5315 03:19:49,410 --> 03:19:49,944 RELATIONSHIP. 5316 03:19:49,944 --> 03:19:52,913 A SET OF PAPERS FROM PubMed. 5317 03:19:52,913 --> 03:19:54,648 THIS SHOWS NOT ONLY INFORMATION 5318 03:19:54,648 --> 03:19:56,317 LIKE TITLE AND JOURNAL NAME BUT 5319 03:19:56,317 --> 03:20:06,827 ALSO SNIP SNIPPET OF TEXT ON 5320 03:20:08,062 --> 03:20:08,996 THE RIGHT SIDE. 5321 03:20:08,996 --> 03:20:11,065 THIS WILL TAKE YOU TO THE 5322 03:20:11,065 --> 03:20:12,900 PUBLICATION ON THE PubMed 5323 03:20:12,900 --> 03:20:13,134 WEBSITE. 5324 03:20:13,134 --> 03:20:14,402 WE HAVE OTHER RESOURCES IN 5325 03:20:14,402 --> 03:20:15,569 TRANSLATOR AS WELL OF COURSE. 5326 03:20:15,569 --> 03:20:18,339 YOU CAN CLICK ON THE SOURCES TAB 5327 03:20:18,339 --> 03:20:23,411 AND IT WILL SHOW SOURCES FOR THE 5328 03:20:23,411 --> 03:20:24,278 RELATIONSHIP BETWEEN VALPROIC 5329 03:20:24,278 --> 03:20:26,947 ACID AND FRAS1, INCLUDING AN 5330 03:20:26,947 --> 03:20:29,216 ENTRY IN THE DATABASE. 5331 03:20:29,216 --> 03:20:31,652 CLICK ON THE LINK AND YOU'LL 5332 03:20:31,652 --> 03:20:33,654 NAVIGATE TO THE CTD HOME PAGE TO 5333 03:20:33,654 --> 03:20:39,527 SEARCH FOR FRAS1 AND LINK TO 5334 03:20:39,527 --> 03:20:39,860 VALPROIC ACID. 5335 03:20:39,860 --> 03:20:41,862 A GOAL IS TO SEND THE USER 5336 03:20:41,862 --> 03:20:44,265 DIRECTLY TO THE PAGE WHERE ENTRY 5337 03:20:44,265 --> 03:20:45,466 ON THE UNDERLYING SOURCE 5338 03:20:45,466 --> 03:20:47,768 DATABASE IF IT EXISTS, IT SHOWS 5339 03:20:47,768 --> 03:20:48,235 THE CONNECTION. 5340 03:20:48,235 --> 03:20:51,072 THIS IS A LARGE LIFT SINCE 5341 03:20:51,072 --> 03:20:53,340 DIFFERENT DATABASES HAVE 5342 03:20:53,340 --> 03:20:54,075 DIFFERENT WAYS OF ACCESSING 5343 03:20:54,075 --> 03:20:55,543 INFORMATION BUT WE THINK WE CAN 5344 03:20:55,543 --> 03:20:58,946 MAKE IT WORK FOR A LARGE NUMBER 5345 03:20:58,946 --> 03:21:00,581 OF UNDERLYING SOURCES. 5346 03:21:00,581 --> 03:21:02,450 AND THAT PREVIOUS EXAMPLE SHOWED 5347 03:21:02,450 --> 03:21:04,752 A STRAIGHTFORWARD GRAPH WITH 5348 03:21:04,752 --> 03:21:07,822 FAIRLY DIRECT CONNECTIONS 5349 03:21:07,822 --> 03:21:10,391 BETWEEN FRAS1 AND VALPROIC ACID. 5350 03:21:10,391 --> 03:21:11,525 ANOTHER SHOWS MORE DEPTH 5351 03:21:11,525 --> 03:21:17,965 TRANSLATE TRANSLATOR CAN 5352 03:21:17,965 --> 03:21:18,332 PROVIDE. 5353 03:21:18,332 --> 03:21:19,900 THIS RECOMMENDS A SET OF 5354 03:21:19,900 --> 03:21:25,339 PATHWAYS THAT CONNECT A FORM OF 5355 03:21:25,339 --> 03:21:28,075 COLLAGEN ACE. 5356 03:21:28,075 --> 03:21:29,677 IF YOU SAY SPECIFICALLY YOU'RE 5357 03:21:29,677 --> 03:21:30,911 INTERESTED IN CONNECTIONS 5358 03:21:30,911 --> 03:21:31,912 THROUGH COLLAGEN 1A 1 YOU CAN 5359 03:21:31,912 --> 03:21:34,081 CLICK ON THAT NODE IN THE GRAPH 5360 03:21:34,081 --> 03:21:35,950 TO HIGHLIGHT PATHS THAT INCLUDE 5361 03:21:35,950 --> 03:21:36,851 THAT NODE SPECIFICALLY. 5362 03:21:36,851 --> 03:21:39,253 YOU COULD CLICK ON THAT NODE A 5363 03:21:39,253 --> 03:21:40,988 SECOND TIME TO DESELECT AND GRAY 5364 03:21:40,988 --> 03:21:43,057 OUT ANY PATHS THAT GO THROUGH 5365 03:21:43,057 --> 03:21:44,725 THAT NODE IF YOU DECIDE IT 5366 03:21:44,725 --> 03:21:48,329 WASN'T VALUABLE TO YOUR ANALYSIS 5367 03:21:48,329 --> 03:21:49,964 OF THE RESULT. 5368 03:21:49,964 --> 03:21:51,932 WE'VE UPDATED COUNCIL IN THE 5369 03:21:51,932 --> 03:21:53,901 PAST ON EXCITING OUTCOMES FROM 5370 03:21:53,901 --> 03:21:54,768 TRANSLATOR INCLUDING CLINICAL 5371 03:21:54,768 --> 03:21:56,103 TRIALS THAT WERE INITIATED FROM 5372 03:21:56,103 --> 03:21:58,806 RESEARCH THAT STARTED WITH THE 5373 03:21:58,806 --> 03:21:59,907 TRANSLATOR QUERY BUT SOME BEST 5374 03:21:59,907 --> 03:22:01,008 STORIES COME FROM THE WORK OF 5375 03:22:01,008 --> 03:22:02,209 THE PRECISION MEDICINE INSTITUTE 5376 03:22:02,209 --> 03:22:04,645 AT THE UNIVERSITY OF ALABAMA 5377 03:22:04,645 --> 03:22:07,681 BIRMINGHAM, PART OF THE 5378 03:22:07,681 --> 03:22:09,016 CONSORTIUM SINCE INCEPTION, THE 5379 03:22:09,016 --> 03:22:11,819 TEAM WORKS CLOSELY WITH 5380 03:22:11,819 --> 03:22:15,789 CLINICIANS WHO SEE PATIENTS WITH 5381 03:22:15,789 --> 03:22:16,323 RARE CONDITIONS, USING 5382 03:22:16,323 --> 03:22:19,493 TRANSLATOR TO COME UP WITH 5383 03:22:19,493 --> 03:22:21,462 POTENTIAL TREATMENTS, WRITE UP 5384 03:22:21,462 --> 03:22:24,665 RESEARCH REPORTS AND GIVE 5385 03:22:24,665 --> 03:22:25,299 PATIENTS' PHYSICIANS SUGGESTIONS 5386 03:22:25,299 --> 03:22:26,734 ALLOWING DOCTORS TO EVALUATE 5387 03:22:26,734 --> 03:22:28,269 OPTIONS AND POSSIBLY RECOMMEND 5388 03:22:28,269 --> 03:22:29,570 NEW TREATMENT. 5389 03:22:29,570 --> 03:22:32,106 OFTEN REPURPOSING A DRUG 5390 03:22:32,106 --> 03:22:34,942 INDICATED FOR ANOTHER DISEASE. 5391 03:22:34,942 --> 03:22:40,681 EARLY EXAMPLE WAS CYCLIC 5392 03:22:40,681 --> 03:22:43,284 VOMITING SYNDROME, LIVES WERE 5393 03:22:43,284 --> 03:22:45,686 CHANGED FOR THE BETTER BASED ON 5394 03:22:45,686 --> 03:22:46,787 TRANSLATOR RECOMMENDATIONS. 5395 03:22:46,787 --> 03:22:54,662 ANOTHER EXAMPLE WAS A RARE 5396 03:22:54,662 --> 03:22:59,600 DISORDER DLG 4, SHINE SYNDROME 5397 03:22:59,600 --> 03:23:02,102 IS NAMED FOR SYMPTOMS, AS YOU 5398 03:23:02,102 --> 03:23:03,771 CAN SEE ON THE SCREEN. 5399 03:23:03,771 --> 03:23:06,307 IT'S CAUSED BY MUTATIONS IN DLG 5400 03:23:06,307 --> 03:23:09,276 4 GENE THAT CAUSE LOSS OF 5401 03:23:09,276 --> 03:23:14,715 FUNCTION OR HAPLOINEFFICIENCY. 5402 03:23:14,715 --> 03:23:15,716 RESEARCHERS WERE ASKED TO LOOK 5403 03:23:15,716 --> 03:23:22,556 FOR TREATMENTS FOR THIS VERY 5404 03:23:22,556 --> 03:23:23,290 RARE SYNDROME. 5405 03:23:23,290 --> 03:23:26,160 IT'S NOT FOUND IN UNDERLYING 5406 03:23:26,160 --> 03:23:28,028 DATABASES, THEY LOOKED FOR 5407 03:23:28,028 --> 03:23:29,230 TREATMENTS THAT MIGHT UPREGULATE 5408 03:23:29,230 --> 03:23:34,568 THE GENE SPECIFICALLY TO 5409 03:23:34,568 --> 03:23:35,269 COMPENSATE FOR 5410 03:23:35,269 --> 03:23:35,703 HAPLOINSUFFICIENCY. 5411 03:23:35,703 --> 03:23:37,371 TRANSLATOR RETURNED MANY 5412 03:23:37,371 --> 03:23:38,672 POTENTIAL TREATMENTS, A FEW 5413 03:23:38,672 --> 03:23:39,974 OPTIONS MAY BE WORTH 5414 03:23:39,974 --> 03:23:41,141 CONSIDERING. 5415 03:23:41,141 --> 03:23:42,943 BASED ON THIS REPORT AND DOCTORS 5416 03:23:42,943 --> 03:23:45,746 REVIEW ONE PATIENT WAS STARTED 5417 03:23:45,746 --> 03:23:47,181 ON COMMON BLOOD PRESSURE 5418 03:23:47,181 --> 03:23:49,817 TREATMENT, AFTER FIVE MONTHS THE 5419 03:23:49,817 --> 03:23:50,684 PATIENT SHOWED MEASURABLE 5420 03:23:50,684 --> 03:23:52,386 IMPROVEMENTS IN MOTOR AND 5421 03:23:52,386 --> 03:23:52,987 BEHAVIORAL SKILLS. 5422 03:23:52,987 --> 03:23:55,489 YOU CAN SEE THAT IN A REMARKABLE 5423 03:23:55,489 --> 03:23:56,924 WAY BECAUSE THE PATIENT'S MOTHER 5424 03:23:56,924 --> 03:23:59,326 SENT IN IMAGES OF HER COLORING 5425 03:23:59,326 --> 03:24:01,395 BOOKS BEFORE HER TREATMENT AND 5426 03:24:01,395 --> 03:24:03,330 THEN AFTER TREATMENT. 5427 03:24:03,330 --> 03:24:05,666 WHEN SHE REMARKED WE'VE SEEN A 5428 03:24:05,666 --> 03:24:07,668 HUGE IMPROVEMENT IN PEPPA PIG, I 5429 03:24:07,668 --> 03:24:09,837 REALLY THOUGHT THAT WAS A GREAT 5430 03:24:09,837 --> 03:24:10,938 EXAMPLE OF A PARENT 5431 03:24:10,938 --> 03:24:12,906 UNDERSTANDING THEIR CHILD'S 5432 03:24:12,906 --> 03:24:14,875 ABILITIES IN COMMUNING THEM TO 5433 03:24:14,875 --> 03:24:16,410 THE PHYSICIAN IN NON-CLINICAL 5434 03:24:16,410 --> 03:24:17,044 TERMS. 5435 03:24:17,044 --> 03:24:19,146 WE HAVE MANY OTHER EXAMPLES OF 5436 03:24:19,146 --> 03:24:20,347 RESULTS FROM TRANSLATOR QUERIES 5437 03:24:20,347 --> 03:24:22,583 LEADING TO ADVANCES AT DIFFERENT 5438 03:24:22,583 --> 03:24:22,883 LEVELS. 5439 03:24:22,883 --> 03:24:25,619 WE KNOW SEVERAL CASES WHERE 5440 03:24:25,619 --> 03:24:26,754 TRANSLATOR RESULTS LED TO 5441 03:24:26,754 --> 03:24:27,921 CLINICAL TRIALS INCLUDING 5442 03:24:27,921 --> 03:24:32,526 CLINICAL TRIAL FOR TREATMENT OF 5443 03:24:32,526 --> 03:24:33,327 ACTIVITY-DEPENDENT NEURAL 5444 03:24:33,327 --> 03:24:37,865 PROTECTIVE PROGRAM SYNDROME AS 5445 03:24:37,865 --> 03:24:41,468 TRIALS TESTING ACUTE AND LONG 5446 03:24:41,468 --> 03:24:42,236 COVID TREATMENTS. 5447 03:24:42,236 --> 03:24:44,605 TRANSLATOR HAS DEVELOP FOR EARLY 5448 03:24:44,605 --> 03:24:45,205 PRE-CLINICAL RESEARCH ALL THE 5449 03:24:45,205 --> 03:24:49,043 WAY TO THE CLINICAL TRIALS 5450 03:24:49,043 --> 03:24:50,010 STAGE. 5451 03:24:50,010 --> 03:24:51,545 THIS PRESENTATION IS FOCUSED ON 5452 03:24:51,545 --> 03:24:52,546 UPDATE ON WHERE WE'VE COME FROM 5453 03:24:52,546 --> 03:24:59,987 AND WHERE WE ARE NOW AS FAR AS 5454 03:24:59,987 --> 03:25:03,057 TRANSLATOR SYSTEM BUT WE HAVE 5455 03:25:03,057 --> 03:25:04,458 IDEAS FOR IMPROVEMENTS, SOME 5456 03:25:04,458 --> 03:25:07,328 ONLY POSSIBLE WITH ADDITIONAL 5457 03:25:07,328 --> 03:25:09,930 FUNDING PERIOD. 5458 03:25:09,930 --> 03:25:11,899 I'LL TALK DURING MY CONCEPT 5459 03:25:11,899 --> 03:25:12,399 PRESENTATION ABOUT THIS. 5460 03:25:12,399 --> 03:25:14,768 I WOULD BE REMISS NOT TO MENTION 5461 03:25:14,768 --> 03:25:16,937 THE RECENT SURGE IN RESEARCH 5462 03:25:16,937 --> 03:25:19,340 AROUND LARGE LANGUAGE MODELS 5463 03:25:19,340 --> 03:25:23,711 LIKE CHAT GPT ANDOTHERS. 5464 03:25:23,711 --> 03:25:26,113 FOR THE MOMENT WE'RE USING ONLY 5465 03:25:26,113 --> 03:25:27,781 A FEW TEMPLATED QUERIES IN THE 5466 03:25:27,781 --> 03:25:29,516 ALPHA VERSION OF TRANSLATOR ONE 5467 03:25:29,516 --> 03:25:31,585 WAY WE HOPE TO EXPAND THIS QUERY 5468 03:25:31,585 --> 03:25:33,887 OPTION IS BY ALLOWING USERS TO 5469 03:25:33,887 --> 03:25:35,622 ASK A NATURAL LANGUAGE QUESTION, 5470 03:25:35,622 --> 03:25:37,491 HAVE AN LLM INTERPRET AND FORMAT 5471 03:25:37,491 --> 03:25:41,995 INTO A QUERY THAT TRANSLATOR CAN 5472 03:25:41,995 --> 03:25:44,064 UNDERSTAND AND ALSO POTENTIALLY 5473 03:25:44,064 --> 03:25:44,932 HAVE PUBLICATIONS SUMMARIZED 5474 03:25:44,932 --> 03:25:45,733 ASSOCIATED WITH A GIVEN RESULT 5475 03:25:45,733 --> 03:25:46,700 THAT COMES BACK. 5476 03:25:46,700 --> 03:25:48,469 TO GIVE USE AREA GOOD OVERALL 5477 03:25:48,469 --> 03:25:49,870 IDEA OF TRENDS WITHIN THE PAPERS 5478 03:25:49,870 --> 03:25:51,939 THAT ARE ASSOCIATED WITH THOSE 5479 03:25:51,939 --> 03:25:52,740 RETURNED RESULTS. 5480 03:25:52,740 --> 03:25:54,475 THIS WILL ALLOW FOR THE SYSTEM 5481 03:25:54,475 --> 03:25:56,076 TO BE MORE ACCESSIBLE TO 5482 03:25:56,076 --> 03:25:57,344 RESEARCHERS AND MUCH MORE 5483 03:25:57,344 --> 03:26:01,048 VALUABLE TO THEIR EVERYDAY WORK. 5484 03:26:01,048 --> 03:26:03,317 I WANT TO TAKE A MOMENT TO 5485 03:26:03,317 --> 03:26:05,185 RECOGNIZE MY COLLEAGUES WORKING 5486 03:26:05,185 --> 03:26:06,353 ON TRANSLATOR AT NCATS, TWO 5487 03:26:06,353 --> 03:26:08,889 SITTING RIGHT HERE IN THE ROOM, 5488 03:26:08,889 --> 03:26:10,758 I MAY THROW QUESTIONS AT THEM, 5489 03:26:10,758 --> 03:26:14,061 AS WELL AS THOSE WHO HELPED MAKE 5490 03:26:14,061 --> 03:26:17,131 IT POSSIBLE INCLUDING NCATS ITRB 5491 03:26:17,131 --> 03:26:17,331 TEAM. 5492 03:26:17,331 --> 03:26:18,766 I'D LIKE TO INVITE YOU TO TRY 5493 03:26:18,766 --> 03:26:24,571 OUT THE SYSTEM FOR YOURSELF. 5494 03:26:24,571 --> 03:26:26,306 WE DO WANT TO CREATE A MOBILE 5495 03:26:26,306 --> 03:26:27,641 VERSION OF THE INTERFACE BUT 5496 03:26:27,641 --> 03:26:30,577 RIGHT NOW IT'S NOT FORMATTED SO 5497 03:26:30,577 --> 03:26:32,679 WE DIDN'T INCLUDE A QR CODE LIKE 5498 03:26:32,679 --> 03:26:33,547 JONI LIKES TO DO. 5499 03:26:33,547 --> 03:26:35,716 BUT YOU WILL HAVE TO MAKE A USER 5500 03:26:35,716 --> 03:26:37,151 ACCOUNT TO RUN YOUR OWN 5501 03:26:37,151 --> 03:26:37,418 SEARCHES. 5502 03:26:37,418 --> 03:26:38,685 WITHOUT A USER ACCOUNT YOU CAN 5503 03:26:38,685 --> 03:26:42,723 SEE RESULTS FROM SEVERAL EXAMPLE 5504 03:26:42,723 --> 03:26:43,857 QUERIES INCLUDING RARE DISEASES, 5505 03:26:43,857 --> 03:26:45,359 WITH THAT I'D LIKE TO THANK YOU 5506 03:26:45,359 --> 03:26:47,528 FOR YOUR ATTENTION. 5507 03:26:47,528 --> 03:26:48,962 CHRISTINE AND I ARE HAPPY TO 5508 03:26:48,962 --> 03:26:53,901 TAKE QUESTIONS ABOUT THE 5509 03:26:53,901 --> 03:26:54,401 TRANSLATOR SYSTEM. 5510 03:26:54,401 --> 03:26:55,569 >> CHANGE OF PLANS. 5511 03:26:55,569 --> 03:26:56,870 GO RIGHT INTO YOUR CONCEPT. 5512 03:26:56,870 --> 03:27:00,607 WE'RE RUNNING REALLY LATE AND I 5513 03:27:00,607 --> 03:27:02,443 WANT MAKE SURE THEY CAN WEIGH IN 5514 03:27:02,443 --> 03:27:06,113 ON THE CONCEPTS. 5515 03:27:06,113 --> 03:27:06,613 >> NO PROBLEM. 5516 03:27:06,613 --> 03:27:09,149 ALL RIGHT. 5517 03:27:09,149 --> 03:27:09,783 CLEARANCE OF CONCEPTS. 5518 03:27:09,783 --> 03:27:11,885 CHRISTINE HAD THE CHANCE TO 5519 03:27:11,885 --> 03:27:15,722 INTRODUCE ME, I'LL SKIP PAST 5520 03:27:15,722 --> 03:27:16,590 INTRODUCTION SLIDES. 5521 03:27:16,590 --> 03:27:18,725 SO THANK YOU FOR ALLOWING US TO 5522 03:27:18,725 --> 03:27:19,760 PRESENT THIS CONCEPT. 5523 03:27:19,760 --> 03:27:25,966 THIS IS A CONCEPT FOR RENEWAL OF 5524 03:27:25,966 --> 03:27:27,201 THE TRANSLATOR PROGRAM. 5525 03:27:27,201 --> 03:27:29,136 WE TALK ABOUT TRANSLATOR AND ALL 5526 03:27:29,136 --> 03:27:30,504 THE PROGRESS WE'VE MADE. 5527 03:27:30,504 --> 03:27:32,806 YOU'VE SEEN THE CURRENT ALPHA 5528 03:27:32,806 --> 03:27:34,541 USER INTERFACE HOW RESULTS ARE 5529 03:27:34,541 --> 03:27:34,875 DISPLAYED. 5530 03:27:34,875 --> 03:27:37,511 WE'LL FOCUS ON THE FUTURE AND 5531 03:27:37,511 --> 03:27:40,247 HOW TRANSLATOR CAN BE IMPROVED 5532 03:27:40,247 --> 03:27:46,487 UPON AND DEVELOPED INTO A TOOL. 5533 03:27:46,487 --> 03:27:50,457 SOURCES COVER A WIDE RANGE OF 5534 03:27:50,457 --> 03:27:52,292 NEEDS, DEVELOPED IN A CONTEXTUAL 5535 03:27:52,292 --> 03:27:55,262 BUBBLING BASED ON NEEDS OF THE 5536 03:27:55,262 --> 03:27:58,098 COMMITTEE THEY WERE BUILT TO 5537 03:27:58,098 --> 03:27:58,532 SERVE. 5538 03:27:58,532 --> 03:28:00,534 THAT MEANS THEY ARE NOT WELL 5539 03:28:00,534 --> 03:28:01,835 ALIGNED TO EXPLORE ACROSS THEM 5540 03:28:01,835 --> 03:28:04,137 AND MAKE ALL THE CONNECTIONS 5541 03:28:04,137 --> 03:28:05,305 NEEDED. 5542 03:28:05,305 --> 03:28:06,607 COMPOUNDING THIS ISSUE IS 5543 03:28:06,607 --> 03:28:07,841 RESEARCHERS SOMETIMES AREN'T 5544 03:28:07,841 --> 03:28:10,043 AWARE OF RESOURCES WHICH THEY 5545 03:28:10,043 --> 03:28:11,578 MIGHT FIND RELEVANT DATA, WE 5546 03:28:11,578 --> 03:28:15,983 BUILT TRANSLATOR TO SOLVE THAT 5547 03:28:15,983 --> 03:28:16,216 PROBLEM. 5548 03:28:16,216 --> 03:28:18,252 IT WAS CONCEIVED TO HELP WITH 5549 03:28:18,252 --> 03:28:19,786 DRUG DISCOVERY, STILL PART OF 5550 03:28:19,786 --> 03:28:20,120 THE VISION. 5551 03:28:20,120 --> 03:28:22,656 OTHER GROUPS WORK ON MODELING 5552 03:28:22,656 --> 03:28:25,025 DRUG DISCOVERY AND DRUG 5553 03:28:25,025 --> 03:28:27,361 INTERACTION, THESE ARE STILL IN 5554 03:28:27,361 --> 03:28:28,228 EARLY STAGES. 5555 03:28:28,228 --> 03:28:31,732 INSTEAD WE HAVE TO RELY ON 5556 03:28:31,732 --> 03:28:33,166 EXPENSIVE HIGH-THROUGHPUT WET 5557 03:28:33,166 --> 03:28:34,601 LAB-BASED SCREENS TO NARROW DONE 5558 03:28:34,601 --> 03:28:35,269 THOUSANDS OF POSSIBLE TREATMENTS 5559 03:28:35,269 --> 03:28:37,771 BEFORE THEY CAN BE TESTED MORE 5560 03:28:37,771 --> 03:28:39,940 THOROUGHLY IN CLINICAL TRIALS. 5561 03:28:39,940 --> 03:28:41,775 TO HELP ALLEVIATE ISSUES, TODAY 5562 03:28:41,775 --> 03:28:43,644 WE PROPOSE CONCEPT TO 5563 03:28:43,644 --> 03:28:46,179 SIGNIFICANTLY IMPROVE UPON THE 5564 03:28:46,179 --> 03:28:46,947 CAPABILITIES OF TRANSLATOR 5565 03:28:46,947 --> 03:28:48,148 THROUGH ENTERPRISE LEVEL 5566 03:28:48,148 --> 03:28:50,651 SOFTWARE ENGINEERING AND DATA 5567 03:28:50,651 --> 03:28:52,619 SCIENCE RESEARCH. 5568 03:28:52,619 --> 03:28:54,588 I SHOWED THIS TRANSLATOR 5569 03:28:54,588 --> 03:28:56,456 TIMELINE SLIDE. 5570 03:28:56,456 --> 03:28:58,325 YOU KNOW FEASIBILITY WAS 5571 03:28:58,325 --> 03:28:59,192 ACHIEVED IN 2019. 5572 03:28:59,192 --> 03:29:00,961 AND WE'RE IN THE DEVELOPMENT 5573 03:29:00,961 --> 03:29:01,562 PHASE OF THE PROGRAM. 5574 03:29:01,562 --> 03:29:03,363 THE PROGRAM IS NOW RUNNING FOR 5575 03:29:03,363 --> 03:29:05,666 FOUR YEARS, WE HAVE ONE YEAR 5576 03:29:05,666 --> 03:29:07,634 LEFT OF FUNDING UNTIL THE END OF 5577 03:29:07,634 --> 03:29:08,735 THE CURRENT PARADIGM. 5578 03:29:08,735 --> 03:29:10,270 WE COMPLETED OUR INITIAL PUBLIC 5579 03:29:10,270 --> 03:29:14,308 RELEASE AND SO FAR WE'VE SEEN 5580 03:29:14,308 --> 03:29:16,276 OVER 200 USERS BY I.P. ADDRESS. 5581 03:29:16,276 --> 03:29:18,245 WHAT I'M ASKING TODAY IS A FIVE 5582 03:29:18,245 --> 03:29:22,015 YEAR EXTENSION OF THE TRANSLATOR 5583 03:29:22,015 --> 03:29:23,183 DEVELOPMENT PHASE, PERFORMANCE 5584 03:29:23,183 --> 03:29:23,383 PHASE. 5585 03:29:23,383 --> 03:29:25,152 WE FEEL ANOTHER FIVE YEARS OF 5586 03:29:25,152 --> 03:29:27,354 FUNDING CAN GET THIS READY FOR 5587 03:29:27,354 --> 03:29:28,989 SUSTAINED FUNCTIONALITY AND 5588 03:29:28,989 --> 03:29:29,756 SIGNIFICANT USER GROWTH. 5589 03:29:29,756 --> 03:29:31,558 THIS PERIOD WILL CONTINUE TO 5590 03:29:31,558 --> 03:29:33,093 INCLUDE TWO TO THREE HACKATHON 5591 03:29:33,093 --> 03:29:35,662 TYPE MEETINGS A YEAR WITH 5592 03:29:35,662 --> 03:29:36,530 IN-PERSON COMPONENT WHEN 5593 03:29:36,530 --> 03:29:36,964 POSSIBLE. 5594 03:29:36,964 --> 03:29:39,132 NEXT PHASE WILL BE A FREE AND 5595 03:29:39,132 --> 03:29:40,033 OPEN COMPETITION, WE HAVE SOME 5596 03:29:40,033 --> 03:29:42,202 IDEAS ON HOW TO CHANGE STRUCTURE 5597 03:29:42,202 --> 03:29:44,838 OF THE PROGRAM TO FOCUS EVEN 5598 03:29:44,838 --> 03:29:47,474 MORE INTENSELY ON HIGH QUALITY 5599 03:29:47,474 --> 03:29:50,110 SOFTWARE DEVELOPMENT AND 5600 03:29:50,110 --> 03:29:50,978 IMPROVING RESULTS WE'RE 5601 03:29:50,978 --> 03:29:53,413 RETURNING WHILE REDUCING OVERALL 5602 03:29:53,413 --> 03:29:56,783 COSTS OF THE PROGRAM YEAR TO 5603 03:29:56,783 --> 03:29:59,419 YEAR, CONTINUATION OF USER 5604 03:29:59,419 --> 03:30:00,621 INTERFACE CONTRACT. 5605 03:30:00,621 --> 03:30:04,124 WE HAVE SEVERAL NEW QUERIES IN 5606 03:30:04,124 --> 03:30:04,825 MIND. 5607 03:30:04,825 --> 03:30:06,526 WITH BROADER SCOPE THAN ANY 5608 03:30:06,526 --> 03:30:07,628 CURRENT QUERIES CAN COVER. 5609 03:30:07,628 --> 03:30:10,597 WE WOULD LIKE TO ALLOW USERS TO 5610 03:30:10,597 --> 03:30:13,300 DISCOVER CONNECTIONS BETWEEN TWO 5611 03:30:13,300 --> 03:30:15,469 CONCEPTS OR CONCEPTS AND ALSO TO 5612 03:30:15,469 --> 03:30:16,603 DEFINE CONCEPT AND RELATIONSHIP 5613 03:30:16,603 --> 03:30:19,339 TYPE AND FIND ANY OTHER CONCEPTS 5614 03:30:19,339 --> 03:30:21,174 THAT FIT THAT RELATIONSHIP. 5615 03:30:21,174 --> 03:30:22,709 QUERIES ARE POSSIBLE ON THE BACK 5616 03:30:22,709 --> 03:30:24,344 END OF TRANSLATOR BUT IT'S GOING 5617 03:30:24,344 --> 03:30:25,979 TO TAKE SERIOUS USER STUDIES TO 5618 03:30:25,979 --> 03:30:27,848 DETERMINE HOW BEST TO CREATE 5619 03:30:27,848 --> 03:30:30,150 INTERFACE TO ALLOW USERS TO ASK 5620 03:30:30,150 --> 03:30:32,786 VERY OPEN-ENDED QUERIES LIKE 5621 03:30:32,786 --> 03:30:35,389 THIS. 5622 03:30:35,389 --> 03:30:36,923 WE'RE INTERESTED IN EXPLORING 5623 03:30:36,923 --> 03:30:37,524 COMBINATION THERAPIES AND IT 5624 03:30:37,524 --> 03:30:39,760 COULD BE USEFUL IN THAT REGARD. 5625 03:30:39,760 --> 03:30:41,294 WE EXPECT THIS WOULD REQUIRE 5626 03:30:41,294 --> 03:30:42,496 EFFORT TO SUCCEED SO CONSIDERED 5627 03:30:42,496 --> 03:30:44,364 THIS PART A STRETCH GOAL FOR 5628 03:30:44,364 --> 03:30:46,133 THIS PROPOSED FUNDING PERIOD. 5629 03:30:46,133 --> 03:30:47,567 WE DO HAVE SOME WORK RELATED TO 5630 03:30:47,567 --> 03:30:49,069 THIS BEING DONE BY SOME 5631 03:30:49,069 --> 03:30:50,737 TRANSLATOR P.I.s, SO IT'S 5632 03:30:50,737 --> 03:30:53,140 WITHIN THE REALM OF THEIR 5633 03:30:53,140 --> 03:30:53,473 RESEARCH. 5634 03:30:53,473 --> 03:30:55,442 WE HAVE SEVERAL IDEAS FOR NEW 5635 03:30:55,442 --> 03:30:57,077 FUNCTIONALITY FOR TRANSLATOR AS 5636 03:30:57,077 --> 03:30:57,411 WELL. 5637 03:30:57,411 --> 03:31:02,382 WE'VE IMPLEMENTED CREATION 5638 03:31:02,382 --> 03:31:03,784 ACCOUNTS, MAKING SURE WE KNOW 5639 03:31:03,784 --> 03:31:04,651 WHO IS ACCESSING. 5640 03:31:04,651 --> 03:31:06,286 WOULD LIKE TO EXPAND 5641 03:31:06,286 --> 03:31:07,587 FUNCTIONALITY TO ALLOW FOR 5642 03:31:07,587 --> 03:31:09,456 SEARCH HISTORY AS WELL AS UPLOAD 5643 03:31:09,456 --> 03:31:10,557 YOUR OWN DATA TO INTEGRATE WITH 5644 03:31:10,557 --> 03:31:13,293 ALL THE OTHER KNOWLEDGE THAT 5645 03:31:13,293 --> 03:31:15,295 TRANSLATOR HAS ACCESS TO 5646 03:31:15,295 --> 03:31:17,030 POTENTIALLY WITHOUT SHARING DATA 5647 03:31:17,030 --> 03:31:19,666 MORE BROADLY, COULD LEAD TO 5648 03:31:19,666 --> 03:31:21,635 HAVING A USER WORKSPACE TO DO 5649 03:31:21,635 --> 03:31:23,603 MORE USEFUL ANALYSIS AND 5650 03:31:23,603 --> 03:31:24,905 EXPANSION OF RESULTS FROM 5651 03:31:24,905 --> 03:31:25,439 INITIAL QUERY. 5652 03:31:25,439 --> 03:31:27,874 WE THINK THIS IS SOMETHING THAT 5653 03:31:27,874 --> 03:31:28,842 DRUG COMPANIES MIGHT FIND 5654 03:31:28,842 --> 03:31:32,112 VALUABLE WHICH COULD LEAD TO 5655 03:31:32,112 --> 03:31:33,447 EXCITING PARTNERSHIP 5656 03:31:33,447 --> 03:31:34,648 OPPORTUNITIES. 5657 03:31:34,648 --> 03:31:37,284 IN ADDITION WE'VE BEEN EXPLORING 5658 03:31:37,284 --> 03:31:38,785 HOW TO INCLUDE FIGURES RELEVANT 5659 03:31:38,785 --> 03:31:42,522 AS PART OF THE EVIDENCE 5660 03:31:42,522 --> 03:31:43,190 DISPLAYED. 5661 03:31:43,190 --> 03:31:44,624 ONE TEAM MADE PROGRESS. 5662 03:31:44,624 --> 03:31:46,460 THERE'S EVEN POSSIBILITY WE 5663 03:31:46,460 --> 03:31:47,694 COULD EVENTUALLY EXTRACT 5664 03:31:47,694 --> 03:31:49,963 KNOWLEDGE GRAPHS FROM THE 5665 03:31:49,963 --> 03:31:51,298 MANUSCRIPT FIGURES TO CREATE NEW 5666 03:31:51,298 --> 03:31:54,367 CONNECTIONS HARDER TO FIND 5667 03:31:54,367 --> 03:31:55,569 THROUGH TEXT MINING. 5668 03:31:55,569 --> 03:31:57,971 WE PLAN TO FOCUS STRONGLY ON 5669 03:31:57,971 --> 03:31:59,473 ENTERPRISE LEVEL SOFTWARE 5670 03:31:59,473 --> 03:32:00,073 DEVELOPMENT DURING THIS PHASE 5671 03:32:00,073 --> 03:32:01,675 AND BY THAT I MEAN WE EXPECT OUR 5672 03:32:01,675 --> 03:32:05,312 WORK TO BE UP TO THE STANDARDS 5673 03:32:05,312 --> 03:32:06,413 OF MEDIUM-SIZE COMPANY RELYING 5674 03:32:06,413 --> 03:32:08,148 ON SOFTWARE TO SUPPORT MANY 5675 03:32:08,148 --> 03:32:12,986 CONCURRENT USERS AND STABLE TO 5676 03:32:12,986 --> 03:32:15,155 SUSTAIN BOTTOM LINE, WE'LL 5677 03:32:15,155 --> 03:32:16,156 IMPROVE DOCUMENTATION ABOUT HOW 5678 03:32:16,156 --> 03:32:19,192 SYSTEM OPERATES AND CAN BE 5679 03:32:19,192 --> 03:32:21,061 UTILIZED BY USERS, IMPROVE 5680 03:32:21,061 --> 03:32:24,131 SCALABILITY TO ALLOW FOR 5681 03:32:24,131 --> 03:32:24,998 CONCURRENT USERS, IMPROVE 5682 03:32:24,998 --> 03:32:27,534 SECURITY AT ALL LEVELS, AND 5683 03:32:27,534 --> 03:32:28,735 UTILIZE INDEPENDENT VERIFICATION 5684 03:32:28,735 --> 03:32:30,370 AND VALIDATION SYSTEM TO MAKE 5685 03:32:30,370 --> 03:32:32,105 SURE ALL ASPECTS OF TRANSLATOR 5686 03:32:32,105 --> 03:32:34,741 ARE OPERATING AT OR ABOVE OUR 5687 03:32:34,741 --> 03:32:35,041 STANDARDS. 5688 03:32:35,041 --> 03:32:36,943 WE'VE BEGUN THE PROCESS OF THIS 5689 03:32:36,943 --> 03:32:40,547 VERIFICATION AND VALIDATION 5690 03:32:40,547 --> 03:32:44,818 THROUGH USE OF EXISTING CONTRACT 5691 03:32:44,818 --> 03:32:48,989 BETWEEN NCATS AND MITRE, FINDING 5692 03:32:48,989 --> 03:32:51,258 ISSUES AND SUGGESTING WAYS TO 5693 03:32:51,258 --> 03:32:53,760 FIX THOSE PROBLEMS. 5694 03:32:53,760 --> 03:32:55,962 ANOTHER MAJOR COMPONENT WILL BE 5695 03:32:55,962 --> 03:32:56,930 BUILDING USER TRUST IN THE 5696 03:32:56,930 --> 03:32:59,766 QUALITY OF THE RESULTS THEY SEE 5697 03:32:59,766 --> 03:33:02,435 AND COVERING QUERIES MOST 5698 03:33:02,435 --> 03:33:04,070 VALUABLE TO THEM. 5699 03:33:04,070 --> 03:33:05,806 WE WANT USERS TO KNOW WHERE THE 5700 03:33:05,806 --> 03:33:06,940 INFORMATION COMES FROM AND HOW 5701 03:33:06,940 --> 03:33:09,342 MUCH IS BASED ON ESTABLISHED 5702 03:33:09,342 --> 03:33:11,845 FACT VERSUS EXPERIMENTAL RESULTS 5703 03:33:11,845 --> 03:33:13,046 VERSUS MACHINE PREDICTIONS. 5704 03:33:13,046 --> 03:33:15,115 FINALLY MAKE IT EASIER TO BUILD 5705 03:33:15,115 --> 03:33:17,751 PARTNERSHIP WAS OTHER 5706 03:33:17,751 --> 03:33:18,819 ORGANIZATIONS WHO CAN UTILIZE 5707 03:33:18,819 --> 03:33:20,120 TRANSLATOR AND CONTRIBUTE MORE 5708 03:33:20,120 --> 03:33:22,622 KNOWLEDGE TO THE SYSTEM WHICH 5709 03:33:22,622 --> 03:33:23,857 WILL REQUIRE OUR DEVELOPER USERS 5710 03:33:23,857 --> 03:33:27,027 TO BE SUPPORTED THROUGH USE OF 5711 03:33:27,027 --> 03:33:29,095 APIs AND BACK END SOFTWARE 5712 03:33:29,095 --> 03:33:33,366 TOOLS IN ADDITION TO IMPROVED 5713 03:33:33,366 --> 03:33:33,700 DOCUMENTATION. 5714 03:33:33,700 --> 03:33:35,902 IN AN EFFORT TO GAIN USERS WE'VE 5715 03:33:35,902 --> 03:33:38,205 MADE SOME DIRECT LINKS FROM THE 5716 03:33:38,205 --> 03:33:39,406 GUARD WEBSITE TO TRANSLATOR AND 5717 03:33:39,406 --> 03:33:40,941 EXPECT TO EXPAND THIS 5718 03:33:40,941 --> 03:33:42,075 INTEGRATION AND FIND OTHER 5719 03:33:42,075 --> 03:33:43,877 SIMILAR PARTNERSHIPS WHERE WE 5720 03:33:43,877 --> 03:33:45,545 CAN DIRECT USERS FROM OTHER 5721 03:33:45,545 --> 03:33:47,814 KNOWLEDGE HUBS TO TRANSLATOR. 5722 03:33:47,814 --> 03:33:49,482 CHRISTINE MENTIONED THE LITCOIN 5723 03:33:49,482 --> 03:33:51,218 PROGRAM AND AS IT IS BEING BUILT 5724 03:33:51,218 --> 03:33:53,620 RIGHT NOW WE WILL BE ABLE TO 5725 03:33:53,620 --> 03:33:54,821 INTEGRATE KNOWLEDGE GRAPHS 5726 03:33:54,821 --> 03:33:56,690 GENERATED FROM THAT PROGRAM 5727 03:33:56,690 --> 03:33:58,358 SEAMLESSLY INTO TRANSLATOR AS 5728 03:33:58,358 --> 03:33:58,792 WELL. 5729 03:33:58,792 --> 03:34:00,527 WE EXPECT TO SEE SIGNIFICANT 5730 03:34:00,527 --> 03:34:02,395 USER GROWTH WITH THE GOAL OF 5731 03:34:02,395 --> 03:34:04,197 ABOUT 2,000 MONTHLY ACTIVE 5732 03:34:04,197 --> 03:34:05,699 USERS, SIMILAR TO THE CURRENT 5733 03:34:05,699 --> 03:34:07,968 UTILIZATION OF THE MONARCH 5734 03:34:07,968 --> 03:34:08,435 INITIATIVES. 5735 03:34:08,435 --> 03:34:10,503 AS FAR AS IMPACT WE BELIEVE IN 5736 03:34:10,503 --> 03:34:12,372 ORDER TO SUPPORT TRANSLATIONAL 5737 03:34:12,372 --> 03:34:13,807 SCIENCE WE NEED TO UNDERSTAND 5738 03:34:13,807 --> 03:34:16,643 BIOLOGY AT ALL LEVELS, IF 5739 03:34:16,643 --> 03:34:18,612 MOLECULAR TO POPULATION LEVEL. 5740 03:34:18,612 --> 03:34:19,613 TRANSLATOR ALLOWS FOR THAT 5741 03:34:19,613 --> 03:34:21,248 UNDERSTANDING IN ITS USERS. 5742 03:34:21,248 --> 03:34:22,349 WE BELIEVE TRANSLATOR HAS 5743 03:34:22,349 --> 03:34:23,984 POTENTIAL TO BE FUNDAMENTALLY 5744 03:34:23,984 --> 03:34:25,085 VALUABLE TO RESEARCHERS, SO MUCH 5745 03:34:25,085 --> 03:34:28,154 SO WE WOULD LIKE TO SET 5746 03:34:28,154 --> 03:34:30,323 AUDACIOUS GOAL OF OUR OWN TO 5747 03:34:30,323 --> 03:34:32,626 HAVE TRANSLATOR USED BY RESERVES 5748 03:34:32,626 --> 03:34:36,029 AS OFTEN AS PubMed CURRENTLY 5749 03:34:36,029 --> 03:34:36,463 IS. 5750 03:34:36,463 --> 03:34:38,298 I MENTIONED WE HAVE SOME IDEAS 5751 03:34:38,298 --> 03:34:39,633 FOR CHANGING STRUCTURE OF THE 5752 03:34:39,633 --> 03:34:41,701 PROGRAM TO TIGHTEN ITS FOCUS AND 5753 03:34:41,701 --> 03:34:44,137 REDUCE YEARLY COST OF THE 5754 03:34:44,137 --> 03:34:44,371 PROGRAM. 5755 03:34:44,371 --> 03:34:46,206 WE'VE UTILIZED OTHER 5756 03:34:46,206 --> 03:34:47,207 TRANSACTIONS AUTHORITY FOR 5757 03:34:47,207 --> 03:34:49,142 FUNDING RESEARCH PROJECTS AND 5758 03:34:49,142 --> 03:34:50,810 CONTRACT SYSTEM FOR BUILDING 5759 03:34:50,810 --> 03:34:51,578 TRANSLATOR USER INTERFACE, 5760 03:34:51,578 --> 03:34:53,313 PROPOSING TO CONTINUE WITH THIS 5761 03:34:53,313 --> 03:34:55,415 OVERALL FUNDING PARADIGM BECAUSE 5762 03:34:55,415 --> 03:34:56,950 OF UNIQUENESS OF TRANSLATOR 5763 03:34:56,950 --> 03:34:59,452 WITHIN NCATS PORTFOLIO IN SCOPE 5764 03:34:59,452 --> 03:35:00,186 AND REQUIREMENTS. 5765 03:35:00,186 --> 03:35:02,956 WE PLAN TO CONTINUE USING OTHER 5766 03:35:02,956 --> 03:35:03,623 TRANSACTIONS AUTHORITY FOR 5767 03:35:03,623 --> 03:35:05,292 RESEARCH TEAMS PART OF 5768 03:35:05,292 --> 03:35:06,293 TRANSLATOR. 5769 03:35:06,293 --> 03:35:07,661 THIS IS ESSENTIAL FOR THE 5770 03:35:07,661 --> 03:35:09,095 FLEXIBILITY OF THE PROGRAM AS 5771 03:35:09,095 --> 03:35:10,030 FIELDS OF MACHINE LEARNING 5772 03:35:10,030 --> 03:35:11,498 KNOWLEDGE GRAPHS AN LARGE 5773 03:35:11,498 --> 03:35:12,365 LANGUAGE MODELS ARE CONSTANTLY 5774 03:35:12,365 --> 03:35:14,801 IN A STATE OF FLUX AND CAN CAUSE 5775 03:35:14,801 --> 03:35:15,502 UNEXPECTED SHIFTS IN PRIORITIES 5776 03:35:15,502 --> 03:35:18,138 THAT NEED TO BE HANDLED AT 5777 03:35:18,138 --> 03:35:19,172 PROGRAMMATIC LEVEL. 5778 03:35:19,172 --> 03:35:21,441 IN THE PAST YEAR WE ENDED ONE OF 5779 03:35:21,441 --> 03:35:22,542 THE TRANSLATOR RESEARCH AWARDS 5780 03:35:22,542 --> 03:35:24,077 BECAUSE FOCUS OF THE PROJECT NO 5781 03:35:24,077 --> 03:35:25,812 LONGER ALIGNED WITH NEEDS OF THE 5782 03:35:25,812 --> 03:35:26,579 OVERALL PROGRAM. 5783 03:35:26,579 --> 03:35:28,448 THANKS TO THE OTHER TRANSACTIONS 5784 03:35:28,448 --> 03:35:29,649 AUTHORITY FLEXIBILITY WE WERE 5785 03:35:29,649 --> 03:35:32,052 ABLE TO REDIRECT FUNDS TO OTHER 5786 03:35:32,052 --> 03:35:34,454 RESEARCH TEAMS TO ADD MILESTONES 5787 03:35:34,454 --> 03:35:36,656 TO THEIR WORK. 5788 03:35:36,656 --> 03:35:38,124 WE HAVE SEEN HAVING 14 SEPARATE 5789 03:35:38,124 --> 03:35:41,361 TEAMS CAN LEAD TO SOME 5790 03:35:41,361 --> 03:35:42,896 DIFFICULTIES SO WE PLAN TO 5791 03:35:42,896 --> 03:35:45,398 REDUCE OVERALL NUMBER OF AWARDS 5792 03:35:45,398 --> 03:35:47,467 TO FOCUS TIGHTLY ON PERFORMANCE 5793 03:35:47,467 --> 03:35:48,468 AND RESULT QUALITY IMPROVEMENTS. 5794 03:35:48,468 --> 03:35:50,003 WE EXPECT THESE WILL BE LARGER 5795 03:35:50,003 --> 03:35:52,172 THAN ANY ONE OF OUR CURRENT 5796 03:35:52,172 --> 03:35:53,373 AWARDS BUT OVERALL BUDGET WILL 5797 03:35:53,373 --> 03:35:56,443 BE REDUCED BY SEVERAL MILLION 5798 03:35:56,443 --> 03:35:57,577 DOLLARS YEARLY. 5799 03:35:57,577 --> 03:36:00,080 FOR USER INTERFACE WE'VE BEEN 5800 03:36:00,080 --> 03:36:01,147 UTILIZING CONTRACT MECHANISM 5801 03:36:01,147 --> 03:36:02,382 WITH CONTRACTOR WORKING CLOSELY 5802 03:36:02,382 --> 03:36:04,751 WITH RESEARCH TEAMS TO DEVELOP 5803 03:36:04,751 --> 03:36:07,854 INTERFACE THAT SUPPORTS NEEDS OF 5804 03:36:07,854 --> 03:36:08,822 BOTH USERS AND DEVELOPERS. 5805 03:36:08,822 --> 03:36:11,691 THIS IS ALLOWING US TO SET MILE 5806 03:36:11,691 --> 03:36:16,763 PHONE IS REQUIRE -- MILESTONE 5807 03:36:16,763 --> 03:36:18,365 REQUIREMENTS TIED TO PAYMENT. 5808 03:36:18,365 --> 03:36:21,968 WE WOULD LIKE TO EXTEND FOR 5809 03:36:21,968 --> 03:36:25,038 TWO-YEAR CONTRACT AS PART OF 5810 03:36:25,038 --> 03:36:26,806 THIS CONCEPT. 5811 03:36:26,806 --> 03:36:28,008 BECAUSE THIS CONCEPT INCLUDES 5812 03:36:28,008 --> 03:36:30,176 CONTRACT PORTION THERE ARE A FEW 5813 03:36:30,176 --> 03:36:31,611 TOPICS WE'RE REQUIRED TO 5814 03:36:31,611 --> 03:36:32,278 CONSIDER. 5815 03:36:32,278 --> 03:36:33,346 SIGNIFICANCE OF THE PROJECT 5816 03:36:33,346 --> 03:36:34,781 CAN'T BE OVERSTATED AS WE BUILD 5817 03:36:34,781 --> 03:36:36,182 A TOOL THAT GIVES RESEARCHERS A 5818 03:36:36,182 --> 03:36:38,284 PLACE TO CONNECT ALL THE 5819 03:36:38,284 --> 03:36:40,687 DISPARATE DATA IN THEIR FIELD 5820 03:36:40,687 --> 03:36:41,988 SURROUNDING THEIR WORK AND 5821 03:36:41,988 --> 03:36:43,123 SUPPORTED DRUG DISCOVERY EFFORTS 5822 03:36:43,123 --> 03:36:45,825 IS NCATS PRIORITY. 5823 03:36:45,825 --> 03:36:47,327 USER INTERFACE IS EXTANT AND 5824 03:36:47,327 --> 03:36:48,028 SUPPORTS QUERIES, AVAILABILITY 5825 03:36:48,028 --> 03:36:50,830 OF TECHNOLOGY IS NOT AN ISSUE. 5826 03:36:50,830 --> 03:36:52,799 I DEMONSTRATED SEVERAL USE CASES 5827 03:36:52,799 --> 03:36:54,801 DURING MY UPDATE THAT SHOWED 5828 03:36:54,801 --> 03:36:56,302 CAPABILITIES OF INTERFACE AND WE 5829 03:36:56,302 --> 03:36:57,203 EXPECT SIGNIFICANT IMPROVEMENTS 5830 03:36:57,203 --> 03:36:59,072 TO BE DONE TO THE INTERFACE 5831 03:36:59,072 --> 03:37:02,442 DURING THIS PROPOSED FUNDING 5832 03:37:02,442 --> 03:37:02,876 PERIOD. 5833 03:37:02,876 --> 03:37:05,211 NOW WE WOULD LOVE TO OPEN THE 5834 03:37:05,211 --> 03:37:09,983 CONCEPT TO DISCUSS BY COUNCIL 5835 03:37:09,983 --> 03:37:10,216 MEMBERS. 5836 03:37:10,216 --> 03:37:14,154 IN SUMMARY WE'RE ASKING NCATS 5837 03:37:14,154 --> 03:37:18,091 FUND FOR FIVE YEARS TO IMPROVE 5838 03:37:18,091 --> 03:37:18,758 UPON CAPABILITIES THROUGH 5839 03:37:18,758 --> 03:37:20,927 SOFTWARE DEVELOPMENT AND DATA 5840 03:37:20,927 --> 03:37:21,327 SCIENCE RESEARCH. 5841 03:37:21,327 --> 03:37:23,096 RECENT RELEASE OF ALPHA VERSION 5842 03:37:23,096 --> 03:37:24,631 SHOWS POTENTIAL AND EXCITEMENT 5843 03:37:24,631 --> 03:37:27,934 FOR TRANSLATOR AND WE PLAN TO 5844 03:37:27,934 --> 03:37:30,537 IMPLEMENT MAJOR IMPROVEMENTS TO 5845 03:37:30,537 --> 03:37:31,671 FUNCTIONALITY AND QUALITY OF 5846 03:37:31,671 --> 03:37:33,239 RESULTS DURING THE PROPOSED 5847 03:37:33,239 --> 03:37:33,606 FUNDING PERIOD. 5848 03:37:33,606 --> 03:37:38,878 I'D LIKE TO OPEN THE CONCEPT FOR 5849 03:37:38,878 --> 03:37:44,250 DISCUSSION BY COUNCIL MEMBERS. 5850 03:37:44,250 --> 03:37:46,419 I MENTIONED TWO IDEAS THAT WILL 5851 03:37:46,419 --> 03:37:48,054 REQUIRE INVESTMENT ON THEIR OWN 5852 03:37:48,054 --> 03:37:50,623 BUT COULD BE VALUABLE TO 5853 03:37:50,623 --> 03:37:51,024 TRANSLATOR USERS. 5854 03:37:51,024 --> 03:37:53,860 FIRST WAS EXPLORING SPACE OF 5855 03:37:53,860 --> 03:37:55,829 DRUG COMBINATIONS, USERS TO GET 5856 03:37:55,829 --> 03:37:57,564 SUGGESTIONS FOR COMBINATION 5857 03:37:57,564 --> 03:37:58,565 THERAPIES FOR SPECIFIC DISEASES 5858 03:37:58,565 --> 03:38:00,967 THAT MIGHT BE WORTH ADDITIONAL 5859 03:38:00,967 --> 03:38:01,668 RESEARCH. 5860 03:38:01,668 --> 03:38:03,937 SECOND IS FOCUSED ON IMAGE 5861 03:38:03,937 --> 03:38:05,672 PROCESSING TO EXTRACT KNOWLEDGE 5862 03:38:05,672 --> 03:38:08,074 SUCH AS SIGNALING PATHWAYS AND 5863 03:38:08,074 --> 03:38:09,943 KNOWLEDGE GRAPH ADJACENT IMAGES. 5864 03:38:09,943 --> 03:38:13,780 OUR FIRST QUESTION IS ARE THESE 5865 03:38:13,780 --> 03:38:16,749 THE RIGHT STRETCH GOALS? 5866 03:38:16,749 --> 03:38:21,654 THE OTHER IS WHETHER THE 2,000 5867 03:38:21,654 --> 03:38:26,693 USER GOAL POST, BASED ON CURRENT 5868 03:38:26,693 --> 03:38:28,027 UTEIZATION OF MONARCH GRAPHS. 5869 03:38:28,027 --> 03:38:29,195 WITH THAT SAID THANK YOU VERY 5870 03:38:29,195 --> 03:38:30,597 MUCH FOR YOUR ATTENTION AND I 5871 03:38:30,597 --> 03:38:32,799 LOOK FORWARD TO THE DISCUSSION 5872 03:38:32,799 --> 03:38:33,533 ON THIS TOPIC. 5873 03:38:33,533 --> 03:38:34,801 >> THANK YOU, TYLER. 5874 03:38:34,801 --> 03:38:36,636 WE'LL JUST MOVE RIGHT INTO THE 5875 03:38:36,636 --> 03:38:39,072 DISCUSSION. 5876 03:38:39,072 --> 03:38:45,178 WE HAVE THREE DISCUSSANTS, PAL 5877 03:38:45,178 --> 03:38:48,915 HARRIS, MATTIAS, AND ANIKA. 5878 03:38:48,915 --> 03:38:49,249 DR. HARRIS? 5879 03:38:49,249 --> 03:38:51,784 >> GREAT PRESENTATION. 5880 03:38:51,784 --> 03:38:55,388 I LIKE THIS PROJECT AND WHAT 5881 03:38:55,388 --> 03:38:56,723 YOU'VE DONE. 5882 03:38:56,723 --> 03:38:58,057 COMMENTS AND A RESPONSE. 5883 03:38:58,057 --> 03:39:01,728 I THINK IT'S A VERY GOOD GOAL TO 5884 03:39:01,728 --> 03:39:03,930 PROFESSIONALIZE THE SOFTWARE AND 5885 03:39:03,930 --> 03:39:04,931 CASE HARDEN IT. 5886 03:39:04,931 --> 03:39:05,899 YOU SHOULD DO THAT. 5887 03:39:05,899 --> 03:39:07,200 BUT I WOULD THINK ABOUT DOING 5888 03:39:07,200 --> 03:39:09,502 THAT FIRST WITH THE UNDERLAYER 5889 03:39:09,502 --> 03:39:12,605 AND KEEP THE USER EXPERIENCE 5890 03:39:12,605 --> 03:39:14,274 PRETTY FLUID AS YOU GO BECAUSE 5891 03:39:14,274 --> 03:39:18,478 YOU'LL LEARN A LOT IN THOSE 5892 03:39:18,478 --> 03:39:19,345 FIRST USER SETS. 5893 03:39:19,345 --> 03:39:21,781 THE OTHER THING ON THE 2,000 5894 03:39:21,781 --> 03:39:23,650 MONTHLY USERS, THAT'S THE ONLY 5895 03:39:23,650 --> 03:39:28,655 PART THAT SEEMED UNDERBAKED TO 5896 03:39:28,655 --> 03:39:29,222 ME, UNDERDEVELOPED. 5897 03:39:29,222 --> 03:39:32,625 2,000 USER PER MONTH IS GOOD BUT 5898 03:39:32,625 --> 03:39:34,727 I THINK DIGGING DEEPER, HOW MANY 5899 03:39:34,727 --> 03:39:36,262 ARE RETURN USERS? 5900 03:39:36,262 --> 03:39:38,331 HOW MANY SUCCESSFUL COMPLETIONS? 5901 03:39:38,331 --> 03:39:40,200 AND WHAT IS A SUCCESSFUL 5902 03:39:40,200 --> 03:39:41,834 COMPLETION IN THIS SPACE? 5903 03:39:41,834 --> 03:39:44,437 SPENDING MORE TIME ON YOUR 5904 03:39:44,437 --> 03:39:46,306 EVALUATION CRITERIA AND MAYBE 5905 03:39:46,306 --> 03:39:47,507 DOING A QUICK LOGIC MODEL WOULD 5906 03:39:47,507 --> 03:39:49,475 HELP MAKE SURE YOU'VE GOT THE 5907 03:39:49,475 --> 03:39:52,545 RIGHT GOAL IN MIND BEFORE YOU 5908 03:39:52,545 --> 03:39:52,845 START. 5909 03:39:52,845 --> 03:39:53,846 >> GREAT POINT. 5910 03:39:53,846 --> 03:39:56,149 WE LITERALLY JUST LAST WEEK WERE 5911 03:39:56,149 --> 03:39:58,785 TALKING WITH USER INTERFACE TEAM 5912 03:39:58,785 --> 03:39:59,886 ABOUT IMPLEMENTING GOOGLE 5913 03:39:59,886 --> 03:40:01,955 ANALYTICS SO WE CAN GET MUCH 5914 03:40:01,955 --> 03:40:04,457 DEEPER INTO WHO THOSE USERS ARE, 5915 03:40:04,457 --> 03:40:05,725 WHAT THEY ARE CLICKING ON AND 5916 03:40:05,725 --> 03:40:11,464 SPENDING TIME ON, ON THE SITE. 5917 03:40:11,464 --> 03:40:13,333 WE'LL DIG IN MORE WHEN THAT'S 5918 03:40:13,333 --> 03:40:15,301 IMPLEMENTED ON THEIR END WHICH 5919 03:40:15,301 --> 03:40:20,506 SHOULD BE VERY SOON. 5920 03:40:20,506 --> 03:40:21,174 >> THANK YOU. 5921 03:40:21,174 --> 03:40:23,176 >> YES, REALLY IMPORTANT THAT 5922 03:40:23,176 --> 03:40:26,679 YOU KEEP YOUR USER INTERFACE 5923 03:40:26,679 --> 03:40:27,747 FLEXIBLE. 5924 03:40:27,747 --> 03:40:31,050 UNDERSTAND WITH USERS AND 5925 03:40:31,050 --> 03:40:32,986 ASSIGNMENTS YOU CURRENTLY HAVE 5926 03:40:32,986 --> 03:40:35,855 TWO, HELPFUL FOR YOU TO BUILD 5927 03:40:35,855 --> 03:40:38,024 BASICS FUNCTIONALITIES OUT BUT 5928 03:40:38,024 --> 03:40:38,491 POTENTIAL OBVIOUSLY 5929 03:40:38,491 --> 03:40:41,861 SIGNIFICANTLY BEYOND THOSE TWO 5930 03:40:41,861 --> 03:40:42,195 NARROW USERS. 5931 03:40:42,195 --> 03:40:44,397 KEEP YOUR BASE SOLID. 5932 03:40:44,397 --> 03:40:46,799 MAKE SURE YOU NICELY ARE 5933 03:40:46,799 --> 03:40:50,136 MATCHING INTO THE OTHER CONCEPTS 5934 03:40:50,136 --> 03:40:55,675 EXPLODING IN AND ALLOWING YOU TO 5935 03:40:55,675 --> 03:40:58,411 USE NEW DATA BUT HAVE GOOD 5936 03:40:58,411 --> 03:41:02,548 STRATEGY IN PLACE, WHO USERS ARE 5937 03:41:02,548 --> 03:41:05,184 AND HAVE USER CENTRIC DESIGN SO 5938 03:41:05,184 --> 03:41:09,889 YOU ARE LOOKING BACK TO THE WAY 5939 03:41:09,889 --> 03:41:13,293 YOU MAP YOUR KNOWLEDGE GAPS AND 5940 03:41:13,293 --> 03:41:15,261 THIS IS SIGNIFICANT EFFORT. 5941 03:41:15,261 --> 03:41:18,765 IT IS INDEED HAS POTENTIAL TO 5942 03:41:18,765 --> 03:41:21,067 CHANGE THE WAY WE CONCEIVE GENES 5943 03:41:21,067 --> 03:41:22,902 AND DISEASES AND HOW TO BRING 5944 03:41:22,902 --> 03:41:25,438 THEM TOGETHER BUT DON'T NARROW 5945 03:41:25,438 --> 03:41:29,475 TOO EARLY. 5946 03:41:29,475 --> 03:41:31,244 IT'S EASY FOR SOFTWARE TEAMS TO 5947 03:41:31,244 --> 03:41:37,350 DO THAT, ALLOWS THEM TO MORE 5948 03:41:37,350 --> 03:41:38,351 QUICKLY BUILD SOLUTIONS BUT 5949 03:41:38,351 --> 03:41:40,420 YOU'LL CLOSE DOORS WHICH YOU 5950 03:41:40,420 --> 03:41:41,187 CANNOT OPEN UP BEGIN. 5951 03:41:41,187 --> 03:41:43,122 IF YOU HAVE THAT OPPORTUNITY TO 5952 03:41:43,122 --> 03:41:46,459 REACH OUT AS A USER COMMUNITY 5953 03:41:46,459 --> 03:41:47,994 AND WHAT NCATS IS DOING AS A 5954 03:41:47,994 --> 03:41:50,396 WHOLE WILL HELP YOU TO IDENTIFY 5955 03:41:50,396 --> 03:41:58,738 WHAT YOUR USER COMMUNITIES ARE. 5956 03:41:58,738 --> 03:42:07,714 THERE ARE THE LOW OF -- A LOT OF 5957 03:42:07,714 --> 03:42:08,247 COMMERCIALS, MAYBE ACQUIRE 5958 03:42:08,247 --> 03:42:10,216 LICENSES TO SEE WHAT SOLUTIONS 5959 03:42:10,216 --> 03:42:11,084 ARE BUILT. 5960 03:42:11,084 --> 03:42:17,523 FINAL STATEMENT IS, THIS IS A 5961 03:42:17,523 --> 03:42:18,624 STRATEGY DISCUSSION, OPEN 5962 03:42:18,624 --> 03:42:20,293 SCIENCE OPEN COMMUNITY EFFORT 5963 03:42:20,293 --> 03:42:21,928 MIGHT BE A PLACE WHERE THIS 5964 03:42:21,928 --> 03:42:25,565 COULD PLAY OUT VERY NICELY WITH 5965 03:42:25,565 --> 03:42:27,834 APIs YOU ALREADY ARE HEADED 5966 03:42:27,834 --> 03:42:31,471 THAT WAY BUT IF YOU ESTABLISH A 5967 03:42:31,471 --> 03:42:34,407 FRAMEWORK WHERE THEN OPEN SOURCE 5968 03:42:34,407 --> 03:42:35,942 COMMUNITIES CAN HOOK TOOLS IN 5969 03:42:35,942 --> 03:42:38,077 AND USE YOUR KNOWLEDGE GRAPH FOR 5970 03:42:38,077 --> 03:42:40,113 THEIR SPECIFIC SOLUTIONS THEY 5971 03:42:40,113 --> 03:42:46,119 ARE BUILDING OUT FOR THEIR USER 5972 03:42:46,119 --> 03:42:46,786 COMMUNITIES, SHOULD NOT REPLACE, 5973 03:42:46,786 --> 03:42:51,691 BUT THEY WILL BE NOT BE ROBUST, 5974 03:42:51,691 --> 03:42:55,528 THEY CAN BE A NICE ADD-ON ON 5975 03:42:55,528 --> 03:42:56,095 WHERE YOU STAND. 5976 03:42:56,095 --> 03:42:56,362 >> GREAT. 5977 03:42:56,362 --> 03:42:57,730 THANK YOU VERY MUCH. 5978 03:42:57,730 --> 03:43:02,001 I WILL POINT OUT THAT WE'VE HAD 5979 03:43:02,001 --> 03:43:03,770 OPEN SCIENCE AND OPEN ACCESS, 5980 03:43:03,770 --> 03:43:07,273 PART OF OUR PLAN FROM DAY 1, AND 5981 03:43:07,273 --> 03:43:09,809 WE REALLY TAKE THAT SERIOUSLY. 5982 03:43:09,809 --> 03:43:11,411 BUT AT THE SAME TIME WE'RE 5983 03:43:11,411 --> 03:43:14,147 ALWAYS LOOKING FOR WAYS WE CAN 5984 03:43:14,147 --> 03:43:15,581 PARTNER WITH GROUPS THAT MIGHT 5985 03:43:15,581 --> 03:43:17,550 HAVE ACCESS TO DATA THAT WE 5986 03:43:17,550 --> 03:43:19,085 DON'T HAVE ACCESS TO NOW THROUGH 5987 03:43:19,085 --> 03:43:20,286 THOSE OPEN SOURCES SO THERE'S 5988 03:43:20,286 --> 03:43:23,890 KIND OF A PUSH AND PULL THERE, 5989 03:43:23,890 --> 03:43:28,294 BUT TRUST ME, RESEARCHERS ARE 5990 03:43:28,294 --> 03:43:30,029 VERY STRONGLY, YOU KNOW, INTO 5991 03:43:30,029 --> 03:43:32,999 THE OPEN SCIENCE ASPECT OF THIS, 5992 03:43:32,999 --> 03:43:34,767 AND I DON'T THINK WE WILL HAVE 5993 03:43:34,767 --> 03:43:36,302 ANY TROUBLE MAKING THAT A 5994 03:43:36,302 --> 03:43:39,038 PRIORITY MOVING FORWARD EVEN AS 5995 03:43:39,038 --> 03:43:42,308 WE'RE GOING DEEPER INTO THE SORT 5996 03:43:42,308 --> 03:43:44,710 OF ENTERPRISE LEVEL SOFTWARE 5997 03:43:44,710 --> 03:43:44,911 FOCUS. 5998 03:43:44,911 --> 03:43:47,213 >> BUT I THINK EXACTLY THIS IS 5999 03:43:47,213 --> 03:43:49,749 LAST SENTENCE IS CRITICAL. 6000 03:43:49,749 --> 03:43:53,586 YOU BUILD ENTERPRISE SOFTWARE 6001 03:43:53,586 --> 03:43:54,454 TOOLS OUT AS RESILIENCE WHO WILL 6002 03:43:54,454 --> 03:43:56,756 BE ABLE TO STAND UP AND THEN 6003 03:43:56,756 --> 03:43:58,624 HAVE APIs COME IN WHO MIGHT OR 6004 03:43:58,624 --> 03:44:05,565 MIGHT NOT HAVE THAT LEVEL OF 6005 03:44:05,565 --> 03:44:06,065 SOLUTION. 6006 03:44:06,065 --> 03:44:08,468 >> I THINK PART OF THIS 6007 03:44:08,468 --> 03:44:11,771 DISCUSSION GETS TO THE 6008 03:44:11,771 --> 03:44:13,739 SUSTAINABILITY PIECE AS WELL, 6009 03:44:13,739 --> 03:44:14,941 KEEPING IT SOMEWHAT FLEXIBLE, 6010 03:44:14,941 --> 03:44:18,211 DIGGING MORE INTO WHO USERS ARE, 6011 03:44:18,211 --> 03:44:20,146 PERHAPS INCREASING THAT LEVEL 6012 03:44:20,146 --> 03:44:24,217 BECAUSE YOU NEED A LOT OF 6013 03:44:24,217 --> 03:44:27,520 DIFFERENT GROUPS, YOU KNOW, 6014 03:44:27,520 --> 03:44:28,187 PHYSICIANS, TRANSLATIONAL 6015 03:44:28,187 --> 03:44:30,590 SCIENTISTS, EVEN EDUCATION WHERE 6016 03:44:30,590 --> 03:44:33,826 THIS COULD BENEFIT, AND OF 6017 03:44:33,826 --> 03:44:35,061 COURSE PHARMA. 6018 03:44:35,061 --> 03:44:39,665 I THINK BEING ABLE TO UTILIZE 6019 03:44:39,665 --> 03:44:40,900 THIS IS POWERFUL. 6020 03:44:40,900 --> 03:44:42,235 SO BY HAVING BETTER 6021 03:44:42,235 --> 03:44:43,970 UNDERSTANDING OF USERS I THINK 6022 03:44:43,970 --> 03:44:50,343 COULD THEN HELP UNDERSTAND WHERE 6023 03:44:50,343 --> 03:44:55,915 THIS PRIMARILY MIGHT LAND. 6024 03:44:55,915 --> 03:45:02,121 AND THEN THE OTHER PIECE IS 6025 03:45:02,121 --> 03:45:03,222 COMMUNICATION, THE TOOL IS 6026 03:45:03,222 --> 03:45:05,091 POWERFUL, AND SO YOU HAVE SOME 6027 03:45:05,091 --> 03:45:09,028 REALLY GREAT IDEAS FOR HOW TO 6028 03:45:09,028 --> 03:45:10,429 DISSEMINATE HOW PEOPLE KNOW 6029 03:45:10,429 --> 03:45:12,064 ABOUT IT MORE, KEEPING THAT IN 6030 03:45:12,064 --> 03:45:16,235 MIND, AS WELL AS YOU SAY FROM 6031 03:45:16,235 --> 03:45:17,803 MOLECULAR LEVEL OR POPULATION 6032 03:45:17,803 --> 03:45:20,640 LEVEL PUTTING THE METRICS AROUND 6033 03:45:20,640 --> 03:45:26,979 THAT, YOU TALKED ABOUT THE 6034 03:45:26,979 --> 03:45:28,614 BENEFITS, REPURPOSING, CLINICAL 6035 03:45:28,614 --> 03:45:30,249 TRIALS, EMPHASIZED AS WELL. 6036 03:45:30,249 --> 03:45:31,584 >> THANK YOU. 6037 03:45:31,584 --> 03:45:34,086 WE ARE JUST STARTING TO GET THE 6038 03:45:34,086 --> 03:45:36,389 SYSTEM OUT THERE IN A MORE 6039 03:45:36,389 --> 03:45:36,722 PUBLIC WAY. 6040 03:45:36,722 --> 03:45:38,591 YOU KNOW, YOU SAW THE LINK. 6041 03:45:38,591 --> 03:45:42,194 WE'VE BEEN SHARING THAT MORE 6042 03:45:42,194 --> 03:45:42,428 BROADLY. 6043 03:45:42,428 --> 03:45:44,063 WE SHALL PROBABLY GOING TO REACH 6044 03:45:44,063 --> 03:45:45,064 OUT TO TRAINING PROGRAMS ACROSS 6045 03:45:45,064 --> 03:45:47,033 THE COUNTRY BECAUSE WE FEEL LIKE 6046 03:45:47,033 --> 03:45:50,202 PEOPLE LIKE, YOU KNOW, EARLY 6047 03:45:50,202 --> 03:45:51,003 CAREER INVESTIGATORS, POSTDOCS, 6048 03:45:51,003 --> 03:45:52,505 GRADUATE STUDENTS WILL BE EARLY 6049 03:45:52,505 --> 03:45:53,706 ADOPTERS OF THIS AND REALLY FIND 6050 03:45:53,706 --> 03:45:54,807 VALUE IN IT. 6051 03:45:54,807 --> 03:45:56,676 SO I THINK REACHING OUT TO 6052 03:45:56,676 --> 03:45:57,710 TRAINING PROGRAMS ACROSS THE 6053 03:45:57,710 --> 03:45:59,946 COUNTRY IS A GOOD NEXT STEP FOR 6054 03:45:59,946 --> 03:46:00,913 US FOR GETTING THE SYSTEM IN 6055 03:46:00,913 --> 03:46:02,882 FRONT OF THE PEOPLE THAT WOULD 6056 03:46:02,882 --> 03:46:06,419 ACTUALLY USE IT THE MOST. 6057 03:46:06,419 --> 03:46:08,421 >> ANY OTHER QUESTIONS OR 6058 03:46:08,421 --> 03:46:14,160 THOUGHTS FROM MEMBERS? 6059 03:46:14,160 --> 03:46:15,428 6060 03:46:15,428 --> 03:46:16,028 IF NOT -- 6061 03:46:16,028 --> 03:46:17,830 >> NO FURTHER DISCUSSION I HAVE 6062 03:46:17,830 --> 03:46:21,334 A MOTION TO APPROVE THE CONCEPT. 6063 03:46:21,334 --> 03:46:21,567 SECOND. 6064 03:46:21,567 --> 03:46:22,668 >> SECOND. 6065 03:46:22,668 --> 03:46:25,371 >> ALL IN FAVOR? 6066 03:46:25,371 --> 03:46:25,605 >> AYE. 6067 03:46:25,605 --> 03:46:27,573 >> ANY OPPOSED? 6068 03:46:27,573 --> 03:46:28,574 ANY ABSTENTIONS? 6069 03:46:28,574 --> 03:46:31,077 WITH THAT, CONCEPT IS APPROVED. 6070 03:46:31,077 --> 03:46:31,911 THANK YOU VERY MUCH. 6071 03:46:31,911 --> 03:46:38,184 >> THANK YOU ALL SO MUCH. 6072 03:46:38,184 --> 03:46:39,986 >> I REALIZE WE HAD NO QUESTIONS 6073 03:46:39,986 --> 03:46:41,287 FOR CHRISTINE BECAUSE WE MOVED 6074 03:46:41,287 --> 03:46:44,657 INTO THE CONCEPT SO IF YOU HAVE 6075 03:46:44,657 --> 03:46:45,291 QUESTIONS FOR CHRISTINE, STILL 6076 03:46:45,291 --> 03:46:46,292 OPEN FOR THAT. 6077 03:46:46,292 --> 03:46:53,232 BUT I THINK WE CAN MOVE ON TO 6078 03:46:53,232 --> 03:46:58,804 THE NEXT CONCEPT INTRODUCTION 6079 03:46:58,804 --> 03:47:02,508 WITH BALKI AND KARLIE AS WELL. 6080 03:47:02,508 --> 03:47:05,044 A JOINT ONE. 6081 03:47:05,044 --> 03:47:10,182 >> I'M GOING TO BE BETWEEN THE 6082 03:47:10,182 --> 03:47:14,320 PREVIOUS ENTREE AND NEXT ONE. 6083 03:47:14,320 --> 03:47:17,523 IT'S LATE IN THE DAY. 6084 03:47:17,523 --> 03:47:19,091 I WANT TO QUICKLY LAY FOR YOU 6085 03:47:19,091 --> 03:47:22,762 THE FACT THAT THIS IS A CONCEPT 6086 03:47:22,762 --> 03:47:26,032 THAT CAN BE FUNDED WITH SMALL 6087 03:47:26,032 --> 03:47:30,603 BUSINESS PROGRAMS, THE SMALL 6088 03:47:30,603 --> 03:47:32,738 BUSINESS PROGRAMS AT NCATS HAS 6089 03:47:32,738 --> 03:47:34,507 127 MILLION, LOTS OF BENEFITS, 6090 03:47:34,507 --> 03:47:36,809 WE SUPPORT A LOT OF PROGRAMS 6091 03:47:36,809 --> 03:47:41,180 WITHIN NCATS WHICH HAVE 6092 03:47:41,180 --> 03:47:43,449 TRANSLATIONAL CONFIDENCE SUCH AS 6093 03:47:43,449 --> 03:47:45,117 DIAGNOSTICS, DRUG DISCOVERY AND 6094 03:47:45,117 --> 03:47:48,087 DEVELOPMENT, AND THIS CONCEPT IS 6095 03:47:48,087 --> 03:47:50,956 GOING TO BE ADDRESSING HEALTH 6096 03:47:50,956 --> 03:47:52,458 INEQUITIES IN CLINICAL 6097 03:47:52,458 --> 03:47:52,758 DIAGNOSTICS. 6098 03:47:52,758 --> 03:47:54,593 KARLIE IS GOING TO PRESENT THIS. 6099 03:47:54,593 --> 03:48:05,137 I'M GOING TO STEP AWAY AND HAVE 6100 03:48:08,908 --> 03:48:09,275 HER TAKE OVER. 6101 03:48:09,275 --> 03:48:10,943 >> THANK, I'M A PROGRAM DIRECTOR 6102 03:48:10,943 --> 03:48:13,345 IN THE OFFICE OF DRUG 6103 03:48:13,345 --> 03:48:14,680 DEVELOPMENT PARTNERSHIP 6104 03:48:14,680 --> 03:48:15,748 PROGRAMS, WE'RE PARTNERING WITH 6105 03:48:15,748 --> 03:48:17,383 THE OFFICE OF STRATEGIC 6106 03:48:17,383 --> 03:48:19,251 ALLIANCES TO PRESENT THIS NEW 6107 03:48:19,251 --> 03:48:22,755 GRANT CONCEPT CLEARANCE TO YOU 6108 03:48:22,755 --> 03:48:26,826 TODAY AND IT'S ADDRESSING HEALTH 6109 03:48:26,826 --> 03:48:28,260 INEQUITIES IN CLINICAL 6110 03:48:28,260 --> 03:48:28,994 DIAGNOSTICS. 6111 03:48:28,994 --> 03:48:29,195 OKAY. 6112 03:48:29,195 --> 03:48:32,198 SO AS YOU'RE VERY FAMILIAR WITH 6113 03:48:32,198 --> 03:48:34,266 THIS, IN ADDITION TO THE VISIBLE 6114 03:48:34,266 --> 03:48:35,468 INDICATIONS WE LOOK AT IN 6115 03:48:35,468 --> 03:48:37,770 PATIENTS WE USE A WIDE VARIETY 6116 03:48:37,770 --> 03:48:38,871 OF LABORATORY ASSAYS AND POINT 6117 03:48:38,871 --> 03:48:40,239 OF CARE DEVICES WHEN WE DO 6118 03:48:40,239 --> 03:48:45,211 EVALUATION OF PATIENT IN THE 6119 03:48:45,211 --> 03:48:45,678 CLINIC. 6120 03:48:45,678 --> 03:48:47,947 HOWEVER, THESE ASSAYS UTILIZE 6121 03:48:47,947 --> 03:48:48,948 NON-BIOLOGICAL PARAMETERS AS A 6122 03:48:48,948 --> 03:48:52,151 PROXY FOR DIVERSITY AND GOOD 6123 03:48:52,151 --> 03:48:53,886 EXAMPLE IS SELF-REPORTED RACE 6124 03:48:53,886 --> 03:48:55,521 AND ETHNICITY WHICH DOES NOT 6125 03:48:55,521 --> 03:48:57,156 NECESSARILY CORRELATE WITH 6126 03:48:57,156 --> 03:48:58,691 DIVERSITY OF PATIENT POPULATION. 6127 03:48:58,691 --> 03:49:01,761 WE CAN SEE THAT IN THE 6128 03:49:01,761 --> 03:49:02,261 PERCENTAGE OF EUROPEAN 6129 03:49:02,261 --> 03:49:06,799 CONTRIBUTION TO SEVERAL AFRICAN 6130 03:49:06,799 --> 03:49:11,804 AMERICAN SAMPLES WHICH CAN VARY 6131 03:49:11,804 --> 03:49:14,006 FROM 3.5% IN SOUTH CAROLINA TO 6132 03:49:14,006 --> 03:49:16,442 35% IN SEATTLE. 6133 03:49:16,442 --> 03:49:17,743 WE SEE SIGNIFICANT DIFFERENCES 6134 03:49:17,743 --> 03:49:20,479 IN GENETIC ANCESTRY OF 6135 03:49:20,479 --> 03:49:21,947 INDIVIDUALS WHO SELF-REPORT AS 6136 03:49:21,947 --> 03:49:23,783 HISPANIC, MEXICAN AND PUERTO 6137 03:49:23,783 --> 03:49:24,617 RICAN INDIVIDUALS SELF-REPORT AS 6138 03:49:24,617 --> 03:49:27,486 HISPANIC BUT AS YOU CAN SEE IN 6139 03:49:27,486 --> 03:49:29,655 THIS FIGURE THAT DOESN'T 6140 03:49:29,655 --> 03:49:35,027 NECESSARILY CORRELATE WITH THEIR 6141 03:49:35,027 --> 03:49:36,662 GENETIC BACKGROUND. 6142 03:49:36,662 --> 03:49:38,464 WHAT THIS LEADS TO IS THESE 6143 03:49:38,464 --> 03:49:42,668 ACASE AND POINT OF CARE DEVICES 6144 03:49:42,668 --> 03:49:47,706 OFTEN FAIL MINORITY PATIENT 6145 03:49:47,706 --> 03:49:49,809 POPULATIONS, A FEW EXAMPLES, IF 6146 03:49:49,809 --> 03:49:52,111 YOU'RE NOT FAMILIAR WITH THE 6147 03:49:52,111 --> 03:49:55,281 DRUG THAT INCREASES PLATELET 6148 03:49:55,281 --> 03:49:56,916 COUNTS USED IN DISORDERS, BUT 6149 03:49:56,916 --> 03:49:58,784 EAST ASIAN PATIENTS RECEIVE HALF 6150 03:49:58,784 --> 03:50:02,388 THE DOSE COMPARED WITH NOT, DUE 6151 03:50:02,388 --> 03:50:04,557 TO LIMITED PHARMACOKINETIC 6152 03:50:04,557 --> 03:50:06,325 STUDIES THAT SUGGEST REDUCED 6153 03:50:06,325 --> 03:50:09,061 METABOLISM IN PATIENTS OF EAST 6154 03:50:09,061 --> 03:50:10,696 ASIAN DESCENT. 6155 03:50:10,696 --> 03:50:14,967 THE RESULT IS SOME PATIENTS 6156 03:50:14,967 --> 03:50:15,968 RECEIVE AN APPROPRIATE DOSING, 6157 03:50:15,968 --> 03:50:18,470 IN INSTRUMENTS USED TO MEASURE 6158 03:50:18,470 --> 03:50:21,907 LUNG FUNCTION, LOWER VALUES OF 6159 03:50:21,907 --> 03:50:22,942 FORMAL RANGE FOR AFRICAN 6160 03:50:22,942 --> 03:50:24,376 AMERICAN PATIENTS BUT ADJUSTMENT 6161 03:50:24,376 --> 03:50:27,880 DELAYS OR PREVENTS DIAGNOSES IN 6162 03:50:27,880 --> 03:50:29,081 SOME PATIENTS. 6163 03:50:29,081 --> 03:50:29,949 FRACTURE WRIST TOOLS PLACE 6164 03:50:29,949 --> 03:50:32,885 AFRICAN AMERICAN WOMEN AT LOWER 6165 03:50:32,885 --> 03:50:33,886 RISK OF OSTEOPOROSIS, AND SO 6166 03:50:33,886 --> 03:50:35,855 WHAT HAPPENS IN THIS CASE IS 6167 03:50:35,855 --> 03:50:41,126 THAT A NUMBER OF HIGH RISK 6168 03:50:41,126 --> 03:50:42,228 PATIENTS ARE MISSED, PREVENTIVE 6169 03:50:42,228 --> 03:50:44,096 DRUGS ARE NOT ADMINISTERED. 6170 03:50:44,096 --> 03:50:46,932 THERE ARE BETTER TOOLS NEEDED 6171 03:50:46,932 --> 03:50:49,235 FOR HISPANIC AND LATINO 6172 03:50:49,235 --> 03:50:49,535 POPULATIONS. 6173 03:50:49,535 --> 03:50:51,403 THERE'S RISK ASSESSMENT 6174 03:50:51,403 --> 03:50:52,404 ALGORITHM WITH A 6175 03:50:52,404 --> 03:50:55,241 WELL-ESTABLISHED ROLE IN GUIDING 6176 03:50:55,241 --> 03:50:56,242 CARDIOVASCULAR DISEASE 6177 03:50:56,242 --> 03:50:58,077 MANAGEMENT, HOWEVER THIS 6178 03:50:58,077 --> 03:50:59,845 PARTICULAR RISK ASSESSMENT TOOL 6179 03:50:59,845 --> 03:51:03,349 AS DESIGNED WAS DESIGNED ON A 6180 03:51:03,349 --> 03:51:04,884 PRIMARILY NON-HISPANIC WHITE AND 6181 03:51:04,884 --> 03:51:06,852 AFRICAN AMERICAN INDIVIDUAL 6182 03:51:06,852 --> 03:51:09,154 PATIENT POPULATION, AND EMERGING 6183 03:51:09,154 --> 03:51:10,589 DATA FROM STUDIES INCLUDING 6184 03:51:10,589 --> 03:51:11,790 LARGE NUMBERS OF HISPANIC 6185 03:51:11,790 --> 03:51:12,992 INDIVIDUALS HAS SUGGESTED THESE 6186 03:51:12,992 --> 03:51:17,029 TOOLS ARE NOT ACTUALLY THE BEST 6187 03:51:17,029 --> 03:51:18,097 FOR THAT PATIENT POPULATION. 6188 03:51:18,097 --> 03:51:22,034 THE FLIP SIDE OF THIS IS THAT 6189 03:51:22,034 --> 03:51:23,168 ACTUAL BIOLOGICAL ATTRIBUTES OF 6190 03:51:23,168 --> 03:51:24,103 DIVERSE POPULATIONS ARE 6191 03:51:24,103 --> 03:51:26,872 OVERLOOKED DURING THE ASSAY AND 6192 03:51:26,872 --> 03:51:28,741 DEVICE DEVELOPMENT PROCESS. 6193 03:51:28,741 --> 03:51:30,209 INADEQUATE ATTENTION TO BIOLOGIC 6194 03:51:30,209 --> 03:51:31,777 CAL DIVERSITY OF PATIENT 6195 03:51:31,777 --> 03:51:32,778 POPULATION DURING DEVELOPMENT 6196 03:51:32,778 --> 03:51:35,281 PHASE HAS LED TO RELEASE OF END 6197 03:51:35,281 --> 03:51:37,249 UTILIZATION OF ASSAYS AND 6198 03:51:37,249 --> 03:51:39,018 DEVICES THAT WORK BEST ONLY FOR 6199 03:51:39,018 --> 03:51:39,685 SELECT POPULATIONS. 6200 03:51:39,685 --> 03:51:45,891 WE SEE THIS IN RACIAL 6201 03:51:45,891 --> 03:51:47,226 DIFFERENCES AND DETECTION OF 6202 03:51:47,226 --> 03:51:47,559 FEVER. 6203 03:51:47,559 --> 03:51:50,162 AS YOU SAW, MANY MEDICAL 6204 03:51:50,162 --> 03:51:51,730 DECISION TOOLS DISADVANTAGE 6205 03:51:51,730 --> 03:51:52,998 AFRICAN AMERICAN PATIENTS. 6206 03:51:52,998 --> 03:51:54,767 IT'S A COMMON KNOWLEDGE THAT 6207 03:51:54,767 --> 03:51:56,402 MEDICAL PHOTOGRAPHY HAS FAILED 6208 03:51:56,402 --> 03:51:57,636 PATIENTS WITH DARKER SKIN. 6209 03:51:57,636 --> 03:52:07,813 AND ON THE RIGHT HERE WE HAVE AN 6210 03:52:07,813 --> 03:52:10,616 OPTOMETRY TOOL WHERE RESULTS CAN 6211 03:52:10,616 --> 03:52:12,351 VARY. 6212 03:52:12,351 --> 03:52:14,353 THE FDA EXAMINED EVIDENCE THAT 6213 03:52:14,353 --> 03:52:15,688 PULSE OXIMETERS MAY NOT WORK AS 6214 03:52:15,688 --> 03:52:18,223 WELL ON DARK SKIN. 6215 03:52:18,223 --> 03:52:20,292 IT'S KNOWN THAT THEY DON'T WORK 6216 03:52:20,292 --> 03:52:23,062 QUITE AS WELL WHEN SATURATION OF 6217 03:52:23,062 --> 03:52:26,231 OXYGEN IS LOWER THAN 90%, WHAT 6218 03:52:26,231 --> 03:52:30,602 THIS DOES IS EXEMPLIFY ISSUE FOR 6219 03:52:30,602 --> 03:52:37,142 INDIVIDUALS WHO HAVE DARKER 6220 03:52:37,142 --> 03:52:37,409 PIGMENTS. 6221 03:52:37,409 --> 03:52:39,545 TESTING AND DEVICES SUFFER, 6222 03:52:39,545 --> 03:52:40,746 CAUSING UNDERREPRESENTED GROUPS 6223 03:52:40,746 --> 03:52:45,451 TO RECEIVE INFERIOR MEDICAL CARE 6224 03:52:45,451 --> 03:52:46,986 AND CAN CAUSE MISDIAGNOSIS. 6225 03:52:46,986 --> 03:52:49,488 THESE ISSUES ARE ADDRESSABLE AND 6226 03:52:49,488 --> 03:52:51,156 THERE ARE EXAMPLES. 6227 03:52:51,156 --> 03:52:53,425 THERE ARE SEVERAL GFR ESTIMATES 6228 03:52:53,425 --> 03:52:55,561 THAT MADE SWITCHES TO RACE-FREE 6229 03:52:55,561 --> 03:52:55,828 VERSIONS. 6230 03:52:55,828 --> 03:52:57,296 THERE ARE PRACTICAL STRATEGIES 6231 03:52:57,296 --> 03:52:58,397 FOR IMPROVING CLINICAL 6232 03:52:58,397 --> 03:53:01,333 PHOTOGRAPHY OF DARKER SKIN. 6233 03:53:01,333 --> 03:53:11,710 WE'VE SEEN A UTI RISK 6234 03:53:13,112 --> 03:53:15,114 CALCULATOR, THE MAKER OF THAT 6235 03:53:15,114 --> 03:53:16,648 REMOVED THE RACE VARIABLE AND 6236 03:53:16,648 --> 03:53:19,051 REPLACED IT WITH TWO OTHER 6237 03:53:19,051 --> 03:53:20,586 VARIABLES, LENGTHS OF FEVER AND 6238 03:53:20,586 --> 03:53:24,289 PAST HISTORY OF UTI AND HAS NOW 6239 03:53:24,289 --> 03:53:25,090 RE-RELEASED THAT PARTICULAR 6240 03:53:25,090 --> 03:53:28,494 RESOURCE AND IT IS NOW IN A 6241 03:53:28,494 --> 03:53:29,895 RACE-FREE VERSION. 6242 03:53:29,895 --> 03:53:31,663 WE SEE SOME WORK OUT OF BROWN 6243 03:53:31,663 --> 03:53:33,999 UNIVERSITY ON A SINGLE WAIVE 6244 03:53:33,999 --> 03:53:42,941 LENGTH PULSE OXIMETHRY THAT 6245 03:53:42,941 --> 03:53:45,010 WORKS ON A LARGER VARIETY OF 6246 03:53:45,010 --> 03:53:47,746 PIGMENTS AND CAN AFFECT HOW WE 6247 03:53:47,746 --> 03:53:50,482 IMPLANT DEVICES AND DO INTERNAL 6248 03:53:50,482 --> 03:53:50,816 IMAGING. 6249 03:53:50,816 --> 03:53:52,551 SO WE SEE THAT THIS IS SOMETHING 6250 03:53:52,551 --> 03:53:56,488 THAT IS ADDRESSABLE BUT WE DON'T 6251 03:53:56,488 --> 03:53:59,024 HAVE A FOCUSED INITIATIVE THAT 6252 03:53:59,024 --> 03:54:03,195 ADDRESSES THESE OR PINPOINTS 6253 03:54:03,195 --> 03:54:06,231 WHEN THIS IS OCCURRING. 6254 03:54:06,231 --> 03:54:07,099 SO INEQUITABLE DEVICES, 6255 03:54:07,099 --> 03:54:11,136 LABORATORY ASSAYS, CAN LEAD TO 6256 03:54:11,136 --> 03:54:12,938 DELAYS IN CARE OR INACCURATE 6257 03:54:12,938 --> 03:54:13,205 DIAGNOSES. 6258 03:54:13,205 --> 03:54:16,175 WE WANT TO ADDRESS A GAP FOR ALL 6259 03:54:16,175 --> 03:54:16,975 PATIENTS BY PROMOTING 6260 03:54:16,975 --> 03:54:18,610 DEVELOPMENT OF IMPROVED ASSAYS 6261 03:54:18,610 --> 03:54:26,718 AND DEVICES OR DEVELOPMENT OF 6262 03:54:26,718 --> 03:54:30,656 ALTERNATIVE ASSAYS THAT ADDRESS 6263 03:54:30,656 --> 03:54:34,493 THIS, SO WE PROPOSE THIS TO 6264 03:54:34,493 --> 03:54:37,863 ADDRESS HEALTH INEQUITIES AND 6265 03:54:37,863 --> 03:54:38,163 DISPARITIES. 6266 03:54:38,163 --> 03:54:39,531 AND INVESTIGATORS THAT COME IN 6267 03:54:39,531 --> 03:54:40,833 UNDER THIS PARTICULAR INITIATIVE 6268 03:54:40,833 --> 03:54:43,802 WOULD BE EXPECTED TO DEVELOP 6269 03:54:43,802 --> 03:54:48,607 DIAGNOSTICS THAT MEET OR EXCEED 6270 03:54:48,607 --> 03:54:51,443 QUALITY AND ENCOURAGE ASPECTS OF 6271 03:54:51,443 --> 03:54:55,280 SOCIAL DETERMINANTS OF HEALTH. 6272 03:54:55,280 --> 03:54:58,016 THIS IS A GOOD FIT WITHIN NCATS 6273 03:54:58,016 --> 03:54:59,918 AND OTHER INSTITUTES, AND 6274 03:54:59,918 --> 03:55:01,753 CENTERS AT THE NIH. 6275 03:55:01,753 --> 03:55:03,055 IN TERMS OF HEALTH DISPARITIES. 6276 03:55:03,055 --> 03:55:04,923 IT ADDRESSES A KNOWN PROBLEM IN 6277 03:55:04,923 --> 03:55:06,658 HEALTH CARE PROCESSES, WE HAVE 6278 03:55:06,658 --> 03:55:07,893 EVIDENCE THAT THE ACADEMIES ARE 6279 03:55:07,893 --> 03:55:11,029 WORKING TO MOVE AWAY FROM 6280 03:55:11,029 --> 03:55:11,630 NON-BIOLOGICAL PARAMETERS IN 6281 03:55:11,630 --> 03:55:19,138 MEDICINE, AMERICAN ACADEMY OF 6282 03:55:19,138 --> 03:55:20,672 PEDIATRICS CALLED FOR RACE-FREE 6283 03:55:20,672 --> 03:55:21,440 MEDICINE AND THERE'S A 6284 03:55:21,440 --> 03:55:26,044 SIGNIFICANT NEED FOR PLAN TO 6285 03:55:26,044 --> 03:55:27,446 ADDRESS THESE ISSUES IN ORDER TO 6286 03:55:27,446 --> 03:55:30,182 ENSURE THE BEST TREATMENT IS 6287 03:55:30,182 --> 03:55:32,284 AVAILABLE FOR ALL PATIENTS. 6288 03:55:32,284 --> 03:55:34,019 IT WOULDN'T ONLY INFORM DESIGN 6289 03:55:34,019 --> 03:55:36,522 OF SPECIFIC DIAGNOSTICS BUT 6290 03:55:36,522 --> 03:55:39,925 WOULD HELP INFORM WHAT IS 6291 03:55:39,925 --> 03:55:41,226 WORKABLE FOR ADDRESSING PROBLEMS 6292 03:55:41,226 --> 03:55:42,528 AT SALE. 6293 03:55:42,528 --> 03:55:45,264 WE EXPECT THIS WOULD IDENTIFY 6294 03:55:45,264 --> 03:55:46,398 SEVERAL CLINICAL ASSAYS THAT 6295 03:55:46,398 --> 03:55:48,901 FAIL TO INCORPORATE DIVERSE 6296 03:55:48,901 --> 03:55:49,601 PATIENT GROUPS AND RELEVANT 6297 03:55:49,601 --> 03:55:50,435 NON-BIOLOGICAL PARAMETERS AND 6298 03:55:50,435 --> 03:55:51,970 CORRECT TO ENSURE THESE 6299 03:55:51,970 --> 03:55:54,039 TREATMENTS ARE AVAILABLE FOR ALL 6300 03:55:54,039 --> 03:55:55,908 PATIENTS. 6301 03:55:55,908 --> 03:55:59,511 AND SUPPORT WOULD BE PROVIDED TO 6302 03:55:59,511 --> 03:56:00,913 SMALL BUSINESSES DEVELOPING 6303 03:56:00,913 --> 03:56:03,482 ASSAYS AND DEVICES TO ADDRESS 6304 03:56:03,482 --> 03:56:04,683 HEALTH INEQUITIES AND EXPECTED 6305 03:56:04,683 --> 03:56:06,652 LONG TERM OUTCOME WOULD BE 6306 03:56:06,652 --> 03:56:11,657 RELEASE OF NEWER DEVICES THAT DO 6307 03:56:11,657 --> 03:56:12,758 ADDRESS HEALTH INEQUITIES. 6308 03:56:12,758 --> 03:56:14,226 WE PROPOSE THIS CONCEPT TO 6309 03:56:14,226 --> 03:56:17,029 ADDRESS HEALTH INEQUITIES AND 6310 03:56:17,029 --> 03:56:17,629 DISPARITIES IN CLINICAL ASSAY 6311 03:56:17,629 --> 03:56:19,131 AND POINT OF CARE SPACE BROADLY 6312 03:56:19,131 --> 03:56:20,999 AND WE'RE EXCITED ABOUT THIS 6313 03:56:20,999 --> 03:56:22,601 CONCEPT BECAUSE THIS WILL 6314 03:56:22,601 --> 03:56:23,835 ADDRESS KNOWN ISSUE IN CLINICAL 6315 03:56:23,835 --> 03:56:25,737 DIAGNOSTICS THAT HAS BROAD 6316 03:56:25,737 --> 03:56:26,605 IMPACT FOR PATIENT POPULATIONS 6317 03:56:26,605 --> 03:56:28,507 AND OUR HOPE THIS WOULD INCREASE 6318 03:56:28,507 --> 03:56:30,008 EQUITY AMONGST PATIENTS BY 6319 03:56:30,008 --> 03:56:33,278 IMPROVING QUALITY OF CLINICAL 6320 03:56:33,278 --> 03:56:34,613 DIAGNOSTICS FOR ALL PATIENTS. 6321 03:56:34,613 --> 03:56:36,882 WE HAVE A FEW GENERAL QUESTIONS 6322 03:56:36,882 --> 03:56:37,749 FOR COUNCIL MEMBERS. 6323 03:56:37,749 --> 03:56:39,084 WHAT MIGHT IMPROVE THIS 6324 03:56:39,084 --> 03:56:40,185 INITIATIVE AND WHAT ARE KEY 6325 03:56:40,185 --> 03:56:41,486 POINTS TO CONSIDER? 6326 03:56:41,486 --> 03:56:45,090 WE HAVE A COUPLE SPECIFIC 6327 03:56:45,090 --> 03:56:45,424 QUESTIONS. 6328 03:56:45,424 --> 03:56:50,896 ARE THERE PARTICULAR CLINICAL 6329 03:56:50,896 --> 03:56:53,632 THINGS WE SHOULD EMPHASIZE SUCH 6330 03:56:53,632 --> 03:56:55,834 AS LEVERAGE BIOINFORMATICS OR 6331 03:56:55,834 --> 03:56:57,035 GENOMICS? 6332 03:56:57,035 --> 03:56:59,571 WE'VE SEEN EMERGING USE OF A.I. 6333 03:56:59,571 --> 03:57:02,174 IN THE CLINIC AND CLINICAL 6334 03:57:02,174 --> 03:57:03,609 DECISION SUPPORT TOOLS HAS 6335 03:57:03,609 --> 03:57:04,676 BECOME MORE PROMINENT, WE WANT 6336 03:57:04,676 --> 03:57:06,612 TO KNOW WHAT YOU WOULD SUGGEST 6337 03:57:06,612 --> 03:57:07,980 IN TERMS OF CONSIDERING SOFTWARE 6338 03:57:07,980 --> 03:57:10,148 AND A.I. TOOLS UNDER THE 6339 03:57:10,148 --> 03:57:10,582 INITIATIVE. 6340 03:57:10,582 --> 03:57:13,352 WE WOULD WELCOME ANY ADDITIONAL 6341 03:57:13,352 --> 03:57:13,619 COMMENTS. 6342 03:57:13,619 --> 03:57:14,453 >> ALL RIGHT. 6343 03:57:14,453 --> 03:57:15,954 THANK YOU. 6344 03:57:15,954 --> 03:57:22,427 WE'LL OPEN UP TO THE PANELISTS 6345 03:57:22,427 --> 03:57:23,295 HERE. 6346 03:57:23,295 --> 03:57:27,132 GO AHEAD AND PROVIDE SOME 6347 03:57:27,132 --> 03:57:27,432 DISCUSSION. 6348 03:57:27,432 --> 03:57:31,169 THEY ARE ARGUING OVER WHO IS 6349 03:57:31,169 --> 03:57:32,838 GOING FIRST. 6350 03:57:32,838 --> 03:57:33,105 GO FOR IT. 6351 03:57:33,105 --> 03:57:35,874 >> THIS IS AN EXCITING CONCEPT. 6352 03:57:35,874 --> 03:57:40,612 I THINK IT DOES ADDRESS A BIG 6353 03:57:40,612 --> 03:57:44,650 GAP THAT CONTINUES THAT WE ARE 6354 03:57:44,650 --> 03:57:46,451 RECOGNITION OF BUT NOT ANY 6355 03:57:46,451 --> 03:57:50,255 REALLY CONCERTED EFFORTS TO FIND 6356 03:57:50,255 --> 03:57:51,456 SOLUTIONS, SO I THINK REALLY 6357 03:57:51,456 --> 03:57:55,360 EXCITING TO SEE WHERE THIS GOES 6358 03:57:55,360 --> 03:57:59,865 AND I THINK OF COURSE MAKING 6359 03:57:59,865 --> 03:58:03,235 SURE, YOU KNOW, THAT THE 6360 03:58:03,235 --> 03:58:04,336 GRANTEES ARE ENGAGING DIVERSE 6361 03:58:04,336 --> 03:58:06,972 COMMUNITIES AS PART OF THE TEAMS 6362 03:58:06,972 --> 03:58:09,574 IS SUPER IMPORTANT. 6363 03:58:09,574 --> 03:58:13,979 AS WELL AS HAVING GOOD PLAN FOR 6364 03:58:13,979 --> 03:58:14,746 TECHNOLOGY UPTAKE BECAUSE 6365 03:58:14,746 --> 03:58:21,053 THERE'S GOING TO BE RESISTANCE 6366 03:58:21,053 --> 03:58:26,191 TO CHANGE STANDARD OF CARE. 6367 03:58:26,191 --> 03:58:28,860 I THINK COLLABORATION WITH THE 6368 03:58:28,860 --> 03:58:32,631 FDA WILL MAKE SURE THAT HAPPENS. 6369 03:58:32,631 --> 03:58:32,864 >> YES. 6370 03:58:32,864 --> 03:58:34,666 >> THE OTHER THING THAT'S SOUTH 6371 03:58:34,666 --> 03:58:39,504 OF SCOPE BUT HEARING EARLIER THE 6372 03:58:39,504 --> 03:58:41,473 TALK OF DEIMPLEMENTATION, I 6373 03:58:41,473 --> 03:58:51,750 WONDER HOW THIS 6374 03:59:24,182 --> 03:59:25,984 WHAT'S CURRENTLY IN USE WE 6375 03:59:25,984 --> 03:59:27,185 RECOGNIZE THAT THINGS THAT HAVE 6376 03:59:27,185 --> 03:59:29,921 BEEN USED FOR A LONG TIME, IT'S 6377 03:59:29,921 --> 03:59:31,790 HARD TO DECOUPLE A LITTLE BIT. 6378 03:59:31,790 --> 03:59:34,292 BUT WE DO HAVE PLANS TO INCLUDE 6379 03:59:34,292 --> 03:59:45,036 THAT IN THE INITIATIVE, YEAH. T 6380 03:59:53,945 --> 03:59:54,079 WEEK. 6381 03:59:54,079 --> 04:00:04,556 I DON'T HAVE A TON TO ADD. 6382 04:00:06,224 --> 04:00:12,497 PEOPLE ARE GOING TO BE 6383 04:00:12,497 --> 04:00:17,736 INTEGRATING A.I. THE CONCEPT IS 6384 04:00:17,736 --> 04:00:19,171 BIGGER THAN CLINICAL 6385 04:00:19,171 --> 04:00:20,705 DIAGNOSTICS, GETS INTO 6386 04:00:20,705 --> 04:00:21,339 MONITORING, AS WE DECENTRALIZE 6387 04:00:21,339 --> 04:00:22,674 CLINICAL TRIALS THAT ARE GOING 6388 04:00:22,674 --> 04:00:24,543 TO ALLOW PATIENTS TO SELF-SAMPLE 6389 04:00:24,543 --> 04:00:27,579 AT HOME, I THINK WE GET -- IT'S 6390 04:00:27,579 --> 04:00:31,817 EVEN MORE VITAL, YOUR INITIATIVE 6391 04:00:31,817 --> 04:00:35,887 TO DE-RISK TOOLS SO THAT WE 6392 04:00:35,887 --> 04:00:36,655 EMPOWER PEOPLE TO PARTICIPATE 6393 04:00:36,655 --> 04:00:40,091 AND LET THEM DO IT WITH TOOLS 6394 04:00:40,091 --> 04:00:41,159 THAT HAVE BEEN VALIDATED. 6395 04:00:41,159 --> 04:00:44,463 I JUST THINK THIS IS AN AWESOME 6396 04:00:44,463 --> 04:00:44,963 INITIATIVE. 6397 04:00:44,963 --> 04:00:46,865 I LOVE THE LEADERSHIP OF NCATS 6398 04:00:46,865 --> 04:00:48,600 TAKING THIS ON TO BENEFIT 6399 04:00:48,600 --> 04:00:50,135 RESEARCH ACROSS ALL THE OTHER 6400 04:00:50,135 --> 04:00:52,137 INSTITUTES AND ALL OUR DISEASE 6401 04:00:52,137 --> 04:00:54,406 AREAS WE CARE ABOUT. 6402 04:00:54,406 --> 04:00:57,042 >> THANK YOU. 6403 04:00:57,042 --> 04:00:59,244 >> I MIGHT ADD, KARLIE WAS PART 6404 04:00:59,244 --> 04:01:00,979 OF ANOTHER INITIATIVE WE DID IN 6405 04:01:00,979 --> 04:01:04,716 TERMS OF BIAS IN MACHINE 6406 04:01:04,716 --> 04:01:06,685 LEARNING, A.I., CLINICAL CARE. 6407 04:01:06,685 --> 04:01:08,854 YOUR POINT ABOUT THIS USING A.I. 6408 04:01:08,854 --> 04:01:12,023 TOO IF WE'RE LOOKING 6409 04:01:12,023 --> 04:01:12,591 SPECIFICALLY IN UNDERSERVED 6410 04:01:12,591 --> 04:01:13,225 POPULATIONS FOR THIS KIND OF 6411 04:01:13,225 --> 04:01:15,660 WORK WE MIGHT BE ABLE TO PUT 6412 04:01:15,660 --> 04:01:22,334 INSIGHTS WHAT WITH THIS MIGHT 6413 04:01:22,334 --> 04:01:25,170 EXIST, COULD THAT BE A SPECIFIC 6414 04:01:25,170 --> 04:01:29,541 AREA TO DIVE INTO. 6415 04:01:29,541 --> 04:01:31,443 >> THE POINT I HAD BEEN MAKING 6416 04:01:31,443 --> 04:01:33,178 BEFORE WHICH BUILDS ON WHAT YOU 6417 04:01:33,178 --> 04:01:34,813 WERE SAYING, I THINK IT'S SO 6418 04:01:34,813 --> 04:01:37,115 POPULAR TO USE THE WORD A.I. 6419 04:01:37,115 --> 04:01:39,184 I CAN'T THINK OF A TOOL THAT I 6420 04:01:39,184 --> 04:01:40,585 HAVE VETTED THAT HAS ANY KIND OF 6421 04:01:40,585 --> 04:01:42,454 DATA THAT'S PART OF IT THAT 6422 04:01:42,454 --> 04:01:44,456 DOESN'T ACTUALLY HAVE AN A.I. 6423 04:01:44,456 --> 04:01:44,823 COMPONENT. 6424 04:01:44,823 --> 04:01:47,192 DO YOU CALL IT OUT? 6425 04:01:47,192 --> 04:01:49,160 AND USE THAT TERM? 6426 04:01:49,160 --> 04:01:51,496 OR DO YOU ASSUME THAT'S THE 6427 04:01:51,496 --> 04:01:51,997 STATUS QUO? 6428 04:01:51,997 --> 04:01:55,934 I'M IN THE CAMP OF NOT USING THE 6429 04:01:55,934 --> 04:01:57,269 WORD A.I. EVERYWHERE, BUT I MEAN 6430 04:01:57,269 --> 04:01:58,870 IT DOESN'T REALLY MATTER. 6431 04:01:58,870 --> 04:01:59,204 IT'S COMING. 6432 04:01:59,204 --> 04:02:07,245 IT'S GOING TO BE IN EVERYTHING. 6433 04:02:07,245 --> 04:02:09,014 THERE ISN'T ANOTHER DEVICE THAT 6434 04:02:09,014 --> 04:02:11,182 ISN'T A DATA COLLECTOR, SO IT'S 6435 04:02:11,182 --> 04:02:14,119 WHAT IS THE MEDICAL DEVICE, ALSO 6436 04:02:14,119 --> 04:02:15,554 THE SOFTWARE ALSO GENERATING 6437 04:02:15,554 --> 04:02:17,789 DATA, A BIGGER QUESTION, HOW YOU 6438 04:02:17,789 --> 04:02:24,529 GUYS REFLECT THAT IN THE NOFO IS 6439 04:02:24,529 --> 04:02:24,930 IMPORTANT. 6440 04:02:24,930 --> 04:02:27,899 AND I HAVE A GUIDANCE QUESTION. 6441 04:02:27,899 --> 04:02:28,667 I'M WORKING IN THIS SPACE 6442 04:02:28,667 --> 04:02:29,100 EXCLUSIVELY. 6443 04:02:29,100 --> 04:02:31,870 DOES THAT MEAN I SHOULD NOT BE 6444 04:02:31,870 --> 04:02:41,580 VOTING ON THE APPROVAL? 6445 04:02:41,580 --> 04:02:41,780 OKAY. 6446 04:02:41,780 --> 04:02:42,948 >> WE WERE DISCUSSING THESE FOR 6447 04:02:42,948 --> 04:02:45,750 SEVERAL MONTHS, THOUGHT OF THE 6448 04:02:45,750 --> 04:02:46,718 FACT SMALL BUSINESSES 6449 04:02:46,718 --> 04:02:48,153 SPECIFICALLY SUITABLE FOR 6450 04:02:48,153 --> 04:02:49,588 SOMETHING LIKE THIS, BECAUSE WE 6451 04:02:49,588 --> 04:02:53,158 FIND SMALL BUSINESSES TEND TO 6452 04:02:53,158 --> 04:02:56,127 HAVE A LOT MORE CAPITAL AND 6453 04:02:56,127 --> 04:02:58,763 SOCIAL AWARENESS AND BY DOING 6454 04:02:58,763 --> 04:03:00,398 THIS ATTRACT SMALL BUSINESSES 6455 04:03:00,398 --> 04:03:07,739 WHICH HAVE GREATER SENSE OF 6456 04:03:07,739 --> 04:03:09,608 SERVICE AND MOTIVATION TO MAKE 6457 04:03:09,608 --> 04:03:12,711 THIS SUCCESSFUL, A GOOD MARRIAGE 6458 04:03:12,711 --> 04:03:13,845 TO HAVE THE SMALL BUSINESS 6459 04:03:13,845 --> 04:03:15,513 COMMUNITY APPLY FOR GRANTS AND 6460 04:03:15,513 --> 04:03:15,780 CONTRACTS. 6461 04:03:15,780 --> 04:03:18,116 >> I'LL JUST SAY ONE SPECIFIC 6462 04:03:18,116 --> 04:03:19,985 EXAMPLE TO STRESS HOW IMPORTANT 6463 04:03:19,985 --> 04:03:22,821 THAT EMPHASIS IS. 6464 04:03:22,821 --> 04:03:25,824 THERE'S A MANUFACTURER BASED IN 6465 04:03:25,824 --> 04:03:26,257 L.A. 6466 04:03:26,257 --> 04:03:27,759 BODY METRICS. 6467 04:03:27,759 --> 04:03:29,728 MAIN TECHNOLOGY IS A WEARABLE 6468 04:03:29,728 --> 04:03:33,431 RING, THE FDA JUST APPROVED THEM 6469 04:03:33,431 --> 04:03:35,367 AS MOST ACCURATE PULSE OXIMETER 6470 04:03:35,367 --> 04:03:36,034 THAT'S A WEARABLE. 6471 04:03:36,034 --> 04:03:39,037 THEY HAVE BEEN OFFERED TO BE 6472 04:03:39,037 --> 04:03:39,671 BOUGHT BY APPLE. 6473 04:03:39,671 --> 04:03:41,339 THEY HAVE BEEN OFFERED TO BE 6474 04:03:41,339 --> 04:03:43,842 BOUGHT BY OTHER BIG COMPANIES 6475 04:03:43,842 --> 04:03:45,477 BUT THEY KNOW THAT THEIR 6476 04:03:45,477 --> 04:03:47,312 TECHNOLOGY WILL NOT ACTUALLY BE 6477 04:03:47,312 --> 04:03:48,446 USED FOR THE PURPOSE THEY HAVE 6478 04:03:48,446 --> 04:03:50,081 IN MIND WHICH IS TO DO THE RIGHT 6479 04:03:50,081 --> 04:03:52,617 THING, AND THEY ARE STRUGGLING 6480 04:03:52,617 --> 04:03:57,622 TO STAY ALIVE. 6481 04:03:57,622 --> 04:03:59,057 IT'S IMPORTANT TO LET THESE 6482 04:03:59,057 --> 04:03:59,924 FLOWERS BLOOM. 6483 04:03:59,924 --> 04:04:01,459 THE SMALL BUSINESSES ARE WELL 6484 04:04:01,459 --> 04:04:03,662 POSITIONED AND CAN BE MORE 6485 04:04:03,662 --> 04:04:05,397 MISSION FOCUSED THAN WHEN THEY 6486 04:04:05,397 --> 04:04:06,631 GET ACQUIRED, WE DON'T KNOW 6487 04:04:06,631 --> 04:04:10,468 WHAT'S GOING TO HAPPEN TO THE 6488 04:04:10,468 --> 04:04:11,770 GOOD IDEAS OF TECHNOLOGY. 6489 04:04:11,770 --> 04:04:14,939 YEAH, I HEAR THE PLEAS. 6490 04:04:14,939 --> 04:04:16,908 THESE COMPANIES ARE STRUGGLING 6491 04:04:16,908 --> 04:04:17,275 TO SURVIVE. 6492 04:04:17,275 --> 04:04:17,909 >> GREAT. 6493 04:04:17,909 --> 04:04:21,179 GREAT POINTS. 6494 04:04:21,179 --> 04:04:22,714 THANK YOU. 6495 04:04:22,714 --> 04:04:22,914 OKAY. 6496 04:04:22,914 --> 04:04:23,715 >> HEARING NO FURTHER DISCUSSION 6497 04:04:23,715 --> 04:04:28,620 MAY I HAVE A MOTION TO APPROVE 6498 04:04:28,620 --> 04:04:29,921 THE CONCEPT? 6499 04:04:29,921 --> 04:04:30,155 SECOND? 6500 04:04:30,155 --> 04:04:31,256 >> SECOND. 6501 04:04:31,256 --> 04:04:33,758 >> ALL IN FAVOR? 6502 04:04:33,758 --> 04:04:35,694 ANY OPPOSED? 6503 04:04:35,694 --> 04:04:36,828 ANY ABSTENTIONS? 6504 04:04:36,828 --> 04:04:38,263 WITH THAT, OUR LAST CONCEPT OF 6505 04:04:38,263 --> 04:04:40,231 THE DAY IS APPROVED. 6506 04:04:40,231 --> 04:04:42,100 THANK YOU VERY MUCH. 6507 04:04:42,100 --> 04:04:42,434 >> THANK YOU. 6508 04:04:42,434 --> 04:04:45,670 >> THANK YOU VERY MUCH. 6509 04:04:45,670 --> 04:04:48,306 CHRISTINE IS OFF THE HOOK 6510 04:04:48,306 --> 04:04:49,307 COMPLETELY, ANY SPECIFIC 6511 04:04:49,307 --> 04:04:55,447 QUESTIONS FOR CHRISTINE TO OPEN 6512 04:04:55,447 --> 04:04:56,548 THE FLOOR AND OFFER. 6513 04:04:56,548 --> 04:04:57,816 IF NOT, THAT'S OKAY. 6514 04:04:57,816 --> 04:05:02,654 IT'S BEEN A LONG DAY. 6515 04:05:02,654 --> 04:05:03,521 LONG DAY. 6516 04:05:03,521 --> 04:05:05,724 HEARING NONE WE'LL GO AHEAD AND 6517 04:05:05,724 --> 04:05:07,926 CONCLUDE FOR THE DAY, AND JUST 6518 04:05:07,926 --> 04:05:09,994 AGAIN WANT TO SAY THANK YOU FOR 6519 04:05:09,994 --> 04:05:13,264 ALL OF THIS VALUABLE INPUT, WE 6520 04:05:13,264 --> 04:05:14,365 TAKE ALL OF THIS INFORMATION TO 6521 04:05:14,365 --> 04:05:16,868 HEART AS WE START TO NOW DEVELOP 6522 04:05:16,868 --> 04:05:18,636 THE APPROVED CONCEPTS AND MOVE 6523 04:05:18,636 --> 04:05:22,474 THEM FORWARD, SO WE'LL MAKE SURE 6524 04:05:22,474 --> 04:05:23,742 TO INCORPORATE THE COMMENTS AND 6525 04:05:23,742 --> 04:05:26,044 QUESTIONS YOU'VE HAD AND MAKE 6526 04:05:26,044 --> 04:05:27,946 THEM REALLY THINK AS ROBUST AS 6527 04:05:27,946 --> 04:05:29,647 WE POSSIBLY CAN. 6528 04:05:29,647 --> 04:05:32,417 AND WE LOOK FORWARD AGAIN TO 6529 04:05:32,417 --> 04:05:33,718 SEEING YOU IN JANUARY, THOUGH IT 6530 04:05:33,718 --> 04:05:35,820 WILL BE A VIRTUAL MEETING. 6531 04:05:35,820 --> 04:05:39,090 SO WE'LL SEE YOU ON ZOOM. 6532 04:05:39,090 --> 04:05:40,658 AND AGAIN THANK YOU, SAFE 6533 04:05:40,658 --> 04:05:42,494 TRAVELS ON YOUR WAY HOME. 6534 04:05:42,494 --> 04:05:45,463 AND I'LL GAVEL US OUT. 6535 04:05:45,463 --> 04:05:48,399 MEETING IS ADJOURNED. 6536 04:05:48,399 --> 04:05:54,405 6537 04:05:54,405 --> 04:06:04,449